US20070172819A1 - Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors - Google Patents

Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors Download PDF

Info

Publication number
US20070172819A1
US20070172819A1 US11/648,108 US64810806A US2007172819A1 US 20070172819 A1 US20070172819 A1 US 20070172819A1 US 64810806 A US64810806 A US 64810806A US 2007172819 A1 US2007172819 A1 US 2007172819A1
Authority
US
United States
Prior art keywords
thermally stable
composition
group
dna
polymerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/648,108
Inventor
Susan Hardin
Xiaolian Gao
James Briggs
Richard Willson
Shiao-Chun Tu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/648,108 priority Critical patent/US20070172819A1/en
Publication of US20070172819A1 publication Critical patent/US20070172819A1/en
Assigned to Life Technologies Corporation reassignment Life Technologies Corporation ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VISIGEN BIOTECHNOLOGIES, INC.
Assigned to VISIGEN BIOTECHNOLOGIES, INC. reassignment VISIGEN BIOTECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GAO, XIAOLIAN, BRIGGS, JAMES M., HARDIN, SUSAN H., TU, SHIAO-CHUN, WILLSON, RICHARD C.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1252DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6853Nucleic acid amplification reactions using modified primers or templates

Definitions

  • the present invention relates to compositions and methods for altering the fidelity of nucleic acid synthesis.
  • the present invention relates to the following general areas: (1) nucleotide triphosphate monomers having at least one molecular or atomic tag bonded to and/or chemically and/or physically associated with one or more of the phosphate groups of the triphosphate moiety of the monomers, the base moiety, and/or the sugar moiety in the case of a nucleoside analog; (2) methods for enzymatic DNA synthesis with altered fidelity; (3) methods of sequencing DNA, based on the detection of base incorporation using tags bonded to and/or chemically and/or physically associated with the ⁇ and/or ⁇ phosphates of the triphosphate of the nucleotide monomer, the base moiety of a nucleotide or nucleoside monomer, and/or the sugar moiety of a nucleotide or nucleoside monomer, the polymerase or by the release of the tagged pyrophosphate (PPi); (4) a template-mediated primer extension reaction with improved monomer incorporation fidelity using the tagged mono
  • the primary sequences of nucleic acids are crucial for understanding the function and control of genes and for applying many of the basic techniques of molecular biology.
  • the ability to do rapid and reliable DNA sequencing is, therefore, a very important technology.
  • the DNA sequence is an important tool in genomic analysis as well as other applications, such as genetic identification, forensic analysis, genetic counseling, medical diagnostics, etc.
  • disorders, susceptibilities to disorders, and prognoses of disease conditions can be correlated with the presence of particular DNA sequences, or the degree of variation (or mutation) in DNA sequences, at one or more genetic loci.
  • HLA human leukocyte antigen
  • the dideoxy chain termination method serves as the basis for all currently available automated DNA sequencing machines. See, e.g., Sanger et al., Proc. Natl. Acad. Sci., 74: 5463-5467 (1977); Church et al., Science, 240: 185-188 (1988); and Hunkapiller et al., Science, 254: 59-67 (1991)).
  • Other methods include the chemical degradation method, see, e.g., Maxam et al., Proc. Natl. Acad.
  • Fluorescent dyes can be used in a variety of these DNA sequencing techniques.
  • a fluorophore moiety or dye is a molecule capable of generating a fluorescence signal.
  • a quencher moiety is a molecule capable of absorbing the energy of an excited fluorophore, thereby quenching the fluorescence signal that would otherwise be released from the excited fluorophore. In order for a quencher to quench an excited fluorophore, the quencher moiety must be within a minimum quenching distance of the excited fluorophore moiety at some time prior to the fluorophore releasing the stored fluorescence energy.
  • Fluorophore-quencher pairs have been incorporated into oligonucleotide probes in order to monitor biological events based on the fluorophore and quencher being separated or brought within a minimum quenching distance of each other. For example, probes have been developed wherein the intensity of the fluorescence increases due to the separation of the fluorophore-quencher pair. Probes have also been developed which lose their fluorescence because the quencher is brought into proximity with the fluorophore.
  • fluorophore-quencher pairs have been used to monitor hybridization assays and nucleic acid amplification reactions, especially polymerase chain reactions (PCR), by monitoring either the appearance or disappearance of the fluorescence signal generated by the fluorophore molecule.
  • PCR polymerase chain reactions
  • the decreased fluorescence of a fluorophore moiety by collision or direct interaction with a quencher is due mainly to a transfer of energy from the fluorophore in the excited state to the quencher.
  • a plot of F 0 /F versus [Q] yields a straight line with a slope corresponding to the Stern-Volmer constant, K sv .
  • fluorophore moieties preferably have a high quantum yield and a large extinction coefficient so that the dye can be used to detect small quantities of the component being detected.
  • Fluorophore moieties preferably have a large Stokes shift (i.e., the difference between the wavelength at which the dye has maximum absorbance and the wavelength at which the dye has maximum emission) so that the fluorescent emission is readily distinguished from the light source used to excite the dye.
  • One class of fluorescent dyes which has been developed is the energy transfer fluorescent dyes.
  • U.S. Pat. Nos. 5,800,996, and 5,863,727, issued to Lee et al. disclose donor and acceptor energy fluorescent dyes and linkers useful for DNA sequencing, incorporated therein by reference.
  • Other fluorophore-quencher pairs are disclosed in PCT Application Serial No. PCT/US99/29584, incorporated herein by reference.
  • the acceptor molecule is a fluorophore which is excited at the wavelength of light corresponding to the fluorescence emission the excited donor molecule. When excited, the donor dye transmits its energy to the acceptor dye.
  • emission from the donor is partially or totally quenched due to partial or total energy transfer from the excited donor to the acceptor dye, resulting in the excitation of the latter for emission at its characteristic wavelength (i.e., a wavelength different from that of the donor dye which may represent a different color if the emissions are in the visible portion of the spectrum).
  • characteristic wavelength i.e., a wavelength different from that of the donor dye which may represent a different color if the emissions are in the visible portion of the spectrum.
  • Nucleotide triphosphates having a fluorophore moiety attached to the ⁇ -phosphate are of interest as this modification still allows the modified NTPs to be enzyme substrates.
  • Felicia et al. describe the synthesis and spectral properties of a “always-on” fluorescent ATP analog, adenosine-5′-triphosphoroyl-(5-sulfonic acid)naphthyl ethylamindate ( ⁇ -1,5-EDANS) ATP.
  • the analog is a good substrate for E. coli RNA polymerase and can be used to initiate the RNA chain.
  • the ATP analog is incorporated into the RNA synthesized and is a good probe for studies of nucleotide-protein interactions, active site mapping and other ATP-utilizing biological systems. See, e.g., Felicia et al., Arch. Biochem Biophys., 246: 564-571 (1986).
  • Sato et al. disclose a homogeneous enzyme assay that uses a fluorophore moiety (bimane) attached to the ⁇ -phosphate group of the nucleotide and a quencher moiety attached to the 5-position of uracil.
  • the quencher moiety is in the form of a halogen, bound to the C-5 position of the pyrimidine. The quenching that is effected by this combination is eliminated by cleavage of the phosphate bond by the phosphodiesterase enzyme.
  • the halogen quencher used in the assay is very inefficient producing only about a two fold decrease in fluorescent efficiency.
  • an oligonucleotide primer having homology to a single-stranded template nucleic acid is caused to anneal to a template nucleic acid, the annealed mixture is then provided with a DNA polymerase in the presence of nucleoside triphosphates under conditions in which the DNA polymerase extends the primer to form a complementary strand to the template nucleic acid.
  • the primer is extended in the presence of a chain-terminating agent, e.g., a dideoxynucleoside triphosphate, to cause base-specific termination of the primer extension (Sanger).
  • two primers are provided, each having homology to opposite strands of a double-stranded DNA molecule. After the primers are extended, they are separated from their templates, and additional primers caused to anneal to the templates and the extended primers. The additional primers are then extended. The steps of separating, annealing, and extending are repeated in order to geometrically amplify the number of copies of the template nucleic acid (Saiki).
  • pyrophosphorolysis where an oligonucleotide is reduced in length, is detrimental to primer extension reactions.
  • the pyrophosphorolysis is caused by the availability of pyrophosphate.
  • PCR is inhibited by the addition of pyrophosphate even at very low concentrations.
  • this pyrophosphorolysis can be prevented by providing an agent, for example, a pyrophosphatase, capable of removing pyrophosphate.
  • Addition of pyrophosphatase to a PCR greatly enhances the progress of the reaction and provides superior results compared to the reaction without a pyrophosphatase. See U.S. Pat. No. 4,800,159, incorporated herein by reference.
  • a pyrophosphatase to a sequencing reaction provides more uniformity in intensities of bands formed in a polyacrylamide gel used to identify products of the sequencing reaction. This uniformity is due to prevention of degradation of specific DNA products by pyrophosphorolysis. See also, Tabor, S. and Richardson, C. C., J. Biol. Chem. 265:8322 (1990) and U.S. Pat. No. 4,962,020, incorporated herein by reference.
  • Each product or band in a dideoxy sequencing experiment is a polynucleotide complementary to the template and terminated at the 3′ end in a base-specific manner with a dideoxynucleotide.
  • the dideoxy stabilizes the product, preventing further polymerization of the polynucleotide.
  • the bands especially after prolonged reaction, will reduce in intensity or completely disappear (“drop-out” bands).
  • the PPi contained within the enzyme is thought to remain there for an extended period of time. A drop-out may not be readily detected by the operator, leading to errors in the interpretation of the data either by a human or computer-driven analyzer.
  • DNA sequencing is an essential tool in molecular genetic analysis. The ability to determine DNA nucleotide sequences has become increasingly important as efforts have commenced to determine the sequences of the large genomes of humans and other higher organisms.
  • the two most commonly used methods for DNA sequencing are the enzymatic chain-termination method of Sanger and the chemical cleavage technique of Maxam and Gilbert.
  • the PPi-based sequencing methods mentioned above are not without drawbacks.
  • the template must be washed thoroughly between each nucleotide addition to remove all non-incorporated deoxynucleotides. This makes it difficult to sequence a template which is not bound to a solid support.
  • new enzymes must be added with each addition of deoxynucleotide.
  • the present invention overcomes the deficiencies of the prior art and provides a nucleotide polymerization using nucleotides having a molecular and/or atomic tag bonded to or associated with the nucleotide or nucleoside to alter fidelity of nucleotide incorporation.
  • the tag is bonded to or associated with a portion of the nucleotide that is released after nucleotide incorporation in a growing polymer chain.
  • the released portion is the pyrophosphate moiety including the ⁇ and ⁇ phosphate groups.
  • a pyrophosphate group having a molecular and/or atomic tag bonded to or associated therewith is released from the nucleoside triphosphate upon incorporation in a growing polymer chain, the tagged pyrophosphate group does not (significantly) stimulate pyrophosphorolysis.
  • the present invention also provides a method for preventing reverse polymerization or depolymerization of polymer formed using single-molecule sequencing methods as set forth in U.S. Prov. Pat. Appln. Ser. No. 60/216,594, filed Jul. 7, 2000 and U.S. patent application Ser. No. 09/901,782, filed Jul. 9, 2001, incorporated herein by reference.
  • the present invention further provides a method for improving incorporation fidelity by adding a modified PP i to a nucleoside polymerization medium in an amount sufficient to improve incorporation fidelity and/or to inhibit of pyrophosphorolysis of formed products.
  • Preferred modified pyrophosphates include pyrophosphates bearing a group on one or both phosphate moieties that reduce, inhibit or prevent pyrophosphorolysis or pyrophosphates produced from NTPs or dNTPs having a group on the ⁇ and/or ⁇ phosphate moiety.
  • the present invention provides a heterogeneous assay for detecting base incorporation and pyrophosphate cleavage.
  • the assay utilizes labeled NTPs or dNTPs, a target nucleic acid, a primer nucleic acid and a polymerase.
  • the assay includes the steps of flowing the labeled nucleotide triphosphate (NTP, dNTP, etc.) having a molecular and/or atomic tag bonded to or associated with the ⁇ - and/or ⁇ -phosphate past an immobilized component selected from the group consisting of the polymerase, the primer and the target nucleic acid.
  • the appropriate labeled NTP or dNTP is incorporated on the primer strand hybridized to the target nucleic acid using the polymerase and results in the release of a tagged pyrophosphate from the dNTP.
  • the incorporation event or the release event can be detected either by measuring a detectable property of the NTP or dNTP upon binding and/or during incorporation or by measuring a detectable property of the released pyrophosphate.
  • the detectable property can be a property inherent in the molecular or atomic tags or produced as a result of the interaction between the molecular or atomic tag on the phosphates of the label NTP or released pyrophosphate and other tags bonded to or associated with the polymerase, the matrix or mobile or immobile components in the media.
  • the present invention also provides a polymerase immobilized on a solid support and a labeled nucleotide triphosphate selected from the group consisting of dATP, dCTP, dGTP, dTTP, dUTP, ATP, CTP, GTP, UTP and mixtures thereof, where the tags are molecular and the molecules are fluorophores and the detectable property is fluorescent light emission or quenching.
  • the detection of the fluorescent light is preferably accomplished using single molecule detection such as a charge couple device (CCD) camera or intensified CCD camera systems or the like.
  • CCD charge couple device
  • kits and integrated systems for practicing the assays described herein provides a kit for assaying pyrophosphate cleavage, comprising: (a) a plurality of nucleotides triphosphates each having a ⁇ -phosphate with a distinguishing fluorophore moiety attached thereto and each having a quencher moiety sufficiently proximal to the distinguishing fluorophore moiety to prevent fluorescence of the distinguishing fluorophore moiety; wherein the distinguishing fluorophore moiety exists quenched with at least about a 5 fold quenching efficiency when the ⁇ -phosphate is attached to each of the plurality of dNTP moieties and each is unquenched when the ⁇ -phosphate is detached from each of the plurality of dNTP moieties; and (b) a polymerase.
  • the polymerase is immobilized on a solid support.
  • the present invention provides a primer extension method in which the extent of pyrophosphorolysis of a primer extension product is reduced, and solutions and kits useful for practicing the method.
  • the present invention provides a primer extension method wherein “peak drop-out” is reduced and the fidelity of template-sequence reproduction is maximized.
  • the present invention provides an improved method for performing a primer extension reaction including the steps of annealing an oligonucleotide primer to a portion of a template nucleic acid thereby forming a primer template hybrid; adding primer-extension reagents including a NTP or dNTP having a ⁇ - and/or ⁇ -phosphate moiety having a molecular and/or atomic tag bonded to or associated with the ⁇ - and/or ⁇ -phosphate moiety to the primer-template hybrid for extending the primer; and optionally adding a co-substrate-enzyme pair to the primer-template hybrid for conducting a pyrophosphate-utilizing reaction, where the tagged, released pyrophosphate reduces the amount of pyrophosphorolysis in the reaction.
  • the release PP i is a modified PP i and acts to inhibit deleterious interference untagged PP i has on nucleotide polymerization.
  • the present invention provides a method of inhibiting or preventing pyrophosphorolysis during synthesis of a nucleic acid molecule, said method comprising: (a) combining one or more nucleotides having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the nucleoside and a nucleic acid template; (b) incubating the one or more nucleotides and nucleic acid template, under conditions sufficient to form a second nucleic acid molecule complementary to all or a portion of the nucleic acid template.
  • the method of the invention more specifically relates to a method of inhibiting or preventing pyrophosphorolysis, said method comprising: (a) combining a primer with a nucleic acid template under conditions sufficient to form a hybridized product; and (b) incubating said hybridized product in the presence of (i) one or more nucleotides having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the nucleoside, and (ii) a polymerase, and (iii) optionally an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with alcohol group as acceptor, a nucleotidyltransferase, and a carboxy-lyase under conditions sufficient to synthesize a second nucleic acid molecule complementary to all or a portion of said nucleic acid template.
  • the method of the present invention relates to inhibition of pyrophosphorolysis in the synthesis of DNA and RNA molecules using the appropriate nucleotides having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the nucleoside and polymerases (dNTPs/rNTPs and DNA polymerase/RNA polymerase).
  • the present invention provides a primer extension reaction to prevent the inhibition of nucleic acid synthesis during amplification and to prevent band drop out in sequencing reactions.
  • the method to prevent inhibition of nucleic acid synthesis during amplification of a double stranded nucleic acid molecule comprises: (a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3′ termini of the first strand of said nucleic acid molecule and said second primer is complementary to a sequence at or near the 3′ termini of the second strand of said nucleic acid molecule; (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of (i) a polymerase, and (ii) optionally an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as an acceptor, a nucleotidyltransferase and a carboxy-lyase under conditions such that
  • the PP i released in the nucleotide polymerization of this invention do not cause the deleterious effects that nascent PP i can cause, therefore, the need to enzymatically degrade PP i is only for optional protection.
  • the present invention also provides a method of sequencing a DNA molecule comprising: (a) combining a primer with a first DNA molecule under conditions sufficient to form a hybridized product; (b) contacting said hybridized product with nucleotides having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the nucleoside, a DNA polymerase, optionally an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as acceptor, a nucleotidyltransferase and a carboxy-lyase; and a terminator nucleotide to give a reaction mixture; (c) incubating the reaction mixture under conditions sufficient to synthesize a population of DNA molecules complementary to said first DNA molecule, wherein said synthesized DNA molecules are shorter in length than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucle
  • ⁇ - and/or ⁇ -phosphate modified nucleotides will result in improved sequencing using traditional fluorescent sequencing reaction due to a decrease in background and/or reduction in band spreading.
  • the first improvement would result from using ⁇ - and/or ⁇ -phosphate modified dideoxynucleotidesm which are incorporated at improved accuracy (less incorporation of incorrect ddNTP, reducing background signal).
  • the traditional fluorescent sequencing reaction can undergo a two stage improvement by using ⁇ - and/or ⁇ -phosphate modified nucleotides and ⁇ - and/or ⁇ -phosphate modified dideoxy nucleotides.
  • the present invention provides a novel modified PP i -based sequencing method for sequencing reactions, where the method can be performed without intermediate washing steps, enabling the procedure to be carried out simply and rapidly, for example in a single micro titre plate. Moreover, the method can be performed with immobilized DNA in solution or on a support or with mobile DNA and immobilized polymerase in solution or on a support. Furthermore, the method can be readily adapted to permit the sequencing reactions to be continuously monitored in real-time, with a signal being generated and detected, as each nucleotide is incorporated.
  • the present invention provides a method of identifying a base at a target position in a sample DNA sequence wherein an extension primer, which hybridizes to the sample DNA immediately adjacent to the target position is provided and the sample DNA and extension primer are subjected to a polymerase reaction in the presence of a deoxynucleotide having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the nucleoside or dideoxynucleotide having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the nucleoside whereby the tagged deoxynucleotide or tagged dideoxynucleotide will only become incorporated and release tagged pyrophosphate (tPPi) if it is complementary to the base in the target position, any incorporation and/or release of tPPi may be detected via any detection method capable of identifying a detectable property of the
  • the present invention is also ideally suited for single nucleotide extensions reactions because the tagged PP i released during incorporation does not cause the deleterious effects associated with the release of nascent PP i , and where the fidelity of the tagged nucleotide incorporation in improved.
  • the invention also provides a kit for carrying out nucleic acid syntheses with improved fidelity comprising a container including a polymerizing compartment comprising a nucleic acid polymerizing agent, a monomer compartment comprising nucleotide monomers for the polymerizing agent and a fidelity enhancing agent compartment comprising a fidelity enhancing agent, where the fidelity enhancing agent comprises a tagged-phosphate, tagged-pyrophosphate or tagged-polyphosphate or derivatives thereof.
  • the invention also provides a kit for carrying out nucleic acid syntheses with improved fidelity comprising a container including a polymerizing compartment comprising a nucleic acid polymerizing agent and a monomer compartment comprising nucleotide monomers for the polymerizing agent, where the monomers comprise dNTPs, ddNTPs, ⁇ - and/or ⁇ -phosphate modified nucleotides, ⁇ - and/or ⁇ -phosphate modified dideoxy nucleotides or mixtures or combinations thereof.
  • the invention also provides a kit for carrying out nucleic acid syntheses with improved fidelity comprising a container including a polymerizing compartment comprising a nucleic acid polymerizing agent and monomer compartments, each compartment comprising a nucleotide monomer for the polymerizing agent, where the monomers comprise dNTPs, ddNTPs, ⁇ - and/or ⁇ -phosphate tagged dNTPs, ⁇ - and/or ⁇ -phosphate tagged ddNTPs or mixtures or combinations thereof.
  • FIG. 1 depicts the incorporation of ANS- ⁇ -phosphate dATP using Taq polymerase and a primer
  • FIG. 2 depicts the synthesis of extended DNA polymers using all four ANS- ⁇ -phosphated tagged dNTPs and the Taq polymerase;
  • FIG. 3 depicts the synthesis of long DNA polymers using all four ANS- ⁇ -phosphated tagged dNTPs and the Taq polymerase;
  • FIG. 4 depicts the use of ⁇ -modified nucleotides with the Klenow fragment from E. coli DNA polymerase to form DNA polymer
  • FIG. 5 depicts the use of ⁇ -modified nucleotides with the Pfu DNA polymerase that shows this polymerase does not efficiently use ⁇ -modified nucleotides
  • FIG. 6 depicts the use of ⁇ -modified nucleotides using HIV-1 reverse transcriptase to efficiently form DNA polymers
  • FIG. 7 depicts the experimental results for native T7 DNA polymerase and Sequenase
  • FIG. 8 depicts the effect of elevated temperature on ANS-tagged dATPs and ANS-tagged dATPs
  • FIG. 9 depicts the effect of elevated temperature on ANS-tagged dCTPs and ANS-tagged dGTPs
  • FIG. 10 depicts the effect of temperature and time on the ability of Taq DNA Polymerase to produce extended DNA products from primer/template duplexes
  • FIG. 11 depicts the addition of an ANS- ⁇ -tag to natural dNTPs affects the terminal transferase activity of commercially available Taq DNA Polymerase;
  • FIG. 12 depicts a summary of extension results for various polymerase incorporating ANS-tagged dNTPs
  • FIG. 13 depicts data from time course experiments demonstrating similar incorporation of natural and ⁇ -phosphate modified nucleotide using HIV reverse transcriptase.
  • FIG. 14 TOP Representative gels demonstrating the results obtained in single nucleotide extension assays using the Bot-C template. Incorporation of matched (dGTP & ANS-dGTP, above) and mismatched (dTTP & ANS-dTTP, below) nucleotides are shown.
  • BOTTOM Graphic presentation of the fidelity improvements afforded by ANS addition to the ⁇ -phosphate of each dNTP. The increase in percent extension of the natural nucleotide relative to the ANS-tagged nucleotide is indicated above the natural nucleotide.
  • heterogeneous assay refers to an assay method wherein at least one of the reactants in the assay mixture is attached to a solid phase, such as a solid support.
  • oligonucleotide as used herein includes linear oligomers of nucleotides or analogs thereof, including deoxyribonucleosides, ribonucleosides, and the like. Usually, oligonucleotides range in size from a few monomeric units, e.g. 3-4, to several hundreds of monomeric units.
  • oligonucleotide is represented by a sequence of letters, such as “ATGCCTG”, it will be understood that the nucleotides are in 5′-3′ order from left to right and that “A” denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxyguanosine, and “T” denotes thymine, unless otherwise noted.
  • nucleoside refers to a compound consisting of a purine, deazapurine, or pyrimidine nucleoside base, e.g., adenine, guanine, cytosine, uracil, thymine, deazaadenine, deazaguanosine, and the like, linked to a pentose at the 1′ position, including 2′-deoxy and 2′-hydroxyl forms, e.g., as described in Komberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992) and further include, but are not limited to, synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g.
  • Suitable NTPs include both naturally occurring and synthetic nucleotide triphosphates, and are not limited to, ATP, dATP, CTP, dCTP, GTP, dGTP, TTP, dTTP, ITP, dITP, UTP and dUTP.
  • the nucleotide triphosphates used in the methods of the present invention are selected from the group of dATP, dCTP, dGTP, dTTP, dUTP and mixtures thereof.
  • nucleotide refers to a phosphate ester of a nucleoside, e.g., mono, di and triphosphate esters, wherein the most common site of esterification is the hydroxyl group attached to the C-5 position of the pentose and includes deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof such as their dideoxy derivatives: ddATP, ddCTP, ddITP, ddUTP, ddGTP, ddTTP.
  • deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof such as their dideoxy derivatives: ddATP, ddCTP, ddITP, ddUTP, ddGTP, ddTTP.
  • nucleotide as used herein also refers to ribonucleoside triphosphates (NTPs) and their derivatives. Illustrated examples of ribonucleoside triphosphates include, but are not limited to, ATP, CTP, GTP, ITP and UTP.
  • primer refers to a linear oligonucleotide which specifically anneals to a unique polynucleotide sequence and allows for amplification of that unique polynucleotide sequence or to a nucleic acid, e.g., synthetic oligonucleotide, which is capable of annealing to a complementary template nucleic acid and serving as a point of initiation for template-directed nucleic acid synthesis.
  • a primer will include a free hydroxyl group at the 3′-end.
  • sequence determination or “determining a nucleotide sequence” in reference to polynucleotides includes determination of partial as well as full sequence information of the polynucleotide. That is, the term includes sequence comparisons, fingerprinting, and like levels of information about a target polynucleotide, or oligonucleotide, as well as the express identification and ordering of nucleotides, usually each nucleotide, in a target polynucleotide. The term also includes the determination of the identification, ordering, and locations of one, two, or three of the four types of nucleotides within a target polynucleotide.
  • solid-support refers to a material in the solid-phase that interacts with reagents in the liquid phase by heterogeneous reactions.
  • Solid-supports can be derivatized with proteins such as enzymes, peptides, oligonucleotides and polynucleotides by covalent or non-covalent bonding through one or more attachment sites, thereby “immobilizing” the protein or nucleic acid to the solid-support.
  • target nucleic acid or “target polynucleotide” refers to a nucleic acid or polynucleotide whose sequence identity or ordering or location of nucleosides is to be determined using methods described herein.
  • Primer-extension reagent means a reagent including components necessary to effect the enzymatic template-mediated extension of a primer.
  • Primer extension reagents include: (i) a polymerase enzyme, e.g., a thermostable polymerase enzyme such as Taq DNA polymerase, and the like; (ii) a buffer to stabilize pH; (iii) deoxynucleotide triphosphates, e.g., deoxyguanosine 5′-triphosphate, 7-deazadeoxyguanosine 5′-triphosphate, deoxyadenosine 5′-triphosphate, deoxythymidine 5′-triphosphate, deoxycytidine 5′-triphosphate; and, optionally in the case of a Sanger-type DNA sequencing reaction, (iv) dideoxynucleotide triphosphates, e.g., dideoxyguanosine 5′triphosphate, 7-deazadideoxyguanosine
  • pyrophosphate refers to two phosphate molecules bound together by an ester linkage, e.g., the structure ⁇ 2 O 3 P—O—PO 3 ⁇ 2 .
  • nucleotide-degrading enzyme includes all enzymes capable of non-specifically degrading nucleotides, including at least nucleoside triphosphates (NTPs), but optionally also di- and monophosphates, and any mixture or combination of such enzymes, provided that a nucleoside triphosphatase or other NTP degrading activity is present.
  • NTPs nucleoside triphosphates
  • nucleoside triphosphatase or other NTP degrading activity may conveniently be used according to the invention, any enzyme having any nucleotide or nucleoside degrading activity may be used, e.g., enzymes which cleave nucleotides at positions other than at the phosphate group, for example at the base or sugar residues.
  • a nucleoside triphosphate degrading enzyme is essential for the invention.
  • atomic tag means an atom or ion of an atom that when attached to a nucleotide increase the fidelity of a nucleotide polymerizing agent such as a polymerase at the atom tagged nucleotide is incorporated into a nucleotide sequence.
  • molecular tag means an atom or ion of an atom that when attached to a nucleotide increase the fidelity of a nucleotide polymerizing agent such as a polymerase at the atom tagged nucleotide is incorporated into a nucleotide sequence.
  • polymerizing agent means any naturally occurring or synthetic agent capable of polymerizing nucleotides to produce polynucleotide, including polymerases, reverse transcriptases, or the related naturally occurring nucleotide polymerizing systems.
  • polymerizing agent also includes variants of naturally occurring polymerases or reverse transcriptases where one or more amino acids have been added to, removed from or replaced in the nature amino acid sequence.
  • the term covers all known and to be constructed systems capable of forming oligomers or polymers of nucleotides.
  • nucleotide monomers or analogs thereof bearing an atomic and/or molecular tag on a site of the molecule can increase the fidelity of nucleotide polymerization for nucleotide polymerization agents that can incorporated the modified monomers.
  • This increase in fidelity is useful for improving nucleic acid sequencing determinations using any of the standard sequencing reactions such as PCR, rolling circle or the like.
  • these modified monomers may allows the construction of drugs for animal or human use that would increase the fidelity of viral disease replication in vivo decreasing mutagensis allowing the immune system to recognize the virus. Such a medication may be of particular benefit for virus such as the HIV virus that causes AIDS.
  • the present invention relates to a composition
  • a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ and/or ⁇ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation.
  • the present invention relates to a method comprising the step of adding a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ and/or ⁇ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • the present invention relates to a composition
  • a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation.
  • the present invention relates to a method comprising the step of adding a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • the present invention relates to a composition
  • a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation.
  • the present invention relates to a method comprising the step of adding a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • the present invention relates to a method comprising the step of adding a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ and/or ⁇ phosphate group to an assay involving a polymerase and/or a base moiety, where the tag alters fidelity of base incorporation and the assay is selected from the group consisting of genotyping for in vitro reproductive methods (human and other organisms); single nucleotide polymorphism (SNP) detection; DNA sequencing; RNA sequencing; single nucleotide extension assays; amplified DNA product assays; rolling circle product assays; PCR product assays; allele-specific primer extension assays; single-molecule arrays (DNA, RNA, protein) assays; drug toxicity evaluation assays; or the like.
  • the method can be used to extend a nucleic acid molecule by any number of bases depending on the polymerizing reaction selected.
  • the molecule can be extended by a single nucleotide up to many thousands of nucleotide to or hundred of thousands of bases.
  • the present invention relates to a method for making blunt-ended fragments comprising the steps of amplifying a DNA fragment in the presence of a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a ⁇ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation and decreases or eliminates non-templated addition of a base to the 3′ end of the DNA fragment being amplified.
  • the amplifying step is a PCR amplification step.
  • the present invention relates to a composition
  • a pyrophosphorolysis inhibitors selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof: Z-OPO 2 O-Z′ (a) Z-PO 2 O-Z′ (b) Z-OPO 2 -Z′ (c) Z-PO 2 -Z′ (d) Z-OPO 2 —(OP(EE′)O) n —PO 2 O-Z′ (e) Z-OPO 2 —(OP(EE′)O) n PO 2 -Z′ (f) Z-PO 2 —(OP(EE′)O) n PO 2 O-Z′ (g) Z-PO 2 —(OP(EE′)O) n PO 2 -Z′ (h) where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements, E and E′
  • the present invention relates to a method comprising the step of polymerizing a nucleic acid sequence in the presence of a composition comprising a pyrophosphorolysis inhibitors selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof: Z-OPO 2 O-Z′ (a) Z-PO 2 O-Z′ (b) Z-OPO 2 -Z′ (c) Z-PO 2 -Z′ (d) Z-OPO 2 —(OP(EE′)O) n —PO 2 O-Z′ (e) Z-OPO 2 —(OP(EE′)O) n PO 2 -Z′ (f) Z-PO 2 —(OP(EE′)O) n PO 2 O-Z′ (g) Z-PO 2 —(OP(EE′)O) n PO 2 -Z′ (h) where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen,
  • the present invention relates to a heterogeneous assay method for detecting pyrophosphate cleavage, the components of the assay comprising a labeled NTP, a target nucleic acid, a primer nucleic acid and a polymerase, said method comprising: (a) flowing said tagged nucleotide triphosphate (NTP), where a ⁇ and/or ⁇ phosphate group and/or a base moiety of the NTP includes an atomic and/or molecular tag having a detectable property attached thereto or associated therewith; (b) incorporating said NTP on a primer strand hybridized to said target nucleic acid using said polymerase and releasing said ⁇ -phosphate with said fluorophore moiety attached thereto; and (c) detecting said fluorescent moiety thereby detecting pyrophosphate cleavage.
  • NTP tagged nucleotide triphosphate
  • the nucleotide triphosphate is a member selected from the group consisting of deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanosine triphosphate and deoxythymidine triphosphate.
  • the nucleotide triphosphate is a member selected from the group consisting of adenosine triphosphate, cytosine triphosphate, guanosine triphosphate and uridine triphosphate.
  • the tags are a fluorescent species which is detected based upon a change in either intensity measurement or fluorescent lifetime measurement.
  • the nucleotide triphosphate is a plurality of nucleotide triphosphates (NTPs).
  • each of said plurality of nucleotide triphosphates has an indicator of identity associated with the tag.
  • the polymerase is a member selected from the group consisting of a DNA polymerase, a DNA dependent RNA polymerase and a reverse transcriptase, particularly, where the polymerase is a DNA polymerase, especially, where the polymerase is immobilized on a solid support.
  • the polymerase is supported on a solid support that is a member selected from the group consisting of controlled pore glass, a glass plate, polystyrene, an avidin coated polystyrene bead, cellulose, nylon, acrylamide gel and activated dextran.
  • the present invention relates to a nucleotide triphosphate (NTP) probe comprising a NTP including an atomic and/or molecular tag having a detectable property attached thereto or associated therewith a ⁇ and/or ⁇ phosphate group and/or a base moiety of the NTP.
  • NTP nucleotide triphosphate
  • the NTP is a member selected from the group consisting of a deoxynucleotide triphosphate (dNTP), a nucleotide triphosphate (NTP) and analogs thereof, particularly, where there NTP is a deoxynucleotide triphosphate (dNTP), especially, where the deoxynucleotide triphosphate (dNTP) is a member selected from the group consisting of deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanosine triphosphate and deoxythymidine triphosphate.
  • dNTP deoxynucleotide triphosphate
  • NTP nucleotide triphosphate
  • the nucleotide triphosphate is a member selected from the group consisting of adenosine triphosphate, cytosine triphosphate, guanosine triphosphate and uridine triphosphate.
  • the tag is fluorophore, particularly, the fluorophore is a member selected from the group consisting of fluorescein, 5carboxyfluorescein (FAM), rhodamine, 5-(2′-aminoethyl) aminonapthalene-1-sulfonic acid (EDANS), anthranilamide, coumarin, terbium chelate derivatives, Reactive Red 4, BODIPY dyes and cyanine dyes.
  • the tag is attached to said ⁇ and/or ⁇ -phosphate via a linker.
  • the fluorophore linker is an alkylene group having between about 5 to about 12 carbons, particularly, where the fluorophore moiety is a fluorescein or rhodamine dye.
  • the present invention relates to a kit for assaying pyrophosphate cleavage, said kit comprising: (a) a plurality of NTPs at least one NTP including an atomic and/or molecular tag or moiety having distinguishable/detectable property attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the NTP and (b) a polymerase.
  • the tag is a fluorophore and the property is fluorescence.
  • the NTP further includes a quencher attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the NTP, where each fluorophore interacts with said quencher moiety via a mechanism which is a member selected from the group consisting of fluorescence resonance energy transfer (FRET), electron transfer and ground-state complex mechanism.
  • FRET fluorescence resonance energy transfer
  • the present invention relates to a method for performing a primer extension reaction comprising the steps of (a) annealing an oligonucleotide primer to a portion of a template nucleic acid thereby forming a primer-template hybrid; (b) adding primer-extension reagents including a tagged dNTP to afford increased or altered fidelity during incorporation to the primer-template hybrid for extending the primer, where the tagged dNTP includes an atomic and/or molecular tag or moiety having distinguishable/detectable property attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the dNTP.
  • the method can also include the step of adding cosubstrate-enzyme pair to the primer-template hybrid for conducting a pyrophosphate-utilizing reaction in an amount sufficient to reduce peak dropout.
  • the cosubstrate-enzyme pair comprises pyrophosphate dependent phosphofructose kinase and fructose-6-phosphate.
  • the cosubstrate-enzyme pair comprises UDP Glucose Pyrophosphorylase and UDP Glucose.
  • the present invention relates to a kit for performing a primer extension reaction comprising: primer extension reagents and at least one dNTP including an atomic and/or molecular tag or moiety attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the dNTP to increase or alter extension fidelity.
  • the kit can further comprise a compound present in an amount sufficient to reduce peak dropout.
  • the present invention relates to a primer extension solution for the extension of a primer member of a primer template hybrid
  • primer extension reagents at least one dNTP including an atomic and/or molecular tag or moiety attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the dNTP to increase or alter extension fidelity.
  • the solution can further comprise a compound present in an amount sufficient to reduce peak dropout.
  • the cosubstrate-enzyme pair comprises pyrophosphate dependent phosphofructose kinase and fructose-6-phosphate.
  • the cosubstrate-enzyme pair comprises UDP Glucose Pyrophosphorylase and UDP Glucose.
  • the present invention relates to a method of inhibiting or preventing pyrophosphorolysis during synthesis of a nucleic acid molecule, said method comprising (a) combining one or more tagged nucleotides and a nucleic acid template, where the tagged nucleotide comprises an atomic and/or molecular tag or moiety attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the nucleotide; and (b) incubating the one or more nucleotides and nucleic acid template together with a polymerase and an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with alcohol group as acceptor, a nucleotidyltransferase, and a carboxy-lyase, under conditions sufficient to form a second nucleic acid molecule complementary to all or a portion of the nucleic acid template.
  • the present invention relates to a method of inhibiting or preventing pyrophosphorolysis during synthesis of a nucleic acid molecule, said method comprising (a) combining a primer with a nucleic acid template under conditions sufficient to form a hybridized product; and (b) incubating said hybridized product in the presence of (i) one or more tagged nucleotides comprises an atomic and/or molecular tag or moiety attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the nucleotide (ii) a polymerase, and (iii) an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as acceptor, a nucleotidyltransferase, and a carboxy-lyase under conditions sufficient to synthesize a second nucleic acid molecule complementary to all or a portion of said nucleic acid template.
  • the present invention relates to a method to prevent inhibition of nucleic acid synthesis during amplification of a double stranded nucleic acid molecule, comprising (a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3′ termini of the first strand of said nucleic acid molecule and said second primer is complementary to a sequence at or near the 3′ termini of the second strand of said nucleic acid molecule; (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of (i) a polymerase, and (ii) one or more tagged nucleotides comprises an atomic and/or molecular tag or moiety attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the nucleotide under conditions such that a third nucleic acid molecule complementary to said first strand and a fourth nucleic acid molecule complementary to said second strand are synthesized; (
  • hybridizing is in the presence of an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as an acceptor, a nucleotidyltransferase and a carboxy-lyase.
  • an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as an acceptor, a nucleotidyltransferase and a carboxy-lyase.
  • the present invention relates to a method of identifying a base at a target position in a sample DNA sequence wherein an extension primer, which hybridises to the sample DNA either immediately adjacent to or very near (within about 10 bases) to the target position is provided and the sample DNA and extension primer are subjected to a polymerase reaction in the presence of a tagged deoxynucleotide or dideoxynucleotide, where the tagged deoxynucleotide or dideoxynucleotide an atomic and/or molecular tag or moiety having a detectable property attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the deoxynucleotide or dideoxynucleotide, whereby the tagged deoxynucleotide or dideoxynucleotide will only become incorporated and release pyrophosphate (PPi) if it is complementary to the base in the target position, any release of PPi being detected
  • the nucleotide-degrading enzyme is apyrase.
  • the mixture of nucleotide-degrading enzymes is used having nucleoside triphosphatase, nucleoside diphosphatase and nucleoside monophosphatase activity.
  • the nucleotide-degrading enzyme is immobilised on a solid support.
  • the immobilised nucleotide-degrading enzyme is added after nucleotide incorporation by the polymerase has taken place, and then removed prior to a subsequent nucleotide incorporation reaction step.
  • the PPi release is directly detected via the detectable property of the tag.
  • the polymerase reaction and PPi release detection steps are performed substantially simultaneously.
  • the sample DNA is immobilised or provided with means for attachment to a solid support.
  • the sample DNA is first amplified.
  • the extension primer contains a loop and anneals back on itself and the 3′ end of the sample DNA.
  • a native polymerase, an exonuclease deficient (exo-) high fidelity polymerase or a genetically modified polymerase is used.
  • the method can be used for identification of a base in a single target position in a DNA sequence wherein the sample DNA is subjected to amplification; the amplified DNA is immobilized and then subjected to strand separation, the non-immobilized strand being removed and an extension primer, which hybridizes to the immobilized DNA immediately adjacent to the target position, is provided; each of four aliquots of the immobilized single stranded DNA is then subjected to a polymerase reaction in the presence of a tagged deoxynucleotide, each aliquot using a different deoxynucleotide whereby only the tagged deoxynucleotide complementary to the base in the target position becomes incorporated.
  • the method can further comprising adding the identified dNTP to the three non-extended chambers and repeating the cyclic identification process.
  • the present invention relates to a kit for use in a method as defined in any one of claims 49 to 6 . 10 , comprising: (a) a test specific primer which hybridizes to sample DNA so that the target position is directly adjacent to the 3′ end of the primer; (b) a polymerase; and (c) at least one tagged dNTP an atomic and/or molecular tag or moiety having a detectable property attached to and/or associated with a ⁇ and/or ⁇ -phosphate and/or a base moiety of the dNTP.
  • the kit can be used for use with initial PCR amplification, further comprising: (i) a pair of primers for PCR, at least one primer having means permitting immobilization of said primer; (ii) a polymerase for PCR; (iii) a mixture of dNTPs including at least one tagged dNTP.
  • the methods or kits can also be used with a multiplicity of sample DNA sequences, wherein said DNA sequences are arranged in array format on a solid surface.
  • the present invention relates to a composition
  • a composition comprising a deoxyribonucleoside or ribonucleoside including a molecular and/or atomic tag attached to or associated with a ⁇ and/or ⁇ phosphate group, a base moiety, and/or a sugar moiety, where the tag alters fidelity of base incorporation.
  • the present invention relates to a method comprising the step of adding a composition comprising a deoxyribonucleoside or ribonucleoside including a molecular and/or atomic tag attached to or associated with a ⁇ phosphate group, a base moiety, and/or a sugar moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • the present invention relates to a composition
  • a composition comprising a nucleotide or nucleotide analogs including a molecular and/or atomic tag on a ⁇ phosphate group and/or a base moiety adapted to increase the fidelity of viral replication.
  • the virus is HIV.
  • the present invention relates to a method for increasing the fidelity of viral replication comprising administering an therapeutically effective amount of a nucleotide including a molecular and/or atomic tag on a ⁇ phosphate group and/or a base moiety to an animal including a human, where the nucleotide is designed to increase base incorporation fidelity during viral replication.
  • the virus is HIV.
  • the present invention relates to a composition
  • a composition comprising a viral replication fidelity enhancing agent selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof: Z-OPO 2 O-Z′ (a) Z-PO 2 O-Z′ (b) Z-OPO 2 -Z′ (c) Z-PO 2 -Z′ (d) Z-OPO 2 —(OP(EE′)O) n —PO 2 O-Z′ (e) Z-OPO 2 —(OP(EE′)O) n PO 2 -Z′ (f) Z-PO 2 -(OP(EE′)O) n PO 2 O-Z′ (g) Z-PO 2 —(OP(EE′)O) n PO 2 -Z′ (h)
  • Z or Z′ is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements
  • the present invention relates to a method for increasing the fidelity of viral replication comprising administering to an animal including a human a therapeutically effective amount of a viral replication fidelity enhancing agent selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof: Z-OPO 2 O-Z′ (a) Z-PO 2 O-Z′ (b) Z-OPO 2 -Z′ (c) Z-PO 2 -Z′ (d) Z-OPO 2 —(OP(EE′)O) n —PO 2 O-Z′ (e) Z-OPO 2 —(OP(EE′)O) n PO 2 -Z′ (f) Z-PO 2 —(OP(EE′)O) n PO 2 O-Z′ (g) Z-PO 2 —(OP(EE′)O) n PO 2 -Z′ (h) where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen,
  • the present invention also relates to biological memory storage and retrieval systems where the fidelity of the storage and retrieve process is improved by using fidelity enhances described herein.
  • the method would include the step of synthesizing a sequence of monomers corresponding to a given data sequence using the fidelity enhancing agent of this invention. Once the information is stored, the information can be retrieved by sequencing the sequence to retrieve the data sequence.
  • the present invention also relates to agents and methods for ameliorating symptoms of animals including humans infected with a retrovirus, including the step of administering to the animal a therapeutically effective amount of a composition including a dNTP having an atomic and/or molecular tag, preferably, an atomic or molecular tag on ⁇ and/or ⁇ -tagged phosphate of the dNTP, to increase the fidelity of the viruses reverse transcriptase, decrease mutation, increase the immune response to the virus, increase the effectiveness of medications to the virus and ameliorate symptoms associated with the viral infection.
  • a composition including a dNTP having an atomic and/or molecular tag, preferably, an atomic or molecular tag on ⁇ and/or ⁇ -tagged phosphate of the dNTP, to increase the fidelity of the viruses reverse transcriptase, decrease mutation, increase the immune response to the virus, increase the effectiveness of medications to the virus and ameliorate symptoms associated with the viral infection.
  • the present invention also relates to agents and methods for ameliorating symptoms of animals including humans suffering from cancer, including the step of administering to the animal a therapeutically effective amount of a composition including a dNTP having an atomic and/or molecular tag, preferably, an atomic or molecular tag on ⁇ and/or ⁇ -tagged phosphate of the dNTP, to increase the fidelity of the patient's natural polymerases, decrease mutations, increase the immune response to the cancer, increase the effectiveness of medications to the cancer and ameliorate symptoms associated with the cancer.
  • the present invention also relates to agents and methods for ameliorating symptoms of aging in animals including humans, including the step of administering to the animal a therapeutically effective amount of a composition including a dNTP having an atomic and/or molecular tag, preferably, an atomic or molecular tag on ⁇ and/or ⁇ -tagged phosphate of the dNTP, to increase the fidelity of the patient's natural polymerases, decrease mutations, increase cellular vitality, and ameliorate symptoms of aging.
  • the present invention also relates to agents and methods for reducing the evolutionary tendencies of retro virus such as HIV.
  • HIV-1 the causative agent of AIDS
  • HIV-1 has evolved many ways to defeat its human host defenses.
  • One of these ways involves evading the immune system by inaccurately replicating its genome (one mistake per 2,000-5,000 bases).
  • the polymerase responsible for the inaccurate replication is HIV-1 reverse transcriptase (RT).
  • RT converts the single stranded RNA genome into a complementary DNA strand, destroys the RNA template, and uses the nascent DNA strand to template synthesis of the double-stranded DNA version of the HIV-1 genome. Since the HIV genome is approximately 10,000 bases, this error-prone process produces a variant genome essential every time the virus replicates.
  • the mis-incorporated bases can specify altered HIV protein sequences.
  • the immune system in a patient infected with HIV is fighting a losing battle, since viral proteins (antigens) are constantly changing.
  • the activities of these protein variants may be modified and, if the patient is following a drug-treatment therapy, drug-resistant variants may emerge due to selective pressures.
  • virus evolution mediated through inaccurate genome replication is a significant problem, both with HIV-1 and with any virus whose replication is mediated by an error-prone polymerase.
  • the fidelity of HIV-1 RT is improved in vitro by providing the enzyme with nucleotides containing a molecular tag on the ⁇ -phosphate.
  • This unexpected discovery may lead to a novel therapeutic that will neutralize the genetic mutability of this deadly virus. Understanding the mechanism by which RT selects nucleotides for incorporation will produce insights into enzymatic DNA synthesis and evolution of viral diversity.
  • a novel therapeutic that increases enzyme fidelity may minimize antigen evolution, enabling the immune system to eliminate virus and virus infected cells, and minimize the emergence of drug resistance. Understanding why improved accuracy is observed in the context of the modified nucleotide may enable design a small molecule that has this same effect, but that would be more easily delivered into cells.
  • nucleotides can be prepared that improve fidelity of incorporations where the nucleotides include a covalently attached substituent on ⁇ and/or ⁇ phosphate of a NTP, dNTP or ddNTP where the substituent includes a aminonaphthalene-1-sulfonate (ANS) group.
  • the tagged nucleotide and preferably the tagged ⁇ -phosphate of the nucleotide improves the fidelity at which this nucleotide analog is incorporated by commercially available Taq DNA polymerase.
  • pyrophosphatase to a polymerase chain reaction greatly enhances the progress of that reaction, and provides superior results compared to use of the method without a pyrophosphatase (Tabor and Richardson, 1996).
  • addition of a pyrophosphatase to a DNA sequencing reaction provides more uniformity in intensities of bands formed in a polyacrylamide gel used to identify products of the sequencing reaction pyrophosphatase (Tabor and Richardson, 1996). This uniformity is thought to be due to prevention of degradation of specific DNA products via pyrophosphorolysis. Any modification to the nucleotide that is capable of inhibiting the pyrophosphorolysis reaction is useful in this invention.
  • One way to inhibit pyrophosphorolysis is to break down any pyrophosphate that is generated during a polymerase reaction, by adding the enzyme pyrophosphatase. Even trace addition of a pyrophosphatase (one thousandth the molar ratio of DNA polymerase molecules in a solution) to a primer extension reaction completely stabilizes oligonucleotide fragments produced in a polymerase reaction, by preventing pyrophosphorolysis.
  • the agent should be added at a concentration sufficient to either catalyze the hydrolysis of pyrophosphate in the reaction mixture at a rate that will prevent accumulation of pyrophosphate to a level that will lead to pyrophosphorolysis, or prevent accumulation of pyrophosphate in any other manner.
  • pyrophosphorolysis can also be reduced or eliminated by using nucleotides containing molecular and/or atomic substituents on the ⁇ and/or ⁇ phosphate moieties.
  • the present invention provides a heterogeneous assay for the detection of released tagged pyrophosphate.
  • the detection of tagged pyrophosphate is advantageous in a number of biological reactions. For example, in a DNA polymerase reaction, single molecule or bulk, wherein the polymerase selects a single DNA molecule from solution and thereafter incorporates the nucleotide at the 3′-end of a primer strand, the natural consequence of such incorporation is the release of pyrophosphate.
  • each dNTP labeled with a different molecular and/or atomic tag such as a fluorescent dye having a different color attached to the ⁇ - and/or ⁇ -phosphate it is then possible to sequentially record the activity of the polymerase operating on a target DNA.
  • the nucleotide sequence of the target DNA can thereafter be directly read from the order of released dyes attached to the pyrophosphate.
  • the assay solution comprises the four deoxynucleotide triphosphates, each dNTP labeled with a different molecular and/or atomic tag such as a fluorescent dye having a different color attached to the ⁇ - and/or ⁇ -phosphate and activating tags bonded to or associated with the polymerase or other species in the medium, it is then possible also to sequentially record the activity of the polymerase operating on a target DNA.
  • the nucleotide sequence of the target DNA can thereafter be read directly from the order of released dyes attached to the pyrophosphate.
  • the present invention provides a heterogeneous assay method for detecting pyrophosphate release, the components of the assay comprising a labeled NTP, a target nucleic acid, a primer nucleic acid and a polymerase, the method comprising: (a) flowing the labeled nucleotide triphosphate (NTP) having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the NTP, past an immobilized component selected from the group consisting of the polymerase, the primer and the target nucleic acid; (b) incorporating the tagged dNTP on a primer strand hybridized to the target nucleic acid using an enzyme and releasing the ⁇ -phosphate with the fluorophore moiety attached thereto; and (c) detecting the fluorescent moiety thereby detecting NTP binding, incorporation and/or pyrophosphate cleavage.
  • NTP labeled nucleotide triphosphate
  • either the polymerase, the primer or the target nucleic acid is attached to a solid phase, such as a solid support.
  • a solid phase such as a solid support.
  • the polymerase is immobilized on a solid support.
  • the polymerase is a DNA polymerase such as DNA polymerase I, II or III.
  • suitable polymerases include, but are not limited to, a DNA dependent RNA polymerase and reverse transcriptase such as an HIV reverse transcriptase. Specific examples include, but are not limited to, T7 DNA polymerase, T5 DNA polymerase, E. coli DNA polymerase I, T4 DNA polymerase, T7 RNA polymerase and Taq DNA polymerase.
  • the polymerase is bathed in a flowing solution comprising: unlabeled, single-stranded DNA fragments hybridized to an oligonucleotide primer and a mixture of NTPs.
  • a labeled nucleotide triphosphate having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate moiety of the NTP is incorporated into a polynucleotide chain.
  • NTP nucleotide triphosphate
  • the dNTP incorporation into a growing oligonucleotide by a DNA polymerase results in pyrophosphate release.
  • the phosphate ester bond between the ⁇ and ⁇ phosphates of the incorporated nucleotide is cleaved by the DNA polymerase, and the ⁇ - and/or ⁇ -phosphate moieties of the resulting pyrophosphate are released in solution.
  • pyrophosphate also includes substitution of any of the oxygen atoms of the pyrophosphate group with an atom that enables attachment of the molecular moiety that will be detected and provide information about the identity of the incorporated nucleotide, a nitrogen or a sulfur atom or combinations thereof to generate azapyrophosphate, diazapyrophosphte, thiopyrophosphate, dithiopyrophosphate, etc.
  • the fluorophore can be detected either upon nucleotide binding, during incorporation or after the nucleotide and the pyrophosphate are released.
  • release of the pyrophosphate caused by cleavage of the ⁇ - ⁇ bond can switch the fluorophore moiety into a fluorescent state either by fluorophore dequenching or fluorophore activation. This event can then be detected using an ultrasensitive fluorescence detector. Using single molecule detection for example, fluorescent signals appear at the locations of the individual molecules being observed.
  • each type of nucleotide is labeled with a different fluorophore so that the incorporated nucleobases can be sequentially identified by the fluorophores during binding, incorporation or release.
  • the deoxy nucleotide triphosphates (dNTPs) of the present methods include, but are not limited to, deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanosine triphosphate, deoxythymidine triphosphate, deoxyuridine triphosphate or mixtures thereof, each with a unique molecular and/or atomic tag attached to the ⁇ - and/or ⁇ -phosphate moiety of the NTP.
  • the nucleotides of the present invention are modified at various sites with a molecular and/or atomic tag such as a fluorophore or chromophore.
  • a molecular and/or atomic tag such as a fluorophore or chromophore.
  • the fluorophore or chromopore are designed to interact with other tags situated on specific sites of the polymerase or associated with other agents in the medium.
  • the tags can be detected when the labeled dNTP binds to the polymerase, during incorporation or upon release by measuring a detectable property of the tag alone or as a result of an interaction with another tag associated with other agent in the medium including the polymerase itself.
  • the detectable property can of course be fluorescence or induced fluorescence.
  • the tagged dNTPs and formed tagged pyrophosphates can be used in single molecule detection formats.
  • an unlabeled, single-stranded target nucleic acid with a primer hybridized thereto is tethered to the surface of a solid support such as a glass slide.
  • An aqueous solution comprising an enzyme, such as a DNA polymerase, and tagged dNTPs flows across the surface.
  • an individual polymerase molecule is immobilized on a glass slide and the polymerase is bathed in a flowing solution comprising: 1) unlabeled, single-stranded DNA fragments hybridized to an oligonucleotide primer and 2) a mixture of tagged deoxynucleotide triphosphates.
  • a library of oligonucleotides can be immobilized on a solid support such as glass and the glass is bathed in a solution comprising: 1) a polymerizing agent such as a polymerase, 2) unlabeled, single-stranded DNA fragments hybridized to an oligonucleotide primer and 3) a mixture of tagged deoxynucleotide triphosphates.
  • a polymerizing agent such as a polymerase
  • unlabeled, single-stranded DNA fragments hybridized to an oligonucleotide primer
  • 3) a mixture of tagged deoxynucleotide triphosphates a mixture of tagged deoxynucleotide triphosphates.
  • an individual polymerase molecule is immobilized on a glass slide and the polymerase is bathed in a solution comprising: 1) nicked double strained DNA, where the nicking is either affected via chemical means such as Fe-EDTA or via enzymatic means such as DNase, and 2) a mixture of tagged deoxynucleotide triphosphates.
  • an evanescent light field is set up by total internal refection (TIR) of a laser beam at the glass-aqueous solution interface.
  • TIR illumination field is continuously imaged at video-rate with a CCD camera or an intensified charge couple device (ICCD) camera.
  • the present invention relates to a heterogenous assay wherein a material in the solid-phase interacts with reagents in the liquid phase.
  • the nucleic acid is attached to the solid phase.
  • the nucleic acid can be in the solid phase such as immobilized on a solid support, through any one of a variety of well-known covalent linkages or non-covalent interactions.
  • the support is comprised of insoluble materials, such as controlled pore glass, a glass plate or slide, polystyrene, acrylamide gel and activated dextran.
  • the support has a rigid or semi-rigid character, and can be any shape, e.g., spherical, as in beads, rectangular, irregular particles, gels, microspheres, or substantially flat, so long as the support permits single molecule detection.
  • it can be desirable to create an array of physically separate sequencing regions on the support with, for example, wells, microtubes or nanotubes derivatived to capture part of the DNA sequencing complex/enzyme, primer or template such as histidine 5′ derivation, or other random modification so that the complex can stick to the tubes, raised regions, dimples, trenches, rods, pins, inner or outer walls of cylinders, and the like.
  • suitable support materials include, but are not limited to, agarose, polyacrylamide, polystyrene, polyacrylate, hydroxethylmethacrylate, polyamide, polyethylene, polyethyleneoxy, or copolymers and grafts of such.
  • Other embodiments of solid-supports include small particles, non-porous surfaces, addressable arrays, vectors, plasmids, or polynucleotide-immobilizing media.
  • nucleic acid can be attached to the solid support by covalent bonds, or other affinity interactions, to chemically reactive functionality on the solid-supports.
  • the nucleic acid can be attached to solid-supports at their 3′, 5′, sugar, or nucleobase sites.
  • the 3′ site for attachment via a linker to the support is preferred due to the many options available for stable or selectively cleavable linkers.
  • Immobilization is preferably accomplished by a covalent linkage between the support and the nucleic acid.
  • the linkage unit, or linker is designed to be stable and facilitate accessibility of the immobilized nucleic acid to its sequence complement.
  • non-covalent linkages such as between biotin and avidin or stepavidin are useful.
  • other functional group linkers include ester, amide, carbamate, urea, sulfonate, ether, and thioester.
  • a 5′ or 3′ biotinylated nucleotide can be immobilized on avidin or strepavidin bound to a support such as glass.
  • the polymerase is immobilized on a solid support.
  • Suitable solid supports include, but are not limited to, controlled pore glass, a glass plate or slide, polystyrene, and activated dextran.
  • synthetic organic polymers such as polyacrylamide, polymethacrylate, and polystyrene are also illustrative support surfaces.
  • polysaccharides such as cellulose and dextran, are further illustrative examples of support surfaces. Other support surfaces such as fibers are also operable.
  • polymerase immobilization is accomplished using solid chromatography resins, that have been modified or activated to include functional groups that permit the covalent coupling of resin to enzyme.
  • aliphatic linker arms are employed.
  • the enzymes of the present invention can also be noncovalently attached to a solid support surface through, for example, ionic or hydrophobic mechanisms.
  • Covalent attachment of a protein or nucleic acid to a glass or metal oxide surface can be accomplished by first activating the surface with an amino silane. DNA or protein derivatized with amine-reactive functional groups can then attach to the surface (see, K. Narasimhan et al., Enzyme Microb. Technol. 7, 283 (1985); M. J. Heller et al., U.S. Pat. No. 5,605,662; and A. N. Asanov et al., Anal. Chem. 70, 1156 (1998)).
  • the enzyme such as a DNA polymerase, selects a single DNA molecule from solution.
  • the polymerase incorporates a first nucleotide at the 3′-end of the primer strand and releases the respective PP i .
  • the polymerase then translocates to the next position on the target DNA, incorporates a complementary tagged nucleotide, and releases the respective pyrophophate.
  • the tagged nucleotide can be detected upon binding to tagged polymerase, upon incorporation by tagged polymerase, and/or upon release of the tagged pyrophosphate either directly or as a result of interaction with another tag on an agent in the medium.
  • a detection system capable of detecting a detectable property of the tag such as by video-rate imaging using for example, a CCD or ICCD camera, capable of detecting fluorescence from a single tag where the tag is fluorophore or a chromophore.
  • the resulting movie shows the activity of a single polymerase molecule operating on a single molecule of DNA.
  • the nucleotide sequence of the DNA target is read directly from the order of base incorporation by detecting the tag during base binding, base incorporation and/or pyrophosphate release.
  • Each of those events or steps during incorporation provides information about the process and a unique pattern is associated with each nucleotide.
  • the match of each base incorporation pattern is used to increase confidence of each base call. Time, intensity and wavelength or frequency are each monitored to provide maximal confirmatory information.
  • the polymerase releases it and selects another template from solution. Many DNA molecules are thereby sequenced by a single polymerase. The process continues for the life of the enzyme or more specifically, the life of the interacting tag within the enzyme.
  • the lengths of the DNA templates should preferably be significantly uniform ( ⁇ 10%), substantially uniform ( ⁇ 5%) or essentially uniform ( ⁇ 1%) in length to further maximize signal detection from the replication complexes.
  • the target nucleic acid can be prepared by various conventional methods.
  • target nucleic acid can be prepared as inserts of any of the conventional cloning vectors, including those used in conventional DNA sequencing. Extensive guidance for selecting and using appropriate cloning vectors is found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Laboratory, New York, 1989), and like references. Sambrook et al. and Innis et al, editors, PCR Protocols (Academic Press, New York, 1990) also provide guidance for using polymerase chain reactions to prepare target polynucleotides. Cloned or PCR amplified target nucleic acid is prepared which permit attachment to solid supports.
  • the target nucleic acid sequences are from sheared DNA fragments from a subject organism, preferably human, and are treated to provide blunt ends, then ligated to two oligodeoxynucleotides.
  • one oligonucleotide can be derivatized with biotin at its 5′ or 3′ end but the 5′ end is preferred since that will cause fewer steric problems.
  • the first primer may be 5′ biotinylated and the second is complementary to the biotinylated primer and contains a 5′ phosphate. The ligated DNA is denatured, it is brought into contact with a streptavidin-activated slide, and it attaches through the 5′ biotin to the slide.
  • a primer is hybridized to the tethered fragments prior to sequencing.
  • This sequencing primer is the same sequence as the biotinylated primer. Only DNA fragments having each type of ODN can both attach and be sequenced; fragments having two phosphorylated primers will not attach.
  • DNA attachment could also be accomplished by direct covalent coupling as practiced on DNA chips (see, U.S. Pat. No. 5,605,662). Unlike DNA chips that require a dense lawn of probes, preferably, a few DNA molecules are bound per unit surface area. Binding density is easily controlled by adding a carrier to the DNA sample (e.g., free biotin to a biotinylated DNA sample).
  • a carrier e.g., free biotin to a biotinylated DNA sample.
  • the tagged NTP can be detected by a variety of analytical techniques. If the tags are atomic or molecular tags with characteristic NMR, MS and/or other physical or chemical tag response signals, then the reaction can be monitored in real time using pulsed NMR techniques, MS techniques or techniques associated with other physical and/or chemical tag responses. The tags can even be shift reagents. If the tags are molecules that interact with other molecules in the presence of light to produce a fluorescent signature, then the reaction can be monitored using fluorescent spectroscopy on a continuous or discrete format. It should be recognized that tags can be prepared that have any desired detectable property.
  • the enzymatic reaction is monitored using single molecule detection.
  • the single-molecule fluorescence detection of the present invention can be practiced using optical setups including near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, and total internal reflection fluorescence (TIRF) microscopy.
  • Suitable photon detectors include, but are not limited to, photodiodes and intensified CCD cameras.
  • an intensified charge couple device (ICCD) camera is used.
  • ICCD intensified charge couple device
  • each of the NTPs of the present invention has a unique fluorophore associated with it, as such, a four-color instrument can be used having four cameras and four excitation lasers or beam-splitters may be used to monitor fluorescent intensity changes at a number of desire frequencies.
  • a four-color instrument can be used having four cameras and four excitation lasers or beam-splitters may be used to monitor fluorescent intensity changes at a number of desire frequencies.
  • this optical setup to sequence DNA.
  • many different DNA molecules spread on a microscope slide can be imaged and sequenced simultaneously.
  • image analysis algorithms it is possible to track the path of single dyes and distinguish them from fixed background fluorescence and from “accidentally dequenched” dyes moving into the field of view from an origin upstream.
  • the sequencing works by directly detecting the release tagged pyrophosphate, where a single dNTP is feed each time and the polymerase is washed between before the next incorporation.
  • the preferred geometry for ICCD detection of single molecules is total internal reflectance fluorescence (TIRF) microscopy.
  • TIRF total internal reflectance fluorescence
  • a laser beam totally reflects at a glass-water interface.
  • the field does not end abruptly at the reflective interface, but its intensity falls off exponentially with distance.
  • the thin “evanescent” optical field at the interface provides low background and enables the detection of single molecules with signal-to-noise ratios of 12:1 at visible wavelengths (see, M. Tokunaga et al., Biochem. and Biophys. Res. Comm. 235, 47 (1997) and P. Ambrose, Cytometry, 36, 244 (1999)).
  • the penetration of the field beyond the glass depends on the wavelength and the laser beam angle of incidence. Deeper penetrance is obtained for longer wavelengths and for smaller angles to the surface normal within the limit of a critical angle.
  • fluorophores are detected within about 200 nm from the surface which corresponds to the contour length of about 600 base pairs of DNA.
  • a prism-type TIRF geometry for single-molecule imaging as described by Xu and Yeung is used (see, X-H. N. Xu et al., Science, 281, 1650 (1998)).
  • an aqueous solution comprising an enzyme, such as a DNA polymerase, and distinguishable fluorogenic dNTPs, i.e., a characteristic dye for each nucleobase, flows across the surface.
  • An evanescent light field is set up by total internal refection (TIR) of a laser beam at the glass-aqueous solution interface.
  • TIR illumination field is continuously imaged at video-rate with an intensified charge couple device (ICCD) camera. It is thus possible to image the pyrophosphate as it is hydrolyzed by the enzyme.
  • ICCD intensified charge couple device
  • the tagged dNTP Upon incorporation by polymerase, the tagged dNTP is hydrolyzed as usual and the liberated tagged pyrophosphate diffuses into the surrounding medium.
  • the tagged dNTP can be detected upon binding, incorporation or release or the free tagged pyrophosphate can be detected by detecting the detectable property of the tag such as fluorescent and its appearance is imaged at video-rate under a microscope.
  • a flowing stream sweeps the dye away from the parent DNA molecule.
  • the nucleotide sequence is read from the order of released dyes. Sequencing proceeds quickly, as fast as the polymerase progresses along the DNA template.
  • the present invention includes sensors as disclosed in U.S. Pat. No. 5,814,524 which issued to Walt et al., on Sep. 29, 1998, incorporated herein by reference.
  • An optical detection and identification system is disclosed therein that includes an optic sensor, an optic sensing apparatus and methodology for detecting and evaluating one or more analytes or ligands of interest, either alone or in mixtures.
  • the system is comprised of a supporting member and an array formed of heterogeneous, semi-selective polymer films which function as sensing receptor units and are able to detect a variety of different analytes and ligands using spectral recognition patterns. Using this system, it is possible to combine viewing and chemical sensing with imaging fiber chemical sensors.
  • the present invention also provides integrated systems for high-throughput screening of DNA sequencing and pyrophosphate detection.
  • the systems typically include robotic armature which transfers fluid from a source to a destination, a controller which controls the robotic armature, an ICCD camera, a data storage unit which records the detection, and an assay component such as a microtiter dish or a substrate comprising a fixed reactant.
  • robotic armature which transfers fluid from a source to a destination
  • a controller which controls the robotic armature
  • an ICCD camera a data storage unit which records the detection
  • an assay component such as a microtiter dish or a substrate comprising a fixed reactant.
  • a number of robotic fluid transfer systems are available, or can easily be made from existing components.
  • a Zymate XP Zymark Corporation; Hopkinton, Mass.
  • a Microlab 2200 Hamilton; Reno, Nev.
  • pipetting station can be used to transfer parallel samples to 96, 384 or more welled microtiter plates to set up several parallel simultaneous polymerase reactions.
  • Optical images viewed (and, optionally, recorded) by a camera or other recording device are optionally further processed in any of the embodiments herein, e.g., by digitizing the image and storing and analyzing the image on a computer.
  • a camera or other recording device e.g., a photodiode and data storage device
  • a variety of commercially available peripheral equipment and software is available for digitizing, storing and analyzing a digitized video or digitized optical image.
  • the integrated system of the present invention carries light from the specimen field to the charge-coupled device (CCD) camera, which includes an array of picture elements (pixels). The light from the specimen is imaged on the CCD camera.
  • CCD charge-coupled device
  • Particular pixels corresponding to regions of the specimen are sampled to obtain light intensity readings for each position. Multiple pixels are processed in parallel to increase speed.
  • the apparatus and methods of the invention are easily used for viewing any sample, e.g., by fluorescent or dark field microscopic techniques.
  • Suitable donors and acceptors operating on the principle of fluorescence energy transfer include, but are not limited to, 4-acetamido-4′isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 5-(2′-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS); 4-amino-3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; -(4-anilino-lnaphthyl)maleimide; anthranilamide; BODIPY; Brilliant Yellow; coumarin and derivatives: coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4trifluoromethylcouluarin (Coumaran 151); cyanine dyes; cyanosine; 4′,6-
  • certain visible and near IR dyes are known to be sufficiently fluorescent and photostable to be detected as single molecules.
  • the visible dye, BODIPY R6G (525/545), and a larger dye, LI-COR's near-infrared dye, IRD-38 (780/810) can be detected with single-molecule sensitivity and can be used to practice the present invention.
  • linking moieties and methodologies for attaching fluorophore or quencher moieties to nucleotides there are many linking moieties and methodologies for attaching fluorophore or quencher moieties to nucleotides, as exemplified by the following references: Eckstein, editor, Oligonucleotides and Analogues: A Practical Approach (IRL Press, Oxford, 1991); Zuckerman et al., Nucleic Acids Research, 15: 5305-5321 (1987) (3′thiol group on oligonucleotide); Sharma et al., Nucleic Acids Research, 19: 3019 (1991) (3′sulfhydryl); Giusti et al., PCR Methods and Applications, 2: 223-227 (1993) and Fung et al., U.S. Pat. No.
  • the primer extension reaction of the present invention comprises the following steps: (i) providing a template nucleic acid; (ii) annealing an oligonucleotide primer to a portion of the template nucleic acid thereby forming a primer-template hybrid; (iii) adding primer-extension reagents to the primer-template hybrid for extending the primer; and (iv) optionally adding a cosubstrate-enzyme pair to the primer-template hybrid for conducting a pyrophosphate-utilizing reaction.
  • template nucleic acid Any source of nucleic acid can be used as a template nucleic acid provided it can be presented in a single stranded form and is capable of annealing with a primer oligonucleotide.
  • exemplary template nucleic acids include DNA, RNA, which DNA or RNA may be single stranded or double stranded. More particularly, template nucleic acid may be genomic DNA, messenger RNA, cDNA, DNA amplification products from a PCR reaction, and the like. Methods for preparation of template DNA may be found elsewhere (ABI PRISM Dye Primer Cycle Sequencing Core Kit).
  • primer extension reaction in the context of PCR, template nucleic acid is mixed with a pair of PCR primers and primer-extension reagents comprising a buffer, MgCl 2 , deoxynucleotide triphosphates or preferably for increase accuracy of the amplification products, ⁇ and/or ⁇ tagged dNPTs, and a DNA polymerase.
  • a typical PCR reaction includes 20 pmol of each primer, 20 mM buffer at pH 8, 1.5 mM MgCl 2 , 10 to 500 ⁇ M, preferably 200 ⁇ m, of each deoxynucleotide triphosphate (dNTP), and 2 units of Taq polymerase or other suitable thermostable polymerase.
  • dNTP deoxynucleotide triphosphate
  • thermocycled a typical thermocycle profile comprising a denaturation step (e.g. 96° C., 15 s), a primer annealing step (e.g., 55° C., 30 s), and a primer extension step (e.g., 72° C., 90 s).
  • a denaturation step e.g. 96° C., 15 s
  • a primer annealing step e.g., 55° C., 30 s
  • primer extension step e.g., 72° C., 90 s.
  • the thermocycle is repeated from about 10 to about 100 cycles or more.
  • kits and solutions for performing the primer extension methods of the invention.
  • the kits and solutions of the invention include primer extension reagents with the modified (tagged) dNTPs and/or modified PP i and optionally a cosubstrate-enzyme pair.
  • the kits may also include primers.
  • the elements of the kits may be packaged in a single container or multiple containers. In one preferred configuration, a polymerase enzyme and modified (tagged) dNTPs and/or modified PP i are packaged in the same container.
  • This invention may also be used in methods where improvement of the accuracy of the synthesis of nucleic acids by a polymerase is desired and where pyrophosphorolysis is deemed counter-productive.
  • Uses include: polymerase chain reaction, especially ‘Long PCR,’ and cDNA synthesis. Examples of patents describing these methods include U.S. Pat. No. 4,965,188, U.S. Pat. No. 5,079,352, U.S. Pat. No. 5,091,310, U.S. Pat. No. 5,142,033, U.S. Pat. No. 4,683,195, U.S. Pat. No. 4,683,202, U.S. Pat. No. 4,800,159, U.S. Pat. No. 5,512,462 and U.S. Pat. No. 5,405,776, incorporated by reference.
  • a reverse transcriptase polymerase is incubated with the mRNA template and the tagged deoxynucleoside triphosphates.
  • the invention also relates to a kit comprising a container means, such as a box, having in close confinement therein two or more containers such as vials, ampules, tubes, jars or the like, each of which contains the materials necessary to carry out the invention.
  • a container may contain a polymerizing agent such as a DNA or RNA polymerase.
  • Another container may contain a tagged phosphate, pyrophosphate or polyphosphate in an amount sufficient to reduce, inhibit or prevent pyrophosphorolysis.
  • other containers may contain tagged and/or untagged dNTPs.
  • the kit can include a container containing a polymerizing agent such as a DNA or RNA polymerase and other containers containing tagged and/or untagged dNTPs.
  • the contents of the containers are present at working concentrations or requiring a to fold dilution to achieve working concentrations.
  • Other containers may contain other reagents that are necessary for carrying out dideoxy sequencing or amplification (PCR).
  • the solution of the present invention is an aqueous and/or buffered liquid containing the components described above. These components are present in the solution at concentrations sufficient to perform their desired function.
  • the reaction mixture will contain the tagged dNTPs which reduce the level of pyrophosphate and increase polymerase fidelity, a polymerizing agent such as a DNA polymerase, all four dNTPs, and one or more oligonucleotide primers having a single stranded region which are capable of annealing to the target nucleic acid molecule, being extended and thereby amplified.
  • the primer extension reaction may also comprise a chain terminator as described herein, e.g., a dideoxynucleoside triphosphate and the ddNTP may be modified at the ⁇ and/or ⁇ phosphate to reduce background and/or reduce band spreading, which allows for sequencing of the target DNA molecule by the well known Sanger dideoxy sequencing method.
  • a chain terminator as described herein, e.g., a dideoxynucleoside triphosphate and the ddNTP may be modified at the ⁇ and/or ⁇ phosphate to reduce background and/or reduce band spreading, which allows for sequencing of the target DNA molecule by the well known Sanger dideoxy sequencing method.
  • the present invention uses tagged NTPs that having molecular and/or atomic tags bonded to or associated with the ⁇ and ⁇ phosphates so as not to alter the chemistry of the growing polymer chain, allow for detection of the NTPs (including dNTPs and ddNTPs) upon binding, during incorporation and after incorporation via the released tagged pyrophosphate.
  • the present invention can include phosphatases that degrade NTPs (including dNTPs and ddNTPs) or that degrade pyrophosphate.
  • phosphatases that degrade NTPs (including dNTPs and ddNTPs) or that degrade pyrophosphate.
  • the labeled pyrophosphates act to inhibit pyrophosphorolysis, then such degradation enzymes should be tailored to attach the NTPs and not the tagged pyrophosphate.
  • nucleoside di- and/or mono-phosphate degrading enzymes are optional and may be used in combination with a nucleoside tri-phosphate degrading enzyme.
  • Suitable such enzymes include most notably apyrase which is both a nucleoside diphosphatase and triphosphatase, catalyzing the reactions NTP ⁇ NMP+2Pi and NTP ⁇ NDP+Pi (where NTP is a nucleoside triphosphate, NDP is a nucleoside diphospate, NMP is a nucleotide monophosphate and Pi is phosphate).
  • a pyrase may be obtained from Sigma Chemical Company.
  • nucleotide triphosphate degrading enzymes include Pig Pancreas nucleoside triphosphate diphosphohydrolase (Le Bel et al., 1980, J. Biol. Chem., 255, 1227-1233). Further enzymes are described in the literature.
  • nucleoside tri-, di- or monophosphatases may be used. Such enzymes are described in the literature and different enzymes may have different characteristics for deoxynucleotide degradation, e.g., different Km, different efficiencies for a different nucleotides etc. Thus, different combinations of nucleotide degrading enzymes may be used, to increase the efficiency of the nucleotide degradation step in any given system. For example, in some cases, there may be a problem with contamination with kinases which may convert any nucleoside diphosphates remaining to nucleoside triphosphates, when a further nucleoside triphosphate is added.
  • nucleoside disphosphatase it may be advantageous to include a nucleoside disphosphatase to degrade the nucleoside diphosphates.
  • nucleoside disphosphatase it may be advantageous to include a nucleoside disphosphatase to degrade the nucleoside diphosphates.
  • all nucleotides may be degraded to nucleosides by the combined action of nucleoside tri-, di- and monophosphatases.
  • the nucleotide-degrading enzyme is selected to have kinetic characteristics relative to the polymerase such that nucleotides are first efficiently incorporated by the polymerase, and then any non-incorporated nucleotides are degraded.
  • the K m of the nucleotide-degrading enzyme may be higher than that of the polymerase such that nucleotides which are not incorporated by the polymerase are degraded. This allows the sequencing procedure to proceed without washing the template between successive nucleotide additions.
  • a further advantage is that since washing steps are avoided, it is not necessary to add new enzymes e.g. polymerase with each new nucleotide addition, thus improving the economy of the procedure.
  • the nucleotide-degrading enzyme or enzymes are simply included in the polymerase reaction mix, and a sufficient time is allowed between each successive nucleotide addition for degradation of substantially most of the unincorporated nucleotides.
  • the amount of nucleotide-degrading enzyme to be used, and the length of time between nucleotide additions may readily be determined for each particular system, depending on the reactants selected, reaction conditions etc.
  • the nucleotide-degrading enzyme(s) may be included during the polymerase reaction step. This may be achieved simply by adding the enzyme(s) to the polymerase reaction mixture prior to, simultaneously with or after the polymerase reaction (i.e. the chain extension or nucleotide incorporation) has taken place, e.g. prior to, simultaneously with, or after, the polymerase and/or nucleotides are added to the sample/primer.
  • the nucleotide-degrading enzyme(s) may simply be included in solution in a reaction mix for the polymerase reaction, which may be initiated by addition of the polymerase or nucleotide(s).
  • the nucleotide-degrading enzyme(s) may be immobilized on a solid support, e.g. a particulate solid support (e.g. magnetic beads) or a filter, or dipstick etc. and it may be added to the polymerase reaction mixture at a convenient time.
  • such immobilized enzyme(s) may be added after nucleotide incorporation (i.e., chain extension) has taken place, and then, when the incorporated nucleotides are hydrolyzed, the immobilized enzyme may be removed from the reaction mixture (e.g. it may be withdrawn or captured, e.g., magnetically in the case of magnetic beads), before the next nucleotide is added. The procedure may then be repeated to sequence more bases.
  • nucleotide incorporation i.e., chain extension
  • the immobilized enzyme may be removed from the reaction mixture (e.g. it may be withdrawn or captured, e.g., magnetically in the case of magnetic beads), before the next nucleotide is added.
  • the procedure may then be repeated to sequence more bases.
  • Such an arrangement has the advantage that more efficient nucleotide degradation may be achieved as it permits more nucleotide degrading enzyme to be added for a shorter period. This arrangement may also facilitate optimization of the balance between the two competing reactions of DNA polymerization and nucleotide degradation.
  • the immobilization of the nucleotide-degrading enzyme may be combined with the use of the enzyme(s) in solution.
  • a lower amount may be included in the polymerase reaction mixture and, when necessary, nucleotide-degrading activity may be boosted by adding immobilized enzyme as described above.
  • dideoxynucleotide as used herein includes all 2′-deoxynucleotides in which the 3′-hydroxyl group is absent or modified and thus, while able to be added to the primer in the presence of the polymerase, is unable to enter into a subsequent polymerization reaction.
  • the method of the invention may readily be modified to enable the sequencing (i.e. base incorporation) reactions to be continuously monitored in real time. This may simply be achieved by performing the chain extension and detection, or signal-generation, reactions substantially simultaneously by monitoring a detectable property of the tags on the NTPs during binding, incorporation, and/or pyrophosphate release.
  • the sample DNA (i.e., DNA template) may conveniently be single-stranded, and may either by immobilized on a solid support or in solution.
  • a nucleotide degrading enzyme according to the present invention means that it is not necessary to immobilize the template DNA to facilitate washing, since a washing step is no longer required.
  • thermostable enzymes double-stranded DNA templates might also be used.
  • the sample DNA may be provided by any desired source of DNA, including for example PCR or other amplified fragments, inserts in vectors such as M13 or plasmids.
  • the sample DNA may optionally be immobilized or provided with means for attachment to a solid support.
  • the amount of sample DNA available may be small and it may therefore be desirable to amplify the sample DNA before carrying out the method according to the invention.
  • the sample DNA may be amplified, and any method of amplification may be used, for example in vitro by PCR, rolling circle, or Self Sustained Sequence Replication (3SR) or in vivo using a vector and, if desired, in vitro and in vivo amplification may be used in combination.
  • amplification may be modified that the amplified DNA becomes immobilized or is provided with means for attachment to a solid support.
  • a PCR primer may be immobilized or be provided with means for attachment to a solid support.
  • a vector may comprise means for attachment to a solid support adjacent the site of insertion of the sample DNA such that the amplified sample DNA and the means for attachment may be excised together.
  • Immobilization of the amplified DNA may take place as part of PCR amplification itself, as where one or more primers are attached to a support, or alternatively one or more of the PCR primers may carry a functional group permitting subsequent immobilization, e.g. a biotin or thiol group. Immobilization by the 5′ end of a primer allows the strand of DNA emanating from that primer to be attached to a solid support and have its 3′ end remote from the support and available for subsequent hybridization with the extension primer and chain extension by polymerase.
  • the solid support may conveniently take the form of microtitre wells, which are advantageously in the conventional 8 ⁇ 12 format, or dipsticks which may be made of polystyrene activated to bind the primer DNA (K Ahner, Doctoral Theses, Royal Institute of Technology, Swiss, Sweden, 1988).
  • any solid support may conveniently be used, including any of the vast number described in the art, e.g., for separation/immobilization reactions or solid phase assays.
  • the support may also comprise particles, fibers or capillaries made, for example, of agarose, cellulose, alginate, Teflon or polystyrene.
  • Magnetic particles e.g. the superparamagnetic beads produced by Dynal AS (Oslo, Norway) also may be used as a support.
  • the solid support may carry functional groups such as hydroxyl, carboxyl, aldehyde or amino groups, or other moieties such as avidin or streptavidin, for the attachment of primers. These may in general be provided by treating the support to provide a surface coating of a polymer carrying one of such functional groups, e.g. polyurethane together with a polyglycol to provide hydroxyl groups, or a cellulose derivative to provide hydroxyl groups, a polymer or copolymer of acrylic acid or methacrylic acid to provide carboxyl groups or an aminoalkylated polymer to provide amino groups.
  • a polymer carrying one of such functional groups e.g. polyurethane together with a polyglycol to provide hydroxyl groups, or a cellulose derivative to provide hydroxyl groups, a polymer or copolymer of acrylic acid or methacrylic acid to provide carboxyl groups or an aminoalkylated polymer to provide amino groups.
  • U.S. Pat. No. 4,654,267 describes
  • Another aspect of this invention is the use of tagged nucleotides to directly sequence populations of DNA molecules in synchrony.
  • the synchrony is achieved by applying a population of single tagged dNTP to the reaction chamber, monitoring PP i release (as per tag detection), and removing unincoporated dNTPs prior to applying the next tagged dNTP until the sequence of interest in determined.
  • the tagged NTPs and/or pyrophosphate detection method of the present invention thus opens up the possibility for an automated approach for large-scale, non-elecrophoretic sequencing procedures, which allow for continuous measurement of the progress of the polymerization reaction with time.
  • the method of the invention also has the advantage that multiple samples may be handled in parallel.
  • the target DNA may be cDNA synthesized from RNA in the sample and the method of the invention is thus applicable to diagnosis on the basis of characteristic RNA.
  • Such preliminary synthesis can be carried out by a preliminary treatment with a reverse transcriptase, conveniently in the same system of buffers and bases of subsequent PCR steps if used. Since the PCR procedure requires heating to effect strand separation, the reverse transcriptase will be inactivated in the first PCR cycle.
  • RNA is the sample nucleic acid
  • a specific oligonucleotide sequence may be used to retrieve the RNA via a specific RNA sequence.
  • the oligonucleotide can then serve as a primer for cDNA synthesis, as described in WO 89/0982.
  • the methods of the present invention can be used with any source of purified cDNA and RNA.
  • the present invention also relates to using a modified nucleotide to increase fidelity either alone (in a reaction with Taq DNA polymerase or any enzyme that joins nucleic acid monomers) or in combination with a naturally occurring, high-fidelity polymerase or one that is genetically modified for high-fidelity synthesis.
  • the inventors have designed a complementary system using tagged nucleotides, either alone or in combination, with a naturally occurring low-fidelity polymerase or one that is genetically modified for low-fidelity synthesis.
  • the purpose of this embodiment is to enable either random mutagenesis of a particular nucleic acid or targeted mutagenesis of a particular base type alone the length of the nucleic acid polymer.
  • nucleic acid polymer At times, it is desirable to synthesize a nucleic acid polymer at reduced accuracy (essentially a random mutagenesis).
  • a single or a subset of natural nucleotides that produced reduced fidelity synthesis, or ratio thereof, can be used to more precisely target mutagenesis of desired nucleotide type along the length of the nucleic acid polymer.
  • the extension primer is sufficiently large to provide appropriate hybridization with the sequence immediately 5′ of the target position, yet still reasonably short in order to avoid unnecessary chemical synthesis. It will be clear to persons skilled in the art that the size of the extension primer and the stability of hybridization will be dependent to some degree on the ratio of A-T to C-G base pairings, since more hydrogen bonding is available in a C-G pairing.
  • the present invention also relates to improving polymerase base incorporation fidelity acting on a target nucleic acid sequence to which a primer library (pre-existing primer set), where the library comprises an optimized subset of base permutations and combinations of the four bases for a base length between about 6 and about 35 bases.
  • a primer library pre-existing primer set
  • the inventors have developed a robust “classic” sequencing strategy using octamer primers to initiate the DNA synthesizing reaction (Hardin et al. U.S. Pat. No. 6,083,695, incorporated herein by reference)
  • the primers comprising an octamer library are also appropriate to initiate single molecule DNA sequencing and related techniques with the modified nucleotides.
  • complementary library primers will bind to the sequence forming a site for polymerase binding and polymerization. If more than one primer binds, then the polymerase will randomly select and bind to a given primer complemented to a local on the sequence and polymerization will commence. Although it is possible to have two primer molecules bound on a single template, only one primer will be the site of polymerase activity. The increased fidelity will ensure superior library differentiation.
  • the library members can contain a 5′ extension to enable their immobilization to a surface, while still retaining the ability to form at least an 8 base duplex with the template, the unknown nucleic acid sequence (template) added to the surface and then the polymerase and polymerizing components are added to initiate polymerization with improved fidelity through the tagged dNTPs or by the addition of a phosphorolysis inhibitors of this invention.
  • the skilled person will consider the degree of homology between the extension primer to other parts of the amplified sequence and choose the degree of stringency accordingly.
  • Guidance for such routine experimentation can be found in the literature, for example, Molecular Cloning: a laboratory manual by Sambrook, J., Fritsch E. F. and Maniatis, T. (1989). It may be advantageous to ensure that the sequencing primer hybridizes at least one base inside from the 3′ end of the template to eliminate blunt-ended DNA polymerase activity. If separate aliquots are used (i.e., 4 aliquots, one for each base), the extension primer is preferably added before the sample is divided into four aliquots although it may be added separately to each aliquot. It should be noted that the extension primer may be identical with the PCR primer but preferably it is different, to introduce a further element of specificity into the system.
  • oligonucleotides such as octamers
  • a polymerizing agent such as a polymerase and the reaction components are added.
  • primase may be used to synthesize an RNA primer that can subsequently be used by a DNA polymerase to begin DNA synthesis.
  • the site of initiation of the RNA chain is not critical and many reactions can be processed in parallel to obtain the complete DNA sequence.
  • the polymerase reaction in the presence of the extension primer and a deoxynucleotide is carried out using a polymerase which will incorporate dideoxynucleotides, e.g. T7 polymerase, Klenow or Sequenase Ver. 2.0 (USB U.S.A.). Any suitable chain extension sometimes are digested by an exonuclease activity. If such reverse polymerization occurs in the method according to the invention the level of background noise increases. In order to avoid this problem, a nonproofreading polymerase, e.g. exonuclease deficient (exo-) Klenow polymerase may be used.
  • a nonproofreading polymerase e.g. exonuclease deficient (exo-) Klenow polymerase may be used.
  • the sample will contain heterozygous material, that is half the DNA will have one nucleotide at the target position and the other half will have another nucleotide.
  • the sample will contain heterozygous material, that is half the DNA will have one nucleotide at the target position and the other half will have another nucleotide.
  • four aliquots are used in an embodiment according to the invention, two will show a negative signal and two will show half the positive signal. It will be seen therefore that it is desirable to quantitatively determine the amount of signal detected in each sample.
  • bidirectional sequencing i.e. sequencing of both strands of a double-stranded template may be performed.
  • This may be advantageous e.g. in the sequencing of heterozygous material.
  • this may be achieved by immobilizing the double-stranded sample template by one strand, e.g. on particles or in a microtitre well, eluting the second strand and subjecting both strands separately to a sequencing reaction by the method of the invention.
  • Reaction efficiency may be improved by including Mg 2+ ions in the reagent (NTP and/or polymerase) solutions.
  • NTP and/or polymerase reagent
  • the extension reaction will add two bases at the same time and indeed any sequence of successive identical bases in the sample will lead to simultaneous incorporation of corresponding bases into the primer.
  • the amount of pyrophosphate liberated will clearly be proportional to the number of incorporated bases so that there is no difficulty in detecting such repetitions. Since the primer is extended by a single base by the procedure described above (or a sequence of identical bases), the extended primer can serve in exactly the same way in a repeated procedure to determine the next base in the sequence, thus permitting the whole sample to be sequenced.
  • different tagged deoxy- or dideoxynucleotides may be added to separate aliquots of sample-primer mixture or successively to the same sample-primer mixture.
  • the present invention provides two principal methods of sequencing immobilized DNA.
  • the invention provides a first method of sequencing sample DNA wherein the sample DNA is subjected to amplification; the amplified DNA is optionally immobilized and then subjected to strand separation, one strand e.g. the optionally non-immobilized or immobilized strand being removed (i.e., either strand may be sequenced), and an extension primer is provided, which primer hybridizes to the sample DNA immediately adjacent that portion of the DNA to be sequenced; each of four aliquots of the single stranded DNA is then subjected to a polymerase reaction in the presence of a tagged deoxynucleotide, each aliquot using a different tagged deoxynucleotide whereby only the tagged deoxynucleotide complementary to the base in the target position becomes incorporated; the tagged pyrophosphate released by base incorporation being identified.
  • nucleotide degrading enzyme e.g., a phosphatase such as snake venom phosphatase, calf intestinal phosphatase, shrimp alkaline phosphatase, or bacterial alkaline phosphatase.
  • a nucleotide degrading enzyme e.g., a phosphatase such as snake venom phosphatase, calf intestinal phosphatase, shrimp alkaline phosphatase, or bacterial alkaline phosphatase.
  • the four aliquots can be used in a new cycle of nucleotide additions, only if the other three are also extended by addition of the correct dNTP (after which, only one could be extended). This procedure can then be continuously repeated.
  • the invention also provides a second method of sequencing sample DNA wherein the sample DNA is subjected to amplification; the amplified DNA is optionally immobilized and then subjected to strand separation, one strand, e.g., the optionally non immobilized or immobilized strand being removed, and an extension primer is provided, which primer hybridizes to the sample DNA immediately adjacent to that portion of the DNA to be sequenced; the single stranded DNA is then subjected to a polymerase reaction in the presence of a first tagged deoxynucleotide, and the extent of tagged pyrophosphate release is determined, non-incorporated nucleotides being degraded by the nucleotide-degrading enzyme, and the reaction being repeated by successive addition of a second, third and fourth tagged deoxynucleotide until a positive release of pyrophosphate indicates incorporation of a particular tagged deoxynucleotide into the primer, whereupon the procedure is repeated to extend the primer one base (or one base
  • the present invention also provides a step by step polymerization apparatus and method.
  • the apparatus and method includes a tubular member including a zone containing an immobilized polymerizing agent such as a polymerase.
  • the zone is pre-treated by a nucleotide sequence.
  • a plug of inert buffer is moved into the tubular member to displace the reactive solution.
  • the solution As the reactive solution is moved out of the reaction zone, the solution is exposed to a detection procedure that detects the specific detectable property to determine the incorporated dNTP.
  • the wash plug should generally be several multiples of the volume of solution necessary to cover the reaction zone.
  • Another reactive medium plug then follows, followed by a wash plug which allows detection of the next incorporation and so on and so on.
  • the reaction media can include only a single dNTP and the detector looks for free tagged pyrophosphate.
  • combinatorial mathematics can be used to determine the best choice for the next dNTP plug to use.
  • An alternative format for the analysis is to use an array format wherein samples are distributed over a surface, for example a micro-fabricated chip, and thereby an ordered set of samples may be immobilized in a 2 dimensional (2D) format. Many samples can thereby be analyzed in parallel.
  • many immobilized templates may be analyzed in this way by allowing the solution containing the enzymes and one nucleotide to flow over the surface and then detecting the signal produced for each sample. This procedure can then be repeated.
  • several different oligonucleotides complementary to the template may be distributed over the surface followed by hybridization of the template.
  • Incorporation of tagged deoxynucleotides or tagged dideoxynucleotides may be monitored for each oligonucleotide by the signal produced using the various oligonucleotides as primer. By combining the signals from different areas of the surface, sequence-based analyses may be performed by four cycles of polymerase reactions using the various tagged dideoxynucleotides.
  • Two-stage PCR (using nested primers), as described in application WO90/11369, may be used to enhance the signal to noise ratio and thereby increase the sensitivity of the method according to the invention.
  • concentration of target DNA is greatly increased with respect to other DNA which may be present in the sample and a second-stage amplification with at least one primer specific to a different sequence of the target DNA significantly enhances the signal due to the target DNA relative to the ‘background noise’.
  • thermophilic enzyme such as Taq polymerase to permit the repeated temperature cycling without having to add further polymerase, e.g. Klenow fragment, in each cycle of PCR.
  • PCR has been discussed above as a preferred method of initially amplifying target DNA although the skilled person will appreciate that other methods may be used instead of in combination with PCR.
  • a recent development in amplification techniques which does not require temperature cycling or use of a thermostable polymerase is Self Sustained Sequence Replication (3SR) or rolling circle amplification. 3SR is modelled on retroviral replication and may be used for amplification (see for example Gingeras, T. R.
  • the method can be applied to identifying the release of tagged pyrophosphate when dideoxynucleotide residues are incorporated into the end of a DNA chain.
  • the present invention also relates to a method of identification of the base in a single target position in a DNA sequence (mini-sequencing) wherein sample DNA is subjected to amplification; the amplified DNA is immobilized and then subjected to strand separation, the non-immobilized strand being removed and an extension primer, which hybridizes to the immobilized DNA immediately adjacent to the target position, is provided; each of four aliquots of the immobilized single stranded DNA is then subjected to a polymerase reaction in the presence of a dideoxynucleotide, each aliquot using a different dideoxynucleotide whereby only the dideoxynucleotide complementary to the base in the target position becomes incorporated and, because the tagged nucleotides improve the fidelity of incorporation, the signals
  • WO93/23562 defines the term ‘dideoxynucleotide’ as including 3′-protected 2′-deoxynucleotides which act in the same way by preventing further chain extension. However, if the 3′ protecting group is removable, for example by hydrolysis, then chain extension (by a single base) may be followed by unblocking at the 3′ position, leaving the extended chain ready for a further extension reaction. In this way, chain extension can proceed one position at a time without the complication which arises with a sequence of identical bases, as discussed above.
  • the methods A and B referred to above can be modified whereby the base added at each stage is a 3′protected 2′-deoxynucleotide and after the base has been added (and the tag signal or detectable property such as light emission is detected), the 3′-blocking group is removed to permit a further 3′-protected-2′ deoxynucleotide to be added.
  • Suitable protecting groups include acyl groups such as alkanol groups e.g. acetyl or indeed any hydroxyl protecting groups known in the art, for example as described in Protective Groups in Organic Chemistry, JFW McOnie, Plenum Press, 1973.
  • the invention in the above embodiment, provides a simple and rapid method for detection of single base changes.
  • it successfully combines two techniques: solid-phase technology (DNA bound to magnetic beads) and detection of a detectable property associated with the tags on the dNTPs or released PP i .
  • the method can be used to both identify and quantitate selectively amplified DNA fragments. It can also be used for detection of single base substitutions and for estimation of the heterozygosity index for an amplified polymorphic gene fragment.
  • the method can be used to screen for rare point mutations responsible for both acquired and inherited diseases, identify DNA polymorphisms, and even differentiate between drug-resistant and drug-sensitive strains of viruses or bacteria without the need for centrifugations, filtrations, extractions or electrophoresis.
  • the simplicity of the method renders it suitable for many medical (routine analysis in a wide range of inherited disorders) and commercial applications.
  • the DNA template is preferably obtained by PCR, it is relatively straight forward to increase the amount of DNA needed for such an assay.
  • the new approach has several advantages as compared to standard sequencing methods. Firstly, the method is suitable for handling of multiple samples in parallel. Secondly, relatively cost-effective instruments are envisioned. In addition, the method avoids the use of electrophoresis and thereby the loading of samples and casting of gels. A further advantage of the method of the present invention is that it may be used to resolve sequences which cause compressions in the gel-electrophoretic step in standard Sanger sequencing protocols.
  • the method of the invention may also find applicability in other methods of sequencing.
  • a number of iterative sequencing methods advantageously permitting sequencing of double-stranded targets, based on ligation of probes or adaptors and subsequent cleavage have been described (see e.g. U.S. Pat. No. 5,599,675 and Jones, BioTechniques 22: 938-946, 1997).
  • Such methods generally involve ligating a double stranded probe (or adaptor) containing a Class IIS nuclease recognition site to a double stranded target (sample) DNA and cleaving the probe/adaptor-target complex at a site within the target DNA, one or more nucleotides from the ligation site, leaving a shortened target DNA.
  • the ligation and cleavage cycle is then repeated.
  • Sequence information is obtained by identifying one or more nucleotides at the terminus of the target DNA. The identification of the terminal nucleotide(s) may be achieved by chain extension using the method of the present invention.
  • the method of the invention may be used in a sequencing protocol based on strand displacement, e.g. by the introduction of nicks, for example as described by Fu et al., in Nucleic Acids Research 1997, 25(3): 677-679.
  • the sample DNA may be modified by ligating a double-stranded probe or adaptor sequence which serves to introduce a nick e.g. by containing a non- or mono-phosphorylated or dideoxy nucleotide.
  • Use of a strand-displacing polymerase permits a sequencing reaction to take place by extending the 3′ end of probe/adaptor at the nick, nucleotide incorporation being detected according to the method of the present invention.
  • the method of the invention may also be used for real-time detection of known single-base changes.
  • This concept relies on the measurement of the difference in primer extension efficiency by a DNA polymerase of a matched over a mismatched 3′ terminal.
  • the rate of the DNA polymerase catalyzed primer extension is measured by detection of the detectable property associated with the tag such as fluorescence as described previously.
  • single-base detection assay single-stranded DNA fragments are used as template.
  • Two detection primers differing with one base at the 3′-end are designed; one precisely complementary to the non-mutated DNA-sequence and the other precisely complementary to the mutated DNA sequence.
  • the primers are hybridized with the 3′-termini over the base of interest and the primer extension rates are, after incubation with DNA polymerase and deoxynucleotides, measured by detecting the characteristics of the detectable property such as fluorescence of the tag. If the detection primer exactly matches to the template a high extension rate will be observed. In contrast, if the 3′-end of the detection primer does not exactly match to the template (mismatch) the primer extension rate will be much lower or eliminated by the use of tagged dNTPs which increase fidelity via the addition of tagged PPi. The difference in primer extension efficiency by the DNA polymerase of a matched over a mismatched 3′-terminal can then be used for single-base discrimination.
  • the presence of the mutated DNA sequence can be distinguished over the non-mutated sequence.
  • a nucleotide degrading enzyme By performing the assay in the presence of a nucleotide degrading enzyme, it is easier to distinguish between a match and a mismatch of the type that are relatively easy to extend, such as T:G and C:T.
  • kits for use in methods of the invention which will normally include at least the following components: (a) a test specific primer which hybridizes to sample DNA so that the target position is directly adjacent to the 3′ end of the primer; (b) a polymerase; (c) an optional detection enzyme means for identifying pyrophosphate release; (d) a nucleotide-degrading enzyme; (e) deoxynucleotides, or optionally deoxynucleotide analogues having a molecular and/or atomic tag bonded to or associated with a ⁇ - and/or ⁇ -phosphate of the dNTP, optionally including, in place of dATP, a dATP analogue which is capable of acting as a substrate for a polymerase but incapable of acting as a substrate for a said PPi-detection enzyme; and (f) optionally dideoxynucleotides, or optionally dideoxynucleotide analogues, optionally ⁇
  • kit for use with initial PCR amplification then it will also normally include at least the following components: (i) a pair of primers for PCR, at least one primer having a means permitting immobilization of said primer; (ii) a polymerase which is preferably heat stable, for example Taq DNA polymerase; (iii) buffers for the PCR reaction; and (iv) tagged deoxynucleotides and/or tagged PPi (for increased fidelity).
  • a pair of primers for PCR at least one primer having a means permitting immobilization of said primer
  • a polymerase which is preferably heat stable, for example Taq DNA polymerase
  • buffers for the PCR reaction for the PCR reaction
  • tagged deoxynucleotides and/or tagged PPi for increased fidelity
  • ⁇ -phosphate modified dATP could be incorporated by DNA polymerase. Importantly, both biological activity and, unexpectedly, increased fidelity are associated with polymerization of this ⁇ -phosphate modified nucleotide. Since ⁇ -phosphate modified dNTPs are not commercially available, they are designed and synthesized in Dr. Gao's lab. In the following section, the reaction route used to produce the ANS-dATP is provided. This route is also provided as an example for the synthesis of additional ⁇ -tagged dNTPs.
  • the tag can be any tag that alters the fidelity of the polymerizing agent
  • exemplary examples of such tags include alkyl groups having between 1 and 30 carbon atoms, aryl groups having between about 6 and about 40 carbon atoms, or alkaryl and aralkyl groups having between about 7 and about 40 carbon atoms, or mixture or combinations thereof.
  • the substituents can have any number of hetero atoms in the structure provided the structure represents a stable molecular system, where the hetero atoms including P, S, Si, N, O, or any other hetero atom that does not render the nucleotide toxic to the polymerase.
  • Exemplary examples include 4-aminophenol, 6-aminonaphthol, 4-nitrophenol, 6-nitronaphthol, 4-methylphenol, 6-chloronaphthol, 4-methoxyphenol, 6-bromonaphthol, 4-chlorophenol, 6-iodonaphthol, 4-bromophenol, 4,4′-dihydroxybiphenyl, 4-iodophenol, 8-hydroxyquinoline, 4-nitronaphthol, 3-hydroxypyridine, 4-aminonaphthol, umbelliferone, 4-methylnaphthol, resorufin, 4-methoxynaphthol, 8-hydroxypyrene, 4-chloronaphthol, 9-hydroxyanthracene, 4-bromonaphthol, 6-nitro-9-hydroxyanthracene, 4-iodonaphthol, 3-hydroxyflavone, 6-methylnaphthol, fluorescein, 6-methoxynaphthol
  • modified nucleotide include ANS modified nucleotide and Adenosine-5′-( ⁇ -4-nitrophenyl)triphosphate, Adenosine-5′-( ⁇ -4-iodonaphthyl), Guanosine-5′-( ⁇ -4-nitrophenyl)triphosphate, triphosphate Adenosine-5′-( ⁇ -6-methylnaphthyl) triphosphate, Cytosine-5′-( ⁇ -4-nitrophenyl)triphosphate, Thymidine-5′-( ⁇ -4-nitrophenyl) triphosphate, Adenosine-5′-( ⁇ -6-methoxynaphthyl)triphosphate, Uracil-5′-( ⁇ -4-nitrophenyl) triphosphate, 3′-azido-3′-deoxythymidine-5′-( ⁇ -4-nitrophenyl)triphosphate, Adenosine-5′-( ⁇ -6-aminonaphthyl)triphosphate, 3′
  • Adenosine-5′-( ⁇ -6-carboxymethyl-2,7-dichlorofluorescein)triphosphate Adenosine-5′-( ⁇ -(4 or 6 or 8 ethyl naphthyl)triphosphate, Adenosine-5′-( ⁇ -4-phenyl)-( ⁇ ′-4 nitrophenyl) triphosphate, Adenosine-5′-( ⁇ -(4 or 6 or 8 butyl naphthyl)triphosphate, Adenosine-5′-( ⁇ -4-phenyl)-( ⁇ ′-4 aminophenyl)triphosphate, Adenosine-5′-( ⁇ -methyl)triphosphate, Adenosine-5′-( ⁇ -3-aminopropyl)triphosphate, Guanosine-5′-( ⁇ -methyl)triphosphate, Adenosine-5′-( ⁇ -4-aminobutyl) triphosphate, Cytosine-5′-( ⁇ -methyl)triphosphate Adenosine
  • ‘TOP’ represents the primer strand of the DNA duplex molecules used in the primer extension assays. Variants of the template strand are represented by ‘BOT’. The relevant feature of the DNA template is indicated after the hyphen. For example, BOT-T, BOT-C, BOT-G, BOT-A are used to monitor polymerase incorporation efficiency and fidelity for either nucleotides or nucleotide variants of dATP, dGTP, dCTP, and dTTP, respectively.
  • This first example illustrates the incorporation of ANS- ⁇ -phosphate dATP to produce extended DNA products from primer/template duplexes.
  • the reactions were carried out in extension buffer and the resulting radiolabeled products were size separated on a 20% denaturing polyacrylamide gel. Data were collected using a phosphorimaging system.
  • Lane 1 contained 5′ radiolabeled ‘TOP’ probe in extension buffer.
  • Lane 2 contained Taq DNA polymerase, 50 ⁇ M dGTP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-Sau’).
  • Lane 3 contained Taq DNA polymerase, 50 ⁇ M dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-Sau’).
  • Lane 4 contained Taq DNA polymerase, 50 ⁇ M ANS- ⁇ -dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-Sau’).
  • Lane 5 contained Taq DNA polymerase, 50 ⁇ M dGTP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-TC’).
  • Lane 6 contained spill-over from lane 5.
  • Lane 7 contained Taq DNA polymerase, 50 ⁇ M dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-TC’).
  • Lane 8 contained Taq DNA polymerase, 50 ⁇ M ANS- ⁇ -dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-TC’).
  • Lane 9 contained Taq DNA polymerase, 50 ⁇ M dGTP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-3TC’).
  • Lane 10 contained Taq DNA polymerase, 50 ⁇ M dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-3TC’).
  • Lane 11 contained Taq DNA polymerase, ANS- ⁇ -dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-3TC’).
  • Lane 12 contained 5′ radiolabeled ‘TOP’ probe in extension buffer.
  • Lane 13 contained 5′ radiolabeled ‘TOP’ probe and Taq DNA polymerase in extension buffer. Oligonucleotide sequences are shown in Table 1.
  • Quantitative comparison of lane 1 with lane 4 demonstrates that very little non-specific, single-base extension was detected when ANS- ⁇ -dATP was included in the reaction, and the first incorporated base should be dGTP (which was not added to the reaction).
  • Quantitative analysis of lanes 1 and 8 demonstrates that approximately 71% of the TOP primer are extended by a template-directed single base when ANS- ⁇ -dATP was included in the reaction and the first incorporated base should be dATP.
  • Taq DNA polymerase incorporates ⁇ -tagged nucleotides. Equally important to the polymerase's ability to incorporate a ⁇ -tagged nucleotide is its ability to extend the DNA polymer after the modified dATP was incorporated.
  • the relative percent fidelity improvement can be determined of dATP and ANS- ⁇ -phosphate tagged dATP.
  • G is to be incorporated and dATP is the only nucleotide in the reaction medium, then the tagged nucleotide provides about a 3 fold decrease in misextensions.
  • the tagged nucleotide provides about an 11 fold decrease in misextensions.
  • three A's are to be incorporated and dATP is only nucleotide in the reaction medium, then the tagged nucleotide provides about a 14 fold decrease in misextensions.
  • This next example illustrates the synthesis of extended DNA polymers using all four ANS tagged ⁇ -phosphate dNTPs. Products generated in these reactions were separated on a 20% denaturing polyacrylamide gel, the gel was dried and imaged following overnight exposure to a Fuji BAS1000 imaging plate. Referring now to FIG. 2 , an image of (A) the actual gel image, (B) a lightened phosphorimage and (C) an enhanced phosphorimage. Lane descriptions for A, B, and C follow: Lane 1 is the control containing purified 10-base primer extended to 11 and 12 bases by template-mediated addition of ⁇ - 32 P dCTP. Lane 2 includes the same primer that was incubated with double-stranded plasmid DNA at 96° C.
  • Lane 3 includes the same labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes; Taq DNA Polymerase and all four ⁇ -modified dNTPs (100 M, each) were added and the reaction was incubated at 37° C. for 60 minutes.
  • Lane 4 includes the control, purified 10-base primer that was extended to 11 and 12 bases by the addition of ⁇ - 32 P dCTP and was cycled in parallel with the reactions in lanes 5-8.
  • Lane 5 includes the same 32 P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four natural dNTPs (100 ⁇ M, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes.
  • Lane 6 includes the same 32 P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four ⁇ -modified dNTPs (100 ⁇ M, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Lane 7 includes nonpurified, 10-base, ⁇ 32 P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C.
  • Lane 8 includes nonpurified, 10-base ⁇ - 32 P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four ⁇ -modified dNTPs (100 ⁇ M, each) were added.
  • the reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes.
  • Evident in the reactions involving tagged dNTPs is a substantial decrease in pyrophosphorolysis as compared to reactions involving natural nucleotides.
  • This next example illustrates the synthesis of long DNA polymers using all four ANS tagged ⁇ -phosphate dNTPs.
  • Each primer extension reaction was split into two fractions, and one fraction was electrophoresed through a 20% denaturing gel (as described above), while the other was electrophoresed through a 6% denaturing gel to better estimate product lengths.
  • the gel was dried and imaged (overnight) to a Fuji BAS1000 imaging plate.
  • FIG. 3 an image of (A) the actual gel, (B) a lightened phosphorimage of the actual gel, and (C) an enhanced phosphorimage of the actual gel.
  • Lane descriptions for A, B, and C follow: Lane 1 includes 123 Marker with size standards indicated at the left of each panel.
  • Lane 2 contained the control, purified 10-base primer extended to 11 and 12 bases by template-mediated addition of ⁇ - 32 P dCTP.
  • Lane 3 contained the same 32 P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes (to denature template), the reaction was brought to 37° C. (to anneal the primer to the template), Taq DNA polymerase and all four natural dNTPs (100 ⁇ M, each) were added and the reaction was incubated at 37° C. for 60 minutes.
  • Lane 4 includes the same 32 P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C.
  • Lane 5 includes the control, purified 10-base primer that was extended to 11 and 12 bases by the addition of ⁇ - 32 P-dCTP was cycled in parallel with the reactions in lanes 5-8
  • Lane 6 includes the same 32 P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four natural dNTPs (100 ⁇ M, each) were added.
  • Lane 7 includes the same 32 P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four ⁇ -modified dNTPs (100 ⁇ M, each) were added.
  • the reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes.
  • Lane 8 includes nonpurified, 10-base ⁇ 32 P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C.
  • Lane 9 includes nonpurified, 10-base, ⁇ - 32 P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four ⁇ -modified dNTPs (100 ⁇ M, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes.
  • Lane 9 includes nonpurified, 10-base, ⁇ - 32 P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four ⁇ -modified dNTPs (100 ⁇ M, each) were added.
  • the reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5
  • extension products in this reaction are several hundred bases long for both natural and ⁇ -modified dNTPs, and a significant percentage of these products are too large to enter the gel.
  • ⁇ -phosphate tagged dNTPs are used by Taq polymerase to generate long DNA polymers that are non-tagged or native DNA polymer chains.
  • the indicated enzymes (Taq DNA Polymerase, DNA polymerase I-Klenow Fragment Pfu DNA Polymerase, HIV-1 Reverse Transcriptase, T7 DNA Polymerase Sequenase Version 2) were incubated in the manufacturers suggested reaction buffer, 50 M of the indicated nucleotide were added and the reactions, containing aDNA duplex (5′ radiolabeled TOP and the specified template) were incubated at 37° C. for 30-60 minutes. The reaction products were analyzed by size separation through a 20% denaturing gel.
  • Taq DNA polymerase efficiently uses the modified nucleotides to synthesize extended DNA polymers at increased accuracy as shown in FIGS. 1-6 .
  • the Klenow fragment from E. coli DNA polymerase I efficiently uses ⁇ -modified nucleotides, but does not exhibit the extreme fidelity improvements observed with other enzymes as shown in FIG. 4 .
  • Pfu DNA polymerase does not efficiently use ⁇ -modified nucleotides and is, thus, not a preferred enzyme for the single-molecule sequencing system as shown in FIG. 5 .
  • HIV-1 reverse transcriptase efficiently uses the modified nucleotides, and significant fidelity improvement results as shown in FIG. 6 .
  • This experiment illustrates the effect of elevated temperature on ANS-tagged dNTPs. Specifically, ⁇ -tagged dNTPs were heated for 7 minutes at 96° C. Primer extension reactions containing heat-treated or untreated natural or ANS-tagged dNTPs were compared to determine the effect of high temperature. The reactions were carried out in extension buffer and the resulting radiolabeled products were size separated on a 20% denaturing polyacrylamide gel. Data were collected using a phosphorimaging system.
  • Lane 1 contained free ⁇ - 32 P-labeled primer (‘TOP’). Lanes 2-9 are extension reactions containing the ⁇ - 32 P-labeled TOP that was annealed to a single-stranded template (‘BOT T6T’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 ⁇ M) were added and the reactions were carried out at 37° C. for 30 minutes.
  • TOP free ⁇ - 32 P-labeled primer
  • Lanes 2-9 are extension reactions containing the ⁇ - 32 P-labeled TOP that was annealed to a single-stranded template (‘BOT T6T’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 ⁇ M) were added and the reactions were carried out at 37° C. for 30 minutes.
  • Lanes 10-17 are extension reactions containing the ⁇ - 32 P-labeled TOP that was annealed to a single-stranded template (‘BOT A6A’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 ⁇ M) were added and the reactions were carried out at 37° C. for 30 minutes.
  • Each lane contained as follows: untreated natural TTP (Lanes 10-11), heat-treated natural TTP (Lanes 12-13), untreated ANS- ⁇ -tagged TTP (Lanes 14-15), heat-treated ANS ⁇ -tagged TTP (Lanes 16-17).
  • Lane 1 contained free ⁇ - 32 P-labeled primer (‘TOP’). Lanes 2-9 are extension reactions containing the ⁇ - 32 P-labeled TOP that was annealed to a single-stranded template (‘BOT G6G’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 ⁇ M) were added and the reactions were carried out at 37° C. for 30 minutes.
  • TOP free ⁇ - 32 P-labeled primer
  • Lanes 2-9 are extension reactions containing the ⁇ - 32 P-labeled TOP that was annealed to a single-stranded template (‘BOT G6G’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 ⁇ M) were added and the reactions were carried out at 37° C. for 30 minutes.
  • Lanes 10-17 are extension reactions containing the ⁇ - 32 P-labeled TOP that was annealed to a single-stranded template (‘BOT C6C’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 ⁇ M) were added and the reactions were carried out at 37° C. for 30 minutes.
  • BOT C6C single-stranded template
  • the reactions contain ⁇ - 32 P-labeled primer (‘TOP’) duplexed to a single-stranded template (‘BOT-24’) [primer/template ratio—1:9], the appropriate buffer, Taq DNA polymerase and the specified nucleotides.
  • Lanes 1-4 contain all four natural dNTPs (100 ⁇ M, each). The reactions were carried out for 1 minute at temperatures ranging from 10 to 40° C.
  • Lanes 5-8 contain all four ANS- ⁇ -modified dNTPs (100 ⁇ M, each). The reactions were carried out for 1 minute at temperatures ranging from 10 to 40° C.
  • Lanes 9-12 contain all four natural dNTPs (100 ⁇ M, each).
  • Lanes 13-16 contain all four ANS- ⁇ -modified dNTPs (100 ⁇ M, each). The reactions were carried out for 10 minutes at temperatures ranging from 10 to 40° C. Lane 18 is a control containing 5′ radiolabeled primer (‘TOP’) in extension buffer.
  • TOP 5′ radiolabeled primer
  • primer extension reactions were performed to determine the ability of various polymerases to incorporate ⁇ -tagged dNTPs during DNA polymerization.
  • Control reactions contained natural dNTPs to monitor for template-directed nucleotide incorporation as well as for misincorporation as shown in FIG. 12 .
  • the reactions were performed in the appropriate buffer and contained the specified polymerase, primer/template duplex (radiolabeled ‘TOP’ primer annealed to ‘BOT-3TC’ template), and only the indicated dNTP.
  • the reactions were carried out at room temperature or at 37° C. for 30 minutes and were stopped by the addition of 0.5 mM EDTA.
  • the volume of the reaction was then reduced to approximately 2-4 ⁇ L, loading dye was added and the polymerization products were electrophoresed through a 20% denaturing polyacrylamide gel. Arrows indicate the position of the free labeled ‘TOP’. Asterisks indicate 3-base extension.
  • the ANS tag is thermally labile.
  • the fact can be used to allow the construction of DNA sequences with high fidelity and low fidelity regions.
  • a DNA polymerization can be started at low temperature using ANS ⁇ phosphate tagged nucleotides until a give sequence length is attained (from a statistical basis) and then the temperature can be raised to liberate the ANS tag resulting in the extension of the sequence with lowered fidelity.
  • the reverse can be done by starting with lower fidelity (untagged) nucleotides, running the polymerization for a set time, destroying any remaining untagged dNTPs with a phosphatase, and then adding the ANS tagged dNTPs and polymerizing for a second set period.
  • the medium can then be heated to allow a second lower fidelity region to be prepared.
  • the present invention can be used to prepare DNA, RNA or mixed sequences having high fidelity and low fidelity regions.
  • DNA, RNA or mixed sequences can be used to investigate evolutionary trends, analyzing the mutagenecity of different regions of DNA sequences, producing nucleic acid polymers that contain both highly accurate and reduced accuracy regions (in any combination or order) for mutagenesis studies (essentially targeted, random mutagenesis), or determine sites prone to mutations that result in disease states, carcinogenic states or change in cell phenotypes.
  • the present invention also relates to method for preparing DNA, RNA or mixed sequences with regions of different fidelity indices.
  • the present invention also relates to the following pyrophosphorolysis inhibitors selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof: Z-OPO 2 O-Z′ (a) Z-PO 2 O-Z′ (b) Z-OPO 2 -Z′ (c) Z-PO 2 -Z′ (d) Z-OPO 2 —(OP(EE′)O) n —PO 2 O-Z′ (e) Z-OPO 2 —(OP(EE′)O) n PO 2 -Z′ (f) Z-PO 2 —(OP(EE′)O) n PO 2 O-Z′ (g) Z-PO 2 —(OP(EE′)O) n PO 2 -Z′ (h) where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements, E and E′ are an oxygen
  • the present invention relates to any nucleotide or nucleotide analog bearing a tag anywhere on the nucleotide (phosphate groups, base or sugar) that improves the fidelity of nucleotide incorporation.
  • Primer extension experiments were performed with several different DNA polymerases to determine whether any of them could incorporate the ANS- ⁇ -phosphate modified nucleotides (FIG. 12 ). These experiments were performed by incubating the indicated polymerase in appropriate extension buffer, 100 ⁇ M ANS- ⁇ -modified dATP, and a 5′- 32 P end-labeled primer annealed to a template that directed sequential incorporation of dATP, dATP, dATP dGTP. Positive and negative control reactions containing natural dATP or dGTP, respectively, were run in parallel to monitor template-directed nucleotide incorporation or mis-incorporation.
  • Reactions containing dATP should produce 3-base extension products, whereas those containing dGTP should not produce extended products (due to the absence of dATP). No products longer than 3-bases should result, since no reaction contained more than one nucleotide type.
  • the reactions were allowed to proceed for 30 minutes, at which time they were stopped by EDTA addition, lyophilized and resuspended in 3.5 ⁇ l of sequencing loading buffer. Reaction products were heat denatured, loaded onto a 20% denaturing polyacrylamide gel, size-separated (2400 V; 1 hour), and detected via phosphorimaging.
  • Taq DNA polymerase I HIV-1 Reverse Transcriptase (RT)
  • RT HIV-1 Reverse Transcriptase
  • Klenow fragment of E. coli DNA polymerase I Klenow fragment of E. coli DNA polymerase I
  • a modified version of T7 DNA polymerase (Sequenase, Version 2) each incorporate the modified nucleotides.
  • Pfu DNA polymerase appears least able to incorporate these nucleotides.
  • each polymerase responded differently to the modified nucleotides.
  • the fact that several different DNA polymerases incorporate the ANS- ⁇ -phosphate modified nucleotides provides critical feasibility data for the VisiGen Sequencing System.
  • reaction products were heat denatured, loaded onto a 20% denaturing polyacrylamide gel, size-separated, and quantified using a phosphorimaging system (Fuji Medical Systems, Inc.).
  • FIG. 3 A representative primer extension analysis that demonstrates the fidelity improvement is shown ( FIG. 3 ). This is an important experiment because it illustrates the following:
  • Taq DNA polymerase does not randomly incorporate ⁇ -tagged nucleotides. Quantitative comparison of lane 1 with lane 4 demonstrates that very little non-specific, single-base extension is detected when ANS- ⁇ -dATP is included in the reaction, but the first incorporated base should be dGTP (which was not added to the reaction).
  • the ‘BOT-Sau’ template was designed to monitor sequential incorporation of dGTP, dATP, dTTP and dCTP.
  • Taq DNA polymerase accurately incorporates ⁇ -tagged nucleotides. Quantitative analysis of lanes 1 and 8 demonstrates that approximately 70% of the TOP primer strands are extended by a template-directed single base when ANS- ⁇ -dNTP is included in the reaction and the first incorporated base should be dATP. This percentage is very similar to the percent extension observed with natural dATP (75%; lane 7). However, 60% of the extension products resulting from natural dATP incorporation were misextended opposite a template C, and 34% of these products were further extended by the enzyme's terminal transferase activity.
  • DNA strand extension continues following ⁇ -tagged nucleotide incorporation. It was important to demonstrate that the polymerase could continue extension following incorporation of a ⁇ -modified dNTP. This was first accomplished by preparing reactions containing the same end-labeled ‘TOP’ primer hybridized with the ‘BOT-3TC’ template, and ANS-modified dATP. Multiple occurrences of a single-base type in the extension template were used to simplify analysis of the extension products. A single nucleotide is added to the reaction and, thus, only that nucleotide can be incorporated into the growing DNA strand. Comparison of lane 1 with lane 11 demonstrates that multiple modified nucleotides are incorporated and are, therefore, not detrimental to chain extension. Natural dATP (lane 10) is efficiently incorporated opposite Ts in the template, but is also frequently misincorporated opposite a template C. Further, these blunt-ended molecules stimulate the enzyme's terminal transferase activity and account for the formation of the 5 base extension products.
  • the inventors discovered that the fidelities of several commercially relevant DNA polymerases are improved by providing the enzyme with nucleotides containing a molecular moiety at the ⁇ -phosphate. This was further investigated by assaying the percent extension of natural and ⁇ -phosphate modified dNTP in complementary (matched) and noncomplementary (mismatched) nucleotide combinations ( FIG. 14 ). In these experiments, TOP was 5′ end-labeled, gel purified and quantified with regard to both radioactivity and absorbance at 260 nm. Primer/template hybrids were formed by heat denaturing and slow cooling primer and template strands (1:1.2 ratio).
  • Extension reactions were prepared by combining the duplex with reaction buffer, dNTP or ANS-dNTP at 100 ⁇ M, and a DNA polymerase. To increase detection of mismatch incorporation, reactions were incubated for 30 minutes and terminated by adding STOP solution. Terminated reactions were heated, placed on ice, loaded onto a 20% denaturing polyacrylamide gel and electrophoresed for ⁇ 2 hours at 30 W. Gels were dried and imaged with a phosphorimaging system (Fuji Medical Systems, Inc.). Each reaction was repeated at least three times, and the average extension and average deviation were calculated.
  • the magnitude of the fidelity improvement is influenced by the identity of the templating baseversus the incoming nucleotide.
  • C:T provides a different magnitude of improvement (15.98 fold) when compared to T:C (2.93 fold), where the first base is the template base and the second base is the incoming nucleotide. Comparing the percent extension of a natural dNTP with that of an ANS-modified dNTP, it is striking that the modified nucleotide is consistently incorporated at an improved accuracy. Additionally, the time course studies show that the incorporation of the complementary nucleotide (natural or ANS-modified) exhibit similar incorporation profiles, indicating that the fidelity improvements are not due to generally slowed reaction kinetics resulting from nucleotide modification.
  • modified dNTPs can be used to identify a set of nucleotides that work with modified polymerase as an energy transfer pair to achieve high efficiency and accurate sequence reading.
  • the positions that are of interest are the 5′- ⁇ - and 5′- ⁇ , since the modifications at these positions may not or least affect enzyme activity.
  • the inventors plan to incorporate rhodamine derivatives, such as TMR or TAMRA, for FRET detection and DABCYL for quenching detection (the enzyme in using either type of dNTP's will contain fluorescein moiety).
  • An additional linker (L) between the dye moiety and phosphorous provides flexibility to obtain better fit of the nucleotide and the enzymatic active site and may provide stabilization to the resultant modified compound.
  • the alteration at the phosphorous linkage is preferably an O (X ⁇ O).
  • O X ⁇ O
  • the sequence extension can continue after photo-deprotection of the 3′-P hv .
  • the 3′-protection is to be used along with 5′-modifications to overcome potential problems of background reading from fluorescent nucleotides.
  • Examples of the compounds the inventors plan to synthesize are the following: Set 1—these are 5′- ⁇ - or ⁇ -modifications, different dyes are needed so that different nucleotides can be differentiated by different wavelengths. These are the d-rhodamine family of molecules and have been widely used in traditional DNA sequencing. The linker and connector, HNCH 2 CH 2 O will be varied to achieve the best result.
  • AD acceptor dye molecule
  • ⁇ -modified dNTP will require first protecting the active ⁇ -phosphate.
  • the inventors do not intend to spend major effort in making these compounds, unless the ⁇ -modified molecule is a strong candidate with desirable sequencing properties.
  • the linker with dye on one side and nucleotide on the other side the inventors prefer to have amide and phosphate bonds, respectively.
  • the bond formation of the linker is through well-known coupling reactions (through isothiocyannate ester, or NHS ester, etc.).

Abstract

Nucleotide triphosphate probes containing a molecular and/or atomic tag on a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed.

Description

    RELATED APPLICATIONS
  • The present invention claims priority of U.S. patent application Ser. No. 10/007,621 filed Dec. 3, 2001, which claims provisional priority U.S. Provisional Patent Application Ser. No. 60/250,764 filed Dec. 1, 2000.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to compositions and methods for altering the fidelity of nucleic acid synthesis.
  • More particularly, the present invention relates to the following general areas: (1) nucleotide triphosphate monomers having at least one molecular or atomic tag bonded to and/or chemically and/or physically associated with one or more of the phosphate groups of the triphosphate moiety of the monomers, the base moiety, and/or the sugar moiety in the case of a nucleoside analog; (2) methods for enzymatic DNA synthesis with altered fidelity; (3) methods of sequencing DNA, based on the detection of base incorporation using tags bonded to and/or chemically and/or physically associated with the β and/or γ phosphates of the triphosphate of the nucleotide monomer, the base moiety of a nucleotide or nucleoside monomer, and/or the sugar moiety of a nucleotide or nucleoside monomer, the polymerase or by the release of the tagged pyrophosphate (PPi); (4) a template-mediated primer extension reaction with improved monomer incorporation fidelity using the tagged monomers; (5) methods for performing a primer extension reaction, such as a DNA sequencing reaction, or a polymerase chain reaction using the tagged monomers; (6) methods for improving nucleotide incorporation fidelity by adding tagged pyrophosphate (PPi) to a monomer polymerization medium, where the monomers can be tagged or untagged; and (7) kits for conducting nucleotide sequencing, a polymerase chain reaction, a templated-mediated primer extension reaction or similar reaction with improved monomer incorporation fidelity using either tagged pyrophosphate and/or untagged or tagged monomers.
  • 2. Description of the Related Art
  • Sequencing Nucleic Acids Using Tagged Monomers
  • The primary sequences of nucleic acids are crucial for understanding the function and control of genes and for applying many of the basic techniques of molecular biology. The ability to do rapid and reliable DNA sequencing is, therefore, a very important technology. The DNA sequence is an important tool in genomic analysis as well as other applications, such as genetic identification, forensic analysis, genetic counseling, medical diagnostics, etc. With respect to the area of medical diagnostic sequencing, disorders, susceptibilities to disorders, and prognoses of disease conditions, can be correlated with the presence of particular DNA sequences, or the degree of variation (or mutation) in DNA sequences, at one or more genetic loci. Examples of such phenomena include human leukocyte antigen (HLA) typing, cystic fibrosis, tumor progression and heterogeneity, p53 proto-oncogene mutations and ras proto-oncogene mutations. See, e.g., Gyllensten et al., PCR Methods and Applications, 1: 91-98 (1991); U.S. Pat. No. 5,578,443, issued to Santamaria et al., incorporated herein by reference; and U.S. Pat. No. 5,776,677, issued to Tsui et al., incorporated herein by reference.
  • Various approaches to DNA sequencing exist. The dideoxy chain termination method serves as the basis for all currently available automated DNA sequencing machines. See, e.g., Sanger et al., Proc. Natl. Acad. Sci., 74: 5463-5467 (1977); Church et al., Science, 240: 185-188 (1988); and Hunkapiller et al., Science, 254: 59-67 (1991)). Other methods include the chemical degradation method, see, e.g., Maxam et al., Proc. Natl. Acad. Sci., 74: 560-564 (1977); whole-genome approaches see, e.g., Fleischmann et al., Science, 269, 496 (1995); expressed sequence tag sequencing see, e.g., Velculescu et al., Science, 270, (1995); array methods based on sequencing by hybridization, see, e.g., Koster et al., Nature Biotechnology, 14, 1123 (1996); and single molecule sequencing (SMS), see, e.g., Jett et al., J. Biomol. Struct. Dyn. 7, 301 (1989), Schecker et al., Proc. SPIE-Int. Soc. Opt. Eng. 2386, 4 (1995), and Hardin et al. U.S. patent application Ser. No. 09/901,782, filed Jul. 9, 2001, incorporated herein by reference.
  • Fluorescent dyes can be used in a variety of these DNA sequencing techniques. A fluorophore moiety or dye is a molecule capable of generating a fluorescence signal. A quencher moiety is a molecule capable of absorbing the energy of an excited fluorophore, thereby quenching the fluorescence signal that would otherwise be released from the excited fluorophore. In order for a quencher to quench an excited fluorophore, the quencher moiety must be within a minimum quenching distance of the excited fluorophore moiety at some time prior to the fluorophore releasing the stored fluorescence energy.
  • Fluorophore-quencher pairs have been incorporated into oligonucleotide probes in order to monitor biological events based on the fluorophore and quencher being separated or brought within a minimum quenching distance of each other. For example, probes have been developed wherein the intensity of the fluorescence increases due to the separation of the fluorophore-quencher pair. Probes have also been developed which lose their fluorescence because the quencher is brought into proximity with the fluorophore.
  • These fluorophore-quencher pairs have been used to monitor hybridization assays and nucleic acid amplification reactions, especially polymerase chain reactions (PCR), by monitoring either the appearance or disappearance of the fluorescence signal generated by the fluorophore molecule.
  • The decreased fluorescence of a fluorophore moiety by collision or direct interaction with a quencher is due mainly to a transfer of energy from the fluorophore in the excited state to the quencher. The extent of quenching depends on the concentration of quencher and is described by the Stern-Volmer relationship:
    F 0 /F=1+K sv [Q]
    wherein F0 and F correspond to the fluorescence in the absence and presence of quencher, respectively, and [Q] is the quencher concentration. A plot of F0/F versus [Q] yields a straight line with a slope corresponding to the Stern-Volmer constant, Ksv. The foregoing equation takes into account the dynamic and collisional quenching which is the dominant component of the quenching reaction. A linear S-V plot can be obtained when the quenching is completely due to a dynamic (or collisional) process or a static complex formation. A non-linear plot will occur when both static and collisional quenching are occurring simultaneously (see, A. M. Garcia, Methods in Enzymology, 207, 501-511 (1992)).
  • In general, fluorophore moieties preferably have a high quantum yield and a large extinction coefficient so that the dye can be used to detect small quantities of the component being detected. Fluorophore moieties preferably have a large Stokes shift (i.e., the difference between the wavelength at which the dye has maximum absorbance and the wavelength at which the dye has maximum emission) so that the fluorescent emission is readily distinguished from the light source used to excite the dye.
  • One class of fluorescent dyes which has been developed is the energy transfer fluorescent dyes. For instance, U.S. Pat. Nos. 5,800,996, and 5,863,727, issued to Lee et al., disclose donor and acceptor energy fluorescent dyes and linkers useful for DNA sequencing, incorporated therein by reference. Other fluorophore-quencher pairs are disclosed in PCT Application Serial No. PCT/US99/29584, incorporated herein by reference. In energy transfer fluorescent dyes, the acceptor molecule is a fluorophore which is excited at the wavelength of light corresponding to the fluorescence emission the excited donor molecule. When excited, the donor dye transmits its energy to the acceptor dye.
  • Therefore, emission from the donor is partially or totally quenched due to partial or total energy transfer from the excited donor to the acceptor dye, resulting in the excitation of the latter for emission at its characteristic wavelength (i.e., a wavelength different from that of the donor dye which may represent a different color if the emissions are in the visible portion of the spectrum). The advantage of this mechanism is twofold; the emission from the acceptor dye is more intense than that from the donor dye alone when the acceptor has a higher fluorescence quantum yield than the donor (see, Li et al., Bioconjugate Chem., 10: 242-245, (1999)) and attachment of acceptor dyes with differing emission spectra allows differentiation among molecules by fluorescence using a single excitation wavelength.
  • Nucleotide triphosphates having a fluorophore moiety attached to the γ-phosphate are of interest as this modification still allows the modified NTPs to be enzyme substrates. For instance, Felicia et al., describe the synthesis and spectral properties of a “always-on” fluorescent ATP analog, adenosine-5′-triphosphoroyl-(5-sulfonic acid)naphthyl ethylamindate (γ-1,5-EDANS) ATP. Yarbrough et al. 1978, JBC. The analog is a good substrate for E. coli RNA polymerase and can be used to initiate the RNA chain. The ATP analog is incorporated into the RNA synthesized and is a good probe for studies of nucleotide-protein interactions, active site mapping and other ATP-utilizing biological systems. See, e.g., Felicia et al., Arch. Biochem Biophys., 246: 564-571 (1986).
  • In addition, Sato et al., disclose a homogeneous enzyme assay that uses a fluorophore moiety (bimane) attached to the γ-phosphate group of the nucleotide and a quencher moiety attached to the 5-position of uracil. The quencher moiety is in the form of a halogen, bound to the C-5 position of the pyrimidine. The quenching that is effected by this combination is eliminated by cleavage of the phosphate bond by the phosphodiesterase enzyme. The halogen quencher used in the assay is very inefficient producing only about a two fold decrease in fluorescent efficiency.
  • Template-Mediated Primer Extension Reaction
  • In a template-mediated primer extension reaction, an oligonucleotide primer having homology to a single-stranded template nucleic acid is caused to anneal to a template nucleic acid, the annealed mixture is then provided with a DNA polymerase in the presence of nucleoside triphosphates under conditions in which the DNA polymerase extends the primer to form a complementary strand to the template nucleic acid. In a Sanger-type DNA sequencing reaction, the primer is extended in the presence of a chain-terminating agent, e.g., a dideoxynucleoside triphosphate, to cause base-specific termination of the primer extension (Sanger). In a polymerase chain reaction, two primers are provided, each having homology to opposite strands of a double-stranded DNA molecule. After the primers are extended, they are separated from their templates, and additional primers caused to anneal to the templates and the extended primers. The additional primers are then extended. The steps of separating, annealing, and extending are repeated in order to geometrically amplify the number of copies of the template nucleic acid (Saiki).
  • In both DNA sequencing and PCR, it is critically important that the primer extension product accurately replicate the nucleotide sequence of the template nucleic acid. However, under certain conditions, peak “dropout” has been observed wherein certain nucleotides are not represented in the primer extension product. This problem is believed to be caused by pyrophosphorolysis of the primer extension product by a reverse nucleotide addition reaction promoted by the accumulation of pyrophosphates in the reaction mixture. See Mullis; Tabor 1990; Tabor 1996.
  • Pyrophosphate Effects on Nucleic Acid Synthesis and/or Sequencing
  • It has been recognized that pyrophosphorolysis, where an oligonucleotide is reduced in length, is detrimental to primer extension reactions. The pyrophosphorolysis is caused by the availability of pyrophosphate. For example, PCR is inhibited by the addition of pyrophosphate even at very low concentrations. According to U.S. Pat. No. 5,498,523, this pyrophosphorolysis can be prevented by providing an agent, for example, a pyrophosphatase, capable of removing pyrophosphate. Addition of pyrophosphatase to a PCR greatly enhances the progress of the reaction and provides superior results compared to the reaction without a pyrophosphatase. See U.S. Pat. No. 4,800,159, incorporated herein by reference.
  • Similarly, the addition of a pyrophosphatase to a sequencing reaction provides more uniformity in intensities of bands formed in a polyacrylamide gel used to identify products of the sequencing reaction. This uniformity is due to prevention of degradation of specific DNA products by pyrophosphorolysis. See also, Tabor, S. and Richardson, C. C., J. Biol. Chem. 265:8322 (1990) and U.S. Pat. No. 4,962,020, incorporated herein by reference.
  • Each product or band in a dideoxy sequencing experiment is a polynucleotide complementary to the template and terminated at the 3′ end in a base-specific manner with a dideoxynucleotide. The dideoxy stabilizes the product, preventing further polymerization of the polynucleotide. However, in certain regions of the template, the bands, especially after prolonged reaction, will reduce in intensity or completely disappear (“drop-out” bands). In certain sequence contexts, the PPi contained within the enzyme is thought to remain there for an extended period of time. A drop-out may not be readily detected by the operator, leading to errors in the interpretation of the data either by a human or computer-driven analyzer. Since this phenomenon is stimulated by inorganic pyrophosphate, the effect is presumably due to pyrophosphorolysis (reverse polymerization), not 3′-exonucleolytic activity. It is hypothesized that DNA polymerase idling at the end of these terminated products and in the presence of sufficient pyrophosphate will remove the dideoxynucleotide, then extend from the now free 3′-hydroxyl end to another dideoxy termination. In effect, the bands are converted to longer polynucleotides bands. Removal of pyrophosphate as it is generated in the polymerization reaction eliminates this problem.
  • Sequencing by Direct Detection of Released Tagged Pyrophosphate
  • Researchers have used a series of enzyme reactions coupled to pyrophosphate generation to measure DNA polymerase activity. In the first (P. Nyren, Anal. Biochem. 167:235 (1987)), Nyren used ATP: sulfate adenylyltransferase to convert pyrophosphate and adenosine 5′-phosphosulfate to ATP and sulfate ion. The ATP was used to make light with luciferase. In the second (J. C. Johnson et al., Anal. Biochem. 26:137 (1968)), the researchers reacted the pyrophosphate with UDP-glucose in the presence of UTP: glucose-1-phosphate uridylyltransferase to produce UTP and glucose-1-phosphate. In two more steps, polymerase activity was measured spectrophotometrically by the conversion of NADP to NADPH. While these articles describe the use of ATP: sulfate adenylyltransferase and UTP: glucose-1-phosphate uridylyltransferase in measuring DNA polymerase activity, they do not describe their use to prevent or inhibit pyrophosphorolysis in nucleic acid synthesis reactions.
  • DNA sequencing is an essential tool in molecular genetic analysis. The ability to determine DNA nucleotide sequences has become increasingly important as efforts have commenced to determine the sequences of the large genomes of humans and other higher organisms.
  • The two most commonly used methods for DNA sequencing are the enzymatic chain-termination method of Sanger and the chemical cleavage technique of Maxam and Gilbert.
  • Both methods rely on gel electrophoresis to resolve, according to their size, DNA fragments produced from a larger DNA segment. Since the electrophoresis step as well as the subsequent detection of the separated DNA fragments are cumbersome procedures, a great effort has been made to automate these steps. However, despite the fact that automated electrophoresis units are commercially available, electrophoresis is not well suited for large-scale genome projects or clinical sequencing where relatively cost-effective units with high throughput are needed. Thus, the need for nonelectrophoretic methods for sequencing is great and several alternative strategies have been described, such as scanning tunnel electron microscopy (Driscoll et al. 1990, Nature, 346, 294-296), sequencing by hybridization (Bains et al., 1988, J. Theo. Biol. 135, 308-307) and single molecule detection (Jeff et al., 1989, Biomol. Struct. Dynamics, 7, 301-306), to overcome the disadvantages of electrophoresis.
  • Techniques enabling the rapid detection of a single DNA base change are also important tools for genetic analysis. In many cases detection of a single base or a few bases would be a great help in genetic analysis since several genetic diseases and certain cancers are related to minor mutations. A mini-sequencing protocol based on a solid phase principle was described (Hultman, et al., 1988, Nucl. Acid. Res., 17, 4937-4946; Syvanen et al., 1990, Genomics, 8, 684-692). The incorporation of a radio labeled nucleotide was measured and used for analysis of the three-allelic polymorphism of the human apolipoprotein E gene. However, radioactive methods are not well suited for routine clinical applications and hence the development of a simple non-radioactive method for rapid DNA sequence analysis has also been of interest.
  • Methods of sequencing based on the concept of detecting inorganic pyrophosphate (PPi) which is released during a polymerase reaction have been described (WO 93/23564 and WO 89/09283). As each nucleotide is added to a growing nucleic acid strand during a polymerase reaction, a pyrophosphate molecule is released. It has been found that pyrophosphate released under these conditions can be detected enzymically e.g. by the generation of light in the luciferase-luciferin reaction. Such methods enable a base to be identified in a target position and DNA to be sequenced simply and rapidly whilst avoiding the need for electrophoresis and the use of harmful radio labels. See for example U.S. Pat. Nos. 5,498,523, incorporated herein by reference.
  • However, the PPi-based sequencing methods mentioned above are not without drawbacks. The template must be washed thoroughly between each nucleotide addition to remove all non-incorporated deoxynucleotides. This makes it difficult to sequence a template which is not bound to a solid support. In addition new enzymes must be added with each addition of deoxynucleotide.
  • Thus, there is a need for improved methods of sequencing which allow rapid detection, have increase fidelity and provision of sequence information and which are simple and quick to perform, lending themselves readily to automation.
  • SUMMARY OF THE INVENTION
  • The present invention overcomes the deficiencies of the prior art and provides a nucleotide polymerization using nucleotides having a molecular and/or atomic tag bonded to or associated with the nucleotide or nucleoside to alter fidelity of nucleotide incorporation. In a preferred embodiment, the tag is bonded to or associated with a portion of the nucleotide that is released after nucleotide incorporation in a growing polymer chain. Preferably, the released portion is the pyrophosphate moiety including the β and γ phosphate groups.
  • When a pyrophosphate group having a molecular and/or atomic tag bonded to or associated therewith is released from the nucleoside triphosphate upon incorporation in a growing polymer chain, the tagged pyrophosphate group does not (significantly) stimulate pyrophosphorolysis.
  • The present invention also provides a method for preventing reverse polymerization or depolymerization of polymer formed using single-molecule sequencing methods as set forth in U.S. Prov. Pat. Appln. Ser. No. 60/216,594, filed Jul. 7, 2000 and U.S. patent application Ser. No. 09/901,782, filed Jul. 9, 2001, incorporated herein by reference.
  • The present invention further provides a method for improving incorporation fidelity by adding a modified PPi to a nucleoside polymerization medium in an amount sufficient to improve incorporation fidelity and/or to inhibit of pyrophosphorolysis of formed products. Preferred modified pyrophosphates include pyrophosphates bearing a group on one or both phosphate moieties that reduce, inhibit or prevent pyrophosphorolysis or pyrophosphates produced from NTPs or dNTPs having a group on the β and/or γ phosphate moiety.
  • The present invention provides a heterogeneous assay for detecting base incorporation and pyrophosphate cleavage. The assay utilizes labeled NTPs or dNTPs, a target nucleic acid, a primer nucleic acid and a polymerase. The assay includes the steps of flowing the labeled nucleotide triphosphate (NTP, dNTP, etc.) having a molecular and/or atomic tag bonded to or associated with the β- and/or γ-phosphate past an immobilized component selected from the group consisting of the polymerase, the primer and the target nucleic acid. Next, the appropriate labeled NTP or dNTP is incorporated on the primer strand hybridized to the target nucleic acid using the polymerase and results in the release of a tagged pyrophosphate from the dNTP. The incorporation event or the release event can be detected either by measuring a detectable property of the NTP or dNTP upon binding and/or during incorporation or by measuring a detectable property of the released pyrophosphate. The detectable property can be a property inherent in the molecular or atomic tags or produced as a result of the interaction between the molecular or atomic tag on the phosphates of the label NTP or released pyrophosphate and other tags bonded to or associated with the polymerase, the matrix or mobile or immobile components in the media.
  • The present invention also provides a polymerase immobilized on a solid support and a labeled nucleotide triphosphate selected from the group consisting of dATP, dCTP, dGTP, dTTP, dUTP, ATP, CTP, GTP, UTP and mixtures thereof, where the tags are molecular and the molecules are fluorophores and the detectable property is fluorescent light emission or quenching. The detection of the fluorescent light is preferably accomplished using single molecule detection such as a charge couple device (CCD) camera or intensified CCD camera systems or the like.
  • The present invention provides kits and integrated systems for practicing the assays described herein. In certain aspects, the present invention provides a kit for assaying pyrophosphate cleavage, comprising: (a) a plurality of nucleotides triphosphates each having a γ-phosphate with a distinguishing fluorophore moiety attached thereto and each having a quencher moiety sufficiently proximal to the distinguishing fluorophore moiety to prevent fluorescence of the distinguishing fluorophore moiety; wherein the distinguishing fluorophore moiety exists quenched with at least about a 5 fold quenching efficiency when the γ-phosphate is attached to each of the plurality of dNTP moieties and each is unquenched when the γ-phosphate is detached from each of the plurality of dNTP moieties; and (b) a polymerase. Preferably, the polymerase is immobilized on a solid support.
  • The present invention provides a primer extension method in which the extent of pyrophosphorolysis of a primer extension product is reduced, and solutions and kits useful for practicing the method.
  • The present invention provides a primer extension method wherein “peak drop-out” is reduced and the fidelity of template-sequence reproduction is maximized.
  • The present invention provides an improved method for performing a primer extension reaction including the steps of annealing an oligonucleotide primer to a portion of a template nucleic acid thereby forming a primer template hybrid; adding primer-extension reagents including a NTP or dNTP having a β- and/or γ-phosphate moiety having a molecular and/or atomic tag bonded to or associated with the β- and/or γ-phosphate moiety to the primer-template hybrid for extending the primer; and optionally adding a co-substrate-enzyme pair to the primer-template hybrid for conducting a pyrophosphate-utilizing reaction, where the tagged, released pyrophosphate reduces the amount of pyrophosphorolysis in the reaction. One should recognize that the release PPi is a modified PPi and acts to inhibit deleterious interference untagged PPi has on nucleotide polymerization.
  • The present invention provides a method of inhibiting or preventing pyrophosphorolysis during synthesis of a nucleic acid molecule, said method comprising: (a) combining one or more nucleotides having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the nucleoside and a nucleic acid template; (b) incubating the one or more nucleotides and nucleic acid template, under conditions sufficient to form a second nucleic acid molecule complementary to all or a portion of the nucleic acid template.
  • The method of the invention more specifically relates to a method of inhibiting or preventing pyrophosphorolysis, said method comprising: (a) combining a primer with a nucleic acid template under conditions sufficient to form a hybridized product; and (b) incubating said hybridized product in the presence of (i) one or more nucleotides having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the nucleoside, and (ii) a polymerase, and (iii) optionally an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with alcohol group as acceptor, a nucleotidyltransferase, and a carboxy-lyase under conditions sufficient to synthesize a second nucleic acid molecule complementary to all or a portion of said nucleic acid template.
  • Specifically, the method of the present invention relates to inhibition of pyrophosphorolysis in the synthesis of DNA and RNA molecules using the appropriate nucleotides having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the nucleoside and polymerases (dNTPs/rNTPs and DNA polymerase/RNA polymerase).
  • The present invention provides a primer extension reaction to prevent the inhibition of nucleic acid synthesis during amplification and to prevent band drop out in sequencing reactions. Thus, the method to prevent inhibition of nucleic acid synthesis during amplification of a double stranded nucleic acid molecule comprises: (a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3′ termini of the first strand of said nucleic acid molecule and said second primer is complementary to a sequence at or near the 3′ termini of the second strand of said nucleic acid molecule; (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of (i) a polymerase, and (ii) optionally an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as an acceptor, a nucleotidyltransferase and a carboxy-lyase under conditions such that a third nucleic acid molecule complementary to said first strand and a fourth nucleic acid molecule complementary to said second strand are synthesized from nucleosides having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the nucleoside; (c) denaturing said first and third strand and said second and fourth strand; and (d) repeating steps (a) to (c) one or more times. Again, the PPi released in the nucleotide polymerization of this invention do not cause the deleterious effects that nascent PPi can cause, therefore, the need to enzymatically degrade PPi is only for optional protection.
  • The present invention also provides a method of sequencing a DNA molecule comprising: (a) combining a primer with a first DNA molecule under conditions sufficient to form a hybridized product; (b) contacting said hybridized product with nucleotides having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the nucleoside, a DNA polymerase, optionally an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as acceptor, a nucleotidyltransferase and a carboxy-lyase; and a terminator nucleotide to give a reaction mixture; (c) incubating the reaction mixture under conditions sufficient to synthesize a population of DNA molecules complementary to said first DNA molecule, wherein said synthesized DNA molecules are shorter in length than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucleotide at their 3′ termini; and (d) separating said synthesized DNA molecules by size so that at least a part of the nucleotide sequence of said first DNA molecule can be determined.
  • In addition to reducing band drop out, which is believed to result from a ddNTP being added and then being release due to reattaching release pyrophosphate followed by standard extension, thereby, producing under representation of that position in the DNA sequence data, the use of β- and/or γ-phosphate modified nucleotides will result in improved sequencing using traditional fluorescent sequencing reaction due to a decrease in background and/or reduction in band spreading. The first improvement would result from using β- and/or γ-phosphate modified dideoxynucleotidesm which are incorporated at improved accuracy (less incorporation of incorrect ddNTP, reducing background signal). While the second improvement would result from using β- and/or γ-phosphate modified nucleotides to produce identical (or substantially identical) DNA polymers instead of the population of molecules that result from inaccurate incorporation of dNTPs. Thus, the traditional fluorescent sequencing reaction can undergo a two stage improvement by using β- and/or γ-phosphate modified nucleotides and β- and/or γ-phosphate modified dideoxy nucleotides.
  • The present invention provides a novel modified PPi-based sequencing method for sequencing reactions, where the method can be performed without intermediate washing steps, enabling the procedure to be carried out simply and rapidly, for example in a single micro titre plate. Moreover, the method can be performed with immobilized DNA in solution or on a support or with mobile DNA and immobilized polymerase in solution or on a support. Furthermore, the method can be readily adapted to permit the sequencing reactions to be continuously monitored in real-time, with a signal being generated and detected, as each nucleotide is incorporated.
  • The present invention provides a method of identifying a base at a target position in a sample DNA sequence wherein an extension primer, which hybridizes to the sample DNA immediately adjacent to the target position is provided and the sample DNA and extension primer are subjected to a polymerase reaction in the presence of a deoxynucleotide having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the nucleoside or dideoxynucleotide having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the nucleoside whereby the tagged deoxynucleotide or tagged dideoxynucleotide will only become incorporated and release tagged pyrophosphate (tPPi) if it is complementary to the base in the target position, any incorporation and/or release of tPPi may be detected via any detection method capable of identifying a detectable property of the tagged deoxynucleotide, tagged dideoxynucleotide or tagged pyrophosphate, different tagged deoxynucleotides or tagged dideoxynucleotides being added either to separate aliquots of sample-primer mixture or successively to the same sample-primer mixture and subjected to the polymerase reaction to indicate which tagged deoxynucleotide or tagged dideoxynucleotide is incorporated, optionally characterised in that, a nucleotide-degrading enzyme is included during the polymerase reaction step, such that unincorporated nucleotides are eliminated.
  • The present invention is also ideally suited for single nucleotide extensions reactions because the tagged PPi released during incorporation does not cause the deleterious effects associated with the release of nascent PPi, and where the fidelity of the tagged nucleotide incorporation in improved.
  • The invention also provides a kit for carrying out nucleic acid syntheses with improved fidelity comprising a container including a polymerizing compartment comprising a nucleic acid polymerizing agent, a monomer compartment comprising nucleotide monomers for the polymerizing agent and a fidelity enhancing agent compartment comprising a fidelity enhancing agent, where the fidelity enhancing agent comprises a tagged-phosphate, tagged-pyrophosphate or tagged-polyphosphate or derivatives thereof.
  • The invention also provides a kit for carrying out nucleic acid syntheses with improved fidelity comprising a container including a polymerizing compartment comprising a nucleic acid polymerizing agent and a monomer compartment comprising nucleotide monomers for the polymerizing agent, where the monomers comprise dNTPs, ddNTPs, β- and/or γ-phosphate modified nucleotides, β- and/or γ-phosphate modified dideoxy nucleotides or mixtures or combinations thereof.
  • The invention also provides a kit for carrying out nucleic acid syntheses with improved fidelity comprising a container including a polymerizing compartment comprising a nucleic acid polymerizing agent and monomer compartments, each compartment comprising a nucleotide monomer for the polymerizing agent, where the monomers comprise dNTPs, ddNTPs, β- and/or γ-phosphate tagged dNTPs, β- and/or γ-phosphate tagged ddNTPs or mixtures or combinations thereof.
  • DESCRIPTION OF THE DRAWINGS
  • The invention can be better understood with reference to the following detailed description together with the appended illustrative drawings in which like elements are numbered the same:
  • FIG. 1 depicts the incorporation of ANS-γ-phosphate dATP using Taq polymerase and a primer;
  • FIG. 2 depicts the synthesis of extended DNA polymers using all four ANS-γ-phosphated tagged dNTPs and the Taq polymerase;
  • FIG. 3 depicts the synthesis of long DNA polymers using all four ANS-γ-phosphated tagged dNTPs and the Taq polymerase;
  • FIG. 4 depicts the use of γ-modified nucleotides with the Klenow fragment from E. coli DNA polymerase to form DNA polymer;
  • FIG. 5 depicts the use of γ-modified nucleotides with the Pfu DNA polymerase that shows this polymerase does not efficiently use γ-modified nucleotides;
  • FIG. 6 depicts the use of γ-modified nucleotides using HIV-1 reverse transcriptase to efficiently form DNA polymers;
  • FIG. 7 depicts the experimental results for native T7 DNA polymerase and Sequenase;
  • FIG. 8 depicts the effect of elevated temperature on ANS-tagged dATPs and ANS-tagged dATPs;
  • FIG. 9 depicts the effect of elevated temperature on ANS-tagged dCTPs and ANS-tagged dGTPs;
  • FIG. 10 depicts the effect of temperature and time on the ability of Taq DNA Polymerase to produce extended DNA products from primer/template duplexes;
  • FIG. 11 depicts the addition of an ANS-γ-tag to natural dNTPs affects the terminal transferase activity of commercially available Taq DNA Polymerase;
  • FIG. 12 depicts a summary of extension results for various polymerase incorporating ANS-tagged dNTPs;
  • FIG. 13 depicts data from time course experiments demonstrating similar incorporation of natural and γ-phosphate modified nucleotide using HIV reverse transcriptase; and
  • FIG. 14 TOP: Representative gels demonstrating the results obtained in single nucleotide extension assays using the Bot-C template. Incorporation of matched (dGTP & ANS-dGTP, above) and mismatched (dTTP & ANS-dTTP, below) nucleotides are shown. BOTTOM: Graphic presentation of the fidelity improvements afforded by ANS addition to the γ-phosphate of each dNTP. The increase in percent extension of the natural nucleotide relative to the ANS-tagged nucleotide is indicated above the natural nucleotide.
  • DEFINITIONS
  • Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:
  • The term “heterogeneous” assay as used herein refers to an assay method wherein at least one of the reactants in the assay mixture is attached to a solid phase, such as a solid support.
  • The term “oligonucleotide” as used herein includes linear oligomers of nucleotides or analogs thereof, including deoxyribonucleosides, ribonucleosides, and the like. Usually, oligonucleotides range in size from a few monomeric units, e.g. 3-4, to several hundreds of monomeric units. Whenever an oligonucleotide is represented by a sequence of letters, such as “ATGCCTG”, it will be understood that the nucleotides are in 5′-3′ order from left to right and that “A” denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxyguanosine, and “T” denotes thymine, unless otherwise noted.
  • The term “nucleoside” as used herein refers to a compound consisting of a purine, deazapurine, or pyrimidine nucleoside base, e.g., adenine, guanine, cytosine, uracil, thymine, deazaadenine, deazaguanosine, and the like, linked to a pentose at the 1′ position, including 2′-deoxy and 2′-hydroxyl forms, e.g., as described in Komberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992) and further include, but are not limited to, synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g. described generally by Scheit, Nucleotide Analogs (John Wiley, N.Y., 1980). Suitable NTPs include both naturally occurring and synthetic nucleotide triphosphates, and are not limited to, ATP, dATP, CTP, dCTP, GTP, dGTP, TTP, dTTP, ITP, dITP, UTP and dUTP. Preferably, the nucleotide triphosphates used in the methods of the present invention are selected from the group of dATP, dCTP, dGTP, dTTP, dUTP and mixtures thereof.
  • The term “nucleotide” as used herein refers to a phosphate ester of a nucleoside, e.g., mono, di and triphosphate esters, wherein the most common site of esterification is the hydroxyl group attached to the C-5 position of the pentose and includes deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof such as their dideoxy derivatives: ddATP, ddCTP, ddITP, ddUTP, ddGTP, ddTTP. Such derivatives include, for example [aS]dATP, 7-deaza-dGTP and 7-deaza-dATP. The term “nucleotide” as used herein also refers to ribonucleoside triphosphates (NTPs) and their derivatives. Illustrated examples of ribonucleoside triphosphates include, but are not limited to, ATP, CTP, GTP, ITP and UTP.
  • The term “primer” refers to a linear oligonucleotide which specifically anneals to a unique polynucleotide sequence and allows for amplification of that unique polynucleotide sequence or to a nucleic acid, e.g., synthetic oligonucleotide, which is capable of annealing to a complementary template nucleic acid and serving as a point of initiation for template-directed nucleic acid synthesis. Typically, a primer will include a free hydroxyl group at the 3′-end.
  • The phrase “sequence determination” or “determining a nucleotide sequence” in reference to polynucleotides includes determination of partial as well as full sequence information of the polynucleotide. That is, the term includes sequence comparisons, fingerprinting, and like levels of information about a target polynucleotide, or oligonucleotide, as well as the express identification and ordering of nucleotides, usually each nucleotide, in a target polynucleotide. The term also includes the determination of the identification, ordering, and locations of one, two, or three of the four types of nucleotides within a target polynucleotide.
  • The term “solid-support” refers to a material in the solid-phase that interacts with reagents in the liquid phase by heterogeneous reactions. Solid-supports can be derivatized with proteins such as enzymes, peptides, oligonucleotides and polynucleotides by covalent or non-covalent bonding through one or more attachment sites, thereby “immobilizing” the protein or nucleic acid to the solid-support.
  • The phrase “target nucleic acid” or “target polynucleotide” refers to a nucleic acid or polynucleotide whose sequence identity or ordering or location of nucleosides is to be determined using methods described herein.
  • The term “primer-extension reagent” means a reagent including components necessary to effect the enzymatic template-mediated extension of a primer. Primer extension reagents include: (i) a polymerase enzyme, e.g., a thermostable polymerase enzyme such as Taq DNA polymerase, and the like; (ii) a buffer to stabilize pH; (iii) deoxynucleotide triphosphates, e.g., deoxyguanosine 5′-triphosphate, 7-deazadeoxyguanosine 5′-triphosphate, deoxyadenosine 5′-triphosphate, deoxythymidine 5′-triphosphate, deoxycytidine 5′-triphosphate; and, optionally in the case of a Sanger-type DNA sequencing reaction, (iv) dideoxynucleotide triphosphates, e.g., dideoxyguanosine 5′triphosphate, 7-deazadideoxyguanosine 5′-triphosphate, dideoxyadenosine 5′-triphosphate, dideoxythymidine 5′-triphosphate, dideoxycytidine 5′-triphosphate, and the like.
  • As used herein, the term “pyrophosphate” refers to two phosphate molecules bound together by an ester linkage, e.g., the structure −2O3P—O—PO3 −2.
  • The term “nucleotide-degrading enzyme” as used herein includes all enzymes capable of non-specifically degrading nucleotides, including at least nucleoside triphosphates (NTPs), but optionally also di- and monophosphates, and any mixture or combination of such enzymes, provided that a nucleoside triphosphatase or other NTP degrading activity is present. Although nucleotide-degrading enzymes having a phosphatase activity may conveniently be used according to the invention, any enzyme having any nucleotide or nucleoside degrading activity may be used, e.g., enzymes which cleave nucleotides at positions other than at the phosphate group, for example at the base or sugar residues. Thus, a nucleoside triphosphate degrading enzyme is essential for the invention.
  • The term “atomic tag” means an atom or ion of an atom that when attached to a nucleotide increase the fidelity of a nucleotide polymerizing agent such as a polymerase at the atom tagged nucleotide is incorporated into a nucleotide sequence.
  • The term “molecular tag” means an atom or ion of an atom that when attached to a nucleotide increase the fidelity of a nucleotide polymerizing agent such as a polymerase at the atom tagged nucleotide is incorporated into a nucleotide sequence.
  • The term “polymerizing agent” means any naturally occurring or synthetic agent capable of polymerizing nucleotides to produce polynucleotide, including polymerases, reverse transcriptases, or the related naturally occurring nucleotide polymerizing systems. The term polymerizing agent also includes variants of naturally occurring polymerases or reverse transcriptases where one or more amino acids have been added to, removed from or replaced in the nature amino acid sequence. Thus, the term covers all known and to be constructed systems capable of forming oligomers or polymers of nucleotides.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The inventors have found that nucleotide monomers or analogs thereof bearing an atomic and/or molecular tag on a site of the molecule can increase the fidelity of nucleotide polymerization for nucleotide polymerization agents that can incorporated the modified monomers. This increase in fidelity is useful for improving nucleic acid sequencing determinations using any of the standard sequencing reactions such as PCR, rolling circle or the like. Additionally, these modified monomers may allows the construction of drugs for animal or human use that would increase the fidelity of viral disease replication in vivo decreasing mutagensis allowing the immune system to recognize the virus. Such a medication may be of particular benefit for virus such as the HIV virus that causes AIDS.
  • Mutation of amino acids within the polymerase is the classic approach to understand enzyme action and/or modulate enzyme fidelity (Yang S and Chatterjee D K. (1999) PCT WO9910366; Wainberg M A, Drosopoulos W C, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad V R. (1996) Science 271:1282-5; Drosopoulos W C, Rezende L F, Wainberg M A, Prasad V R. (1998) J Mol Med 76:604-12; Lewis D A, Bebenek K, Beard W A, Wilson S H, Kunkel T A. (1999) J Biol Chem 274:32924-30; Kim B, Ayran J C, Sagar S G, Adman E T, Fuller S M, Tran N H, Horrigan J. (1999) J Biol Chem 274:27666-73. In stark distinction to this classical approach, the inventors have found a novel approach in that fidelity is improved by manipulating the substrate.
  • Invention Scope
  • The present invention relates to a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a β and/or γ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation.
  • The present invention relates to a method comprising the step of adding a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a β and/or γ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • The present invention relates to a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a β phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation.
  • The present invention relates to a method comprising the step of adding a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a β phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • The present invention relates to a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a γ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation.
  • The present invention relates to a method comprising the step of adding a composition comprising a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a γ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • The present invention relates to a method comprising the step of adding a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a β and/or γ phosphate group to an assay involving a polymerase and/or a base moiety, where the tag alters fidelity of base incorporation and the assay is selected from the group consisting of genotyping for in vitro reproductive methods (human and other organisms); single nucleotide polymorphism (SNP) detection; DNA sequencing; RNA sequencing; single nucleotide extension assays; amplified DNA product assays; rolling circle product assays; PCR product assays; allele-specific primer extension assays; single-molecule arrays (DNA, RNA, protein) assays; drug toxicity evaluation assays; or the like. The method can be used to extend a nucleic acid molecule by any number of bases depending on the polymerizing reaction selected. Thus, the molecule can be extended by a single nucleotide up to many thousands of nucleotide to or hundred of thousands of bases.
  • The present invention relates to a method for making blunt-ended fragments comprising the steps of amplifying a DNA fragment in the presence of a nucleotides including deoxyribonucleotide, dideoxynucleotide, or ribonucleotide including a molecular and/or atomic tag on a γ phosphate group and/or a base moiety, where the tag alters fidelity of base incorporation and decreases or eliminates non-templated addition of a base to the 3′ end of the DNA fragment being amplified. Preferably, the amplifying step is a PCR amplification step.
  • The present invention relates to a composition comprising a pyrophosphorolysis inhibitors selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof:
    Z-OPO2O-Z′  (a)
    Z-PO2O-Z′  (b)
    Z-OPO2-Z′  (c)
    Z-PO2-Z′  (d)
    Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
    Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
    Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
    Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
    where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements, E and E′ are an oxygen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements and n is an integer having a value between 0 and about 5.
  • The present invention relates to a method comprising the step of polymerizing a nucleic acid sequence in the presence of a composition comprising a pyrophosphorolysis inhibitors selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof:
    Z-OPO2O-Z′  (a)
    Z-PO2O-Z′  (b)
    Z-OPO2-Z′  (c)
    Z-PO2-Z′  (d)
    Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
    Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
    Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
    Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
    where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements, E and E′ are an oxygen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements and n is an integer having a value between 0 and about 5.
  • The present invention relates to a heterogeneous assay method for detecting pyrophosphate cleavage, the components of the assay comprising a labeled NTP, a target nucleic acid, a primer nucleic acid and a polymerase, said method comprising: (a) flowing said tagged nucleotide triphosphate (NTP), where a β and/or γ phosphate group and/or a base moiety of the NTP includes an atomic and/or molecular tag having a detectable property attached thereto or associated therewith; (b) incorporating said NTP on a primer strand hybridized to said target nucleic acid using said polymerase and releasing said γ-phosphate with said fluorophore moiety attached thereto; and (c) detecting said fluorescent moiety thereby detecting pyrophosphate cleavage. In one preferred assay, the nucleotide triphosphate (NTP) is a member selected from the group consisting of deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanosine triphosphate and deoxythymidine triphosphate. In another preferred assay, the nucleotide triphosphate (NTP) is a member selected from the group consisting of adenosine triphosphate, cytosine triphosphate, guanosine triphosphate and uridine triphosphate. In another preferred assay, the tags are a fluorescent species which is detected based upon a change in either intensity measurement or fluorescent lifetime measurement. In another preferred assay, the nucleotide triphosphate (NTP) is a plurality of nucleotide triphosphates (NTPs). In another preferred assay, each of said plurality of nucleotide triphosphates (NTPs) has an indicator of identity associated with the tag. In another preferred assay, the polymerase is a member selected from the group consisting of a DNA polymerase, a DNA dependent RNA polymerase and a reverse transcriptase, particularly, where the polymerase is a DNA polymerase, especially, where the polymerase is immobilized on a solid support. In another preferred assay, the polymerase is supported on a solid support that is a member selected from the group consisting of controlled pore glass, a glass plate, polystyrene, an avidin coated polystyrene bead, cellulose, nylon, acrylamide gel and activated dextran.
  • The present invention relates to a nucleotide triphosphate (NTP) probe comprising a NTP including an atomic and/or molecular tag having a detectable property attached thereto or associated therewith a β and/or γ phosphate group and/or a base moiety of the NTP. In another preferred probe, the NTP is a member selected from the group consisting of a deoxynucleotide triphosphate (dNTP), a nucleotide triphosphate (NTP) and analogs thereof, particularly, where there NTP is a deoxynucleotide triphosphate (dNTP), especially, where the deoxynucleotide triphosphate (dNTP) is a member selected from the group consisting of deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanosine triphosphate and deoxythymidine triphosphate. In another preferred probe, the nucleotide triphosphate (NTP) is a member selected from the group consisting of adenosine triphosphate, cytosine triphosphate, guanosine triphosphate and uridine triphosphate. In another preferred probe, the tag is fluorophore, particularly, the fluorophore is a member selected from the group consisting of fluorescein, 5carboxyfluorescein (FAM), rhodamine, 5-(2′-aminoethyl) aminonapthalene-1-sulfonic acid (EDANS), anthranilamide, coumarin, terbium chelate derivatives, Reactive Red 4, BODIPY dyes and cyanine dyes. In another preferred probe, the tag is attached to said β and/or γ-phosphate via a linker. In another preferred probe, the fluorophore linker is an alkylene group having between about 5 to about 12 carbons, particularly, where the fluorophore moiety is a fluorescein or rhodamine dye.
  • The present invention relates to a kit for assaying pyrophosphate cleavage, said kit comprising: (a) a plurality of NTPs at least one NTP including an atomic and/or molecular tag or moiety having distinguishable/detectable property attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the NTP and (b) a polymerase. In another preferred kit, the tag is a fluorophore and the property is fluorescence. In another preferred kit, the NTP further includes a quencher attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the NTP, where each fluorophore interacts with said quencher moiety via a mechanism which is a member selected from the group consisting of fluorescence resonance energy transfer (FRET), electron transfer and ground-state complex mechanism.
  • The present invention relates to a method for performing a primer extension reaction comprising the steps of (a) annealing an oligonucleotide primer to a portion of a template nucleic acid thereby forming a primer-template hybrid; (b) adding primer-extension reagents including a tagged dNTP to afford increased or altered fidelity during incorporation to the primer-template hybrid for extending the primer, where the tagged dNTP includes an atomic and/or molecular tag or moiety having distinguishable/detectable property attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the dNTP. The method can also include the step of adding cosubstrate-enzyme pair to the primer-template hybrid for conducting a pyrophosphate-utilizing reaction in an amount sufficient to reduce peak dropout. In another preferred method, the cosubstrate-enzyme pair comprises pyrophosphate dependent phosphofructose kinase and fructose-6-phosphate. In another preferred method, the cosubstrate-enzyme pair comprises UDP Glucose Pyrophosphorylase and UDP Glucose.
  • The present invention relates to a kit for performing a primer extension reaction comprising: primer extension reagents and at least one dNTP including an atomic and/or molecular tag or moiety attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the dNTP to increase or alter extension fidelity. The kit can further comprise a compound present in an amount sufficient to reduce peak dropout.
  • The present invention relates to a primer extension solution for the extension of a primer member of a primer template hybrid comprising: primer extension reagents at least one dNTP including an atomic and/or molecular tag or moiety attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the dNTP to increase or alter extension fidelity. The solution can further comprise a compound present in an amount sufficient to reduce peak dropout. In another preferred solution, the cosubstrate-enzyme pair comprises pyrophosphate dependent phosphofructose kinase and fructose-6-phosphate. In another preferred solution, the cosubstrate-enzyme pair comprises UDP Glucose Pyrophosphorylase and UDP Glucose.
  • The present invention relates to a method of inhibiting or preventing pyrophosphorolysis during synthesis of a nucleic acid molecule, said method comprising (a) combining one or more tagged nucleotides and a nucleic acid template, where the tagged nucleotide comprises an atomic and/or molecular tag or moiety attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the nucleotide; and (b) incubating the one or more nucleotides and nucleic acid template together with a polymerase and an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with alcohol group as acceptor, a nucleotidyltransferase, and a carboxy-lyase, under conditions sufficient to form a second nucleic acid molecule complementary to all or a portion of the nucleic acid template.
  • The present invention relates to a method of inhibiting or preventing pyrophosphorolysis during synthesis of a nucleic acid molecule, said method comprising (a) combining a primer with a nucleic acid template under conditions sufficient to form a hybridized product; and (b) incubating said hybridized product in the presence of (i) one or more tagged nucleotides comprises an atomic and/or molecular tag or moiety attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the nucleotide (ii) a polymerase, and (iii) an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as acceptor, a nucleotidyltransferase, and a carboxy-lyase under conditions sufficient to synthesize a second nucleic acid molecule complementary to all or a portion of said nucleic acid template.
  • The present invention relates to a method to prevent inhibition of nucleic acid synthesis during amplification of a double stranded nucleic acid molecule, comprising (a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3′ termini of the first strand of said nucleic acid molecule and said second primer is complementary to a sequence at or near the 3′ termini of the second strand of said nucleic acid molecule; (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of (i) a polymerase, and (ii) one or more tagged nucleotides comprises an atomic and/or molecular tag or moiety attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the nucleotide under conditions such that a third nucleic acid molecule complementary to said first strand and a fourth nucleic acid molecule complementary to said second strand are synthesized; (c) denaturing said first and third strand and said second and fourth strand; and (d) repeating steps (a) to (c) one or more times.
  • The method of claim 47, wherein the hybridizing is in the presence of an enzyme selected from the group consisting of a pentosyltransferase, a phosphotransferase with an alcohol group as an acceptor, a nucleotidyltransferase and a carboxy-lyase.
  • The present invention relates to a method of identifying a base at a target position in a sample DNA sequence wherein an extension primer, which hybridises to the sample DNA either immediately adjacent to or very near (within about 10 bases) to the target position is provided and the sample DNA and extension primer are subjected to a polymerase reaction in the presence of a tagged deoxynucleotide or dideoxynucleotide, where the tagged deoxynucleotide or dideoxynucleotide an atomic and/or molecular tag or moiety having a detectable property attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the deoxynucleotide or dideoxynucleotide, whereby the tagged deoxynucleotide or dideoxynucleotide will only become incorporated and release pyrophosphate (PPi) if it is complementary to the base in the target position, any release of PPi being detected, different deoxynucleotides or dideoxynucleotides being added either to separate aliquots of sample-primer mixture or successively to the same sample-primer mixture and subjected to the polymerase reaction to indicate which deoxynucleotide or dideoxynucleotide is incorporated, characterised in that, a nucleotide-degrading enzyme is included during the polymerase reaction step, such that unincorporated nucleotides are degraded.
  • In another preferred method, the nucleotide-degrading enzyme is apyrase. In another preferred method, the mixture of nucleotide-degrading enzymes is used having nucleoside triphosphatase, nucleoside diphosphatase and nucleoside monophosphatase activity. In another preferred method, the nucleotide-degrading enzyme is immobilised on a solid support. In another preferred method, the immobilised nucleotide-degrading enzyme is added after nucleotide incorporation by the polymerase has taken place, and then removed prior to a subsequent nucleotide incorporation reaction step. In another preferred method, the PPi release is directly detected via the detectable property of the tag. In another preferred method, the polymerase reaction and PPi release detection steps are performed substantially simultaneously. In another preferred method, the sample DNA is immobilised or provided with means for attachment to a solid support. In another preferred method, the sample DNA is first amplified. In another preferred method, the extension primer contains a loop and anneals back on itself and the 3′ end of the sample DNA. In another preferred method, a native polymerase, an exonuclease deficient (exo-) high fidelity polymerase or a genetically modified polymerase is used.
  • In another preferred method, the method can be used for identification of a base in a single target position in a DNA sequence wherein the sample DNA is subjected to amplification; the amplified DNA is immobilized and then subjected to strand separation, the non-immobilized strand being removed and an extension primer, which hybridizes to the immobilized DNA immediately adjacent to the target position, is provided; each of four aliquots of the immobilized single stranded DNA is then subjected to a polymerase reaction in the presence of a tagged deoxynucleotide, each aliquot using a different deoxynucleotide whereby only the tagged deoxynucleotide complementary to the base in the target position becomes incorporated.
  • The method can further comprising adding the identified dNTP to the three non-extended chambers and repeating the cyclic identification process.
  • The present invention relates to a kit for use in a method as defined in any one of claims 49 to 6.10, comprising: (a) a test specific primer which hybridizes to sample DNA so that the target position is directly adjacent to the 3′ end of the primer; (b) a polymerase; and (c) at least one tagged dNTP an atomic and/or molecular tag or moiety having a detectable property attached to and/or associated with a β and/or γ-phosphate and/or a base moiety of the dNTP. The kit can be used for use with initial PCR amplification, further comprising: (i) a pair of primers for PCR, at least one primer having means permitting immobilization of said primer; (ii) a polymerase for PCR; (iii) a mixture of dNTPs including at least one tagged dNTP. The methods or kits can also be used with a multiplicity of sample DNA sequences, wherein said DNA sequences are arranged in array format on a solid surface.
  • The present invention relates to a composition comprising a deoxyribonucleoside or ribonucleoside including a molecular and/or atomic tag attached to or associated with a β and/or γ phosphate group, a base moiety, and/or a sugar moiety, where the tag alters fidelity of base incorporation.
  • The present invention relates to a method comprising the step of adding a composition comprising a deoxyribonucleoside or ribonucleoside including a molecular and/or atomic tag attached to or associated with a β phosphate group, a base moiety, and/or a sugar moiety, where the tag alters fidelity of base incorporation to a nucleotide polymerization medium comprising a nucleotide polymerase.
  • The present invention relates to a composition comprising a nucleotide or nucleotide analogs including a molecular and/or atomic tag on a β phosphate group and/or a base moiety adapted to increase the fidelity of viral replication. In another preferred composition, the virus is HIV.
  • The present invention relates to a method for increasing the fidelity of viral replication comprising administering an therapeutically effective amount of a nucleotide including a molecular and/or atomic tag on a β phosphate group and/or a base moiety to an animal including a human, where the nucleotide is designed to increase base incorporation fidelity during viral replication. In another preferred method, the virus is HIV.
  • The present invention relates to a composition comprising a viral replication fidelity enhancing agent selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof:
    Z-OPO2O-Z′  (a)
    Z-PO2O-Z′  (b)
    Z-OPO2-Z′  (c)
    Z-PO2-Z′  (d)
    Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
    Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
    Z-PO2-(OP(EE′)O)nPO2O-Z′  (g)
    Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
    where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements, E and E′ are an oxygen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements and n is an integer having a value between 0 and about 5, and where the agent is adapted to increase the fidelity of viral replication. In another preferred composition, the virus is HIV.
  • The present invention relates to a method for increasing the fidelity of viral replication comprising administering to an animal including a human a therapeutically effective amount of a viral replication fidelity enhancing agent selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof:
    Z-OPO2O-Z′  (a)
    Z-PO2O-Z′  (b)
    Z-OPO2-Z′  (c)
    Z-PO2-Z′  (d)
    Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
    Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
    Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
    Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
    where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements, E and E′ are an oxygen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements and n is an integer having a value between 0 and about 5, where the nucleotide is designed to increase base incorporation fidelity during viral replication. In another preferred method, the virus is HIV.
  • The present invention also relates to biological memory storage and retrieval systems where the fidelity of the storage and retrieve process is improved by using fidelity enhances described herein. The method would include the step of synthesizing a sequence of monomers corresponding to a given data sequence using the fidelity enhancing agent of this invention. Once the information is stored, the information can be retrieved by sequencing the sequence to retrieve the data sequence.
  • The present invention also relates to agents and methods for ameliorating symptoms of animals including humans infected with a retrovirus, including the step of administering to the animal a therapeutically effective amount of a composition including a dNTP having an atomic and/or molecular tag, preferably, an atomic or molecular tag on β and/or γ-tagged phosphate of the dNTP, to increase the fidelity of the viruses reverse transcriptase, decrease mutation, increase the immune response to the virus, increase the effectiveness of medications to the virus and ameliorate symptoms associated with the viral infection.
  • The present invention also relates to agents and methods for ameliorating symptoms of animals including humans suffering from cancer, including the step of administering to the animal a therapeutically effective amount of a composition including a dNTP having an atomic and/or molecular tag, preferably, an atomic or molecular tag on β and/or γ-tagged phosphate of the dNTP, to increase the fidelity of the patient's natural polymerases, decrease mutations, increase the immune response to the cancer, increase the effectiveness of medications to the cancer and ameliorate symptoms associated with the cancer.
  • The present invention also relates to agents and methods for ameliorating symptoms of aging in animals including humans, including the step of administering to the animal a therapeutically effective amount of a composition including a dNTP having an atomic and/or molecular tag, preferably, an atomic or molecular tag on β and/or γ-tagged phosphate of the dNTP, to increase the fidelity of the patient's natural polymerases, decrease mutations, increase cellular vitality, and ameliorate symptoms of aging.
  • The present invention also relates to agents and methods for reducing the evolutionary tendencies of retro virus such as HIV. HIV-1, the causative agent of AIDS, has evolved many ways to defeat its human host defenses. One of these ways involves evading the immune system by inaccurately replicating its genome (one mistake per 2,000-5,000 bases). The polymerase responsible for the inaccurate replication is HIV-1 reverse transcriptase (RT). RT converts the single stranded RNA genome into a complementary DNA strand, destroys the RNA template, and uses the nascent DNA strand to template synthesis of the double-stranded DNA version of the HIV-1 genome. Since the HIV genome is approximately 10,000 bases, this error-prone process produces a variant genome essential every time the virus replicates. The mis-incorporated bases can specify altered HIV protein sequences. Thus, the immune system in a patient infected with HIV is fighting a losing battle, since viral proteins (antigens) are constantly changing. Additionally, the activities of these protein variants may be modified and, if the patient is following a drug-treatment therapy, drug-resistant variants may emerge due to selective pressures. Thus, virus evolution mediated through inaccurate genome replication is a significant problem, both with HIV-1 and with any virus whose replication is mediated by an error-prone polymerase.
  • The fidelity of HIV-1 RT is improved in vitro by providing the enzyme with nucleotides containing a molecular tag on the γ-phosphate. This unexpected discovery may lead to a novel therapeutic that will neutralize the genetic mutability of this deadly virus. Understanding the mechanism by which RT selects nucleotides for incorporation will produce insights into enzymatic DNA synthesis and evolution of viral diversity. Ultimately, a novel therapeutic that increases enzyme fidelity may minimize antigen evolution, enabling the immune system to eliminate virus and virus infected cells, and minimize the emergence of drug resistance. Understanding why improved accuracy is observed in the context of the modified nucleotide may enable design a small molecule that has this same effect, but that would be more easily delivered into cells.
  • Fidelity
  • The inventors have found that novel nucleotides can be prepared that improve fidelity of incorporations where the nucleotides include a covalently attached substituent on β and/or γ phosphate of a NTP, dNTP or ddNTP where the substituent includes a aminonaphthalene-1-sulfonate (ANS) group. The tagged nucleotide and preferably the tagged γ-phosphate of the nucleotide improves the fidelity at which this nucleotide analog is incorporated by commercially available Taq DNA polymerase.
  • Pyrophosphorolysis Inhibition
  • Addition of pyrophosphatase to a polymerase chain reaction greatly enhances the progress of that reaction, and provides superior results compared to use of the method without a pyrophosphatase (Tabor and Richardson, 1996). Similarly addition of a pyrophosphatase to a DNA sequencing reaction provides more uniformity in intensities of bands formed in a polyacrylamide gel used to identify products of the sequencing reaction pyrophosphatase (Tabor and Richardson, 1996). This uniformity is thought to be due to prevention of degradation of specific DNA products via pyrophosphorolysis. Any modification to the nucleotide that is capable of inhibiting the pyrophosphorolysis reaction is useful in this invention. One way to inhibit pyrophosphorolysis is to break down any pyrophosphate that is generated during a polymerase reaction, by adding the enzyme pyrophosphatase. Even trace addition of a pyrophosphatase (one thousandth the molar ratio of DNA polymerase molecules in a solution) to a primer extension reaction completely stabilizes oligonucleotide fragments produced in a polymerase reaction, by preventing pyrophosphorolysis. The agent should be added at a concentration sufficient to either catalyze the hydrolysis of pyrophosphate in the reaction mixture at a rate that will prevent accumulation of pyrophosphate to a level that will lead to pyrophosphorolysis, or prevent accumulation of pyrophosphate in any other manner. The amount of agent needed is readily determined by standard techniques. However, the inventors have discovered that pyrophosphorolysis can also be reduced or eliminated by using nucleotides containing molecular and/or atomic substituents on the β and/or γ phosphate moieties.
  • Nucleic Acid Sequencing Using Tagged PPi Detection
  • In certain embodiments, the present invention provides a heterogeneous assay for the detection of released tagged pyrophosphate. The detection of tagged pyrophosphate is advantageous in a number of biological reactions. For example, in a DNA polymerase reaction, single molecule or bulk, wherein the polymerase selects a single DNA molecule from solution and thereafter incorporates the nucleotide at the 3′-end of a primer strand, the natural consequence of such incorporation is the release of pyrophosphate. If the assay solution comprises the four deoxynucleotide triphosphates, each dNTP labeled with a different molecular and/or atomic tag such as a fluorescent dye having a different color attached to the β- and/or γ-phosphate, it is then possible to sequentially record the activity of the polymerase operating on a target DNA. The nucleotide sequence of the target DNA can thereafter be directly read from the order of released dyes attached to the pyrophosphate. If the assay solution comprises the four deoxynucleotide triphosphates, each dNTP labeled with a different molecular and/or atomic tag such as a fluorescent dye having a different color attached to the β- and/or γ-phosphate and activating tags bonded to or associated with the polymerase or other species in the medium, it is then possible also to sequentially record the activity of the polymerase operating on a target DNA. The nucleotide sequence of the target DNA can thereafter be read directly from the order of released dyes attached to the pyrophosphate.
  • As such, the present invention provides a heterogeneous assay method for detecting pyrophosphate release, the components of the assay comprising a labeled NTP, a target nucleic acid, a primer nucleic acid and a polymerase, the method comprising: (a) flowing the labeled nucleotide triphosphate (NTP) having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the NTP, past an immobilized component selected from the group consisting of the polymerase, the primer and the target nucleic acid; (b) incorporating the tagged dNTP on a primer strand hybridized to the target nucleic acid using an enzyme and releasing the γ-phosphate with the fluorophore moiety attached thereto; and (c) detecting the fluorescent moiety thereby detecting NTP binding, incorporation and/or pyrophosphate cleavage. In the heterogeneous assay of the present invention, either the polymerase, the primer or the target nucleic acid is attached to a solid phase, such as a solid support. Preferably, in the methods of the present invention, the polymerase is immobilized on a solid support.
  • In certain aspects, the polymerase is a DNA polymerase such as DNA polymerase I, II or III. In other aspects, suitable polymerases include, but are not limited to, a DNA dependent RNA polymerase and reverse transcriptase such as an HIV reverse transcriptase. Specific examples include, but are not limited to, T7 DNA polymerase, T5 DNA polymerase, E. coli DNA polymerase I, T4 DNA polymerase, T7 RNA polymerase and Taq DNA polymerase. Those of skill in the art will know of other enzymes or polymerases suitable for use in the present invention. In certain aspects, the polymerase is bathed in a flowing solution comprising: unlabeled, single-stranded DNA fragments hybridized to an oligonucleotide primer and a mixture of NTPs.
  • In certain aspects of the present invention, a labeled nucleotide triphosphate (NTP) having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate moiety of the NTP is incorporated into a polynucleotide chain. The dNTP incorporation into a growing oligonucleotide by a DNA polymerase results in pyrophosphate release. In this reaction, the phosphate ester bond between the α and β phosphates of the incorporated nucleotide is cleaved by the DNA polymerase, and the β- and/or γ-phosphate moieties of the resulting pyrophosphate are released in solution. As used herein, the term pyrophosphate also includes substitution of any of the oxygen atoms of the pyrophosphate group with an atom that enables attachment of the molecular moiety that will be detected and provide information about the identity of the incorporated nucleotide, a nitrogen or a sulfur atom or combinations thereof to generate azapyrophosphate, diazapyrophosphte, thiopyrophosphate, dithiopyrophosphate, etc.
  • If the tag is a fluorophore, then the fluorophore can be detected either upon nucleotide binding, during incorporation or after the nucleotide and the pyrophosphate are released. In certain aspects, release of the pyrophosphate caused by cleavage of the α-β bond can switch the fluorophore moiety into a fluorescent state either by fluorophore dequenching or fluorophore activation. This event can then be detected using an ultrasensitive fluorescence detector. Using single molecule detection for example, fluorescent signals appear at the locations of the individual molecules being observed. In certain aspects, each type of nucleotide is labeled with a different fluorophore so that the incorporated nucleobases can be sequentially identified by the fluorophores during binding, incorporation or release. Preferably, the deoxy nucleotide triphosphates (dNTPs) of the present methods include, but are not limited to, deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanosine triphosphate, deoxythymidine triphosphate, deoxyuridine triphosphate or mixtures thereof, each with a unique molecular and/or atomic tag attached to the β- and/or γ-phosphate moiety of the NTP.
  • As is described in detail hereinbelow, the nucleotides of the present invention, both purine and pyrimidine varieties, are modified at various sites with a molecular and/or atomic tag such as a fluorophore or chromophore. In certain aspects, the fluorophore or chromopore are designed to interact with other tags situated on specific sites of the polymerase or associated with other agents in the medium. Once the tagged dNTPs are produced, they can be used to sequence DNA strands by direct single molecule detection. The tags can be detected when the labeled dNTP binds to the polymerase, during incorporation or upon release by measuring a detectable property of the tag alone or as a result of an interaction with another tag associated with other agent in the medium including the polymerase itself. The detectable property can of course be fluorescence or induced fluorescence. The ultrasensitivity of the present methods provide unprecedented economy and represent substantial improvements over the methods of the prior art.
  • The tagged dNTPs and formed tagged pyrophosphates can be used in single molecule detection formats. In certain embodiments, an unlabeled, single-stranded target nucleic acid with a primer hybridized thereto is tethered to the surface of a solid support such as a glass slide. An aqueous solution comprising an enzyme, such as a DNA polymerase, and tagged dNTPs flows across the surface. In another embodiment, an individual polymerase molecule is immobilized on a glass slide and the polymerase is bathed in a flowing solution comprising: 1) unlabeled, single-stranded DNA fragments hybridized to an oligonucleotide primer and 2) a mixture of tagged deoxynucleotide triphosphates. In yet another embodiment, a library of oligonucleotides can be immobilized on a solid support such as glass and the glass is bathed in a solution comprising: 1) a polymerizing agent such as a polymerase, 2) unlabeled, single-stranded DNA fragments hybridized to an oligonucleotide primer and 3) a mixture of tagged deoxynucleotide triphosphates. In a further embodiment, an individual polymerase molecule is immobilized on a glass slide and the polymerase is bathed in a solution comprising: 1) nicked double strained DNA, where the nicking is either affected via chemical means such as Fe-EDTA or via enzymatic means such as DNase, and 2) a mixture of tagged deoxynucleotide triphosphates.
  • If the tags are capable of fluoresceing or luminesceing, then an evanescent light field is set up by total internal refection (TIR) of a laser beam at the glass-aqueous solution interface. In certain aspects, the TIR illumination field is continuously imaged at video-rate with a CCD camera or an intensified charge couple device (ICCD) camera.
  • Solid Phase
  • The present invention relates to a heterogenous assay wherein a material in the solid-phase interacts with reagents in the liquid phase. In certain aspects, the nucleic acid is attached to the solid phase. The nucleic acid can be in the solid phase such as immobilized on a solid support, through any one of a variety of well-known covalent linkages or non-covalent interactions. The support is comprised of insoluble materials, such as controlled pore glass, a glass plate or slide, polystyrene, acrylamide gel and activated dextran. In other aspects, the support has a rigid or semi-rigid character, and can be any shape, e.g., spherical, as in beads, rectangular, irregular particles, gels, microspheres, or substantially flat, so long as the support permits single molecule detection. In some embodiments, it can be desirable to create an array of physically separate sequencing regions on the support with, for example, wells, microtubes or nanotubes derivatived to capture part of the DNA sequencing complex/enzyme, primer or template such as histidine 5′ derivation, or other random modification so that the complex can stick to the tubes, raised regions, dimples, trenches, rods, pins, inner or outer walls of cylinders, and the like. Other suitable support materials include, but are not limited to, agarose, polyacrylamide, polystyrene, polyacrylate, hydroxethylmethacrylate, polyamide, polyethylene, polyethyleneoxy, or copolymers and grafts of such. Other embodiments of solid-supports include small particles, non-porous surfaces, addressable arrays, vectors, plasmids, or polynucleotide-immobilizing media.
  • As used in the methods of the present invention, nucleic acid can be attached to the solid support by covalent bonds, or other affinity interactions, to chemically reactive functionality on the solid-supports. The nucleic acid can be attached to solid-supports at their 3′, 5′, sugar, or nucleobase sites. In certain embodiments, the 3′ site for attachment via a linker to the support is preferred due to the many options available for stable or selectively cleavable linkers. Immobilization is preferably accomplished by a covalent linkage between the support and the nucleic acid. The linkage unit, or linker, is designed to be stable and facilitate accessibility of the immobilized nucleic acid to its sequence complement. Alternatively, non-covalent linkages such as between biotin and avidin or stepavidin are useful. Examples of other functional group linkers include ester, amide, carbamate, urea, sulfonate, ether, and thioester. A 5′ or 3′ biotinylated nucleotide can be immobilized on avidin or strepavidin bound to a support such as glass.
  • In other aspects of the heterogenous assay of the present invention, the polymerase is immobilized on a solid support. Suitable solid supports include, but are not limited to, controlled pore glass, a glass plate or slide, polystyrene, and activated dextran. In other aspects, synthetic organic polymers such as polyacrylamide, polymethacrylate, and polystyrene are also illustrative support surfaces. In addition, polysaccharides such as cellulose and dextran, are further illustrative examples of support surfaces. Other support surfaces such as fibers are also operable.
  • In other aspects, polymerase immobilization is accomplished using solid chromatography resins, that have been modified or activated to include functional groups that permit the covalent coupling of resin to enzyme. Typically, aliphatic linker arms are employed. The enzymes of the present invention can also be noncovalently attached to a solid support surface through, for example, ionic or hydrophobic mechanisms.
  • Covalent attachment of a protein or nucleic acid to a glass or metal oxide surface can be accomplished by first activating the surface with an amino silane. DNA or protein derivatized with amine-reactive functional groups can then attach to the surface (see, K. Narasimhan et al., Enzyme Microb. Technol. 7, 283 (1985); M. J. Heller et al., U.S. Pat. No. 5,605,662; and A. N. Asanov et al., Anal. Chem. 70, 1156 (1998)).
  • The ordinarily skilled artisan will know numerous other schemes for linking nucleic acid and proteins to support surfaces. Moreover, the choice of support surface and the method of immobilizing the enzyme is largely a matter of convenience and depends on the practitioner's familiarity with, and preference for, various supports surfaces, as well as preference for various immobilizing schemes, and knowledge of the substrate.
  • In assay operation, the enzyme, such as a DNA polymerase, selects a single DNA molecule from solution. The polymerase incorporates a first nucleotide at the 3′-end of the primer strand and releases the respective PPi. The polymerase then translocates to the next position on the target DNA, incorporates a complementary tagged nucleotide, and releases the respective pyrophophate. The tagged nucleotide can be detected upon binding to tagged polymerase, upon incorporation by tagged polymerase, and/or upon release of the tagged pyrophosphate either directly or as a result of interaction with another tag on an agent in the medium. These events can then be recorded sequentially using a detection system capable of detecting a detectable property of the tag such as by video-rate imaging using for example, a CCD or ICCD camera, capable of detecting fluorescence from a single tag where the tag is fluorophore or a chromophore. The resulting movie shows the activity of a single polymerase molecule operating on a single molecule of DNA. The nucleotide sequence of the DNA target is read directly from the order of base incorporation by detecting the tag during base binding, base incorporation and/or pyrophosphate release. Each of those events or steps during incorporation provides information about the process and a unique pattern is associated with each nucleotide. The match of each base incorporation pattern is used to increase confidence of each base call. Time, intensity and wavelength or frequency are each monitored to provide maximal confirmatory information.
  • When the first nucleic acid molecule has been sequenced, the polymerase releases it and selects another template from solution. Many DNA molecules are thereby sequenced by a single polymerase. The process continues for the life of the enzyme or more specifically, the life of the interacting tag within the enzyme.
  • To minimize signals that are not optimally positioned, assays using immobilized polymerase are preferred because once the detector system such as a CCD or ICCD camera is focused on the plane containing the polymerase, the focus will not have to be changed during a sequencing run. Otherwise, the plane of focus may need to be changed due to translocation of the polymerase through the medium as polymerization proceeded. Not only is changing the focal plane more difficult, the translocation of the polymerizing sites could result in a change in the number of polymerizing sites within a given viewing field over time and adversely affect data integrity. Moreover, the lengths of the DNA templates should preferably be significantly uniform (±10%), substantially uniform (±5%) or essentially uniform (±1%) in length to further maximize signal detection from the replication complexes.
  • Since there are approximately 3.4 angstroms between base pairs, a 1000 bases synthesis would involve approximately 3400 angstroms movement of either DNA through the polymerase or polymerase along the DNA. Thus, if the polymerase is immobilized and DNA is passed through the polymerase, signal remains localized at the position of the polymerase. If, however, the template or primer is immobilized, the signal produced during incorporation may move by the distance of the sequence read length. Therefore, if the DNA primer or template is immobilized, in order to minimize or eliminate overlap between the sequencing complexes it is preferred that the immobilized molecules are separated by a distance of 10 times, 5 times, or approximately the distance of the desired sequence read. By so doing, the essentially random motion of the extending strands that results from their presence in the polymerizing solution will not interfere with neighboring sequencing complexes.
  • Of course, computer programs could be written to analyze the data over time and correct for most of the adverse affects of polymerase translocation. Moreover, for sparsely populated sequencing reactions, the likelihood of changes in the number of active polymerizing sites per view field can be reduced.
  • Preparation of Target Nucleic Acid
  • The target nucleic acid can be prepared by various conventional methods. For example, target nucleic acid can be prepared as inserts of any of the conventional cloning vectors, including those used in conventional DNA sequencing. Extensive guidance for selecting and using appropriate cloning vectors is found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Laboratory, New York, 1989), and like references. Sambrook et al. and Innis et al, editors, PCR Protocols (Academic Press, New York, 1990) also provide guidance for using polymerase chain reactions to prepare target polynucleotides. Cloned or PCR amplified target nucleic acid is prepared which permit attachment to solid supports.
  • Preferably, the target nucleic acid sequences are from sheared DNA fragments from a subject organism, preferably human, and are treated to provide blunt ends, then ligated to two oligodeoxynucleotides. For example, one oligonucleotide can be derivatized with biotin at its 5′ or 3′ end but the 5′ end is preferred since that will cause fewer steric problems. Further, the first primer may be 5′ biotinylated and the second is complementary to the biotinylated primer and contains a 5′ phosphate. The ligated DNA is denatured, it is brought into contact with a streptavidin-activated slide, and it attaches through the 5′ biotin to the slide. A primer is hybridized to the tethered fragments prior to sequencing. This sequencing primer is the same sequence as the biotinylated primer. Only DNA fragments having each type of ODN can both attach and be sequenced; fragments having two phosphorylated primers will not attach.
  • DNA attachment could also be accomplished by direct covalent coupling as practiced on DNA chips (see, U.S. Pat. No. 5,605,662). Unlike DNA chips that require a dense lawn of probes, preferably, a few DNA molecules are bound per unit surface area. Binding density is easily controlled by adding a carrier to the DNA sample (e.g., free biotin to a biotinylated DNA sample).
  • Detection
  • The tagged NTP can be detected by a variety of analytical techniques. If the tags are atomic or molecular tags with characteristic NMR, MS and/or other physical or chemical tag response signals, then the reaction can be monitored in real time using pulsed NMR techniques, MS techniques or techniques associated with other physical and/or chemical tag responses. The tags can even be shift reagents. If the tags are molecules that interact with other molecules in the presence of light to produce a fluorescent signature, then the reaction can be monitored using fluorescent spectroscopy on a continuous or discrete format. It should be recognized that tags can be prepared that have any desired detectable property.
  • In certain embodiments, the enzymatic reaction is monitored using single molecule detection. The single-molecule fluorescence detection of the present invention can be practiced using optical setups including near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, and total internal reflection fluorescence (TIRF) microscopy. Suitable photon detectors include, but are not limited to, photodiodes and intensified CCD cameras. In a preferred embodiment, an intensified charge couple device (ICCD) camera is used. The use of a ICCD camera to image individual fluorescent dye molecules in a fluid near the surface of the glass slide is advantageous for several reasons. With an ICCD optical setup, it is possible to acquire a sequence of images (movies) of fluorophores. In certain aspects, each of the NTPs of the present invention has a unique fluorophore associated with it, as such, a four-color instrument can be used having four cameras and four excitation lasers or beam-splitters may be used to monitor fluorescent intensity changes at a number of desire frequencies. Thus, it is possible to use this optical setup to sequence DNA. In addition, many different DNA molecules spread on a microscope slide can be imaged and sequenced simultaneously. Moreover, with the use of image analysis algorithms, it is possible to track the path of single dyes and distinguish them from fixed background fluorescence and from “accidentally dequenched” dyes moving into the field of view from an origin upstream.
  • In certain other embodiments, the sequencing works by directly detecting the release tagged pyrophosphate, where a single dNTP is feed each time and the polymerase is washed between before the next incorporation.
  • In certain aspects, the preferred geometry for ICCD detection of single molecules is total internal reflectance fluorescence (TIRF) microscopy. In TIRF, a laser beam totally reflects at a glass-water interface. The field does not end abruptly at the reflective interface, but its intensity falls off exponentially with distance. The thin “evanescent” optical field at the interface provides low background and enables the detection of single molecules with signal-to-noise ratios of 12:1 at visible wavelengths (see, M. Tokunaga et al., Biochem. and Biophys. Res. Comm. 235, 47 (1997) and P. Ambrose, Cytometry, 36, 244 (1999)).
  • The penetration of the field beyond the glass depends on the wavelength and the laser beam angle of incidence. Deeper penetrance is obtained for longer wavelengths and for smaller angles to the surface normal within the limit of a critical angle. In typical assays, fluorophores are detected within about 200 nm from the surface which corresponds to the contour length of about 600 base pairs of DNA. Preferably, a prism-type TIRF geometry for single-molecule imaging as described by Xu and Yeung is used (see, X-H. N. Xu et al., Science, 281, 1650 (1998)).
  • DNA, proteins and lipids have all been detected in complex samples with single-molecule sensitivity using labeled probes (see, L. Edman et al., Proc. Natl. Acad. Sci. USA, 93, 6710 (1996); M. Kinjo et al., Nucleic Acids Res. 23, 1795 (1995); A. Castro and J. G. K. Williams, Anal. Chem. 69, 3915 (1997); S. Nie, et al., Science 266, 1018 (1994); S. Nie, et al., Anal. Chem. 67, 2849 (1995); and T. Schmidt et al., Proc. Natl. Acad. Sci. USA 9, 2926 (1996)). In addition to simple detection, single fluorophores are also characterized with respect to fluorescence lifetime, spectral shifts and rotational orientation. In a preferred aspect of the present invention, an aqueous solution comprising an enzyme, such as a DNA polymerase, and distinguishable fluorogenic dNTPs, i.e., a characteristic dye for each nucleobase, flows across the surface. An evanescent light field is set up by total internal refection (TIR) of a laser beam at the glass-aqueous solution interface. In certain aspects, the TIR illumination field is continuously imaged at video-rate with an intensified charge couple device (ICCD) camera. It is thus possible to image the pyrophosphate as it is hydrolyzed by the enzyme.
  • Upon incorporation by polymerase, the tagged dNTP is hydrolyzed as usual and the liberated tagged pyrophosphate diffuses into the surrounding medium. The tagged dNTP can be detected upon binding, incorporation or release or the free tagged pyrophosphate can be detected by detecting the detectable property of the tag such as fluorescent and its appearance is imaged at video-rate under a microscope. A flowing stream sweeps the dye away from the parent DNA molecule. As the DNA molecule continues to move through the polymerase due to the immobilized polymerase, the nucleotide sequence is read from the order of released dyes. Sequencing proceeds quickly, as fast as the polymerase progresses along the DNA template.
  • In another embodiment, the present invention includes sensors as disclosed in U.S. Pat. No. 5,814,524 which issued to Walt et al., on Sep. 29, 1998, incorporated herein by reference. An optical detection and identification system is disclosed therein that includes an optic sensor, an optic sensing apparatus and methodology for detecting and evaluating one or more analytes or ligands of interest, either alone or in mixtures. The system is comprised of a supporting member and an array formed of heterogeneous, semi-selective polymer films which function as sensing receptor units and are able to detect a variety of different analytes and ligands using spectral recognition patterns. Using this system, it is possible to combine viewing and chemical sensing with imaging fiber chemical sensors.
  • High Throughput Screening
  • The present invention also provides integrated systems for high-throughput screening of DNA sequencing and pyrophosphate detection. The systems typically include robotic armature which transfers fluid from a source to a destination, a controller which controls the robotic armature, an ICCD camera, a data storage unit which records the detection, and an assay component such as a microtiter dish or a substrate comprising a fixed reactant. A number of robotic fluid transfer systems are available, or can easily be made from existing components. For example, a Zymate XP (Zymark Corporation; Hopkinton, Mass.) automated robot using a Microlab 2200 (Hamilton; Reno, Nev.) pipetting station can be used to transfer parallel samples to 96, 384 or more welled microtiter plates to set up several parallel simultaneous polymerase reactions.
  • Optical images viewed (and, optionally, recorded) by a camera or other recording device (e.g., a photodiode and data storage device) are optionally further processed in any of the embodiments herein, e.g., by digitizing the image and storing and analyzing the image on a computer. A variety of commercially available peripheral equipment and software is available for digitizing, storing and analyzing a digitized video or digitized optical image. In certain aspects, the integrated system of the present invention carries light from the specimen field to the charge-coupled device (CCD) camera, which includes an array of picture elements (pixels). The light from the specimen is imaged on the CCD camera. Particular pixels corresponding to regions of the specimen (e.g., individual polymerase sites on a glass surface) are sampled to obtain light intensity readings for each position. Multiple pixels are processed in parallel to increase speed. The apparatus and methods of the invention are easily used for viewing any sample, e.g., by fluorescent or dark field microscopic techniques.
  • There is a great deal of practical guidance available in the literature for providing an exhaustive list of fluorescent and chromogenic molecules and their relevant optical properties (see, for example, Berlman, Handbook of Fluorescence Spectra of Aromatic Molecules, 2nd Edition (Academic Press, New York, 1971); Griffiths, Colour and Constitution of Organic Molecules (Academic Press, New York, 1976); Bishop, Ed., Indicators (Pergamon Press, Oxford, 1972); Haugland, Handbook of Fluorescent Probes and Research Chemicals (Molecular Probes, Eugene, 1992) Pringsheim, Fluorescence and Phosphorescence (Interscience Publishers, New York, 1949); and the like. Further, there is extensive guidance in the literature for derivatizing fluorophore and quencher molecules for covalent attachment via common reactive groups that can be added to a nucleotide, as exemplified by the following references: Haugland (supra); Ullman et al., U.S. Pat. No. 3,996,345; Khanna et al., U.S. Pat. No. 4,351,760, incorporated herein by reference.
  • Suitable donors and acceptors operating on the principle of fluorescence energy transfer (FRET) include, but are not limited to, 4-acetamido-4′isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 5-(2′-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS); 4-amino-3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; -(4-anilino-lnaphthyl)maleimide; anthranilamide; BODIPY; Brilliant Yellow; coumarin and derivatives: coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4trifluoromethylcouluarin (Coumaran 151); cyanine dyes; cyanosine; 4′,6-diaminidino-2phenylindole (DAPI); 5′,5″-dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red); 7-diethylamino-3-(4′-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4′-diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid; 4,4′ diisothiocyanatostilbene-2,2′-disulfonic acid; 5-dimethylamino naphthalene-1-sulfonyl chloride (DNS, dansylchloride); 4-dimethylaminophenylazophenyl-4′-isothiocyanate (DABITC); eosin and derivatives: eosin, eosin isothiocyanate, erythrosin and derivatives: erythrosin B, erythrosin, isothiocyanate; ethidium; fluorescein and derivatives: 5carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl) aminofluorescein (DTAF), 2′,7′dimethoxy-4′5′-dichloro-6-carboxyfluorescein (JOE), fluorescein, fluorescein isothiocyanate, QFITC, (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferoneortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives: pyrene, pyrene butyrate, succinimidyl 1-pyrene; butyrate quantum dots; Reactive Red 4 (Cibacron™ Brilliant Red 3B-A) rhodamine and derivatives: 6-carboxy-X-rhodamine (ROX), 6carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101, sulfonyl chloride derivative ofsulforhodamine 101 (Texas Red); N,N, N′,N′-tetramethyl-6-carboxyrhodamine (TAMRA); tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid; terbium chelate derivatives; Cy 3; Cy 5; Cy 5.5; Cy 7; IRD 700; IRD 800; La Jolla Blue; phthalo cyanine; and naphthalo cyanine.
  • In certain embodiments, certain visible and near IR dyes are known to be sufficiently fluorescent and photostable to be detected as single molecules. In this aspect the visible dye, BODIPY R6G (525/545), and a larger dye, LI-COR's near-infrared dye, IRD-38 (780/810) can be detected with single-molecule sensitivity and can be used to practice the present invention.
  • There are many linking moieties and methodologies for attaching fluorophore or quencher moieties to nucleotides, as exemplified by the following references: Eckstein, editor, Oligonucleotides and Analogues: A Practical Approach (IRL Press, Oxford, 1991); Zuckerman et al., Nucleic Acids Research, 15: 5305-5321 (1987) (3′thiol group on oligonucleotide); Sharma et al., Nucleic Acids Research, 19: 3019 (1991) (3′sulfhydryl); Giusti et al., PCR Methods and Applications, 2: 223-227 (1993) and Fung et al., U.S. Pat. No. 4,757,141 (5′phosphoamino group via Aminolink™ II available from Applied Biosystems, Foster City, Calif.) Stabinsky, U.S. Pat. No. 4,739,044 (3′aminoalkylphosphoryl group); AP3 Labeling Technology (U.S. Pat. Nos. 5,047,519 and 5,151,507, assigned to E.I. DuPont de Nemours & Co); Agrawal et al., Tetrahedron Letters, 31: 1543-1546 (1990) (attachment via phosphoramidate linkages); Sproat et al., Nucleic Acids Research, 15: 4837 (1987) (5′mercapto group); Nelson et al., Nucleic Acids Research, 17: 7187-7194 (1989) (3′amino group); and the like.
  • Primer Extension Reaction
  • Generally, the primer extension reaction of the present invention comprises the following steps: (i) providing a template nucleic acid; (ii) annealing an oligonucleotide primer to a portion of the template nucleic acid thereby forming a primer-template hybrid; (iii) adding primer-extension reagents to the primer-template hybrid for extending the primer; and (iv) optionally adding a cosubstrate-enzyme pair to the primer-template hybrid for conducting a pyrophosphate-utilizing reaction.
  • Any source of nucleic acid can be used as a template nucleic acid provided it can be presented in a single stranded form and is capable of annealing with a primer oligonucleotide. Exemplary template nucleic acids include DNA, RNA, which DNA or RNA may be single stranded or double stranded. More particularly, template nucleic acid may be genomic DNA, messenger RNA, cDNA, DNA amplification products from a PCR reaction, and the like. Methods for preparation of template DNA may be found elsewhere (ABI PRISM Dye Primer Cycle Sequencing Core Kit). Standard protocols for primer-template annealing and primer extension in the context of PCR or Sanger-type sequencing may be found elsewhere (Innis; Deiffenbach; ABI PRISM Dye Primer Protocol; ABI PRISM Dye Terminator Protocol). Generally, to perform a primer extension reaction in the context of PCR, template nucleic acid is mixed with a pair of PCR primers and primer-extension reagents comprising a buffer, MgCl2, deoxynucleotide triphosphates or preferably for increase accuracy of the amplification products, β and/or γ tagged dNPTs, and a DNA polymerase. For example, a typical PCR reaction includes 20 pmol of each primer, 20 mM buffer at pH 8, 1.5 mM MgCl2, 10 to 500 μM, preferably 200 μm, of each deoxynucleotide triphosphate (dNTP), and 2 units of Taq polymerase or other suitable thermostable polymerase.
  • The reaction mixture is then thermocycled, a typical thermocycle profile comprising a denaturation step (e.g. 96° C., 15 s), a primer annealing step (e.g., 55° C., 30 s), and a primer extension step (e.g., 72° C., 90 s). Typically, the thermocycle is repeated from about 10 to about 100 cycles or more.
  • Kits and Solutions of the Invention
  • In another aspect, the present invention includes kits and solutions for performing the primer extension methods of the invention. The kits and solutions of the invention include primer extension reagents with the modified (tagged) dNTPs and/or modified PPi and optionally a cosubstrate-enzyme pair. Optionally, the kits may also include primers. The elements of the kits may be packaged in a single container or multiple containers. In one preferred configuration, a polymerase enzyme and modified (tagged) dNTPs and/or modified PPi are packaged in the same container.
  • This invention may also be used in methods where improvement of the accuracy of the synthesis of nucleic acids by a polymerase is desired and where pyrophosphorolysis is deemed counter-productive. Uses include: polymerase chain reaction, especially ‘Long PCR,’ and cDNA synthesis. Examples of patents describing these methods include U.S. Pat. No. 4,965,188, U.S. Pat. No. 5,079,352, U.S. Pat. No. 5,091,310, U.S. Pat. No. 5,142,033, U.S. Pat. No. 4,683,195, U.S. Pat. No. 4,683,202, U.S. Pat. No. 4,800,159, U.S. Pat. No. 5,512,462 and U.S. Pat. No. 5,405,776, incorporated by reference. In the case of cDNA synthesis, a reverse transcriptase polymerase is incubated with the mRNA template and the tagged deoxynucleoside triphosphates.
  • The invention also relates to a kit comprising a container means, such as a box, having in close confinement therein two or more containers such as vials, ampules, tubes, jars or the like, each of which contains the materials necessary to carry out the invention. For example, a container may contain a polymerizing agent such as a DNA or RNA polymerase. Another container may contain a tagged phosphate, pyrophosphate or polyphosphate in an amount sufficient to reduce, inhibit or prevent pyrophosphorolysis. And other containers may contain tagged and/or untagged dNTPs. Alternatively, the kit can include a container containing a polymerizing agent such as a DNA or RNA polymerase and other containers containing tagged and/or untagged dNTPs.
  • Preferably, the contents of the containers are present at working concentrations or requiring a to fold dilution to achieve working concentrations. Other containers may contain other reagents that are necessary for carrying out dideoxy sequencing or amplification (PCR).
  • Thus, the solution of the present invention is an aqueous and/or buffered liquid containing the components described above. These components are present in the solution at concentrations sufficient to perform their desired function. If the reaction mixture is intended to amplify a target nucleic acid molecule, the reaction mixture will contain the tagged dNTPs which reduce the level of pyrophosphate and increase polymerase fidelity, a polymerizing agent such as a DNA polymerase, all four dNTPs, and one or more oligonucleotide primers having a single stranded region which are capable of annealing to the target nucleic acid molecule, being extended and thereby amplified. The primer extension reaction may also comprise a chain terminator as described herein, e.g., a dideoxynucleoside triphosphate and the ddNTP may be modified at the β and/or γ phosphate to reduce background and/or reduce band spreading, which allows for sequencing of the target DNA molecule by the well known Sanger dideoxy sequencing method.
  • The present invention uses tagged NTPs that having molecular and/or atomic tags bonded to or associated with the β and γ phosphates so as not to alter the chemistry of the growing polymer chain, allow for detection of the NTPs (including dNTPs and ddNTPs) upon binding, during incorporation and after incorporation via the released tagged pyrophosphate. Optionally, the present invention can include phosphatases that degrade NTPs (including dNTPs and ddNTPs) or that degrade pyrophosphate. However, when the labeled pyrophosphates act to inhibit pyrophosphorolysis, then such degradation enzymes should be tailored to attach the NTPs and not the tagged pyrophosphate.
  • Detailed nucleoside di- and/or mono-phosphate degrading enzymes are optional and may be used in combination with a nucleoside tri-phosphate degrading enzyme. Suitable such enzymes include most notably apyrase which is both a nucleoside diphosphatase and triphosphatase, catalyzing the reactions NTP−NMP+2Pi and NTP−NDP+Pi (where NTP is a nucleoside triphosphate, NDP is a nucleoside diphospate, NMP is a nucleotide monophosphate and Pi is phosphate). A pyrase may be obtained from Sigma Chemical Company. Other suitable nucleotide triphosphate degrading enzymes include Pig Pancreas nucleoside triphosphate diphosphohydrolase (Le Bel et al., 1980, J. Biol. Chem., 255, 1227-1233). Further enzymes are described in the literature.
  • Different combinations of nucleoside tri-, di- or monophosphatases may be used. Such enzymes are described in the literature and different enzymes may have different characteristics for deoxynucleotide degradation, e.g., different Km, different efficiencies for a different nucleotides etc. Thus, different combinations of nucleotide degrading enzymes may be used, to increase the efficiency of the nucleotide degradation step in any given system. For example, in some cases, there may be a problem with contamination with kinases which may convert any nucleoside diphosphates remaining to nucleoside triphosphates, when a further nucleoside triphosphate is added. In such a case, it may be advantageous to include a nucleoside disphosphatase to degrade the nucleoside diphosphates. Advantageously all nucleotides may be degraded to nucleosides by the combined action of nucleoside tri-, di- and monophosphatases.
  • Generally speaking, the nucleotide-degrading enzyme is selected to have kinetic characteristics relative to the polymerase such that nucleotides are first efficiently incorporated by the polymerase, and then any non-incorporated nucleotides are degraded. Thus, for example, if desired, the Km of the nucleotide-degrading enzyme may be higher than that of the polymerase such that nucleotides which are not incorporated by the polymerase are degraded. This allows the sequencing procedure to proceed without washing the template between successive nucleotide additions. A further advantage is that since washing steps are avoided, it is not necessary to add new enzymes e.g. polymerase with each new nucleotide addition, thus improving the economy of the procedure. Thus, the nucleotide-degrading enzyme or enzymes are simply included in the polymerase reaction mix, and a sufficient time is allowed between each successive nucleotide addition for degradation of substantially most of the unincorporated nucleotides.
  • The amount of nucleotide-degrading enzyme to be used, and the length of time between nucleotide additions may readily be determined for each particular system, depending on the reactants selected, reaction conditions etc.
  • As mentioned above, the nucleotide-degrading enzyme(s) may be included during the polymerase reaction step. This may be achieved simply by adding the enzyme(s) to the polymerase reaction mixture prior to, simultaneously with or after the polymerase reaction (i.e. the chain extension or nucleotide incorporation) has taken place, e.g. prior to, simultaneously with, or after, the polymerase and/or nucleotides are added to the sample/primer.
  • In one embodiment, the nucleotide-degrading enzyme(s) may simply be included in solution in a reaction mix for the polymerase reaction, which may be initiated by addition of the polymerase or nucleotide(s). Alternatively, the nucleotide-degrading enzyme(s) may be immobilized on a solid support, e.g. a particulate solid support (e.g. magnetic beads) or a filter, or dipstick etc. and it may be added to the polymerase reaction mixture at a convenient time. For example, such immobilized enzyme(s) may be added after nucleotide incorporation (i.e., chain extension) has taken place, and then, when the incorporated nucleotides are hydrolyzed, the immobilized enzyme may be removed from the reaction mixture (e.g. it may be withdrawn or captured, e.g., magnetically in the case of magnetic beads), before the next nucleotide is added. The procedure may then be repeated to sequence more bases.
  • Such an arrangement has the advantage that more efficient nucleotide degradation may be achieved as it permits more nucleotide degrading enzyme to be added for a shorter period. This arrangement may also facilitate optimization of the balance between the two competing reactions of DNA polymerization and nucleotide degradation.
  • In a further embodiment, the immobilization of the nucleotide-degrading enzyme may be combined with the use of the enzyme(s) in solution. For example, a lower amount may be included in the polymerase reaction mixture and, when necessary, nucleotide-degrading activity may be boosted by adding immobilized enzyme as described above. The term dideoxynucleotide as used herein includes all 2′-deoxynucleotides in which the 3′-hydroxyl group is absent or modified and thus, while able to be added to the primer in the presence of the polymerase, is unable to enter into a subsequent polymerization reaction.
  • The method of the invention may readily be modified to enable the sequencing (i.e. base incorporation) reactions to be continuously monitored in real time. This may simply be achieved by performing the chain extension and detection, or signal-generation, reactions substantially simultaneously by monitoring a detectable property of the tags on the NTPs during binding, incorporation, and/or pyrophosphate release.
  • The sample DNA (i.e., DNA template) may conveniently be single-stranded, and may either by immobilized on a solid support or in solution. The use of a nucleotide degrading enzyme according to the present invention means that it is not necessary to immobilize the template DNA to facilitate washing, since a washing step is no longer required. By using thermostable enzymes, double-stranded DNA templates might also be used. The sample DNA may be provided by any desired source of DNA, including for example PCR or other amplified fragments, inserts in vectors such as M13 or plasmids.
  • In order to repeat the method cyclically and thereby sequence the sample DNA and, also to aid separation of a single stranded sample DNA from its complementary strand, the sample DNA may optionally be immobilized or provided with means for attachment to a solid support. Moreover, the amount of sample DNA available may be small and it may therefore be desirable to amplify the sample DNA before carrying out the method according to the invention.
  • The sample DNA may be amplified, and any method of amplification may be used, for example in vitro by PCR, rolling circle, or Self Sustained Sequence Replication (3SR) or in vivo using a vector and, if desired, in vitro and in vivo amplification may be used in combination. Whichever method of amplification is used the procedure may be modified that the amplified DNA becomes immobilized or is provided with means for attachment to a solid support. For example, a PCR primer may be immobilized or be provided with means for attachment to a solid support. Also, a vector may comprise means for attachment to a solid support adjacent the site of insertion of the sample DNA such that the amplified sample DNA and the means for attachment may be excised together.
  • Immobilization of the amplified DNA may take place as part of PCR amplification itself, as where one or more primers are attached to a support, or alternatively one or more of the PCR primers may carry a functional group permitting subsequent immobilization, e.g. a biotin or thiol group. Immobilization by the 5′ end of a primer allows the strand of DNA emanating from that primer to be attached to a solid support and have its 3′ end remote from the support and available for subsequent hybridization with the extension primer and chain extension by polymerase.
  • The solid support may conveniently take the form of microtitre wells, which are advantageously in the conventional 8×12 format, or dipsticks which may be made of polystyrene activated to bind the primer DNA (K Ahner, Doctoral Theses, Royal Institute of Technology, Stockholm, Sweden, 1988). However, any solid support may conveniently be used, including any of the vast number described in the art, e.g., for separation/immobilization reactions or solid phase assays. Thus, the support may also comprise particles, fibers or capillaries made, for example, of agarose, cellulose, alginate, Teflon or polystyrene. Magnetic particles e.g. the superparamagnetic beads produced by Dynal AS (Oslo, Norway) also may be used as a support.
  • The solid support may carry functional groups such as hydroxyl, carboxyl, aldehyde or amino groups, or other moieties such as avidin or streptavidin, for the attachment of primers. These may in general be provided by treating the support to provide a surface coating of a polymer carrying one of such functional groups, e.g. polyurethane together with a polyglycol to provide hydroxyl groups, or a cellulose derivative to provide hydroxyl groups, a polymer or copolymer of acrylic acid or methacrylic acid to provide carboxyl groups or an aminoalkylated polymer to provide amino groups. U.S. Pat. No. 4,654,267 describes the introduction of many such surface coatings.
  • Another aspect of this invention is the use of tagged nucleotides to directly sequence populations of DNA molecules in synchrony. The synchrony is achieved by applying a population of single tagged dNTP to the reaction chamber, monitoring PPi release (as per tag detection), and removing unincoporated dNTPs prior to applying the next tagged dNTP until the sequence of interest in determined.
  • The tagged NTPs and/or pyrophosphate detection method of the present invention thus opens up the possibility for an automated approach for large-scale, non-elecrophoretic sequencing procedures, which allow for continuous measurement of the progress of the polymerization reaction with time. The method of the invention also has the advantage that multiple samples may be handled in parallel. The target DNA may be cDNA synthesized from RNA in the sample and the method of the invention is thus applicable to diagnosis on the basis of characteristic RNA. Such preliminary synthesis can be carried out by a preliminary treatment with a reverse transcriptase, conveniently in the same system of buffers and bases of subsequent PCR steps if used. Since the PCR procedure requires heating to effect strand separation, the reverse transcriptase will be inactivated in the first PCR cycle. When mRNA is the sample nucleic acid, it may be advantageous to submit the initial sample, e.g. a serum sample, to treatment with an immobilized polydT oligonucleotide in order to retrieve all mRNA via the terminal polyA sequences thereof. Alternatively, a specific oligonucleotide sequence may be used to retrieve the RNA via a specific RNA sequence. The oligonucleotide can then serve as a primer for cDNA synthesis, as described in WO 89/0982. Of course, the methods of the present invention can be used with any source of purified cDNA and RNA.
  • The present invention also relates to using a modified nucleotide to increase fidelity either alone (in a reaction with Taq DNA polymerase or any enzyme that joins nucleic acid monomers) or in combination with a naturally occurring, high-fidelity polymerase or one that is genetically modified for high-fidelity synthesis. Additionally, the inventors have designed a complementary system using tagged nucleotides, either alone or in combination, with a naturally occurring low-fidelity polymerase or one that is genetically modified for low-fidelity synthesis. The purpose of this embodiment is to enable either random mutagenesis of a particular nucleic acid or targeted mutagenesis of a particular base type alone the length of the nucleic acid polymer. At times, it is desirable to synthesize a nucleic acid polymer at reduced accuracy (essentially a random mutagenesis). In this system, a single or a subset of natural nucleotides (that produced reduced fidelity synthesis), or ratio thereof, can be used to more precisely target mutagenesis of desired nucleotide type along the length of the nucleic acid polymer.
  • Advantageously, the extension primer is sufficiently large to provide appropriate hybridization with the sequence immediately 5′ of the target position, yet still reasonably short in order to avoid unnecessary chemical synthesis. It will be clear to persons skilled in the art that the size of the extension primer and the stability of hybridization will be dependent to some degree on the ratio of A-T to C-G base pairings, since more hydrogen bonding is available in a C-G pairing.
  • The present invention also relates to improving polymerase base incorporation fidelity acting on a target nucleic acid sequence to which a primer library (pre-existing primer set), where the library comprises an optimized subset of base permutations and combinations of the four bases for a base length between about 6 and about 35 bases. The inventors have developed a robust “classic” sequencing strategy using octamer primers to initiate the DNA synthesizing reaction (Hardin et al. U.S. Pat. No. 6,083,695, incorporated herein by reference) The primers comprising an octamer library are also appropriate to initiate single molecule DNA sequencing and related techniques with the modified nucleotides. As an example, by contacting a target nucleic acid sequence with such a library, complementary library primers will bind to the sequence forming a site for polymerase binding and polymerization. If more than one primer binds, then the polymerase will randomly select and bind to a given primer complemented to a local on the sequence and polymerization will commence. Although it is possible to have two primer molecules bound on a single template, only one primer will be the site of polymerase activity. The increased fidelity will ensure superior library differentiation. Alternatively, the library members can contain a 5′ extension to enable their immobilization to a surface, while still retaining the ability to form at least an 8 base duplex with the template, the unknown nucleic acid sequence (template) added to the surface and then the polymerase and polymerizing components are added to initiate polymerization with improved fidelity through the tagged dNTPs or by the addition of a phosphorolysis inhibitors of this invention.
  • Also, the skilled person will consider the degree of homology between the extension primer to other parts of the amplified sequence and choose the degree of stringency accordingly. Guidance for such routine experimentation can be found in the literature, for example, Molecular Cloning: a laboratory manual by Sambrook, J., Fritsch E. F. and Maniatis, T. (1989). It may be advantageous to ensure that the sequencing primer hybridizes at least one base inside from the 3′ end of the template to eliminate blunt-ended DNA polymerase activity. If separate aliquots are used (i.e., 4 aliquots, one for each base), the extension primer is preferably added before the sample is divided into four aliquots although it may be added separately to each aliquot. It should be noted that the extension primer may be identical with the PCR primer but preferably it is different, to introduce a further element of specificity into the system.
  • Alternatively, can have multiple (individual oligonucleotides such as octamers) on surface where polymerization starts when a polymerizing agent such as a polymerase and the reaction components are added.
  • Additionally, primase may be used to synthesize an RNA primer that can subsequently be used by a DNA polymerase to begin DNA synthesis. The site of initiation of the RNA chain is not critical and many reactions can be processed in parallel to obtain the complete DNA sequence.
  • The polymerase reaction in the presence of the extension primer and a deoxynucleotide is carried out using a polymerase which will incorporate dideoxynucleotides, e.g. T7 polymerase, Klenow or Sequenase Ver. 2.0 (USB U.S.A.). Any suitable chain extension sometimes are digested by an exonuclease activity. If such reverse polymerization occurs in the method according to the invention the level of background noise increases. In order to avoid this problem, a nonproofreading polymerase, e.g. exonuclease deficient (exo-) Klenow polymerase may be used. Otherwise it is desirable to add fluoride ions or nucleotide monophosphates which suppress 3′ digestion by polymerase. The precise reaction conditions, concentrations of reactants etc. may readily be determined for each system according to choice. However, it may be advantageous to use an excess of polymerase over primer/template to ensure that all free 3′ ends are extended.
  • In the method of the invention there is a need for a DNA polymerase with high efficiency in each extension step due to the rapid increase of background signal which may take place if templates which are not fully extended accumulate. An induced-fit binding mechanism in the polymerization step selects very efficiently for binding of the correct dNTP with a net contribution towards fidelity of 10-106. Exonuclease deficient polymerases, such as (exo-) Klenow or Sequenase 2.0, catalyze incorporation of a nucleotide only when the complementary dNTP was present, confirming a high fidelity of these enzymes even in the absence of proof-reading exonuclease activity.
  • In certain circumstances, e.g. with longer sample templates, it may be advantageous to use a polymerase which has a lower Km for incorporation of the correct (matched) nucleotide, than for the incorrect (mismatched) nucleotide. This may improve the accuracy and efficiency of the method.
  • In many diagnostic applications, for example genetic testing for carriers of inherited disease, the sample will contain heterozygous material, that is half the DNA will have one nucleotide at the target position and the other half will have another nucleotide. Thus if four aliquots are used in an embodiment according to the invention, two will show a negative signal and two will show half the positive signal. It will be seen therefore that it is desirable to quantitatively determine the amount of signal detected in each sample.
  • Also, it will be appreciated that if two or more of the same base are adjacent the 3′-end of the primer a larger signal will be produced. In the case of a homozygous sample it will be clear that there will be three negative and one positive signal when the sample is in four aliquots.
  • Further to enhance accuracy of the method, bidirectional sequencing i.e. sequencing of both strands of a double-stranded template may be performed. This may be advantageous e.g. in the sequencing of heterozygous material. Conveniently, this may be achieved by immobilizing the double-stranded sample template by one strand, e.g. on particles or in a microtitre well, eluting the second strand and subjecting both strands separately to a sequencing reaction by the method of the invention.
  • Reaction efficiency may be improved by including Mg2+ ions in the reagent (NTP and/or polymerase) solutions. It will be appreciated that when the target base immediately 3′- of the primer has an identical base 3′- thereto, and the polymerization is effected with a deoxynucleotide (rather than a dideoxynucleotide) the extension reaction will add two bases at the same time and indeed any sequence of successive identical bases in the sample will lead to simultaneous incorporation of corresponding bases into the primer. However, the amount of pyrophosphate liberated will clearly be proportional to the number of incorporated bases so that there is no difficulty in detecting such repetitions. Since the primer is extended by a single base by the procedure described above (or a sequence of identical bases), the extended primer can serve in exactly the same way in a repeated procedure to determine the next base in the sequence, thus permitting the whole sample to be sequenced.
  • As mentioned above, in the method of the invention, different tagged deoxy- or dideoxynucleotides may be added to separate aliquots of sample-primer mixture or successively to the same sample-primer mixture. This covers the situations where both individual and multiple target DNA samples are used in a given reaction, which sample DNAs may be the same or different. Thus, for example, as will be discussed in more detail below, in certain embodiments of the invention, there may be one reaction in one container, (in the sense of one sample DNA, i.e. one target DNA sequence, being extended) whereas in other embodiments different primer-sample combinations may be present in the same reaction chamber, but kept separate by e.g. area-selective immobilization.
  • The present invention provides two principal methods of sequencing immobilized DNA.
  • The invention provides a first method of sequencing sample DNA wherein the sample DNA is subjected to amplification; the amplified DNA is optionally immobilized and then subjected to strand separation, one strand e.g. the optionally non-immobilized or immobilized strand being removed (i.e., either strand may be sequenced), and an extension primer is provided, which primer hybridizes to the sample DNA immediately adjacent that portion of the DNA to be sequenced; each of four aliquots of the single stranded DNA is then subjected to a polymerase reaction in the presence of a tagged deoxynucleotide, each aliquot using a different tagged deoxynucleotide whereby only the tagged deoxynucleotide complementary to the base in the target position becomes incorporated; the tagged pyrophosphate released by base incorporation being identified. After identification of the incorporated nucleotide a nucleotide degrading enzyme is added, e.g., a phosphatase such as snake venom phosphatase, calf intestinal phosphatase, shrimp alkaline phosphatase, or bacterial alkaline phosphatase. Upon separating the nucleotide degrading enzyme from the different aliquots, for example if it is immobilized on magnetic beads, the four aliquots can be used in a new cycle of nucleotide additions, only if the other three are also extended by addition of the correct dNTP (after which, only one could be extended). This procedure can then be continuously repeated.
  • The invention also provides a second method of sequencing sample DNA wherein the sample DNA is subjected to amplification; the amplified DNA is optionally immobilized and then subjected to strand separation, one strand, e.g., the optionally non immobilized or immobilized strand being removed, and an extension primer is provided, which primer hybridizes to the sample DNA immediately adjacent to that portion of the DNA to be sequenced; the single stranded DNA is then subjected to a polymerase reaction in the presence of a first tagged deoxynucleotide, and the extent of tagged pyrophosphate release is determined, non-incorporated nucleotides being degraded by the nucleotide-degrading enzyme, and the reaction being repeated by successive addition of a second, third and fourth tagged deoxynucleotide until a positive release of pyrophosphate indicates incorporation of a particular tagged deoxynucleotide into the primer, whereupon the procedure is repeated to extend the primer one base (or one base-type) at a time and to determine the base which is immediately 3′- of the extended primer at each stage.
  • The present invention also provides a step by step polymerization apparatus and method. The apparatus and method includes a tubular member including a zone containing an immobilized polymerizing agent such as a polymerase. The zone is pre-treated by a nucleotide sequence. A plug of solution containing a polymerization reaction mixture containing tagged dNTPs, where each dNTP has a different tag having a different value for a specific detectable property such as absorption coefficient or fluoresceing frequency and where the tag are bonded to or associated with the β and/or γ phosphate of the triphosphate moiety. After a specified period of time, a plug of inert buffer is moved into the tubular member to displace the reactive solution. As the reactive solution is moved out of the reaction zone, the solution is exposed to a detection procedure that detects the specific detectable property to determine the incorporated dNTP. The wash plug should generally be several multiples of the volume of solution necessary to cover the reaction zone. Another reactive medium plug then follows, followed by a wash plug which allows detection of the next incorporation and so on and so on. Alternatively, the reaction media can include only a single dNTP and the detector looks for free tagged pyrophosphate. Each of these step-bγ-step polymerization methods is amenable of microarray configuration. Additionally, for the single dNTP apparatus and method, combinatorial mathematics can be used to determine the best choice for the next dNTP plug to use.
  • An alternative format for the analysis is to use an array format wherein samples are distributed over a surface, for example a micro-fabricated chip, and thereby an ordered set of samples may be immobilized in a 2 dimensional (2D) format. Many samples can thereby be analyzed in parallel. Using the method of the invention, many immobilized templates may be analyzed in this way by allowing the solution containing the enzymes and one nucleotide to flow over the surface and then detecting the signal produced for each sample. This procedure can then be repeated. Alternatively, several different oligonucleotides complementary to the template may be distributed over the surface followed by hybridization of the template. Incorporation of tagged deoxynucleotides or tagged dideoxynucleotides may be monitored for each oligonucleotide by the signal produced using the various oligonucleotides as primer. By combining the signals from different areas of the surface, sequence-based analyses may be performed by four cycles of polymerase reactions using the various tagged dideoxynucleotides.
  • Two-stage PCR (using nested primers), as described in application WO90/11369, may be used to enhance the signal to noise ratio and thereby increase the sensitivity of the method according to the invention. By such preliminary amplification, the concentration of target DNA is greatly increased with respect to other DNA which may be present in the sample and a second-stage amplification with at least one primer specific to a different sequence of the target DNA significantly enhances the signal due to the target DNA relative to the ‘background noise’.
  • Any suitable polymerase may be used, although it is preferred to use a thermophilic enzyme such as Taq polymerase to permit the repeated temperature cycling without having to add further polymerase, e.g. Klenow fragment, in each cycle of PCR. PCR has been discussed above as a preferred method of initially amplifying target DNA although the skilled person will appreciate that other methods may be used instead of in combination with PCR. A recent development in amplification techniques which does not require temperature cycling or use of a thermostable polymerase is Self Sustained Sequence Replication (3SR) or rolling circle amplification. 3SR is modelled on retroviral replication and may be used for amplification (see for example Gingeras, T. R. et al PNAS (USA) 87:1874-1878 and Gingeras, T. R. et al PCR Methods and Applications Vol. 1, pp 25-33). Rolling circle amplification is described in more detail in U.S. Pat. No. ______, incorporated herein by reference.
  • As indicated above, the method can be applied to identifying the release of tagged pyrophosphate when dideoxynucleotide residues are incorporated into the end of a DNA chain. The present invention also relates to a method of identification of the base in a single target position in a DNA sequence (mini-sequencing) wherein sample DNA is subjected to amplification; the amplified DNA is immobilized and then subjected to strand separation, the non-immobilized strand being removed and an extension primer, which hybridizes to the immobilized DNA immediately adjacent to the target position, is provided; each of four aliquots of the immobilized single stranded DNA is then subjected to a polymerase reaction in the presence of a dideoxynucleotide, each aliquot using a different dideoxynucleotide whereby only the dideoxynucleotide complementary to the base in the target position becomes incorporated and, because the tagged nucleotides improve the fidelity of incorporation, the signals from the other nucleotides are at background; the four aliquots are then subjected to extension in the presence of all four deoxynucleotides, whereby in each aliquot the DNA which has not reacted with the dideoxynucleotide is extended to form double stranded DNA while the dideoxy blocked DNA remains as single stranded DNA; followed by identification of the double stranded and/or single stranded DNA to indicate which dideoxynucleotide was incorporated and hence which base was present in the target position. Clearly, the release of tagged pyrophosphate in the chain terminating dideoxynucleotide reaction will indicate which base was incorporated but the relatively large amount of tagged pyrophosphate released in the subsequent deoxynucleotide primer extension reactions (so-called chase reactions) gives a much larger signal and is thus more sensitive.
  • It will usually be desirable to run a control with no dideoxynucleotides and a ‘zero control’ containing a mixture of all four dideoxynucleotides. WO93/23562 defines the term ‘dideoxynucleotide’ as including 3′-protected 2′-deoxynucleotides which act in the same way by preventing further chain extension. However, if the 3′ protecting group is removable, for example by hydrolysis, then chain extension (by a single base) may be followed by unblocking at the 3′ position, leaving the extended chain ready for a further extension reaction. In this way, chain extension can proceed one position at a time without the complication which arises with a sequence of identical bases, as discussed above.
  • Thus, the methods A and B referred to above can be modified whereby the base added at each stage is a 3′protected 2′-deoxynucleotide and after the base has been added (and the tag signal or detectable property such as light emission is detected), the 3′-blocking group is removed to permit a further 3′-protected-2′ deoxynucleotide to be added. Suitable protecting groups include acyl groups such as alkanol groups e.g. acetyl or indeed any hydroxyl protecting groups known in the art, for example as described in Protective Groups in Organic Chemistry, JFW McOnie, Plenum Press, 1973.
  • The invention, in the above embodiment, provides a simple and rapid method for detection of single base changes. In one format it successfully combines two techniques: solid-phase technology (DNA bound to magnetic beads) and detection of a detectable property associated with the tags on the dNTPs or released PPi. The method can be used to both identify and quantitate selectively amplified DNA fragments. It can also be used for detection of single base substitutions and for estimation of the heterozygosity index for an amplified polymorphic gene fragment. This means that the method can be used to screen for rare point mutations responsible for both acquired and inherited diseases, identify DNA polymorphisms, and even differentiate between drug-resistant and drug-sensitive strains of viruses or bacteria without the need for centrifugations, filtrations, extractions or electrophoresis. The simplicity of the method renders it suitable for many medical (routine analysis in a wide range of inherited disorders) and commercial applications.
  • The positive experimental results presented below clearly show the method of the invention is applicable to an on-line automatic non-electrophoretic DNA sequencing approach, with step-wise incorporation of single deoxynucleotides. After amplification to yield single-stranded DNA and annealing of the primer, the template/primer-fragment is used in a repeated cycle of dNTP incubations. Samples are continuously monitored for a detectable property of the tagged PPi such as fluorescence. As the synthesis of DNA is accompanied by release of tagged pyrophosphate (PPi) in an amount equal to the amount of nucleotide incorporated, signals derived from the detectable property of the tag are observed only when complementary bases are incorporated. Due to the ability of the method to determine PPi quantitatively, it is possible to distinguish incorporation of a single base from two or several simultaneous incorporations. Since the DNA template is preferably obtained by PCR, it is relatively straight forward to increase the amount of DNA needed for such an assay.
  • As mentioned above our results open the possibility for a novel approach for large-scale non-electrophoretic DNA sequencing, which allows for continuous determination of the progress of the polymerization reaction with time. For the success of such an approach there is a need for high efficiency of the DNA polymerase due to the rapid increase of background signal if templates accumulate which are not “in phase”.
  • The new approach has several advantages as compared to standard sequencing methods. Firstly, the method is suitable for handling of multiple samples in parallel. Secondly, relatively cost-effective instruments are envisioned. In addition, the method avoids the use of electrophoresis and thereby the loading of samples and casting of gels. A further advantage of the method of the present invention is that it may be used to resolve sequences which cause compressions in the gel-electrophoretic step in standard Sanger sequencing protocols.
  • The method of the invention may also find applicability in other methods of sequencing. For example, a number of iterative sequencing methods, advantageously permitting sequencing of double-stranded targets, based on ligation of probes or adaptors and subsequent cleavage have been described (see e.g. U.S. Pat. No. 5,599,675 and Jones, BioTechniques 22: 938-946, 1997).
  • Such methods generally involve ligating a double stranded probe (or adaptor) containing a Class IIS nuclease recognition site to a double stranded target (sample) DNA and cleaving the probe/adaptor-target complex at a site within the target DNA, one or more nucleotides from the ligation site, leaving a shortened target DNA. The ligation and cleavage cycle is then repeated. Sequence information is obtained by identifying one or more nucleotides at the terminus of the target DNA. The identification of the terminal nucleotide(s) may be achieved by chain extension using the method of the present invention.
  • Further to permit sequencing of a double stranded DNA, the method of the invention may be used in a sequencing protocol based on strand displacement, e.g. by the introduction of nicks, for example as described by Fu et al., in Nucleic Acids Research 1997, 25(3): 677-679. In such a method the sample DNA may be modified by ligating a double-stranded probe or adaptor sequence which serves to introduce a nick e.g. by containing a non- or mono-phosphorylated or dideoxy nucleotide. Use of a strand-displacing polymerase permits a sequencing reaction to take place by extending the 3′ end of probe/adaptor at the nick, nucleotide incorporation being detected according to the method of the present invention.
  • The method of the invention may also be used for real-time detection of known single-base changes. This concept relies on the measurement of the difference in primer extension efficiency by a DNA polymerase of a matched over a mismatched 3′ terminal. The rate of the DNA polymerase catalyzed primer extension is measured by detection of the detectable property associated with the tag such as fluorescence as described previously. In the single-base detection assay, single-stranded DNA fragments are used as template. Two detection primers differing with one base at the 3′-end are designed; one precisely complementary to the non-mutated DNA-sequence and the other precisely complementary to the mutated DNA sequence. The primers are hybridized with the 3′-termini over the base of interest and the primer extension rates are, after incubation with DNA polymerase and deoxynucleotides, measured by detecting the characteristics of the detectable property such as fluorescence of the tag. If the detection primer exactly matches to the template a high extension rate will be observed. In contrast, if the 3′-end of the detection primer does not exactly match to the template (mismatch) the primer extension rate will be much lower or eliminated by the use of tagged dNTPs which increase fidelity via the addition of tagged PPi. The difference in primer extension efficiency by the DNA polymerase of a matched over a mismatched 3′-terminal can then be used for single-base discrimination. Thus, the presence of the mutated DNA sequence can be distinguished over the non-mutated sequence. By performing the assay in the presence of a nucleotide degrading enzyme, it is easier to distinguish between a match and a mismatch of the type that are relatively easy to extend, such as T:G and C:T.
  • The invention also comprises kits for use in methods of the invention which will normally include at least the following components: (a) a test specific primer which hybridizes to sample DNA so that the target position is directly adjacent to the 3′ end of the primer; (b) a polymerase; (c) an optional detection enzyme means for identifying pyrophosphate release; (d) a nucleotide-degrading enzyme; (e) deoxynucleotides, or optionally deoxynucleotide analogues having a molecular and/or atomic tag bonded to or associated with a β- and/or γ-phosphate of the dNTP, optionally including, in place of dATP, a dATP analogue which is capable of acting as a substrate for a polymerase but incapable of acting as a substrate for a said PPi-detection enzyme; and (f) optionally dideoxynucleotides, or optionally dideoxynucleotide analogues, optionally γ-tagged ddATP being replaced by a ddATP analogue which is capable of acting as a substrate for a polymerase but incapable of acting as a substrate for a said PPi-detection enzyme.
  • If the kit is for use with initial PCR amplification then it will also normally include at least the following components: (i) a pair of primers for PCR, at least one primer having a means permitting immobilization of said primer; (ii) a polymerase which is preferably heat stable, for example Taq DNA polymerase; (iii) buffers for the PCR reaction; and (iv) tagged deoxynucleotides and/or tagged PPi (for increased fidelity).
  • Single-Molecule DNA Sequencing System
  • Engineering a polymerase to function as a direct molecular sensor of DNA base identity during base incorporation will significantly increase the speed and utility of an enzymatic DNA sequencing system possible. At this point, direct readout from a polymerase to determine base sequence has been described in U.S. Provisional Patent Application No. 60/216,594 filed: Jul. 7, 2000. This sequencing system combines several cutting-edge technologies, including single-molecule detection, fluorescent molecule chemistry, computational biochemistry, and genetic engineering of biomolecules.
  • The inventors have tested whether γ-phosphate modified dATP could be incorporated by DNA polymerase. Importantly, both biological activity and, unexpectedly, increased fidelity are associated with polymerization of this γ-phosphate modified nucleotide. Since γ-phosphate modified dNTPs are not commercially available, they are designed and synthesized in Dr. Gao's lab. In the following section, the reaction route used to produce the ANS-dATP is provided. This route is also provided as an example for the synthesis of additional γ-tagged dNTPs.
  • Synthesis of γ-Phosphate Modified dNTPs
  • Yarbrough and co-workers reported the use of fluorescent nucleotides (A and U) by DNA-dependent RNA polymerase (Yarbrough et al., 1979). Following these examples, the inventors synthesized a DNA version of aminonaphthalene-1-sulfonate (ANS) γ-phosphoamide ATP. Specifically, ANS γ-phosphoamide dATP was synthesized as shown below:
    Figure US20070172819A1-20070726-C00001
  • Using diode array UV detection HPLC, the fraction containing the desired product was easily identified by the distinct absorption of the ANS group at 366 nm. Additionally, 31P N spectra were recorded for the γ-phosphate tagged dATP and non-modified dATP in an aqueous solution. For each compound, three characteristic resonances were observed, confirming the triphosphate moiety in the γ-tagged dATP. The combined analyses—1H NMR, HPLC and UV spectra—provide supporting evidence for the formation of the correct compound.
  • Although ANS was used in this example, the tag can be any tag that alters the fidelity of the polymerizing agent, exemplary examples of such tags include alkyl groups having between 1 and 30 carbon atoms, aryl groups having between about 6 and about 40 carbon atoms, or alkaryl and aralkyl groups having between about 7 and about 40 carbon atoms, or mixture or combinations thereof. The substituents can have any number of hetero atoms in the structure provided the structure represents a stable molecular system, where the hetero atoms including P, S, Si, N, O, or any other hetero atom that does not render the nucleotide toxic to the polymerase. Exemplary examples include 4-aminophenol, 6-aminonaphthol, 4-nitrophenol, 6-nitronaphthol, 4-methylphenol, 6-chloronaphthol, 4-methoxyphenol, 6-bromonaphthol, 4-chlorophenol, 6-iodonaphthol, 4-bromophenol, 4,4′-dihydroxybiphenyl, 4-iodophenol, 8-hydroxyquinoline, 4-nitronaphthol, 3-hydroxypyridine, 4-aminonaphthol, umbelliferone, 4-methylnaphthol, resorufin, 4-methoxynaphthol, 8-hydroxypyrene, 4-chloronaphthol, 9-hydroxyanthracene, 4-bromonaphthol, 6-nitro-9-hydroxyanthracene, 4-iodonaphthol, 3-hydroxyflavone, 6-methylnaphthol, fluorescein, 6-methoxynaphthol, 3-hydroxybenzoflavone, 1-hydroxy-2-propyne, 1-hydroxy-4-pentyne, 1-hydroxy-3-butyne, 1-hydroxy-5-hexyne, Methanol, Ethanol, Propanol, Isopropanol, Butanol, Tert-butanol, Hexanol, Cyclohexanol, Heptanol, Octanol, Decanol, Undecanol, Dodecanol, 1-acetoxymethanol (CH30OCCH2-O-NTP), 2-acetoxyethanol, 3-acetoxypropanol, 4-acetoxybutanol, 5-acetoxypentanol, 6-acetoxyhexanol, 2-nitroethanol, 3-nitropropanol, 4-nitrobutanol, 5-nitropentanol, 5-nitrohexanol, 1-hydroxy-3-propene, 1-hydroxy-2-cyclohexene, 1-hydroxy-4-butene, 1-hydroxy-3-propaldehyde, 1-hydroxy-5-pentene, 1-hydroxy-4-butanaldehyde, 1-hydroxy-6-hexene, 1-hydroxy-3-Butanone, Phenol, 4-methyl-3-hydroxypyridine, 4-Carboxyphenol, 5-methoxy-3-hydroxypyridine, 4-Acetoxymethylphenol, 5-nitro-3-hydroxypyridine, 4-nitrophenol, 5-acetoxymethyl-3-hydroxypyridine, 4-methylphenol, 6-methyl-8-hydroxyquinoline, 4-methoxyphenol 6-methoxy-8-hydroxyquinoline, 4-ethylphenol, 4-methyl-8-hydroxyquinoline, 4-butylphenol, 6-nitro-8-hydroxyquinoline, naphthol, 4-acetoxymethyl-8-hydroxyquinoline, 4 or 6 or 8 methylnaphthol pyrene, 4 or 6 or 8 methoxynaphthol, 6-methyl-8-hydroxypyrene, 4 or 6 or 8 nitronaphthol, 6-ethyl-8-hydroxypyrene, 4 or 6 or 8 ethylnaphthol, 6-nitro-8-hydroxypyrene, 4 or 6 or 8 butylnaphthol 6-(carboxysuccinimidylester)fluorescein, 4 or 6 or 8 acetoxymethylnaphthol, 6-carboxymethyl-2,7-dichlorofluorescein, Methanol Cyclohexanol, 2-carboxy ethanol, 3-carboxypropanol, 4-carboxybutanol, 2-hydroxyethanol, 3-hydroxypropanol, 4-hydroxybutanol, 2-aminoethanol, 2-nitroethanol, 3-aminopropanol, 3-nitropropanol, 4-aminobutanol, 4-nitrobutanol, or any other similar substituent. Exemplary modified nucleotide include ANS modified nucleotide and Adenosine-5′-(γ-4-nitrophenyl)triphosphate, Adenosine-5′-(γ-4-iodonaphthyl), Guanosine-5′-(γ-4-nitrophenyl)triphosphate, triphosphate Adenosine-5′-(γ-6-methylnaphthyl) triphosphate, Cytosine-5′-(γ-4-nitrophenyl)triphosphate, Thymidine-5′-(γ-4-nitrophenyl) triphosphate, Adenosine-5′-(γ-6-methoxynaphthyl)triphosphate, Uracil-5′-(γ-4-nitrophenyl) triphosphate, 3′-azido-3′-deoxythymidine-5′-(γ-4-nitrophenyl)triphosphate, Adenosine-5′-(γ-6-aminonaphthyl)triphosphate, 3′-azido-2′,3′-dideoxythymidine-5′-(γ-4-nitrophenyl)triphosphate, Adenosine-5′-(γ-6-nitronaphthyl)triphosphate, 2′,3′-didehydro-2′,3′-dideoxythyrnidine-5′-(γ-4-nitrophenyl)triphosphate, Adenosine-5′-(γ-6-chloronaphthyl)triphosphate, Adenosine-5′-(γ-4-aminophenyl)triphosphate, Adenosine-5′-(γ-6-bromonaphthyl)triphosphate, Adenosine-5′-(γ-4-methylphenyl)triphosphate, Adenosine-5′-(γ-6-iodonaphthyl)triphosphate, Adenosine-5′-(γ-4-methoxyphenyl)triphosphate, Adenosine-5′-(γ-4′-hydroxybiphenyl)triphosphate, Adenosine-5′-(γ-4-chlorophenyl)triphosphate, Adenosine-5′-(γ-8-quinolyl)triphosphate, Adenosine-5′-(γ-4-bromophenyl)triphosphate, Adenosine-5′-(γ-3-pyridyl)triphosphate, Adenosine-5′-(γ-umbelliferone), Adenosine-5′-(γ-4-iodophenyl)triphosphate, Adenosine-5′-(γ-4-nitronaphthyl) triphosphate, Adenosine-5′-(γ-resorufin)triphosphate, Adenosine-5′-(γ-pyrene)triphosphate, Adenosine-5′-(γ-4-aminonaphthyl)triphosphate, Adenosine-5′-(γ-anthracene)triphosphate, Adenosine-5′-(Γ-6-nitroanthracene)triphosphate, Adenosine-5′-(γ-4-methylnaphthyl)triphosphate, Adenosine-5′-(γ-flavonyl)triphosphate, Adenosine-5′-(γ-4-methoxynaphthyl)triphosphate, Adenosine-5′-(γ-fluorescein)triphosphate, Adenosine-5′-(γ-benzoflavone)triphosphate, Adenosine-5′-(γ-4-chloronaphthyl)triphosphate, Adenosine-5′-(γ-(4-nitrophenyl)-γ′-(4-aminophenyl) triphosphate, Adenosine-5′-(γ-4-bromonaphthyl)triphosphate, Adenosine-5′-(γ-(4-nitrophenyl)-γ′-(4-nitronaphthyl)triphosphate, Adenosine-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-acetoxypropyl)triphosphate, Guanosine-5′-(γ-methyl)triphosphate, Cytosine-5′-(γ-methyl) triphosphate, Adenosine-5′-(γ-acetoxymethyl)triphosphate (CH30OCCH, —O-NTP), Thymidine-5′-(γ-methyl)triphosphate, Uracil-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-acetoxyethyl)triphosphate, 3′-azido-3′-deoxythymidine-5-(γ-methyl)triphosphate, Adenosine-5′-(γ-acetoxybutyl)triphosphate, 3′-azido-2′,3′-dideoxythymidine-5′-(γ-methyl)triphosphate, Adenosine-5′-(y, acetoxypentyl) triphosphate, 2′,3′-didehydro-2′,3′-dideoxythymidine-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-acetoxyhexyl)triphosphate, Adenosine-5′-(γ-ethyl)triphosphate, Adenosine-5′-(γ-2-nitroethyl) triphosphate, Adenosine-5′-(γ-propyl)triphosphate, Adenosine-5′-(γ-4-butyl)triphosphate, Adenosine-5′-(γ-3-nitropropyl)triphosphate, Adenosine-5′-(γ-hexyl)triphosphate, Adenosine-5′-(γ-octyl)triphosphate, Adenosine-5′-(γ-4-nitrobutyl)triphosphate, Adenosine-5′-(γ-decyl)triphosphate, Adenosine-5′-(γ-dodecyl)triphosphate, Adenosine-5′-(γ-5-nitropentyl)triphosphate, Adenosine-5′-(γ-isopropyl)triphosphate, Adenosine-5′-(γ-tert-butyl)triphosphate, Adenosine-5′-(γ-methyl)-(γ′-ethyl) triphosphate, Adenosine-5′-(γ-cyclohexyl)triphosphate, Adenosine-5′-(γ-methyl)-(γ′-propyl) triphosphate, Adenosine-5′-(γ-2-propenyl)triphosphate, Adenosine-5′-(γ-3-butenyl)triphosphate, Guanosine-5′-(γ-2-propenyl)triphosphate, Adenosine-5′-(γ-4-pentenyl)triphosphate, Cytosine-5′-(γ-2-propenyl)triphosphate, Adenosine-5′-(γ-5-hexenyl)triphosphate, Thymidine-5′-(γ-2-propenyl) triphosphate, Adenosine-5′-(γ-cyclohexenyl)triphosphate, Uracil-5′-(7-2-propenyl)triphosphate, Adenosine-5′-(γ-3-propanaldehyde)triphosphate, 3′-azido-3′-deoxythymidine-5′-(γ-2-propenyl) triphosphate, Adenosine-5′-(γ-4-butanaldehyde)triphosphate, 3′-azido-2′,3′-dideoxythymidine-5′-(γ-2-propenyl)triphosphate, Adenosine-5′-(γ-3-butanone)triphosphate, 2′,3′-didehydro-2′,3′-dideoxythyrmidine-5′-(γ-2-propenyl)triphosphate, Adenosine-5′-(γ-2-propynyl)triphosphate, 3′-azido-2′,3′-dideoxythymidine-5′-(γ-2-propynyl)triphosphate, Guanosine-5′-(γ-2-propynyl) triphosphate, Cytosine-5′-(γ-2-propynyl)triphosphate, 2′,3′-didehydro-2′,3′-dideoxythymidine-5′-(γ-2-propynyl)triphosphate Thymidine 5′-(γ-2-propynyl)triphosphate, Uracil-5′-(γ-2-propynyl) triphosphate, Adenosine-5′-(γ-3-butynyl)triphosphate, 3′-azido-3′-deoxythymidine-5′-(γ-2-propynyl) triphosphate, Adenosine-5′-(γ-4-pentynyl)triphosphate, Adenosine-5′-(γ-5-pentynyl)triphosphate, Adenosine-5′-(γ-4-phenyl)triphosphate, Adenosine-5′-(γ-(4 or 6 or 8 acetoxymethyl naphthyl) triphosphate, Guanosine-5′-(γ-4-phenyl)triphosphate, Cytosine-5′-(γ-4-phenyl)triphosphate, Adenosine-5′-(γ-(4-methylpyridyl)triphosphate, Thymidine-5′-(γ-4-phenyl)triphosphate, Uracil-5′-(γ-4-phenyl)triphosphate, Adenosine-5′-(γ-(5-methoxypyridyl)triphosphate, 3′-azido-3′-deoxythymidine-5′-(γ-4-phenyl)triphosphate, Adenosine-5′-(γ-(5-nitropyridyl)triphosphate, 3′-azido-2′,3′-dideoxythymidine-5′-(γ-4-phenyl)triphosphate, Adenosine-5′-(γ-(5-acetoxymethylpyridyl)triphosphate, 2′,3′-didehydro-2′,3′-dideoxythymidine-5′-(γ-4-phenyl) triphosphate, Adenosine-5′-(γ-(6-methyl-1-quinolyl)triphosphate, Adenosine-5′-(γ-4-carboxyphenyl)triphosphate, Adenosine-5′-(γ-(6-methoxy-1-quinolyl)triphosphate, Adenosine-5′-(γ-(4-acetoxymethyl)phenyl)triphosphate, Adenosine-5′-(γ-(4-methyl-1-quinolyl)triphosphate, Adenosine-5′-(γ-4-nitrophenyl)triphosphate, Adenosine-5′-(γ-4-methylphenyl)triphosphate, Adenosine-5′-(γ-(6-nitro-1-quinolyl)triphosphate, Adenosine-5′-(γ-4-methoxyphenyl)triphosphate, Adenosine-5′-(γ-(4-acetoxymethylpyrenyl)triphosphate, Adenosine-5′-(γ-4-ethylphenyl) triphosphate, Adenosine-5′-(γ-(6-methylpyrenyl)triphosphate, Adenosine-5′-(γ-4-butylphenyl) triphosphate, Adenosine 5′-(γ-naphthyl)triphosphate, Adenosine-5′-(γ-(6-ethylpyrenyl)triphosphate, Adenosine-5′-(γ-(4 or 6 or 8 methyl naphthyl)triphosphate, Adenosine-5′-(γ-(6-nitropyrenyl) triphosphate, Adenosine-5′-(γ-(4 or 6 or 8 methoxynaphthyl)triphosphate, Adenosine-5′-(γ-6-(carboxysuccinimidyl fluorescein)triphosphate, Adenosine-5′-(γ-(4 or 6 or 8 nitro naphthyl) triphosphate. Adenosine-5′-(γ-6-carboxymethyl-2,7-dichlorofluorescein)triphosphate, Adenosine-5′-(γ-(4 or 6 or 8 ethyl naphthyl)triphosphate, Adenosine-5′-(γ-4-phenyl)-(γ′-4 nitrophenyl) triphosphate, Adenosine-5′-(γ-(4 or 6 or 8 butyl naphthyl)triphosphate, Adenosine-5′-(γ-4-phenyl)-(γ′-4 aminophenyl)triphosphate, Adenosine-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-3-aminopropyl)triphosphate, Guanosine-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-4-aminobutyl) triphosphate, Cytosine-5′-(γ-methyl)triphosphate Adenosine-5′-(γ-cyclohexyl)triphosphate, Thymidine-5′-(γ-methyl)triphosphate Adenosine-5′-(γ-2-carboxyethyl)triphosphate, Uracil-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-3-carboxypropyl)triphosphate, 3′-azido-3′-deoxythymidine-5′-(7-methyl)triphosphate, Adenosine-5′-(γ-4-carboxybutyl)triphosphate, 3′-azido-2′,3′-dideoxythymidine-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-2-hydroxyethyl)triphosphate, 2′,3′-didehydro-2′,3′-dideoxythymidine-5′-(γ-methyl)triphosphate, Adenosine-5′-(γ-3-hydroxypropyl) triphosphate, Adenosine-5′-(γ-ethyl)triphosphate, Adenosine-5′-(γ-propyl)triphosphate, Adenosine-5′-(γ-4-hydroxybutyl)triphosphate, Adenosine-5′-(γ-4-butyl)triphosphate, Adenosine-5′-(γ-2-nitroethyl)triphosphate, Adenosine-5′-(γ-hexyl)triphosphate, Adenosine-5′-(γ-3-nitropropyl) triphosphate, Adenosine-5′-(γ-isopropyl)triphosphate, Adenosine-5′-(γ-4-nitrobutyl)triphosphate, Adenosine-5′-(γ-tert-butyl)triphosphate, Adenosine-5′-(γ-methyl)-(γ′-ethyl)triphosphate, Adenosine-5′-(γ-cyclohexyl)triphosphate, Adenosine-5′-(γ-2-aminoethyl)triphosphate, Adenosine-5′-(γ-methyl)-(γ′-propyl)triphosphate, or any other similar substituted nucleotide.
  • Polymerase Activity Assays Using Tagged dNTP(s)
  • The ability of a commercially available polymerase to incorporate the novel dNTPs synthesized was monitored using primer extension assays.
    TABLE I
    Primer Strand Definitions Used in Examples
    Primer Strand:
    TOP 5′ GGT ACT AAG CGG CCG CAT G 3′
    Template Strands:
    BOT-T 3′ CCA TGA TTC GCC GGC GTA CT 5′
    BOT-C 3′ CCA TGA TTC GCC GGC GTA CC 5′
    BOT-G 3′ CCA TGA TTC GCC GGC GTA CG 5′
    BOT-A 3′ CCA TGA TTC GCC GGC GTA CA 5′
    BOT-Sau 3′ CCA TGA TTC GCC GGC GTA CCT AG 5′
    BOT-TC 3′ CCA TGA TTC GCC GGC GTA CTC 5′
    BOT-3TC 3′ CCA TGA TTC GCC GGC GTA CTT TC 5′
  • ‘TOP’ represents the primer strand of the DNA duplex molecules used in the primer extension assays. Variants of the template strand are represented by ‘BOT’. The relevant feature of the DNA template is indicated after the hyphen. For example, BOT-T, BOT-C, BOT-G, BOT-A are used to monitor polymerase incorporation efficiency and fidelity for either nucleotides or nucleotide variants of dATP, dGTP, dCTP, and dTTP, respectively.
  • γ-Phosphate-Tagged dNTP Incorporation by Tag Polymerase
  • The following example illustrates that commercially available Taq DNA polymerase efficiently incorporates the ANS-γ-phosphate dNTPs, the syntheses and characterization of which are described above.
  • This first example illustrates the incorporation of ANS-γ-phosphate dATP to produce extended DNA products from primer/template duplexes. The reactions were carried out in extension buffer and the resulting radiolabeled products were size separated on a 20% denaturing polyacrylamide gel. Data were collected using a phosphorimaging system. Referring now FIG. 1, Lane 1 contained 5′ radiolabeled ‘TOP’ probe in extension buffer. Lane 2 contained Taq DNA polymerase, 50 μM dGTP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-Sau’). Lane 3 contained Taq DNA polymerase, 50 μM dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-Sau’). Lane 4 contained Taq DNA polymerase, 50 μM ANS-γ-dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-Sau’). Lane 5 contained Taq DNA polymerase, 50 μM dGTP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-TC’). Lane 6 contained spill-over from lane 5. Lane 7 contained Taq DNA polymerase, 50 μM dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-TC’). Lane 8 contained Taq DNA polymerase, 50 μM ANS-γ-dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-TC’). Lane 9 contained Taq DNA polymerase, 50 μM dGTP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-3TC’). Lane 10 contained Taq DNA polymerase, 50 μM dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-3TC’). Lane 11 contained Taq DNA polymerase, ANS-γ-dATP incubated with a DNA duplex (radiolabeled TOP with excess ‘BOT-3TC’). Lane 12 contained 5′ radiolabeled ‘TOP’ probe in extension buffer. Lane 13 contained 5′ radiolabeled ‘TOP’ probe and Taq DNA polymerase in extension buffer. Oligonucleotide sequences are shown in Table 1.
  • Quantitative comparison of lane 1 with lane 4 demonstrates that very little non-specific, single-base extension was detected when ANS-γ-dATP was included in the reaction, and the first incorporated base should be dGTP (which was not added to the reaction). Quantitative analysis of lanes 1 and 8 demonstrates that approximately 71% of the TOP primer are extended by a template-directed single base when ANS-γ-dATP was included in the reaction and the first incorporated base should be dATP. Thus, Taq DNA polymerase incorporates γ-tagged nucleotides. Equally important to the polymerase's ability to incorporate a γ-tagged nucleotide is its ability to extend the DNA polymer after the modified dATP was incorporated. Comparison of lane 1 with lane 11 demonstrated that a DNA strand was extended after a γ-tagged nucleotide was incorporated. Thus, incorporation of a modified nucleotide was not detrimental to polymerase activity. Note, too, that extension of the primer strand by incorporation of an ANS-γ-nucleotide depended upon Watson-Crick base-pairing rules. In fact, the fidelity of nucleotide incorporation was increased at least 15-fold by the addition of this tag to the γ-phosphate.
  • Analyzing the data from FIG. 1, the percentages for correct versus incorrect extension can be determined. Table II tabulates these result.
    TABLE II
    Percent of Correct Extension versus Percent Incorrect Extension
    Percent Total
    Percent Mis- Percent
    Lane Descriptor Expected Result Correct Extended Extended
    1 Background No Extension 89.91 10.09 10.9
    2 dGTP 1 base Extension 52.99 19.97 72.97
    3 dATP No Extension 61.99 38.01 38.01
    4 g-dATP No Extension 87.43 12.57 12.57
    5 dGTP No Extension 24.99 75.01 75.01
    6 Spill
    7 dATP 1 base Extension 15.24 69.01 84.25
    8 g-dATP 1 base Extension 71.14 6.51 77.64
    9 dGTP No Extension 32.20 67.80 67.80
    10 dATP 3 base Extension 27.11 54.92 82.03
    11 g-dATP 3 base Extension 73.43 3.87 77.31
    12 Background No Extension 95.19 4.81 4.81
    13 Background No Extension 95.92 4.08 4.08
  • From the data, the relative percent fidelity improvement can be determined of dATP and ANS-γ-phosphate tagged dATP. When G is to be incorporated and dATP is the only nucleotide in the reaction medium, then the tagged nucleotide provides about a 3 fold decrease in misextensions. When a single A is to be incorporated and dATP is only nucleotide in the reaction medium, then the tagged nucleotide provides about an 11 fold decrease in misextensions. When three A's are to be incorporated and dATP is only nucleotide in the reaction medium, then the tagged nucleotide provides about a 14 fold decrease in misextensions.
  • This next example illustrates the synthesis of extended DNA polymers using all four ANS tagged γ-phosphate dNTPs. Products generated in these reactions were separated on a 20% denaturing polyacrylamide gel, the gel was dried and imaged following overnight exposure to a Fuji BAS1000 imaging plate. Referring now to FIG. 2, an image of (A) the actual gel image, (B) a lightened phosphorimage and (C) an enhanced phosphorimage. Lane descriptions for A, B, and C follow: Lane 1 is the control containing purified 10-base primer extended to 11 and 12 bases by template-mediated addition of α-32P dCTP. Lane 2 includes the same primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes (to denature template). The reaction was brought to 37° C. (to anneal the primer to the template), Taq DNA polymerase and all four natural dNTPs (100 μM, each) were added and the reaction was incubated at 37° C. for 60 minutes. Lane 3 includes the same labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes; Taq DNA Polymerase and all four γ-modified dNTPs (100 M, each) were added and the reaction was incubated at 37° C. for 60 minutes. Lane 4 includes the control, purified 10-base primer that was extended to 11 and 12 bases by the addition of α-32P dCTP and was cycled in parallel with the reactions in lanes 5-8. Lane 5 includes the same 32P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four natural dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Lane 6 includes the same 32P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four γ-modified dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Lane 7 includes nonpurified, 10-base, γ32P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four natural dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Lane 8 includes nonpurified, 10-base γ-32P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four γ-modified dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Evident in the reactions involving tagged dNTPs is a substantial decrease in pyrophosphorolysis as compared to reactions involving natural nucleotides.
  • This next example illustrates the synthesis of long DNA polymers using all four ANS tagged γ-phosphate dNTPs. Each primer extension reaction was split into two fractions, and one fraction was electrophoresed through a 20% denaturing gel (as described above), while the other was electrophoresed through a 6% denaturing gel to better estimate product lengths. The gel was dried and imaged (overnight) to a Fuji BAS1000 imaging plate. Referring now to FIG. 3, an image of (A) the actual gel, (B) a lightened phosphorimage of the actual gel, and (C) an enhanced phosphorimage of the actual gel. Lane descriptions for A, B, and C follow: Lane 1 includes 123 Marker with size standards indicated at the left of each panel. Lane 2 contained the control, purified 10-base primer extended to 11 and 12 bases by template-mediated addition of α-32P dCTP. Lane 3 contained the same 32P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes (to denature template), the reaction was brought to 37° C. (to anneal the primer to the template), Taq DNA polymerase and all four natural dNTPs (100 μM, each) were added and the reaction was incubated at 37° C. for 60 minutes. Lane 4 includes the same 32P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° CV., Taq DNA polymerase and all four γ-modified dNTPs (100 μM, each) were added and the reaction was incubated at 37° C. for 60 minutes. Lane 5 includes the control, purified 10-base primer that was extended to 11 and 12 bases by the addition of α-32P-dCTP was cycled in parallel with the reactions in lanes 5-8 Lane 6 includes the same 32P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four natural dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Lane 7 includes the same 32P-labeled primer that was incubated with double-stranded plasmid DNA at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four γ-modified dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Lane 8 includes nonpurified, 10-base γ32P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four natural dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes. Lane 9 includes nonpurified, 10-base, γ-32P-labeled primer that was incubated with double-stranded DNA plasmid at 96° C. for 3 minutes, the reaction was brought to 37° C. for 10 minutes, during which time Taq DNA polymerase and all four γ-modified dNTPs (100 μM, each) were added. The reaction was cycled 25 times at 96° C. for 10 seconds, 37° C. for 1 minute, and 70° C. for 5 minutes.
  • The majority of extension products in this reaction are several hundred bases long for both natural and γ-modified dNTPs, and a significant percentage of these products are too large to enter the gel. Thus, demonstrating that the γ-phosphate tagged dNTPs are used by Taq polymerase to generate long DNA polymers that are non-tagged or native DNA polymer chains.
  • Different Polymerases React Differently to they Modified Nucleotides
  • The indicated enzymes (Taq DNA Polymerase, DNA polymerase I-Klenow Fragment Pfu DNA Polymerase, HIV-1 Reverse Transcriptase, T7 DNA Polymerase Sequenase Version 2) were incubated in the manufacturers suggested reaction buffer, 50 M of the indicated nucleotide were added and the reactions, containing aDNA duplex (5′ radiolabeled TOP and the specified template) were incubated at 37° C. for 30-60 minutes. The reaction products were analyzed by size separation through a 20% denaturing gel.
  • Taq DNA polymerase efficiently uses the modified nucleotides to synthesize extended DNA polymers at increased accuracy as shown in FIGS. 1-6.
  • The Klenow fragment from E. coli DNA polymerase I efficiently uses γ-modified nucleotides, but does not exhibit the extreme fidelity improvements observed with other enzymes as shown in FIG. 4.
  • Pfu DNA polymerase does not efficiently use γ-modified nucleotides and is, thus, not a preferred enzyme for the single-molecule sequencing system as shown in FIG. 5.
  • HIV-1 reverse transcriptase efficiently uses the modified nucleotides, and significant fidelity improvement results as shown in FIG. 6.
  • Polymerization activity is difficult to detect in the reaction products generated by native T7 DNA polymerase (due to the presence of the enzyme's exonuclease activity). However, its genetically modified derivative, Sequenase, shows that the γ-modified nucleotides are efficiently incorporated, and that incorporation fidelity is improved, relative to non-modified nucleotides. The experimental results for native T7 DNA polymerase and Sequenase are shown in FIG. 7.
  • Thus, for Taq polymerase or HIV-1 reverse transcriptase, improved fidelity, due to the use of the γ-modified dNTPs of this invention, enables single-molecule DNA sequencing. However, not all polymerases equally utilize the γ-modified nucleotides of this invention, specifically, Klenow, Sequenase, HIV-1 reverse transcriptase and Taq polymerases incorporate the modified nucleotides of this invention, while the Pfu DNA polymerase does not appear to incorporate (or incorporates very inefficiently) the modified nucleotides of this invention.
  • Elevated Temperature Affects the Stability of ANS-γ-Phosphate-Tagged dNTPs
  • This experiment illustrates the effect of elevated temperature on ANS-tagged dNTPs. Specifically, γ-tagged dNTPs were heated for 7 minutes at 96° C. Primer extension reactions containing heat-treated or untreated natural or ANS-tagged dNTPs were compared to determine the effect of high temperature. The reactions were carried out in extension buffer and the resulting radiolabeled products were size separated on a 20% denaturing polyacrylamide gel. Data were collected using a phosphorimaging system.
  • Referring to FIG. 8. Lane 1 contained free γ-32P-labeled primer (‘TOP’). Lanes 2-9 are extension reactions containing the γ-32P-labeled TOP that was annealed to a single-stranded template (‘BOT T6T’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 μM) were added and the reactions were carried out at 37° C. for 30 minutes. Each lane contained as follows: untreated natural dATP (Lanes 2-3), heat-treated natural dATP (Lanes 4-5), untreated ANS-γ-tagged dATP (Lanes 6-7), heat-treated ANS γ-tagged dATP (Lanes 8-9) Lanes 10-17 are extension reactions containing the γ-32P-labeled TOP that was annealed to a single-stranded template (‘BOT A6A’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 μM) were added and the reactions were carried out at 37° C. for 30 minutes. Each lane contained as follows: untreated natural TTP (Lanes 10-11), heat-treated natural TTP (Lanes 12-13), untreated ANS-γ-tagged TTP (Lanes 14-15), heat-treated ANS γ-tagged TTP (Lanes 16-17).
  • Referring to FIG. 9. Lane 1 contained free γ-32P-labeled primer (‘TOP’). Lanes 2-9 are extension reactions containing the γ-32P-labeled TOP that was annealed to a single-stranded template (‘BOT G6G’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 μM) were added and the reactions were carried out at 37° C. for 30 minutes. Each lane contained as follows: untreated natural dCTP (Lanes 2-3), heat-treated natural dCTP (Lanes 4-5), untreated ANS-γ-tagged dCTP (Lanes 6-7), heat-treated ANS-γ-tagged dCTP (Lanes 8-9) Lanes 10-17 are extension reactions containing the γ-32P-labeled TOP that was annealed to a single-stranded template (‘BOT C6C’) at 96° C. for 3 minutes (to form primer-template duplex) Taq DNA polymerase and the specified dNTPs (10 μM) were added and the reactions were carried out at 37° C. for 30 minutes. Each lane contained as follows: untreated natural dGTP (Lanes 10-11), heat-treated natural dGTP (Lanes 12-13), untreated ANS-γ-tagged dGTP (Lanes 14-15), heat-treated ANS-γ-tagged dGTP (Lanes 16-17).
  • Comparison between the lanes containing untreated and heat-treated natural dNTPs does not show significant, if any, change in terms of extension patterns and amount of completely extended products. In contrast, after heat-treatment the ANS-γ-tagged dNTPs behave more like their natural counterparts, indicating that the ANS-tag is heat-labile, which results in a possible loss thereof.
  • Temperature and Time of Extension can be Used to Modulate the Rate of dNTP Incorporation by Tag Polymerase
  • This following example illustrates the effect of temperature and time on the ability of Taq DNA Polymerase to produce extended DNA products from primer/template duplexes. The reactions were carried out in extension buffer and the resulting radiolabeled products were size separated on a 10% denaturing polyacrylamide gel. Data were collected using a phosphorimaging system. Referring now to FIG. 10.
  • The reactions contain γ-32P-labeled primer (‘TOP’) duplexed to a single-stranded template (‘BOT-24’) [primer/template ratio—1:9], the appropriate buffer, Taq DNA polymerase and the specified nucleotides. Lanes 1-4 contain all four natural dNTPs (100 μM, each). The reactions were carried out for 1 minute at temperatures ranging from 10 to 40° C. Lanes 5-8 contain all four ANS-γ-modified dNTPs (100 μM, each). The reactions were carried out for 1 minute at temperatures ranging from 10 to 40° C. Lanes 9-12 contain all four natural dNTPs (100 μM, each). The reactions were carried out for 10 minutes at temperatures ranging from 10 to 40° C. Lanes 13-16 contain all four ANS-γ-modified dNTPs (100 μM, each). The reactions were carried out for 10 minutes at temperatures ranging from 10 to 40° C. Lane 18 is a control containing 5′ radiolabeled primer (‘TOP’) in extension buffer.
  • Quantitative comparison of lanes 1 through 4 and 5 through 8 demonstrates that temperature affects the amount of completely extended product when the reaction is carried out for 1 minute, regardless of the type of dNTPs used (natural vs γ-modified dNTPs). The same is true for lanes 9 through 12 and 13 through 16 when the reaction duration is 10 minutes. It is evident that time also affects the rate of polymerization with either types of nucleotides. Thus temperature and/or time can be used to modify polymerization rate of Taq DNA polymerase.
  • ANS γ-Phosphate-Modification of dNTPs Affects the Terminal Transferase Activity of Tag DNA Polymerase
  • This example demonstrates that the addition of an ANS-γ-tag to natural dNTPs affects the terminal transferase activity of commercially available Taq DNA Polymerase. The extension reactions were carried out in extension buffer at 37° C. for 30 minutes and the resulting radiolabeled products were size separated on a 10% denaturing polyacrylamide gel. Data were collected using a phosphorimaging system. Referring now to FIG. 1 Lane 1 is a control reaction and contained Taq DNA Polymerase and DNA duplex (radiolabeled ‘TOP’ probe and single-stranded ‘BOT-24’ template at equal molar concentrations). No nucleotides are added. Lane 2 contained Taq polymerase, DNA duplex and all four natural dNTPs (100 μM, each). Lane 3 contained Taq polymerase, DNA duplex and all four γ-modified dNTPs (100 μM, each).
  • Quantitative comparison of Lanes 2 and 3 demonstrates that in the reactions involving γ-modified dNTPs there is a substantial decrease in the terminal transferase activity of Taq DNA polymerase. The major extension product in Lane 2 is a result of this activity, while the major extension product in Lane 3 is due to a template-directed addition of nucleotides. If, however, the presence of a non-templated base is desirable or necessary for cloning or other purposes, it can be added by elevating the reaction temperature as shown in FIGS. 8 and 9 and allowing the heat treated nucleotides to act as substrates for the enzymes terminal transferase activity.
  • Summary of Polymerase Incorporation Results
  • Different Polymerases React Differently to the ANS-γ-modified Nucleotides: primer extension reactions were performed to determine the ability of various polymerases to incorporate γ-tagged dNTPs during DNA polymerization. Control reactions contained natural dNTPs to monitor for template-directed nucleotide incorporation as well as for misincorporation as shown in FIG. 12. The reactions were performed in the appropriate buffer and contained the specified polymerase, primer/template duplex (radiolabeled ‘TOP’ primer annealed to ‘BOT-3TC’ template), and only the indicated dNTP. The reactions were carried out at room temperature or at 37° C. for 30 minutes and were stopped by the addition of 0.5 mM EDTA. The volume of the reaction was then reduced to approximately 2-4 μL, loading dye was added and the polymerization products were electrophoresed through a 20% denaturing polyacrylamide gel. Arrows indicate the position of the free labeled ‘TOP’. Asterisks indicate 3-base extension.
  • From the data, the inventors have found that the ANS tag is thermally labile. The fact can be used to allow the construction of DNA sequences with high fidelity and low fidelity regions. Thus, a DNA polymerization can be started at low temperature using ANS γ phosphate tagged nucleotides until a give sequence length is attained (from a statistical basis) and then the temperature can be raised to liberate the ANS tag resulting in the extension of the sequence with lowered fidelity. The reverse can be done by starting with lower fidelity (untagged) nucleotides, running the polymerization for a set time, destroying any remaining untagged dNTPs with a phosphatase, and then adding the ANS tagged dNTPs and polymerizing for a second set period. Optionally, the medium can then be heated to allow a second lower fidelity region to be prepared. Thus, the present invention can be used to prepare DNA, RNA or mixed sequences having high fidelity and low fidelity regions. Such DNA, RNA or mixed sequences can be used to investigate evolutionary trends, analyzing the mutagenecity of different regions of DNA sequences, producing nucleic acid polymers that contain both highly accurate and reduced accuracy regions (in any combination or order) for mutagenesis studies (essentially targeted, random mutagenesis), or determine sites prone to mutations that result in disease states, carcinogenic states or change in cell phenotypes. The present invention also relates to method for preparing DNA, RNA or mixed sequences with regions of different fidelity indices.
  • The present invention also relates to the following pyrophosphorolysis inhibitors selected from the group consisting of compounds of the following general formulas or mixtures or combinations thereof:
    Z-OPO2O-Z′  (a)
    Z-PO2O-Z′  (b)
    Z-OPO2-Z′  (c)
    Z-PO2-Z′  (d)
    Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
    Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
    Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
    Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
    where Z or Z′is a hydrogen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements, E and E′ are an oxygen atom or a thermally stable substituent comprising primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements and n is an integer having a value between 0 and about 5. The term primarily means that other atoms can be present, but in very small amounts.
  • The present invention relates to any nucleotide or nucleotide analog bearing a tag anywhere on the nucleotide (phosphate groups, base or sugar) that improves the fidelity of nucleotide incorporation.
  • Different DNA Polymerases React Differently to the γ-Phosphate Modified Nucleotides
  • Primer extension experiments were performed with several different DNA polymerases to determine whether any of them could incorporate the ANS-γ-phosphate modified nucleotides (FIG. 12). These experiments were performed by incubating the indicated polymerase in appropriate extension buffer, 100 μM ANS-γ-modified dATP, and a 5′-32P end-labeled primer annealed to a template that directed sequential incorporation of dATP, dATP, dATP dGTP. Positive and negative control reactions containing natural dATP or dGTP, respectively, were run in parallel to monitor template-directed nucleotide incorporation or mis-incorporation. Reactions containing dATP should produce 3-base extension products, whereas those containing dGTP should not produce extended products (due to the absence of dATP). No products longer than 3-bases should result, since no reaction contained more than one nucleotide type. The reactions were allowed to proceed for 30 minutes, at which time they were stopped by EDTA addition, lyophilized and resuspended in 3.5 μl of sequencing loading buffer. Reaction products were heat denatured, loaded onto a 20% denaturing polyacrylamide gel, size-separated (2400 V; 1 hour), and detected via phosphorimaging.
  • The inventors observed that Taq DNA polymerase I, HIV-1 Reverse Transcriptase (RT), Klenow fragment of E. coli DNA polymerase I, and a modified version of T7 DNA polymerase (Sequenase, Version 2) each incorporate the modified nucleotides. Interestingly, the high-fidelity enzyme Pfu DNA polymerase appears least able to incorporate these nucleotides. The inventors discovered that each polymerase responded differently to the modified nucleotides. The fact that several different DNA polymerases incorporate the ANS-γ-phosphate modified nucleotides provides critical feasibility data for the VisiGen Sequencing System. Note that the expected 3-base extension products accumulate in reactions containing ANS-γ-dATP, whereas the lanes containing natural dATP or dGTP produce increased amounts of mis-extended products. Thus, the presence of the ANS-modification on the γ-phosphate appears to increase the accuracy of the reaction, and this may improve the accuracy of the VisiGen Sequencing System.
  • DNA Polymerase Efficiently Incorporates γ-Phosphate Modified Nucleotides
  • To begin to understand the unexpected observation that γ-modified dNTPs improve the accuracy at which polymerases synthesize DNA strands, the inventors investigated the incorporation efficiency of ANS-γ-modified dNTPs relative to their natural counterparts. These experiments were performed by incubating polymerase in extension buffer, 100 μM of the indicated natural or ANS-γ-modified dNTP, and a 5-32P end-labeled primer (TOP)/single-stranded template (BOT-‘X’) duplex for 0.5, 1, 2, 3, 5, 10 or 30 minutes. The sequences of the oligonucleotide templates are shown (Table 1). Intensities of non-extended primer band (I0) versus extended primer band (I1) were quantified with a Fuji MacBas 1000 Image software version 3.0. To calculate the relative percent extension, background was first subtracted from each band value and the following calculation was applied to each reaction: Relative Percent Extension=((I1)/(I0+I1))×100. The percent extensions observed in the time course experiments are plotted and demonstrate that DNA polymerase incorporates each ANS-γ-phosphate modified nucleotide at a similar efficiency as the corresponding natural nucleotide, thus providing additional feasibility data for the VisiGen Sequencing System (FIG. 13).
  • γ-Phosphate Modified Nucleotides Improve Reaction Fidelity
  • Experiments demonstrating that commercially available Taq DNA polymerase efficiently incorporates the modified nucleotides provides feasibility data for the VisiGen Sequencing System and, unexpectedly, data demonstrating that this modification increases the fidelity of nucleotide incorporation (patent pending). In these experiments, Taq DNA polymerase (2.5 units/reaction; Promega Corporation) was incubated in polymerase reaction buffer with 10,000 cpm of 5-32P end-labeled ‘TOP’ primer, 10 ng of the indicated single-stranded template, and the specified dNTP. The sequences of the oligonucleotides are shown (Table 1). Extension reactions were incubated for 30 minutes, and terminated by the addition of 1 μl of 0.5 M EDTA. The reactions were lyophilized and resuspended in 3.5 μl of sequencing loading buffer. Reaction products were heat denatured, loaded onto a 20% denaturing polyacrylamide gel, size-separated, and quantified using a phosphorimaging system (Fuji Medical Systems, Inc.).
  • A representative primer extension analysis that demonstrates the fidelity improvement is shown (FIG. 3). This is an important experiment because it illustrates the following:
  • 1) Taq DNA polymerase does not randomly incorporate γ-tagged nucleotides. Quantitative comparison of lane 1 with lane 4 demonstrates that very little non-specific, single-base extension is detected when ANS-γ-dATP is included in the reaction, but the first incorporated base should be dGTP (which was not added to the reaction). The ‘BOT-Sau’ template was designed to monitor sequential incorporation of dGTP, dATP, dTTP and dCTP.
  • 2) Taq DNA polymerase accurately incorporates γ-tagged nucleotides. Quantitative analysis of lanes 1 and 8 demonstrates that approximately 70% of the TOP primer strands are extended by a template-directed single base when ANS-γ-dNTP is included in the reaction and the first incorporated base should be dATP. This percentage is very similar to the percent extension observed with natural dATP (75%; lane 7). However, 60% of the extension products resulting from natural dATP incorporation were misextended opposite a template C, and 34% of these products were further extended by the enzyme's terminal transferase activity.
  • 3) DNA strand extension continues following γ-tagged nucleotide incorporation. It was important to demonstrate that the polymerase could continue extension following incorporation of a γ-modified dNTP. This was first accomplished by preparing reactions containing the same end-labeled ‘TOP’ primer hybridized with the ‘BOT-3TC’ template, and ANS-modified dATP. Multiple occurrences of a single-base type in the extension template were used to simplify analysis of the extension products. A single nucleotide is added to the reaction and, thus, only that nucleotide can be incorporated into the growing DNA strand. Comparison of lane 1 with lane 11 demonstrates that multiple modified nucleotides are incorporated and are, therefore, not detrimental to chain extension. Natural dATP (lane 10) is efficiently incorporated opposite Ts in the template, but is also frequently misincorporated opposite a template C. Further, these blunt-ended molecules stimulate the enzyme's terminal transferase activity and account for the formation of the 5 base extension products.
  • 4) Extension of the primer strand by incorporation of an ANS-γ-nucleotide is dependent upon Watson-Crick base pairing rules. In fact, the fidelity of nucleotide incorporation is increased by γ-phosphate modification (patent pending).
  • Comparison of Relative Fidelity Improvement: Single Nucleotide Extension Assays
  • The inventors discovered that the fidelities of several commercially relevant DNA polymerases are improved by providing the enzyme with nucleotides containing a molecular moiety at the γ-phosphate. This was further investigated by assaying the percent extension of natural and γ-phosphate modified dNTP in complementary (matched) and noncomplementary (mismatched) nucleotide combinations (FIG. 14). In these experiments, TOP was 5′ end-labeled, gel purified and quantified with regard to both radioactivity and absorbance at 260 nm. Primer/template hybrids were formed by heat denaturing and slow cooling primer and template strands (1:1.2 ratio). Extension reactions were prepared by combining the duplex with reaction buffer, dNTP or ANS-dNTP at 100 μM, and a DNA polymerase. To increase detection of mismatch incorporation, reactions were incubated for 30 minutes and terminated by adding STOP solution. Terminated reactions were heated, placed on ice, loaded onto a 20% denaturing polyacrylamide gel and electrophoresed for ˜2 hours at 30 W. Gels were dried and imaged with a phosphorimaging system (Fuji Medical Systems, Inc.). Each reaction was repeated at least three times, and the average extension and average deviation were calculated.
  • Interestingly, the magnitude of the fidelity improvement is influenced by the identity of the templating baseversus the incoming nucleotide. As an example, C:T provides a different magnitude of improvement (15.98 fold) when compared to T:C (2.93 fold), where the first base is the template base and the second base is the incoming nucleotide. Comparing the percent extension of a natural dNTP with that of an ANS-modified dNTP, it is striking that the modified nucleotide is consistently incorporated at an improved accuracy. Additionally, the time course studies show that the incorporation of the complementary nucleotide (natural or ANS-modified) exhibit similar incorporation profiles, indicating that the fidelity improvements are not due to generally slowed reaction kinetics resulting from nucleotide modification.
  • Kinetic analysis of the ANS-γ-phosphate fidelity affect is warranted in Phase II of the project since similar nucleotides will be used in the VisiGen Single-Molecule Sequencing System. It is likely that these nucleotides will exhibit altered incorporation fidelities, similar to the ANS-modified nucleotides. If increased fidelity is associated with incorporation of the fluorescently-modified nucleotides designed for the VisiGen Sequencing System, the accuracy of the single molecule sequence will increase and the number of reactions that need to be performed in parallel to obtain highly accurate information will decrease.
  • The fidelity improving nucleotides—“Designer Nucleotides”—are being pursued as a VisiGen intermediate product. We anticipate a shorter route to this product. VisiGen's designer nucleotides will improve the accuracy at which a DNA strand is synthesized and should be quite useful in any enzymatic extension assay (patent pending). Perhaps derivatives of these nucleotides will enable highly accurate in vitro DNA synthesis that rivals, or possibly exceeds, the accuracy at which a DNA strand is replicated in vivo. Thus, Phase II of our project, “Real-time DNA Sequencing: Nucleotide Synthesis and Use”, will support kinetic analysis and M13 forward mutation assays of ANS-modified nucleotides. Data from these studies will define the ‘fidelity factor’ for each modified nucleotide, and enable us to better understand the importance of the modification relative to the natural nucleotide. It is unlikely that the first molecular moiety chosen, ANS, is the one that produces the optimal designer nucleotide. Future studies (not supported by this award), will define the parameters that affect replication fidelity by examining the contribution of specific tag modifications on matched versus mismatched nucleotide selection. However, the kinetic and forward mutation studies supported by a Phase II award will provide feasibility data that will enable us to begin discussions with larger companies and/or private investors interested in either a short- or long-term technology—designer nucleotides that improve reaction fidelity and single-molecule DNA sequencing, respectively.
  • Chemically Engineer Nucleotides (NIH Phase II)
  • Synthesis of γ- and/or β-Modified and 3′-Modified dNTP
  • Potential candidate compounds for use in our FRET or quenching detection of polymerase reactions are summarized in the following synthetic scheme:
    Figure US20070172819A1-20070726-C00002
  • In above scheme, N=A, C, G, T; X=O, N, S, CH2, etc.; L=linker, such as —(CH2)n—, —(CH2CH2O)n—; R=fluorophore or quencher moieties, such as ANS, FAM, FITC, rhodamine, cyanine, pyrene, perylene; Phv is a photolabile group.
  • These modified dNTPs can be used to identify a set of nucleotides that work with modified polymerase as an energy transfer pair to achieve high efficiency and accurate sequence reading. The positions that are of interest are the 5′-γ- and 5′-β, since the modifications at these positions may not or least affect enzyme activity. The inventors plan to incorporate rhodamine derivatives, such as TMR or TAMRA, for FRET detection and DABCYL for quenching detection (the enzyme in using either type of dNTP's will contain fluorescein moiety). An additional linker (L) between the dye moiety and phosphorous provides flexibility to obtain better fit of the nucleotide and the enzymatic active site and may provide stabilization to the resultant modified compound. The alteration at the phosphorous linkage is preferably an O (X═O). For all 5‘-modified dNTP’s, if the 3′-OH is not blocked, the sequence will proceed continuously. The protection of the 3′-O position with a photolabile group causes reaction to pause after the addition of a dNTP. The sequence extension can continue after photo-deprotection of the 3′-Phv. The 3′-protection is to be used along with 5′-modifications to overcome potential problems of background reading from fluorescent nucleotides.
  • Specifically, examples of the compounds the inventors plan to synthesize are the following: Set 1—these are 5′-γ- or β-modifications, different dyes are needed so that different nucleotides can be differentiated by different wavelengths. These are the d-rhodamine family of molecules and have been widely used in traditional DNA sequencing. The linker and connector, HNCH2CH2O will be varied to achieve the best result.
    AD-NHCH2CH2OPγPβPα-dN N=A, C, G, T)
    Pγ(AD-NHCH2CH2O)PβPα-dN (N=A, C, G, T)
    where AD: acceptor dye molecule, AD is selected from Lee et al., 1997; AD=5dR110, 5dR6G, 5dTMR, 5dROX
  • Set 2—These are 5′-quencher (Q), 3′-Phv modifications. Our laboratory has used this photolabile group in the synthesis of several photogenerated reagents, and have studied this reaction in great detail.
    Q-NHCH2CH2OPγPβPα-dN-3′-OCO2CH2CH(CH3)[(2-NO2)Ph], (N=A, C, G, T)
    Pγ(AD-NHCH2CH2O)PβPα-dN-3′-OCO2CH2CH(CH3)[(2-NO2)Ph (N=A, C, G, T)
  • The inventors will closely monitor the results of our experiments and implement changes in our synthesis plan as necessary.
  • The synthesis of γ-modified triphosphates will begin with typical reactions for triphosphate esterification, using a coupling reagent such as that shown in the Phase I Final Project Report section for the synthesis of γ-ANS-dATP. Although the reaction is simple, the isolation of the product requires great care since the compound may not be quite stable. For separation of the ANS dNTP products, low temperature was used and light must be kept away in the process. Rhodamine molecules are not stable under basic conditions and caution will be taken. However, since the inventors have had long time experiences in synthesis and there is a large of amount of information on the type of chemistry which can be used, the inventors do not anticipate significant problems. The synthesis of β-modified dNTP will require first protecting the active γ-phosphate. The inventors do not intend to spend major effort in making these compounds, unless the β-modified molecule is a strong candidate with desirable sequencing properties. To connect the linker with dye on one side and nucleotide on the other side, the inventors prefer to have amide and phosphate bonds, respectively. The bond formation of the linker is through well-known coupling reactions (through isothiocyannate ester, or NHS ester, etc.).
  • All references cited herein are incorporated by reference. While this invention has been described fully and completely, it should be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described. Although the invention has been disclosed with reference to its preferred embodiments, from reading this description those of skill in the art may appreciate changes and modification that may be made which do not depart from the scope and spirit of the invention as described above and claimed hereafter.

Claims (58)

1. A composition comprising a modified nucleotide including a molecular and/or atomic tag, a nucleotide polymerizing agent, a primer, a template and a pyrophosphorolysis inhibitor, where the modified nucleotide alters base incorporation fidelity of the nucleotide polymerizing agent relative to a base incorporation fidelity of the agent in the absence of the modified nucleotide and where the pryophosphorolysis inhibitor reduces pryophosphorolysis.
2. The composition of claim 1, wherein the modified nucleotide comprises a β and/or γ phosphate modified nucleotide.
3. The composition of claim 1, wherein the modified nucleotide comprises a β phosphate modified nucleotide.
4. The composition of claim 1, wherein the modified nucleotide comprises a γ phosphate modified nucleotide.
5. The composition of claim 4, wherein the tag comprises a molecule.
6. The composition of claim 5, wherein the tag is ANS.
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. A composition comprising a nucleotide including a molecular and/or atomic tag on a phosphate group and a virus, where the nucleotide alters viral replication fidelity.
18. The composition of claim 17, wherein the virus is HIV.
19. (canceled)
20. (canceled)
21. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2O-Z′  (a)
Z-PO2O-Z′  (b)
Z-OPO2-Z′  (c)
Z-PO2-Z′  (d)
Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
22. The composition of claim 21, wherein the thermally stable substituents comprise primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements.
23. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2O-Z′  (a)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
24. The composition of claim 23, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
25. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2O-Z′  (b)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
26. The composition of claim 25, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
27. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2-Z′  (c)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
28. The composition of claim 27, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
29. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2-Z′  (d)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
30. The composition of claim 29, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
31. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
32. The composition of claim 31, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
33. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
34. The composition of claim 33, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
35. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
36. The composition of claim 35, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
37. The composition of claim 1, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
38. The composition of claim 37, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
39. The composition of claim 21, 23, 25, 27, 29, 31, 33, 35, or 37, wherein Z and/or Z′are tags.
40. The composition of claim 17, wherein the pyrophosphorolysis inhibitor selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2O-Z′  (a)
Z-PO2O-Z′  (b)
Z-OPO2-Z′  (c)
Z-PO2-Z′  (d)
Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
41. The composition of claim 23, wherein the thermally stable substituents comprise primarily one or more atoms selected from the group carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy valence requirements.
42. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2O-Z′  (a)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
43. The composition of claim 42, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
44. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2O-Z′  (b)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
45. The composition of claim 44, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
46. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2-Z′  (c)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
47. The composition of claim 46, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
48. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2-Z′  (d)
where Z or Z′is a hydrogen atom or a thermally stable substituent and E and E′ are an oxygen atom or a thermally stable substituent.
49. The composition of claim 48, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
50. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2—(OP(EE′)O)n—PO2O-Z′  (e)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
51. The composition of claim 50, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
52. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-OPO2—(OP(EE′)O)nPO2-Z′  (f)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
53. The composition of claim 52, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
54. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2—(OP(EE′)O)nPO2O-Z′  (g)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
55. The composition of claim 54, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
56. The composition of claim 17, wherein the pyrophosphorolysis inhibitor is selected from the group consisting of compounds of the following general formulas and mixtures or combinations thereof:

Z-PO2—(OP(EE′)O)nPO2-Z′  (h)
where Z or Z′is a hydrogen atom or a thermally stable substituent, E and E′ are an oxygen atom or a thermally stable substituent and n is an integer having a value between 0 and about 5.
57. The composition of claim 56, wherein the thermally stable substituents comprise one or more atoms selected from the group consisting of carbon, nitrogen, oxygen, sulfur and phosphorus with sufficient hydrogen atoms to satisfy the groups valence requirements.
58. The composition of claim 40, 42, 44, 46, 48, 50, 52, 54, or 56, wherein Z and/or Z′are tags.
US11/648,108 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors Abandoned US20070172819A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/648,108 US20070172819A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25076400P 2000-12-01 2000-12-01
US10/007,621 US7211414B2 (en) 2000-12-01 2001-12-03 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US11/648,108 US20070172819A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/007,621 Continuation US7211414B2 (en) 2000-12-01 2001-12-03 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity

Publications (1)

Publication Number Publication Date
US20070172819A1 true US20070172819A1 (en) 2007-07-26

Family

ID=22949045

Family Applications (12)

Application Number Title Priority Date Filing Date
US10/007,621 Expired - Fee Related US7211414B2 (en) 2000-12-01 2001-12-03 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US11/648,723 Abandoned US20070172869A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis
US11/648,107 Abandoned US20070172859A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: methods for direct detection of tagged monomers
US11/648,721 Active 2025-05-14 US8314216B2 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US11/648,114 Abandoned US20070172860A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions and methods
US11/648,108 Abandoned US20070172819A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors
US12/352,353 Abandoned US20100216122A1 (en) 2000-12-01 2009-01-12 Enzymatic nucleic acid synthesis: methods for direct detection of tagged monomers
US12/985,421 Abandoned US20110184163A1 (en) 2000-12-01 2011-01-06 Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis
US13/644,469 Expired - Lifetime US8648179B2 (en) 2000-12-01 2012-10-04 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US14/137,199 Expired - Fee Related US9243284B2 (en) 2000-12-01 2013-12-20 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US14/977,167 Expired - Lifetime US9845500B2 (en) 2000-12-01 2015-12-21 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US15/809,558 Abandoned US20180100191A1 (en) 2000-12-01 2017-11-10 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US10/007,621 Expired - Fee Related US7211414B2 (en) 2000-12-01 2001-12-03 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US11/648,723 Abandoned US20070172869A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis
US11/648,107 Abandoned US20070172859A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: methods for direct detection of tagged monomers
US11/648,721 Active 2025-05-14 US8314216B2 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US11/648,114 Abandoned US20070172860A1 (en) 2000-12-01 2006-12-29 Enzymatic nucleic acid synthesis: compositions and methods

Family Applications After (6)

Application Number Title Priority Date Filing Date
US12/352,353 Abandoned US20100216122A1 (en) 2000-12-01 2009-01-12 Enzymatic nucleic acid synthesis: methods for direct detection of tagged monomers
US12/985,421 Abandoned US20110184163A1 (en) 2000-12-01 2011-01-06 Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis
US13/644,469 Expired - Lifetime US8648179B2 (en) 2000-12-01 2012-10-04 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US14/137,199 Expired - Fee Related US9243284B2 (en) 2000-12-01 2013-12-20 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US14/977,167 Expired - Lifetime US9845500B2 (en) 2000-12-01 2015-12-21 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US15/809,558 Abandoned US20180100191A1 (en) 2000-12-01 2017-11-10 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis

Country Status (4)

Country Link
US (12) US7211414B2 (en)
EP (1) EP1354064A2 (en)
AU (1) AU2002227156A1 (en)
WO (1) WO2002044425A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064366A1 (en) * 2000-07-07 2003-04-03 Susan Hardin Real-time sequence determination
US20070172866A1 (en) * 2000-07-07 2007-07-26 Susan Hardin Methods for sequence determination using depolymerizing agent
US20070250274A1 (en) * 2006-02-06 2007-10-25 Visigen Biotechnologies, Inc. Method for analyzing dynamic detectable events at the single molecule level
US20080091005A1 (en) * 2006-07-20 2008-04-17 Visigen Biotechnologies, Inc. Modified nucleotides, methods for making and using same
US20080241938A1 (en) * 2006-07-20 2008-10-02 Visigen Biotechnologies, Inc. Automated synthesis or sequencing apparatus and method for making and using same
US20080241951A1 (en) * 2006-07-20 2008-10-02 Visigen Biotechnologies, Inc. Method and apparatus for moving stage detection of single molecular events
US20090186343A1 (en) * 2003-01-28 2009-07-23 Visigen Biotechnologies, Inc. Methods for preparing modified biomolecules, modified biomolecules and methods for using same
US20110003343A1 (en) * 2009-03-27 2011-01-06 Life Technologies Corporation Conjugates of biomolecules to nanoparticles
US8314216B2 (en) 2000-12-01 2012-11-20 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
WO2013028563A2 (en) 2011-08-19 2013-02-28 Synthetic Genomics, Inc. Integrated method for high-throughput identification of novel pesticidal compositions and uses therefor

Families Citing this family (399)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5823720A (en) * 1996-02-16 1998-10-20 Bitmoore High precision cutting tools
US6780591B2 (en) * 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7875440B2 (en) 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US20040106110A1 (en) * 1998-07-30 2004-06-03 Solexa, Ltd. Preparation of polynucleotide arrays
US20100130368A1 (en) * 1998-07-30 2010-05-27 Shankar Balasubramanian Method and system for sequencing polynucleotides
US6982146B1 (en) * 1999-08-30 2006-01-03 The United States Of America As Represented By The Department Of Health And Human Services High speed parallel molecular nucleic acid sequencing
US7560254B2 (en) 2001-08-29 2009-07-14 Ge Healthcare Bio-Sciences Corp. Allele specific primer extension
EP1497304B1 (en) * 2002-04-12 2014-06-25 Catalyst Assets LLC Dual-labeled nucleotides
US20030228611A1 (en) * 2002-05-01 2003-12-11 President And Fellows Of Harvard College Nucleic acid memory device
EP1546353A4 (en) * 2002-08-29 2006-02-01 Amersham Biosciences Corp Allele specific primer extension
AU2003263023B2 (en) * 2002-08-29 2008-09-11 Global Life Sciences Solutions Usa Llc Terminal phosphate blocked nucleoside polyphosphates
WO2004020603A2 (en) * 2002-08-29 2004-03-11 Amersham Biosciences Corp Analyte detection
US7563600B2 (en) * 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
EP1590479B1 (en) * 2003-02-05 2010-11-24 GE Healthcare Bio-Sciences Corp. Nucleic acid amplification
US7233393B2 (en) * 2004-08-05 2007-06-19 Applera Corporation Signal noise reduction for imaging in biological analysis
US7462452B2 (en) 2004-04-30 2008-12-09 Pacific Biosciences Of California, Inc. Field-switch sequencing
US7482120B2 (en) * 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
CA2596495A1 (en) * 2005-02-09 2006-08-17 Pacific Biosciences Of California, Inc. Nucleotide compositions and uses thereof
JP2006262829A (en) * 2005-03-25 2006-10-05 Hitachi High-Technologies Corp Method for pre-treating biological sample, analysis system and element for pre-treating biological sample
US9169510B2 (en) * 2005-06-21 2015-10-27 The Trustees Of Columbia University In The City Of New York Pyrosequencing methods and related compositions
WO2007020847A1 (en) * 2005-08-19 2007-02-22 Sumitomo Bakelite Co., Ltd. Method for producing cdna and rna chains and nucleotide-immobilized support
WO2007041621A2 (en) * 2005-10-03 2007-04-12 Xingsheng Sean Ling Hybridization assisted nanopore sequencing
WO2007070542A2 (en) * 2005-12-12 2007-06-21 The Government Of The United States Of America As Represented By The Secretary Of The Deptartment Ofhealth And Human Services Nanoprobes for detection or modification of molecules
US8703734B2 (en) 2005-12-12 2014-04-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoprobes for detection or modification of molecules
US8053191B2 (en) 2006-08-31 2011-11-08 Westend Asset Clearinghouse Company, Llc Iterative nucleic acid assembly using activation of vector-encoded traits
US20080108804A1 (en) * 2006-11-02 2008-05-08 Kabushiki Kaisha Dnaform Method for modifying RNAS and preparing DNAS from RNAS
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
EP2201136B1 (en) 2007-10-01 2017-12-06 Nabsys 2.0 LLC Nanopore sequencing by hybridization of probes to form ternary complexes and variable range alignment
WO2009046445A1 (en) * 2007-10-04 2009-04-09 Halcyon Molecular Sequencing nucleic acid polymers with electron microscopy
JP2011515102A (en) 2008-03-28 2011-05-19 パシフィック バイオサイエンシーズ オブ カリフォルニア, インコーポレイテッド Compositions and methods for nucleic acid sequencing
EP2682460B1 (en) 2008-07-07 2017-04-26 Oxford Nanopore Technologies Limited Enzyme-pore constructs
US8882980B2 (en) * 2008-09-03 2014-11-11 Nabsys, Inc. Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
US9650668B2 (en) 2008-09-03 2017-05-16 Nabsys 2.0 Llc Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels
US8383345B2 (en) 2008-09-12 2013-02-26 University Of Washington Sequence tag directed subassembly of short sequencing reads into long sequencing reads
US8486865B2 (en) * 2008-11-03 2013-07-16 The Regents Of The University Of California Methods for detecting modification resistant nucleic acids
EP2607496B1 (en) 2008-12-23 2014-07-16 Illumina, Inc. Methods useful in nucleic acid sequencing protocols
EP2411536B1 (en) * 2009-03-27 2014-09-17 Nabsys, Inc. Methods for analyzing biomolecules and probes bound thereto
US8455260B2 (en) * 2009-03-27 2013-06-04 Massachusetts Institute Of Technology Tagged-fragment map assembly
EP2427572B1 (en) * 2009-05-01 2013-08-28 Illumina, Inc. Sequencing methods
US8246799B2 (en) * 2009-05-28 2012-08-21 Nabsys, Inc. Devices and methods for analyzing biomolecules and probes bound thereto
ES2628739T3 (en) 2009-10-15 2017-08-03 Ibis Biosciences, Inc. Multiple displacement amplification
US10207240B2 (en) 2009-11-03 2019-02-19 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
WO2011066185A1 (en) 2009-11-25 2011-06-03 Gen9, Inc. Microfluidic devices and methods for gene synthesis
US9217144B2 (en) 2010-01-07 2015-12-22 Gen9, Inc. Assembly of high fidelity polynucleotides
PT2531880T (en) 2010-02-01 2016-10-31 Illumina Inc Focusing methods and optical systems and assemblies using the same
US8481903B2 (en) 2010-03-06 2013-07-09 Alexander Triener Systems, methods, and apparatuses including a moveable optical component for detecting optical signals from a sample
WO2011127099A1 (en) 2010-04-05 2011-10-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US8715933B2 (en) 2010-09-27 2014-05-06 Nabsys, Inc. Assay methods using nicking endonucleases
WO2012055929A1 (en) 2010-10-26 2012-05-03 Illumina, Inc. Sequencing methods
AU2011323107B2 (en) 2010-11-05 2015-09-10 Illumina, Inc. Linking sequence reads using paired code tags
US9074251B2 (en) 2011-02-10 2015-07-07 Illumina, Inc. Linking sequence reads using paired code tags
US10457935B2 (en) 2010-11-12 2019-10-29 Gen9, Inc. Protein arrays and methods of using and making the same
JP6118725B2 (en) 2010-11-12 2017-04-19 ジェン9・インコーポレイテッドGen9,INC. Methods and devices for nucleic acid synthesis
JP5998148B2 (en) 2010-11-16 2016-09-28 ナブシス 2.0 エルエルシー Method for sequencing biomolecules by detecting the relative position of hybridized probes
EP2643484A4 (en) 2010-11-22 2014-04-16 Univ California Methods of identifying a cellular nascent rna transcript
US8932813B2 (en) * 2010-12-13 2015-01-13 Life Technologies Corporation Polymerization of nucleic acids using activation by polyphosphorolysis (APP) reactions
CN107083421A (en) * 2010-12-17 2017-08-22 纽约哥伦比亚大学理事会 The DNA detected using the nucleotides through modification and nano-pore is sequenced in synthesis
US8951781B2 (en) 2011-01-10 2015-02-10 Illumina, Inc. Systems, methods, and apparatuses to image a sample for biological or chemical analysis
US9738930B2 (en) 2011-01-28 2017-08-22 The Broad Institute, Inc. Paired end bead amplification and high throughput sequencing
CN103403188B (en) 2011-01-31 2016-03-30 伊鲁米那股份有限公司 For reducing the method for nucleic acid damaging
EP2670894B1 (en) 2011-02-02 2017-11-29 University Of Washington Through Its Center For Commercialization Massively parallel continguity mapping
WO2012109574A2 (en) 2011-02-11 2012-08-16 Nabsys, Inc. Assay methods using dna binding proteins
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
EP2718465B1 (en) 2011-06-09 2022-04-13 Illumina, Inc. Method of making an analyte array
WO2013022961A1 (en) 2011-08-08 2013-02-14 3The Broad Institute Compositions and methods for co-amplifying subsequences of a nucleic acid fragment sequence
EP2748318B1 (en) 2011-08-26 2015-11-04 Gen9, Inc. Compositions and methods for high fidelity assembly of nucleic acids
AU2012316218B2 (en) 2011-09-26 2016-03-17 Gen-Probe Incorporated Algorithms for sequence determinations
EP3305400A3 (en) 2011-10-28 2018-06-06 Illumina, Inc. Microarray fabrication system and method
EP2776165A2 (en) 2011-11-07 2014-09-17 Illumina, Inc. Integrated sequencing apparatuses and methods of use
US9200274B2 (en) 2011-12-09 2015-12-01 Illumina, Inc. Expanded radix for polymeric tags
NO2694769T3 (en) 2012-03-06 2018-03-03
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
US20130261984A1 (en) 2012-03-30 2013-10-03 Illumina, Inc. Methods and systems for determining fetal chromosomal abnormalities
CA3138752C (en) 2012-04-03 2024-02-06 Illumina, Inc. Integrated optoelectronic read head and fluidic cartridge useful for nucleic acid sequencing
US20130274148A1 (en) 2012-04-11 2013-10-17 Illumina, Inc. Portable genetic detection and analysis system and method
CN111876409A (en) 2012-04-24 2020-11-03 Gen9股份有限公司 Method for sorting nucleic acids and multiplex preparations in vitro cloning
US9012022B2 (en) 2012-06-08 2015-04-21 Illumina, Inc. Polymer coatings
US8895249B2 (en) 2012-06-15 2014-11-25 Illumina, Inc. Kinetic exclusion amplification of nucleic acid libraries
CN113512577A (en) 2012-06-25 2021-10-19 Gen9股份有限公司 Methods for nucleic acid assembly and high throughput sequencing
WO2014008448A1 (en) 2012-07-03 2014-01-09 Sloan Kettering Institute For Cancer Research Quantitative assessment of human t-cell repertoire recovery after allogeneic hematopoietic stem cell transplantation
NL2017959B1 (en) 2016-12-08 2018-06-19 Illumina Inc Cartridge assembly
CA3040684C (en) 2012-08-20 2023-02-07 Hod Finkelstein Method and system for fluorescence lifetime based sequencing
US10116490B2 (en) * 2012-09-07 2018-10-30 Nokia Solutions And Networks Oy Usage control for subscriber group
US9637782B2 (en) 2012-09-28 2017-05-02 Pacific Biosciences Of California, Inc. Charged triplet-state quenchers for mitigation of photo-induced damage
US9181583B2 (en) 2012-10-23 2015-11-10 Illumina, Inc. HLA typing using selective amplification and sequencing
US9914966B1 (en) 2012-12-20 2018-03-13 Nabsys 2.0 Llc Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation
US9683230B2 (en) 2013-01-09 2017-06-20 Illumina Cambridge Limited Sample preparation on a solid support
EP2956550B1 (en) 2013-01-18 2020-04-08 Nabsys 2.0 LLC Enhanced probe binding
US9805407B2 (en) 2013-01-25 2017-10-31 Illumina, Inc. Methods and systems for using a cloud computing environment to configure and sell a biological sample preparation cartridge and share related data
US9512422B2 (en) 2013-02-26 2016-12-06 Illumina, Inc. Gel patterned surfaces
US20160023208A1 (en) 2013-03-13 2016-01-28 Illumina, Inc. Multilayer fluidic devices and methods for their fabrication
CA2898456C (en) 2013-03-13 2020-11-10 Illumina, Inc. Methods and compositions for nucleic acid sequencing
CA2898459C (en) 2013-03-14 2021-02-02 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
US9193998B2 (en) 2013-03-15 2015-11-24 Illumina, Inc. Super resolution imaging
EP3388442A1 (en) 2013-03-15 2018-10-17 Illumina Cambridge Limited Modified nucleosides or nucleotides
US20140274747A1 (en) 2013-03-15 2014-09-18 Illumina, Inc. Super resolution imaging
CN111500680A (en) 2013-06-25 2020-08-07 普罗格诺西斯生物科学公司 Method and system for detecting spatial distribution of biological targets in a sample
DK3017065T3 (en) 2013-07-01 2018-11-26 Illumina Inc Catalyst-free Surface functionalization and polymer grafting
WO2015002789A1 (en) 2013-07-03 2015-01-08 Illumina, Inc. Sequencing by orthogonal synthesis
BR112016000456B1 (en) 2013-08-08 2021-06-01 Illumina, Inc REAGENTS REUSE SYSTEM AND METHOD
AU2014312043A1 (en) 2013-08-30 2016-02-25 Illumina France Manipulation of droplets on hydrophilic or variegated-hydrophilic surfaces
US10540783B2 (en) * 2013-11-01 2020-01-21 Illumina, Inc. Image analysis useful for patterned objects
US9546398B2 (en) 2013-11-14 2017-01-17 Agilent Technologies, Inc. Polymerase idling method for single molecule DNA sequencing
US10689696B2 (en) 2013-12-03 2020-06-23 Illumina, Inc. Methods and systems for analyzing image data
CN105980832B (en) 2013-12-10 2019-08-16 伊鲁米那股份有限公司 Biosensor and its manufacturing method for biological or chemical analysis
AU2014364926B2 (en) 2013-12-20 2017-12-14 Illumina, Inc. Preserving genomic connectivity information in fragmented genomic DNA samples
CN106062212A (en) 2013-12-23 2016-10-26 伊鲁米那股份有限公司 Structured substrates for improving detection of light emissions and methods relating to the same
US9677132B2 (en) 2014-01-16 2017-06-13 Illumina, Inc. Polynucleotide modification on solid support
CN105917006B (en) 2014-01-16 2021-03-09 伊鲁米那股份有限公司 Amplicon preparation and sequencing on solid support
CA2940048C (en) 2014-02-18 2023-03-14 Illumina, Inc. Methods and compositions for dna profiling
EP3698874A1 (en) 2014-03-11 2020-08-26 Illumina, Inc. Disposable, integrated microfluidic cartridge and methods of making the same
CA3060708A1 (en) 2014-04-29 2015-11-05 Illumina, Inc Multiplexed single cell gene expression analysis using template switch and tagmentation
EP3143161B1 (en) 2014-05-16 2021-04-21 Illumina, Inc. Nucleic acid synthesis techniques
WO2015183871A1 (en) 2014-05-27 2015-12-03 Illumina, Inc. Systems and methods for biochemical analysis including a base instrument and a removable cartridge
WO2015187670A2 (en) 2014-06-03 2015-12-10 Illumina, Inc. Compositions, systems, and methods for detecting events using tethers anchored to or adjacent to nanopores
US20150353989A1 (en) 2014-06-09 2015-12-10 Illumina Cambridge Limited Sample preparation for nucleic acid amplification
AU2015273232B2 (en) 2014-06-13 2021-09-16 Illumina Cambridge Limited Methods and compositions for preparing sequencing libraries
US10017759B2 (en) 2014-06-26 2018-07-10 Illumina, Inc. Library preparation of tagged nucleic acid
EP3702471A1 (en) 2014-06-27 2020-09-02 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
EP3161152B1 (en) 2014-06-30 2018-12-26 Illumina, Inc. Methods and compositions using one-sided transposition
JP6510029B2 (en) 2014-07-15 2019-05-08 イラミーナ インコーポレーテッド Biochemically operated electronic devices
CA3176503A1 (en) 2014-07-21 2016-01-28 Illumina, Inc Polynucleotide enrichment using crispr-cas systems
GB201414098D0 (en) 2014-08-08 2014-09-24 Illumina Cambridge Ltd Modified nucleotide linkers
US9982250B2 (en) 2014-08-21 2018-05-29 Illumina Cambridge Limited Reversible surface functionalization
WO2016040602A1 (en) 2014-09-11 2016-03-17 Epicentre Technologies Corporation Reduced representation bisulfite sequencing using uracil n-glycosylase (ung) and endonuclease iv
EP3191606B1 (en) 2014-09-12 2020-05-27 Illumina, Inc. Methods for detecting the presence of polymer subunits using chemiluminescence
WO2016044233A1 (en) 2014-09-18 2016-03-24 Illumina, Inc. Methods and systems for analyzing nucleic acid sequencing data
WO2016054096A1 (en) 2014-09-30 2016-04-07 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
EP3204148B1 (en) 2014-10-09 2020-07-08 Illumina, Inc. Method and device for separating immiscible liquids to effectively isolate at least one of the liquids
US9897791B2 (en) 2014-10-16 2018-02-20 Illumina, Inc. Optical scanning systems for in situ genetic analysis
SG10201903408VA (en) 2014-10-17 2019-05-30 Illumina Cambridge Ltd Contiguity preserving transposition
AU2015340767B2 (en) 2014-10-31 2020-01-30 Illumina Cambridge Limited Novel polymers and DNA copolymer coatings
DK3215616T3 (en) 2014-11-05 2020-03-02 Illumina Cambridge Ltd Reducing DNA damage during sample preparation and sequencing using siderophore chelators
GB201419731D0 (en) 2014-11-05 2014-12-17 Illumina Cambridge Ltd Sequencing from multiple primers to increase data rate and density
MY182476A (en) 2014-11-11 2021-01-25 Illumina Cambridge Ltd Methods and arrays for producing and sequencing monoclonal clusters of nucleic acid
EP3218513B1 (en) 2014-11-11 2018-10-31 Illumina, Inc. Polynucleotide amplification using crispr-cas systems
EP3234187B1 (en) 2014-12-15 2021-02-17 Illumina, Inc. Method for single molecular placement on a substrate
KR20210135626A (en) 2015-02-10 2021-11-15 일루미나, 인코포레이티드 The method and the composition for analyzing the cellular constituent
CN107847930B (en) 2015-03-20 2020-06-30 亿明达股份有限公司 Fluid cartridges for use in a vertical or substantially vertical position
US9976174B2 (en) 2015-03-24 2018-05-22 Illumina Cambridge Limited Methods, carrier assemblies, and systems for imaging samples for biological or chemical analysis
CN107532205B (en) 2015-03-31 2021-06-08 伊卢米纳剑桥有限公司 Surface concatemerization of templates
ES2955488T3 (en) 2015-04-10 2023-12-01 Spatial Transcriptomics Ab Multiplex analysis of biological specimens of spatially distinguished nucleic acids
US10900030B2 (en) 2015-04-14 2021-01-26 Illumina, Inc. Structured substrates for improving detection of light emissions and methods relating to the same
US10844428B2 (en) 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
RU2724998C2 (en) 2015-05-11 2020-06-29 Иллюмина, Инк. Platform for detecting and analyzing therapeutic agents
CA2987397C (en) 2015-05-29 2022-03-01 Illumina, Inc. Sample carrier and assay system for conducting designated reactions
EP3303584B1 (en) 2015-05-29 2019-10-09 Epicentre Technologies Corporation Methods of analyzing nucleic acids
AU2016269785B2 (en) 2015-05-29 2019-02-28 Illumina Cambridge Limited Enhanced utilization of surface primers in clusters
JP6595005B2 (en) 2015-06-03 2019-10-23 イラミーナ インコーポレーテッド Compositions, systems, and methods for sequencing polynucleotides using tethers immobilized to a polymerase adjacent to a nanopore
GB2556713B (en) 2015-07-06 2021-06-23 Illumina Inc Balanced AC modulation for driving droplet operations electrodes
CN115261468A (en) 2015-07-06 2022-11-01 伊卢米纳剑桥有限公司 Sample preparation for nucleic acid amplification
EP3320399A1 (en) 2015-07-07 2018-05-16 Illumina, Inc. Selective surface patterning via nanoimprinting
ES2945607T3 (en) 2015-07-17 2023-07-04 Illumina Inc Polymer sheets for sequencing applications
CA2993463A1 (en) 2015-07-27 2017-02-02 Illumina, Inc. Spatial mapping of nucleic acid sequence information
AU2016298541B2 (en) 2015-07-30 2019-10-31 Illumina, Inc. Orthogonal deblocking of nucleotides
BR112018002173B8 (en) 2015-08-14 2024-02-06 Illumina Inc Systems and methods using magnetic response sensors to determine a genetic trait
CN108474805A (en) 2015-08-24 2018-08-31 亿明达股份有限公司 For accumulator and flow control system in biological and chemical setting-out line road
CN115928221A (en) 2015-08-28 2023-04-07 Illumina公司 Single cell nucleic acid sequence analysis
WO2017037078A1 (en) 2015-09-02 2017-03-09 Illumina Cambridge Limited Systems and methods of improving droplet operations in fluidic systems
US10450598B2 (en) 2015-09-11 2019-10-22 Illumina, Inc. Systems and methods for obtaining a droplet having a designated concentration of a substance-of-interest
WO2017070363A1 (en) 2015-10-22 2017-04-27 Illumina, Inc. Filler fluid for fluidic devices
AU2016364722B2 (en) 2015-12-01 2020-10-22 Illumina, Inc. Digital microfluidic system for single-cell isolation and characterization of analytes
US11319593B2 (en) 2015-12-17 2022-05-03 Illumina, Inc. Distinguishing methylation levels in complex biological samples
CA3008031A1 (en) 2016-01-11 2017-07-20 Illumina Singapore Pte Ltd Detection apparatus having a microfluorometer, a fluidic system, and a flow cell latch clamp module
SG10201906262UA (en) 2016-03-24 2019-08-27 Illumina Inc Photonic superlattice-based devices and compositions for use in luminescent imaging, and methods of using the same
ES2861350T3 (en) 2016-03-28 2021-10-06 Illumina Inc Multi-plane microarrays
WO2017176677A1 (en) * 2016-04-04 2017-10-12 The Trustees Of Columbia University In The City Of New York Flourescence energy transfer-based single molecule/ensemble dna sequencing by synthesis
US11326206B2 (en) 2016-04-07 2022-05-10 Pacific Biosciences Of California, Inc. Methods of quantifying target nucleic acids and identifying sequence variants
ES2786974T3 (en) 2016-04-07 2020-10-14 Illumina Inc Methods and systems for the construction of standard nucleic acid libraries
EP4224219A3 (en) 2016-04-22 2023-08-30 Illumina Inc Photonic stucture-based devices and compositions for use in luminescent imaging of multiple sites within a pixel, and methods of using the same
CN109477137B (en) 2016-05-11 2023-05-30 伊鲁米那股份有限公司 Polynucleotide enrichment and amplification Using the ARGONAUTE System
CA3021915A1 (en) 2016-05-18 2017-11-23 Illumina, Inc. Self-assembled patterning using patterned hydrophobic surfaces
WO2018018008A1 (en) 2016-07-22 2018-01-25 Oregon Health & Science University Single cell whole genome libraries and combinatorial indexing methods of making thereof
WO2018064116A1 (en) 2016-09-28 2018-04-05 Illumina, Inc. Methods and systems for data compression
CN111781139B (en) 2016-10-14 2023-09-12 亿明达股份有限公司 Clamping box assembly
ES2927350T3 (en) 2016-10-19 2022-11-04 Illumina Inc Methods for chemical ligation of nucleic acids
CA3044231A1 (en) 2016-11-16 2018-05-24 Illumina, Inc. Validation methods and systems for sequence variant calls
GB201619458D0 (en) 2016-11-17 2017-01-04 Spatial Transcriptomics Ab Method for spatial tagging and analysing nucleic acids in a biological specimen
DK3551753T3 (en) 2016-12-09 2022-09-05 Broad Inst Inc DIAGNOSTICS BASED ON CRISPR EFFECTOR SYSTEM
PL3558510T3 (en) 2016-12-22 2023-03-13 Illumina, Inc. Array including sequencing primer and non-sequencing entity
CN110325651A (en) 2016-12-22 2019-10-11 伊鲁米那股份有限公司 Array with quality control tracer
KR102512186B1 (en) 2016-12-22 2023-03-20 일루미나, 인코포레이티드 Array comprising a resin film and a patterned polymer layer
CA3048415C (en) 2016-12-30 2023-02-28 Omniome, Inc. Method and system employing distinguishable polymerases for detecting ternary complexes and identifying cognate nucleotides
GB201704754D0 (en) 2017-01-05 2017-05-10 Illumina Inc Kinetic exclusion amplification of nucleic acid libraries
IL299500B2 (en) 2017-01-06 2024-02-01 Illumina Inc Phasing correction
AU2018208462B2 (en) 2017-01-10 2021-07-29 Pacific Biosciences Of California, Inc. Polymerases engineered to reduce nucleotide-independent DNA binding
SG11201905640XA (en) 2017-01-17 2019-08-27 Illumina Inc Oncogenic splice variant determination
CA3050247A1 (en) 2017-01-18 2018-07-26 Illumina, Inc. Methods and systems for generation and error-correction of unique molecular index sets with heterogeneous molecular lengths
SG11201906567YA (en) 2017-01-20 2019-08-27 Omniome Inc Allele-specific capture of nucleic acids
SG11201906569XA (en) 2017-01-20 2019-08-27 Omniome Inc Genotyping by polymerase binding
WO2018136487A1 (en) 2017-01-20 2018-07-26 Omniome, Inc. Process for cognate nucleotide detection in a nucleic acid sequencing workflow
GB201701689D0 (en) 2017-02-01 2017-03-15 Illumia Inc System and method with fiducials of non-closed shapes
GB201701686D0 (en) 2017-02-01 2017-03-15 Illunina Inc System & method with fiducials having offset layouts
GB201701688D0 (en) 2017-02-01 2017-03-15 Illumia Inc System and method with fiducials in non-recliner layouts
WO2018152162A1 (en) 2017-02-15 2018-08-23 Omniome, Inc. Distinguishing sequences by detecting polymerase dissociation
IL303805A (en) 2017-02-21 2023-08-01 Illumina Inc Tagmentation using immobilized transposomes with linkers
JP2020513815A (en) 2017-03-15 2020-05-21 ザ・ブロード・インスティテュート・インコーポレイテッド Diagnostic method for virus detection based on clustered short repeat palindrome effector system
US11021740B2 (en) 2017-03-15 2021-06-01 The Broad Institute, Inc. Devices for CRISPR effector system based diagnostics
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
US11104937B2 (en) 2017-03-15 2021-08-31 The Broad Institute, Inc. CRISPR effector system based diagnostics
JP7062681B2 (en) 2017-03-20 2022-05-06 イルミナ インコーポレイテッド Methods and Compositions for Preparing Nucleic Acid Libraries
EP3607087A4 (en) 2017-04-04 2020-12-30 Omniome, Inc. Fluidic apparatus and methods useful for chemical and biological reactions
EP3913053A1 (en) 2017-04-23 2021-11-24 Illumina Cambridge Limited Compositions and methods for improving sample identification in indexed nucleic acid libraries
CA3060979C (en) 2017-04-23 2023-07-11 Illumina Cambridge Limited Compositions and methods for improving sample identification in indexed nucleic acid libraries
FI3842545T3 (en) 2017-04-23 2023-01-31 Compositions and methods for improving sample identification in indexed nucleic acid libraries
US10161003B2 (en) 2017-04-25 2018-12-25 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
SG11201909697TA (en) 2017-05-01 2019-11-28 Illumina Inc Optimal index sequences for multiplex massively parallel sequencing
US11028436B2 (en) 2017-05-08 2021-06-08 Illumina, Inc. Universal short adapters for indexing of polynucleotide samples
KR20240013852A (en) 2017-06-07 2024-01-30 오레곤 헬스 앤드 사이언스 유니버시티 Single Cell Whole Genome Libraries for Methylation Sequencing
EP3642362A1 (en) 2017-06-20 2020-04-29 Illumina, Inc. Methods and compositions for addressing inefficiencies in amplification reactions
US11578180B2 (en) 2017-07-18 2023-02-14 Pacific Biosciences Of California, Inc. Method of chemically modifying plastic surfaces
CN110785813A (en) 2017-07-31 2020-02-11 伊鲁米那股份有限公司 Sequencing system with multi-path biological sample aggregation
EP4289967A2 (en) 2017-08-01 2023-12-13 Illumina, Inc. Spatial indexing of genetic material and library preparation using hydrogel beads and flow cells
JP7032452B2 (en) 2017-08-01 2022-03-08 イルミナ インコーポレイテッド Hydrogel beads for nucleotide sequencing
EP3545106B1 (en) 2017-08-01 2022-01-19 Helitec Limited Methods of enriching and determining target nucleotide sequences
CN111182972B (en) 2017-08-15 2022-03-08 欧姆尼奥姆股份有限公司 Scanning device and method for detecting chemical and biological analytes
US11447818B2 (en) 2017-09-15 2022-09-20 Illumina, Inc. Universal short adapters with variable length non-random unique molecular identifiers
KR102317911B1 (en) 2017-10-16 2021-10-26 일루미나, 인코포레이티드 Deep learning-based splice site classification
CN113627458A (en) 2017-10-16 2021-11-09 因美纳有限公司 Variant pathogenicity classifier based on recurrent neural network
WO2019136376A1 (en) 2018-01-08 2019-07-11 Illumina, Inc. High-throughput sequencing with semiconductor-based detection
KR102239487B1 (en) 2018-01-08 2021-04-14 일루미나, 인코포레이티드 High-throughput sequencing using semiconductor-based detection
CA3065939A1 (en) 2018-01-15 2019-07-18 Illumina, Inc. Deep learning-based variant classifier
FI3746568T3 (en) 2018-01-29 2023-12-12 Broad Inst Inc Crispr effector system based diagnostics
EP3749777A4 (en) 2018-02-06 2021-11-24 Omniome, Inc. Compositions and techniques for nucleic acid primer extension
KR20220123327A (en) 2018-02-13 2022-09-06 일루미나, 인코포레이티드 DNA sequencing using hydrogel beads
CN110832086A (en) 2018-04-02 2020-02-21 伊鲁米那股份有限公司 Compositions and methods for making controls for sequence-based genetic testing
WO2019200338A1 (en) 2018-04-12 2019-10-17 Illumina, Inc. Variant classifier based on deep neural networks
EP3782158A1 (en) 2018-04-19 2021-02-24 Omniome, Inc. Improving accuracy of base calls in nucleic acid sequencing methods
KR20230005427A (en) 2018-04-20 2023-01-09 일루미나, 인코포레이티드 Methods of encapsulating single cells, the encapsulated cells and uses thereof
CN112567047A (en) 2018-04-26 2021-03-26 欧姆尼欧美公司 Methods and compositions for stabilizing nucleic acid-nucleotide-polymerase complexes
KR102443569B1 (en) 2018-05-15 2022-09-15 일루미나, 인코포레이티드 Compositions and methods for chemical cleavage and deprotection of surface-associated oligonucleotides
CN110785499A (en) 2018-05-25 2020-02-11 伊鲁米那股份有限公司 Circulating RNA identification specific for preeclampsia
WO2019231568A1 (en) 2018-05-31 2019-12-05 Omniome, Inc. Increased signal to noise in nucleic acid sequencing
US11180794B2 (en) 2018-05-31 2021-11-23 Omniome, Inc. Methods and compositions for capping nucleic acids
KR102507415B1 (en) 2018-06-04 2023-03-07 일루미나, 인코포레이티드 High-throughput single-cell transcriptome libraries and methods of making and of using
US20200251183A1 (en) 2018-07-11 2020-08-06 Illumina, Inc. Deep Learning-Based Framework for Identifying Sequence Patterns that Cause Sequence-Specific Errors (SSEs)
CA3107165A1 (en) 2018-07-24 2020-01-30 Omniome, Inc. Serial formation of ternary complex species
US20210163944A1 (en) 2018-08-07 2021-06-03 The Broad Institute, Inc. Novel cas12b enzymes and systems
BR112021002779A2 (en) 2018-08-15 2021-05-04 Illumina, Inc. compositions and methods to improve library enrichment
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US10731141B2 (en) 2018-09-17 2020-08-04 Omniome, Inc. Engineered polymerases for improved sequencing
WO2020072816A1 (en) 2018-10-03 2020-04-09 The Broad Institute, Inc. Crispr effector system based diagnostics for hemorrhagic fever detection
CN111328419B (en) 2018-10-15 2021-10-19 因美纳有限公司 Method and system based on neural network implementation
KR20210084440A (en) 2018-10-26 2021-07-07 일루미나, 인코포레이티드 Control of Polymer Beads for DNA Processing
AU2019374098A1 (en) 2018-10-31 2021-01-07 Illumina Singapore Pte. Ltd. Polymerases, compositions, and methods of use
NL2022043B1 (en) 2018-11-21 2020-06-03 Akershus Univ Hf Tagmentation-Associated Multiplex PCR Enrichment Sequencing
EP4293126A3 (en) 2018-11-30 2024-01-17 Illumina, Inc. Analysis of multiple analytes using a single assay
US10710076B2 (en) 2018-12-04 2020-07-14 Omniome, Inc. Mixed-phase fluids for nucleic acid sequencing and other analytical assays
JP2022511207A (en) 2018-12-05 2022-01-31 イルミナ ケンブリッジ リミテッド Methods and compositions for cluster formation by bridge amplification
JP2022511206A (en) 2018-12-05 2022-01-31 イラミーナ インコーポレーテッド Polymerase, composition, and usage
GB201820341D0 (en) 2018-12-13 2019-01-30 10X Genomics Inc Method for transposase-mediated spatial tagging and analysing genomic DNA in a biological specimen
GB201820300D0 (en) 2018-12-13 2019-01-30 10X Genomics Inc Method for spatial tagging and analysing genomic DNA in a biological specimen
EP3894598B1 (en) 2018-12-14 2024-01-03 Illumina Cambridge Limited Decreasing phasing with unlabeled nucleotides during sequencing
AU2019411267A1 (en) 2018-12-17 2021-01-07 Illumina Cambridge Limited Primer oligonucleotide for sequencing
JP7296409B2 (en) 2018-12-17 2023-06-22 イルミナ ケンブリッジ リミテッド Compositions for use in polynucleotide sequencing
CA3103633A1 (en) 2018-12-18 2020-06-25 Illumina Cambridge Limited Methods and compositions for paired end sequencing using a single surface primer
MX2020013379A (en) 2018-12-19 2021-04-28 Illumina Inc Methods for improving polynucleotide cluster clonality priority.
WO2020132350A2 (en) 2018-12-20 2020-06-25 Omniome, Inc. Temperature control for analysis of nucleic acids and other analytes
US11293061B2 (en) 2018-12-26 2022-04-05 Illumina Cambridge Limited Sequencing methods using nucleotides with 3′ AOM blocking group
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
AU2020206443A1 (en) 2019-01-11 2021-04-15 Illumina Cambridge Limited Complex surface-bound transposome complexes
US11499189B2 (en) 2019-02-14 2022-11-15 Pacific Biosciences Of California, Inc. Mitigating adverse impacts of detection systems on nucleic acids and other biological analytes
EP3927467A4 (en) 2019-02-20 2022-12-14 Pacific Biosciences of California, Inc. Scanning apparatus and methods for detecting chemical and biological analytes
CA3113841A1 (en) 2019-03-01 2020-09-10 Illumina, Inc. High-throughput single-nuclei and single-cell libraries and methods of making and of using
NL2023311B9 (en) 2019-03-21 2021-03-12 Illumina Inc Artificial intelligence-based generation of sequencing metadata
US11210554B2 (en) 2019-03-21 2021-12-28 Illumina, Inc. Artificial intelligence-based generation of sequencing metadata
NL2023314B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based quality scoring
WO2020191387A1 (en) 2019-03-21 2020-09-24 Illumina, Inc. Artificial intelligence-based base calling
NL2023312B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based base calling
NL2023316B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based sequencing
US11676685B2 (en) 2019-03-21 2023-06-13 Illumina, Inc. Artificial intelligence-based quality scoring
NL2023310B1 (en) 2019-03-21 2020-09-28 Illumina Inc Training data generation for artificial intelligence-based sequencing
US11593649B2 (en) 2019-05-16 2023-02-28 Illumina, Inc. Base calling using convolutions
US11644406B2 (en) 2019-06-11 2023-05-09 Pacific Biosciences Of California, Inc. Calibrated focus sensing
BR112021012755A2 (en) 2019-07-12 2022-04-26 Illumina Cambridge Ltd Compositions and methods for preparing nucleic acid sequencing libraries using crispr/cas9 immobilized on a solid support
WO2021009494A1 (en) 2019-07-12 2021-01-21 Illumina Cambridge Limited Nucleic acid library preparation using electrophoresis
WO2021011803A1 (en) 2019-07-16 2021-01-21 Omniome, Inc. Synthetic nucleic acids having non-natural structures
US10656368B1 (en) 2019-07-24 2020-05-19 Omniome, Inc. Method and system for biological imaging using a wide field objective lens
US11180520B2 (en) 2019-09-10 2021-11-23 Omniome, Inc. Reversible modifications of nucleotides
US20220290245A1 (en) 2019-09-11 2022-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Cancer detection and classification
WO2021076152A1 (en) 2019-10-18 2021-04-22 Omniome, Inc. Methods and compositions for capping nucleic acids
US20210139867A1 (en) 2019-11-08 2021-05-13 Omniome, Inc. Engineered polymerases for improved sequencing by binding
EP4055185A1 (en) 2019-11-08 2022-09-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
CN113677807A (en) 2019-11-22 2021-11-19 因美纳有限公司 Pre-eclampsia-specific circulating RNA markers
DE202019106694U1 (en) 2019-12-02 2020-03-19 Omniome, Inc. System for sequencing nucleic acids in fluid foam
DE202019106695U1 (en) 2019-12-02 2020-03-19 Omniome, Inc. System for sequencing nucleic acids in fluid foam
CN113631721A (en) 2019-12-04 2021-11-09 因美纳有限公司 Preparation of DNA sequencing library for detection of DNA pathogens in plasma
WO2021127436A2 (en) 2019-12-19 2021-06-24 Illumina, Inc. High-throughput single-cell libraries and methods of making and of using
SG11202106899SA (en) 2019-12-23 2021-09-29 10X Genomics Inc Methods for spatial analysis using rna-templated ligation
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
WO2021158511A1 (en) 2020-02-04 2021-08-12 Omniome, Inc. Flow cells and methods for their manufacture and use
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
CN115136244A (en) 2020-02-20 2022-09-30 因美纳有限公司 Many-to-many base interpretation based on artificial intelligence
US20210265015A1 (en) 2020-02-20 2021-08-26 Illumina, Inc. Hardware Execution and Acceleration of Artificial Intelligence-Based Base Caller
US20210265016A1 (en) 2020-02-20 2021-08-26 Illumina, Inc. Data Compression for Artificial Intelligence-Based Base Calling
US20210265018A1 (en) 2020-02-20 2021-08-26 Illumina, Inc. Knowledge Distillation and Gradient Pruning-Based Compression of Artificial Intelligence-Based Base Caller
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
CA3173798A1 (en) 2020-03-03 2021-09-10 Pacific Biosciences Of California, Inc. Methods and compositions for sequencing double stranded nucleic acids
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
JP2023520203A (en) 2020-03-30 2023-05-16 イルミナ インコーポレイテッド Methods and compositions for preparing nucleic acid libraries
CN115916999A (en) 2020-04-22 2023-04-04 10X基因组学有限公司 Methods for spatial analysis using targeted RNA depletion
CN115836135A (en) 2020-05-05 2023-03-21 加利福尼亚太平洋生物科学股份有限公司 Compositions and methods for modifying polymerase-nucleic acid complexes
US11188778B1 (en) 2020-05-05 2021-11-30 Illumina, Inc. Equalization-based image processing and spatial crosstalk attenuator
CA3177286A1 (en) 2020-05-12 2021-11-18 Illumina Inc. Generating nucleic acids with modified bases using recombinant terminal deoxynucleotidyl transferase
EP4153775A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
EP4153776A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Spatial analysis to detect sequence variants
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
WO2021247543A2 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Nucleic acid library methods
WO2021247568A1 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Spatial trancriptomics for antigen-receptors
EP4162074A1 (en) 2020-06-08 2023-04-12 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
WO2021252617A1 (en) 2020-06-09 2021-12-16 Illumina, Inc. Methods for increasing yield of sequencing libraries
WO2021252591A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
AU2021288692A1 (en) 2020-06-11 2023-02-02 Nautilus Subsidiary, Inc. Methods and systems for computational decoding of biological, chemical, and physical entities
CN115867560A (en) 2020-06-22 2023-03-28 伊鲁米纳剑桥有限公司 Nucleosides and nucleotides having 3' acetal capping groups
EP4172362A1 (en) 2020-06-25 2023-05-03 10X Genomics, Inc. Spatial analysis of dna methylation
EP4176081A1 (en) 2020-07-02 2023-05-10 Illumina, Inc. A method to calibrate nucleic acid library seeding efficiency in flowcells
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
EP4179109A1 (en) 2020-07-08 2023-05-17 Illumina, Inc. Beads as transposome carriers
EP4192951A1 (en) 2020-08-06 2023-06-14 Illumina, Inc. Preparation of rna and dna sequencing libraries using bead-linked transposomes
CN116323971A (en) 2020-08-18 2023-06-23 Illumina公司 Sequence-specific targeted transposition and selection and sorting of nucleic acids
US20220067489A1 (en) 2020-08-28 2022-03-03 Illumina, Inc. Detecting and Filtering Clusters Based on Artificial Intelligence-Predicted Base Calls
KR20230069135A (en) 2020-09-11 2023-05-18 일루미나 케임브리지 리미티드 Methods for Enriching Target Sequences in Sequencing Libraries Using Hairpin Adapters
CA3198842A1 (en) 2020-10-21 2022-04-28 Illumina, Inc. Sequencing templates comprising multiple inserts and compositions and methods for improving sequencing throughput
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
AU2021409136A1 (en) 2020-12-21 2023-06-29 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
CN116997411A (en) 2021-01-13 2023-11-03 加利福尼亚太平洋生物科学股份有限公司 Surface structuring using colloid assembly
CN117043352A (en) 2021-01-29 2023-11-10 伊鲁米纳公司 Methods, compositions and kits for improving the seeding efficiency of a flow cell using polynucleotides
CA3208854A1 (en) 2021-02-04 2022-08-11 Illumina, Inc. Long indexed-linked read generation on transposome bound beads
WO2022174054A1 (en) 2021-02-13 2022-08-18 The General Hospital Corporation Methods and compositions for in situ macromolecule detection and uses thereof
WO2022197752A1 (en) 2021-03-16 2022-09-22 Illumina, Inc. Tile location and/or cycle based weight set selection for base calling
AU2022238446A1 (en) 2021-03-18 2023-09-07 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
WO2022204032A1 (en) 2021-03-22 2022-09-29 Illumina Cambridge Limited Methods for improving nucleic acid cluster clonality
KR20230163434A (en) 2021-03-29 2023-11-30 일루미나, 인코포레이티드 Compositions and methods for assessing DNA damage and normalizing amplicon size bias in libraries
AU2022252197A1 (en) 2021-03-29 2023-09-21 Illumina, Inc. Improved methods of library preparation
WO2022212330A1 (en) 2021-03-30 2022-10-06 Illumina, Inc. Improved methods of isothermal complementary dna and library preparation
IL307164A (en) 2021-03-31 2023-11-01 Illumina Inc Methods of preparing directional tagmentation sequencing libraries using transposon-based technology with unique molecular identifiers for error correction
WO2022212180A1 (en) 2021-03-31 2022-10-06 Illumina, Inc. Artificial intelligence-based base caller with contextual awareness
WO2022213027A1 (en) 2021-04-02 2022-10-06 Illumina, Inc. Machine-learning model for detecting a bubble within a nucleotide-sample slide for sequencing
US20220336054A1 (en) 2021-04-15 2022-10-20 Illumina, Inc. Deep Convolutional Neural Networks to Predict Variant Pathogenicity using Three-Dimensional (3D) Protein Structures
US20220356519A1 (en) 2021-05-10 2022-11-10 Pacific Biosciences Of California, Inc. Single-molecule seeding and amplification on a surface
US20220356515A1 (en) 2021-05-10 2022-11-10 Pacific Biosciences Of California, Inc. Dna amplification buffer replenishment during rolling circle amplification
KR20240009435A (en) 2021-05-20 2024-01-22 일루미나, 인코포레이티드 Compositions and methods for sequencing by synthesis
US20230016633A1 (en) 2021-06-15 2023-01-19 Illumina, Inc. Hydrogel-free surface functionalization for sequencing
WO2022272260A1 (en) 2021-06-23 2022-12-29 Illumina, Inc. Compositions, methods, kits, cartridges, and systems for sequencing reagents
WO2023278966A1 (en) 2021-06-29 2023-01-05 Illumina, Inc. Machine-learning model for generating confidence classifications for genomic coordinates
US20220415442A1 (en) 2021-06-29 2022-12-29 Illumina Software, Inc. Signal-to-noise-ratio metric for determining nucleotide-base calls and base-call quality
WO2023278184A1 (en) 2021-06-29 2023-01-05 Illumina, Inc. Methods and systems to correct crosstalk in illumination emitted from reaction sites
WO2023278608A1 (en) 2021-06-29 2023-01-05 Illumina, Inc. Self-learned base caller, trained using oligo sequences
US20230005253A1 (en) 2021-07-01 2023-01-05 Illumina, Inc. Efficient artificial intelligence-based base calling of index sequences
US20230027409A1 (en) 2021-07-13 2023-01-26 Illumina, Inc. Methods and systems for real time extraction of crosstalk in illumination emitted from reaction sites
US11455487B1 (en) 2021-10-26 2022-09-27 Illumina Software, Inc. Intensity extraction and crosstalk attenuation using interpolation and adaptation for base calling
WO2023003757A1 (en) 2021-07-19 2023-01-26 Illumina Software, Inc. Intensity extraction with interpolation and adaptation for base calling
US20230021577A1 (en) 2021-07-23 2023-01-26 Illumina Software, Inc. Machine-learning model for recalibrating nucleotide-base calls
WO2023004357A1 (en) 2021-07-23 2023-01-26 Illumina, Inc. Methods for preparing substrate surface for dna sequencing
AU2022319125A1 (en) 2021-07-28 2024-01-18 Illumina, Inc. Quality score calibration of basecalling systems
WO2023014741A1 (en) 2021-08-03 2023-02-09 Illumina Software, Inc. Base calling using multiple base caller models
US20230047225A1 (en) 2021-08-14 2023-02-16 Illumina, Inc. Polymerases, compositions, and methods of use
AU2022331421A1 (en) 2021-08-17 2024-01-04 Illumina, Inc. Methods and compositions for identifying methylated cytosines
EP4196605A1 (en) 2021-09-01 2023-06-21 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
CN117561573A (en) 2021-09-17 2024-02-13 因美纳有限公司 Automatic identification of the source of faults in nucleotide sequencing from base interpretation error patterns
US20230095961A1 (en) 2021-09-21 2023-03-30 Illumina, Inc. Graph reference genome and base-calling approach using imputed haplotypes
WO2023049215A1 (en) 2021-09-22 2023-03-30 Illumina, Inc. Compressed state-based base calling
US20230096386A1 (en) 2021-09-30 2023-03-30 Illumina Cambridge Limited Polynucleotide sequencing
WO2023056328A2 (en) 2021-09-30 2023-04-06 Illumina, Inc. Solid supports and methods for depleting and/or enriching library fragments prepared from biosamples
US20230114905A1 (en) 2021-10-11 2023-04-13 Nautilus Biotechnology, Inc. Highly multiplexable analysis of proteins and proteomes
WO2023069927A1 (en) 2021-10-20 2023-04-27 Illumina, Inc. Methods for capturing library dna for sequencing
WO2023081485A1 (en) 2021-11-08 2023-05-11 Pacific Biosciences Of California, Inc. Stepwise sequencing of a polynucleotide with a homogenous reaction mixture
CN117581303A (en) 2021-12-02 2024-02-20 因美纳有限公司 Generating cluster-specific signal corrections for determining nucleotide base detection
WO2023122363A1 (en) 2021-12-23 2023-06-29 Illumina Software, Inc. Dynamic graphical status summaries for nucelotide sequencing
US20230215515A1 (en) 2021-12-23 2023-07-06 Illumina Software, Inc. Facilitating secure execution of external workflows for genomic sequencing diagnostics
US20230207050A1 (en) 2021-12-28 2023-06-29 Illumina Software, Inc. Machine learning model for recalibrating nucleotide base calls corresponding to target variants
WO2023129764A1 (en) 2021-12-29 2023-07-06 Illumina Software, Inc. Automatically switching variant analysis model versions for genomic analysis applications
CA3223362A1 (en) 2022-01-20 2023-07-27 Xiaolin Wu Methods of detecting methylcytosine and hydroxymethylcytosine by sequencing
CA3224595A1 (en) 2022-02-25 2023-08-31 Steven Norberg Machine-learning models for detecting and adjusting values for nucleotide methylation levels
WO2023164660A1 (en) 2022-02-25 2023-08-31 Illumina, Inc. Calibration sequences for nucelotide sequencing
WO2023183937A1 (en) 2022-03-25 2023-09-28 Illumina, Inc. Sequence-to-sequence base calling
US20230314324A1 (en) 2022-03-29 2023-10-05 Nautilus Subsidiary, Inc. Integrated arrays for single-analyte processes
WO2023196572A1 (en) 2022-04-07 2023-10-12 Illumina Singapore Pte. Ltd. Altered cytidine deaminases and methods of use
US20230360732A1 (en) 2022-04-25 2023-11-09 Nautilus Subsidiary, Inc. Systems and methods for assessing and improving the quality of multiplex molecular assays
WO2023212601A1 (en) 2022-04-26 2023-11-02 Illumina, Inc. Machine-learning models for selecting oligonucleotide probes for array technologies
WO2023209606A1 (en) 2022-04-29 2023-11-02 Illumina Cambridge Limited Methods and systems for encapsulating lyophilised microspheres
US20230368866A1 (en) 2022-05-10 2023-11-16 Illumina Software, Inc. Adaptive neural network for nucelotide sequencing
WO2023235353A2 (en) 2022-06-03 2023-12-07 Illumina, Inc. Circulating rna biomarkers for preeclampsia
US20230407386A1 (en) 2022-06-09 2023-12-21 Illumina, Inc. Dependence of base calling on flow cell tilt
US20230420080A1 (en) 2022-06-24 2023-12-28 Illumina Software, Inc. Split-read alignment by intelligently identifying and scoring candidate split groups
US20230420075A1 (en) 2022-06-27 2023-12-28 Illumina Software, Inc. Accelerators for a genotype imputation model
WO2024006705A1 (en) 2022-06-27 2024-01-04 Illumina Software, Inc. Improved human leukocyte antigen (hla) genotyping
US20230420082A1 (en) 2022-06-27 2023-12-28 Illumina Software, Inc. Generating and implementing a structural variation graph genome
WO2024015962A1 (en) 2022-07-15 2024-01-18 Pacific Biosciences Of California, Inc. Blocked asymmetric hairpin adaptors
WO2024026356A1 (en) 2022-07-26 2024-02-01 Illumina, Inc. Rapid single-cell multiomics processing using an executable file
WO2024039516A1 (en) 2022-08-19 2024-02-22 Illumina, Inc. Third dna base pair site-specific dna detection

Citations (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654267A (en) * 1982-04-23 1987-03-31 Sintef Magnetic polymer particles and process for the preparation thereof
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4994373A (en) * 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
US4997928A (en) * 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
US5001050A (en) * 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5079352A (en) * 1986-08-22 1992-01-07 Cetus Corporation Purified thermostable enzyme
US5079169A (en) * 1990-05-22 1992-01-07 The Regents Of The Stanford Leland Junior University Method for optically manipulating polymer filaments
US5091310A (en) * 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5188934A (en) * 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
US5198543A (en) * 1989-03-24 1993-03-30 Consejo Superior Investigaciones Cientificas PHI29 DNA polymerase
US5200313A (en) * 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5403708A (en) * 1992-07-06 1995-04-04 Brennan; Thomas M. Methods and compositions for determining the sequence of nucleic acids
US5405747A (en) * 1991-09-25 1995-04-11 The Regents Of The University Of California Office Of Technology Transfer Method for rapid base sequencing in DNA and RNA with two base labeling
US5405776A (en) * 1988-01-13 1995-04-11 Life Technologies, Inc. Cloned genes encoding reverse transcriptase lacking RNase H activity
US5494030A (en) * 1993-08-12 1996-02-27 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen in biological systems
US5498523A (en) * 1988-07-12 1996-03-12 President And Fellows Of Harvard College DNA sequencing with pyrophosphatase
US5510270A (en) * 1989-06-07 1996-04-23 Affymax Technologies N.V. Synthesis and screening of immobilized oligonucleotide arrays
US5512462A (en) * 1994-02-25 1996-04-30 Hoffmann-La Roche Inc. Methods and reagents for the polymerase chain reaction amplification of long DNA sequences
US5599675A (en) * 1994-04-04 1997-02-04 Spectragen, Inc. DNA sequencing by stepwise ligation and cleavage
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5601982A (en) * 1995-02-07 1997-02-11 Sargent; Jeannine P. Method and apparatus for determining the sequence of polynucleotides
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5620854A (en) * 1993-08-25 1997-04-15 Regents Of The University Of California Method for identifying biochemical and chemical reactions and micromechanical processes using nanomechanical and electronic signal identification
US5631134A (en) * 1992-11-06 1997-05-20 The Trustees Of Boston University Methods of preparing probe array by hybridation
US5707804A (en) * 1994-02-01 1998-01-13 The Regents Of The University Of California Primers labeled with energy transfer coupled dyes for DNA sequencing
US5707797A (en) * 1993-01-08 1998-01-13 Ctrc Research Foundation Color imaging method for mapping stretched DNA hybridized with fluorescently labeled oligonucleotide probes
US5706805A (en) * 1993-08-12 1998-01-13 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen tension in biological systems
US5720928A (en) * 1988-09-15 1998-02-24 New York University Image processing and analysis of individual nucleic acid molecules
US5723298A (en) * 1996-09-16 1998-03-03 Li-Cor, Inc. Cycle labeling and sequencing with thermostable polymerases
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5755943A (en) * 1984-03-29 1998-05-26 Li-Cor, Inc. DNA sequencing
US5858671A (en) * 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US5863727A (en) * 1996-05-03 1999-01-26 The Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US6015714A (en) * 1995-03-17 2000-01-18 The United States Of America As Represented By The Secretary Of Commerce Characterization of individual polymer molecules based on monomer-interface interactions
US6020481A (en) * 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
US6027709A (en) * 1997-01-10 2000-02-22 Li-Cor Inc. Fluorescent cyanine dyes
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
US6048690A (en) * 1991-11-07 2000-04-11 Nanogen, Inc. Methods for electronic fluorescent perturbation for analysis and electronic perturbation catalysis for synthesis
US6200748B1 (en) * 1984-01-16 2001-03-13 California Institute Of Technology Tagged extendable primers and extension products
US6207421B1 (en) * 1984-03-29 2001-03-27 Li-Cor, Inc. DNA sequencing and DNA terminators
US6207229B1 (en) * 1997-11-13 2001-03-27 Massachusetts Institute Of Technology Highly luminescent color-selective materials and method of making thereof
US6210891B1 (en) * 1996-09-27 2001-04-03 Pyrosequencing Ab Method of sequencing DNA
US6210896B1 (en) * 1998-08-13 2001-04-03 Us Genomics Molecular motors
US6221592B1 (en) * 1998-10-20 2001-04-24 Wisconsin Alumi Research Foundation Computer-based methods and systems for sequencing of individual nucleic acid molecules
US6232075B1 (en) * 1998-12-14 2001-05-15 Li-Cor, Inc. Heterogeneous assay for pyrophosphate detection
US20020025529A1 (en) * 1999-06-28 2002-02-28 Stephen Quake Methods and apparatus for analyzing polynucleotide sequences
US6355420B1 (en) * 1997-02-12 2002-03-12 Us Genomics Methods and products for analyzing polymers
US6362002B1 (en) * 1995-03-17 2002-03-26 President And Fellows Of Harvard College Characterization of individual polymer molecules based on monomer-interface interactions
US6524829B1 (en) * 1998-09-30 2003-02-25 Molecular Machines & Industries Gmbh Method for DNA- or RNA-sequencing
US20030044781A1 (en) * 1999-05-19 2003-03-06 Jonas Korlach Method for sequencing nucleic acid molecules
US6534269B2 (en) * 2000-02-23 2003-03-18 City Of Hope Pyrophosphorolysis activated polymerization (PAP): application to allele-specific amplification and nucleic acid sequence determination
US20030055257A1 (en) * 1999-11-03 2003-03-20 Applera Corporation Water-soluble rhodamine dye conjugates
US20030064366A1 (en) * 2000-07-07 2003-04-03 Susan Hardin Real-time sequence determination
US20030064400A1 (en) * 2001-08-24 2003-04-03 Li-Cor, Inc. Microfluidics system for single molecule DNA sequencing
US6558945B1 (en) * 1999-03-08 2003-05-06 Aclara Biosciences, Inc. Method and device for rapid color detection
US20040015964A1 (en) * 2001-04-25 2004-01-22 Mccann Thomas Matthew Methods and systems for load sharing signaling messages among signaling links in networks utilizing international signaling protocols
US6727059B1 (en) * 1999-05-10 2004-04-27 Centre National De La Recherche Scientifique (Cnrs) Method for controlling the fidelity and processivity of reverse transcriptase by incorporation and polymerization of nucleotide analogs accepted as substrates for the reverse transcription reaction without blocking its elongation
US20050042633A1 (en) * 2003-04-08 2005-02-24 Li-Cor, Inc. Composition and method for nucleic acid sequencing
US20050042649A1 (en) * 1998-07-30 2005-02-24 Shankar Balasubramanian Arrayed biomolecules and their use in sequencing
US6869764B2 (en) * 2000-06-07 2005-03-22 L--Cor, Inc. Nucleic acid sequencing using charge-switch nucleotides
US6982146B1 (en) * 1999-08-30 2006-01-03 The United States Of America As Represented By The Department Of Health And Human Services High speed parallel molecular nucleic acid sequencing
US6982186B2 (en) * 2003-09-25 2006-01-03 Dongbuanam Semiconductor Inc. CMOS image sensor and method for manufacturing the same
US6995274B2 (en) * 2000-09-19 2006-02-07 Li-Cor, Inc. Cyanine dyes
US7005518B2 (en) * 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
US7008766B1 (en) * 1997-07-28 2006-03-07 Medical Biosystems, Ltd. Nucleic acid sequence analysis
US20060057565A1 (en) * 2000-09-11 2006-03-16 Jingyue Ju Combinatorial fluorescence energy transfer tags and uses thereof
US20060061755A1 (en) * 2004-09-17 2006-03-23 Stephen Turner Apparatus and method for analysis of molecules
US20060063173A1 (en) * 2000-06-07 2006-03-23 Li-Cor, Inc. Charge switch nucleotides
US20060060766A1 (en) * 2004-09-17 2006-03-23 Stephen Turner Apparatus and methods for optical analysis of molecules
US7037687B2 (en) * 1998-05-01 2006-05-02 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7052839B2 (en) * 2001-08-29 2006-05-30 Amersham Biosciences Corp Terminal-phosphate-labeled nucleotides and methods of use
US20070036502A1 (en) * 2001-09-27 2007-02-15 Levene Michael J Zero-mode waveguides
US20070042398A1 (en) * 2005-06-30 2007-02-22 Li-Cor, Inc. Cyanine dyes and methods of use
US20070044538A1 (en) * 2005-09-01 2007-03-01 Li-Cor, Inc. Gas flux system chamber design and positioning method
US20070048748A1 (en) * 2004-09-24 2007-03-01 Li-Cor, Inc. Mutant polymerases for sequencing and genotyping
US7205048B2 (en) * 2001-09-17 2007-04-17 Invitrogen Corporation Functionalized fluorescent nanocrystal compositions and methods of making
US20070111350A1 (en) * 1997-11-25 2007-05-17 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US20080032307A1 (en) * 2004-07-28 2008-02-07 Helicos Biosciences, Inc. Use of Single-Stranded Nucleic Acid Binding Proteins In Sequencing
US7329496B2 (en) * 1990-12-06 2008-02-12 Affymetrix, Inc. Sequencing of surface immobilized polymers utilizing microflourescence detection
US20080076123A1 (en) * 2006-09-27 2008-03-27 Helicos Biosciences Corporation Polymerase variants for DNA sequencing
US20080076189A1 (en) * 2006-03-30 2008-03-27 Visigen Biotechnologies, Inc. Modified surfaces for the detection of biomolecules at the single molecule level
US20080091005A1 (en) * 2006-07-20 2008-04-17 Visigen Biotechnologies, Inc. Modified nucleotides, methods for making and using same
US7501245B2 (en) * 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US7645596B2 (en) * 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules

Family Cites Families (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4351760A (en) 1979-09-07 1982-09-28 Syva Company Novel alkyl substituted fluorescent compounds and polyamino acid conjugates
SE429036B (en) 1979-12-17 1983-08-08 Haustrup Plastic As CONTAINER WITH A CLOSING PART
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5241060A (en) * 1982-06-23 1993-08-31 Enzo Diagnostics, Inc. Base moiety-labeled detectable nucleatide
IT1172599B (en) 1983-11-09 1987-06-18 Santarelli Franco MECHANISM TO OPERATE THE DISC BRAKES OF MOTOR VEHICLES OR OTHER
US5171534A (en) 1984-01-16 1992-12-15 California Institute Of Technology Automated DNA sequencing technique
US5366603A (en) 1984-03-29 1994-11-22 Li-Cor, Inc. Sequencing near infrared and infrared fluorescence labeled DNA for detecting useing laser diodes
US5571388A (en) 1984-03-29 1996-11-05 Li-Cor, Inc. Sequencing near infrared and infrared fluorescense labeled DNA for detecting using laser diodes and suitable labels thereof
US6004446A (en) 1984-03-29 1999-12-21 Li-Cor, Inc. DNA Sequencing
US4729947A (en) 1984-03-29 1988-03-08 The Board Of Regents Of The University Of Nebraska DNA sequencing
US5230781A (en) 1984-03-29 1993-07-27 Li-Cor, Inc. Sequencing near infrared and infrared fluorescence labeled DNA for detecting using laser diodes
US6086737A (en) 1984-03-29 2000-07-11 Li-Cor, Inc. Sequencing near infrared and infrared fluorescence labeled DNA for detecting using laser diodes and suitable labels therefor
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4764460A (en) 1985-11-08 1988-08-16 Hoffmann-La Roche Inc. Recombinant sigma NS protein
US5151507A (en) 1986-07-02 1992-09-29 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
CA1340806C (en) 1986-07-02 1999-11-02 James Merrill Prober Method, system and reagents for dna sequencing
US5047519A (en) 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US5849478A (en) 1986-08-14 1998-12-15 Cashman; Daniel P. Blocked-polymerase polynucleotide immunoassay method and kit
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
JP2527340B2 (en) 1986-12-15 1996-08-21 アプライド バイオシステムズ インコーポレイテッド 5- and 6-succinimidyl carboxylate isomers of rhodamine dyes
US5202231A (en) * 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US4793705A (en) 1987-10-07 1988-12-27 The United States Of America As Represented By The United States Department Of Energy Single molecule tracking
US4962037A (en) 1987-10-07 1990-10-09 United States Of America Method for rapid base sequencing in DNA and RNA
US4971903A (en) 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US4962020A (en) 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
FR2641793B1 (en) 1988-12-26 1993-10-01 Setratech METHOD OF IN VIVO RECOMBINATION OF DNA SEQUENCES HAVING BASIC MATCHING
KR920700360A (en) 1989-03-22 1992-02-19 하리크 프리드리히 Sliding bearing
GB8910880D0 (en) 1989-05-11 1989-06-28 Amersham Int Plc Sequencing method
US5198060A (en) * 1989-05-15 1993-03-30 Stephen Kurtin Method for replicating solvent-sensitive images
US4979824A (en) 1989-05-26 1990-12-25 Board Of Trustees Of The Leland Stanford Junior University High sensitivity fluorescent single particle and single molecule detection apparatus and method
IT1231157B (en) 1989-07-20 1991-11-19 Crc Ricerca Chim NEW FUNCTIONAL HYBRID GENES OF BACILLUS THURINGIENSIS OBTAINED THROUGH IN VIVO RECOMBINATION.
US6984487B1 (en) 1989-08-22 2006-01-10 Hsc Research Development Corporation Cystic fibrosis gene
GB8920571D0 (en) 1989-09-12 1989-10-25 Carr Robert J G Examination of objects of macromolecular size
WO1991006678A1 (en) 1989-10-26 1991-05-16 Sri International Dna sequencing
US5274240A (en) 1990-01-12 1993-12-28 The Regents Of The University Of California Capillary array confocal fluorescence scanner and method
US5091652A (en) * 1990-01-12 1992-02-25 The Regents Of The University Of California Laser excited confocal microscope fluorescence scanner and method
IL97222A (en) 1990-02-16 1995-08-31 Orion Yhtymae Oy Method and reagent for determining specific nucleotide variations
US5401847A (en) 1990-03-14 1995-03-28 Regents Of The University Of California DNA complexes with dyes designed for energy transfer as fluorescent markers
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
AU1248292A (en) 1990-12-06 1992-07-08 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5578443A (en) 1991-03-06 1996-11-26 Regents Of The University Of Minnesota DNA sequence-based HLA typing method
US5119463A (en) * 1991-04-09 1992-06-02 Abbott Laboratories Compound optical probe employing single optical waveguide
JP3123249B2 (en) 1991-09-10 2001-01-09 株式会社日立製作所 DNA molecule length measuring method and measuring device
JPH05244997A (en) 1992-03-04 1993-09-24 Hitachi Ltd Method for determining base sequence of dna or rna
AU3816993A (en) * 1992-03-19 1993-10-21 Regents Of The University Of California, The Multiple tag labeling method for DNA sequencing
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
GB9208733D0 (en) 1992-04-22 1992-06-10 Medical Res Council Dna sequencing method
GB9210168D0 (en) 1992-05-12 1992-06-24 Cemu Bioteknik Ab Method of sequencing dna
JP2575270B2 (en) * 1992-11-10 1997-01-22 浜松ホトニクス株式会社 Method for determining base sequence of nucleic acid, method for detecting single molecule, apparatus therefor and method for preparing sample
DE69433811T2 (en) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego DNA SEQUENCING BY MASS SPECTROMONY
WO1994018218A1 (en) 1993-02-01 1994-08-18 Seq, Ltd. Methods and apparatus for dna sequencing
US5324401A (en) * 1993-02-05 1994-06-28 Iowa State University Research Foundation, Inc. Multiplexed fluorescence detector system for capillary electrophoresis
US5403707A (en) * 1993-05-14 1995-04-04 Eastman Kodak Company Diagnostic compositions, elements, methods and test kits for amplification and detection of retroviral DNA using primers having matched melting temperatures
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5424841A (en) * 1993-05-28 1995-06-13 Molecular Dynamics Apparatus for measuring spatial distribution of fluorescence on a substrate
US5473060A (en) 1993-07-02 1995-12-05 Lynx Therapeutics, Inc. Oligonucleotide clamps having diagnostic applications
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6458758B1 (en) 1993-08-16 2002-10-01 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
EP0730645A1 (en) * 1993-11-26 1996-09-11 Btg International Limited Translational enhancer dna
JPH07203998A (en) 1994-01-26 1995-08-08 Hamamatsu Photonics Kk Method for determining nucleic acid base sequence
US5869255A (en) * 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6593148B1 (en) 1994-03-01 2003-07-15 Li-Cor, Inc. Cyanine dye compounds and labeling methods
US5459325A (en) 1994-07-19 1995-10-17 Molecular Dynamics, Inc. High-speed fluorescence scanner
CA2172273A1 (en) * 1994-07-29 1996-02-15 Geert Maertens Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US5695934A (en) 1994-10-13 1997-12-09 Lynx Therapeutics, Inc. Massively parallel sequencing of sorted polynucleotides
SE9500342D0 (en) * 1995-01-31 1995-01-31 Marek Kwiatkowski Novel chain terminators, the use thereof for nucleic acid sequencing and synthesis and a method of their preparation
WO1996027025A1 (en) 1995-02-27 1996-09-06 Ely Michael Rabani Device, compounds, algorithms, and methods of molecular characterization and manipulation with molecular parallelism
US5538898A (en) 1995-03-16 1996-07-23 International Business Machines Corporation Method suitable for identifying a code sequence of a biomolecule
AU5525296A (en) 1995-03-24 1996-10-16 Ely Michael Rabani Assembly of complex molecular and supramolecular objects and devices and uses thereof
EP0735144B1 (en) * 1995-03-28 2002-06-05 Japan Science and Technology Corporation Method for molecular indexing of genes using restriction enzymes
US5961923A (en) 1995-04-25 1999-10-05 Irori Matrices with memories and uses thereof
DE19515552A1 (en) 1995-04-27 1996-10-31 Europ Lab Molekularbiolog Simultaneous sequencing of nucleic acids
AU5797696A (en) 1995-05-19 1996-11-29 Ely Michael Rabani Parallel multiplex polynucleotide sequencing
EP0745686A1 (en) 1995-06-01 1996-12-04 Roche Diagnostics GmbH The use of DNA polymerase 3'-intrinsic editing activity
US5776674A (en) 1995-06-05 1998-07-07 Seq, Ltd Chemical biochemical and biological processing in thin films
US5635728A (en) * 1995-06-19 1997-06-03 Denoptix, Inc. Rotating scanner system for reading multiple storage layer radiation screens
DE29509993U1 (en) 1995-06-20 1995-09-14 Textilma Ag Plant for the production of at least one knitted band with crocheted rubber threads
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
AU6898296A (en) 1995-08-14 1997-03-12 Ely Michael Rabani Methods and devices for parallel multiplex polynucleotide sequencing
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US6165765A (en) 1995-10-18 2000-12-26 Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences DNA polymerase having ability to reduce innate selective discrimination against fluorescent dye-labeled dideoxynucleotides
US5814524A (en) 1995-12-14 1998-09-29 Trustees Of Tufts College Optical sensor apparatus for far-field viewing and making optical analytical measurements at remote locations
US5972603A (en) 1996-02-09 1999-10-26 President And Fellows Of Harvard College DNA polymerase with modified processivity
US5715534A (en) * 1996-02-23 1998-02-10 Mobley; Gwennette Q. Hats and caps with moveable bills or brims
US6162931A (en) 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
US6083695A (en) 1996-04-15 2000-07-04 The University Of Houston Optimized primer library for gene sequencing and method of using same
WO1997039150A1 (en) 1996-04-15 1997-10-23 University Of Southern California Synthesis of fluorophore-labeled dna
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5846727A (en) 1996-06-06 1998-12-08 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Microsystem for rapid DNA sequencing
US5866336A (en) * 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5906723A (en) * 1996-08-26 1999-05-25 The Regents Of The University Of California Electrochemical detector integrated on microfabricated capillary electrophoresis chips
AU3829197A (en) 1996-09-03 1998-03-26 Pioneer Hi-Bred International, Inc. Method and apparatus for single molecule two color fluorescent detection and molecular weight and concentration determination
US5830659A (en) 1996-09-13 1998-11-03 University Of Utah Research Foundation Active microtubule-based separations by kinesins
EE9600101A (en) 1996-09-27 1998-04-15 Tartu Ülikool Method and method for determining the nucleotide sequence of DNA by laser spectroscopy
US6291164B1 (en) 1996-11-22 2001-09-18 Invitrogen Corporation Methods for preventing inhibition of nucleic acid synthesis by pyrophosphate
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
US20030104372A1 (en) * 1996-12-23 2003-06-05 Pyrosequencing Ab. Allele specific primer extension
FR2758262B1 (en) 1997-01-14 2004-11-19 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION IN THE FORM OF A GEL CONTAINING A MIXTURE OF AN ASSOCIATIVE COPOLYMER, A SURFACTANT AND AN INSOLUBLE CONDITIONING AGENT
US5804386A (en) 1997-01-15 1998-09-08 Incyte Pharmaceuticals, Inc. Sets of labeled energy transfer fluorescent primers and their use in multi component analysis
US6136543A (en) 1997-01-31 2000-10-24 Hitachi, Ltd. Method for determining nucleic acids base sequence and apparatus therefor
US6403311B1 (en) * 1997-02-12 2002-06-11 Us Genomics Methods of analyzing polymers using ordered label strategies
EP0975802B1 (en) 1997-04-01 2004-06-23 Manteia S.A. Method of nucleic acid sequencing
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US5928869A (en) 1997-05-30 1999-07-27 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
KR100414142B1 (en) * 1997-06-05 2004-05-07 간사이 페인트 가부시키가이샤 Phosphoric acid-containing nonaqueous acid solution and its coating method
US5888792A (en) * 1997-07-11 1999-03-30 Incyte Pharmaceuticals, Inc. ATP-dependent RNA helicase protein
US6245506B1 (en) 1997-07-30 2001-06-12 Bbi Bioseq, Inc. Integrated sequencing device
CA2302393A1 (en) 1997-08-29 1999-03-04 Life Technologies, Inc. High fidelity polymerases and uses thereof
WO2000004364A2 (en) 1998-07-15 2000-01-27 Ljl Biosystems, Inc. Evanescent field illumination devices and methods
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6399334B1 (en) * 1997-09-24 2002-06-04 Invitrogen Corporation Normalized nucleic acid libraries and methods of production thereof
US6008379A (en) 1997-10-01 1999-12-28 The Perkin-Elmer Corporation Aromatic-substituted xanthene dyes
US6485944B1 (en) 1997-10-10 2002-11-26 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
CA2305449A1 (en) 1997-10-10 1999-04-22 President & Fellows Of Harvard College Replica amplification of nucleic acid arrays
JP2001522607A (en) 1997-11-12 2001-11-20 マクギル・ユニヴァーシティ DNA demethylase and its therapeutic and diagnostic uses
US5990479A (en) * 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5936087A (en) * 1997-11-25 1999-08-10 The Perkin-Elmer Corporation Dibenzorhodamine dyes
GB9803382D0 (en) 1998-02-19 1998-04-15 Secr Defence Detection system
WO1999044045A1 (en) 1998-02-27 1999-09-02 Massachusetts Institute Of Technology Single molecule detection with surface-enhanced raman scattering and applications in dna or rna sequencing
WO1999053034A1 (en) 1998-04-09 1999-10-21 University Of Nebraska Board Of Regents Improved live attenuated viruses for use as vectors or vaccines
JP2002512794A (en) 1998-04-29 2002-05-08 リボザイム・ファーマシューティカルズ・インコーポレーテッド Nucleotide triphosphates and their incorporation into ribozymes
US7875440B2 (en) 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6287821B1 (en) * 1998-06-11 2001-09-11 Orchid Biosciences, Inc. Nucleotide analogues with 3'-pro-fluorescent fluorophores in nucleic acid sequence analysis
EP1102781B1 (en) 1998-07-29 2003-12-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. New cofactors for methyltransferases
GB0002310D0 (en) 2000-02-01 2000-03-22 Solexa Ltd Polynucleotide sequencing
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US6790671B1 (en) 1998-08-13 2004-09-14 Princeton University Optically characterizing polymers
US6263286B1 (en) 1998-08-13 2001-07-17 U.S. Genomics, Inc. Methods of analyzing polymers using a spatial network of fluorophores and fluorescence resonance energy transfer
IL141310A0 (en) 1998-08-13 2002-03-10 Us Genomics Inc Optically characterizing polymers
US6280939B1 (en) 1998-09-01 2001-08-28 Veeco Instruments, Inc. Method and apparatus for DNA sequencing using a local sensitive force detector
GB9828785D0 (en) 1998-12-30 1999-02-17 Amersham Pharm Biotech Ab Sequencing systems
GB9901475D0 (en) 1999-01-22 1999-03-17 Pyrosequencing Ab A method of DNA sequencing
WO2000050642A1 (en) 1999-02-23 2000-08-31 Caliper Technologies Corp. Sequencing by incorporation
JP2002537858A (en) 1999-03-10 2002-11-12 エーエスエム サイエンティフィック, インコーポレイテッド Methods for direct sequencing of nucleic acids
IL145422A0 (en) 1999-03-18 2002-06-30 Exiqon As One step sample preparation and detection of nucleic acids in complex in biological samples
US6436640B1 (en) 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
CA2368169C (en) 1999-03-18 2012-07-10 Exiqon A/S Detection of mutations in genes by specific lna primers
WO2000058507A1 (en) 1999-03-30 2000-10-05 Solexa Ltd. Polynucleotide sequencing
GB9907813D0 (en) 1999-04-06 1999-06-02 Medical Biosystems Ltd Synthesis
GB9907812D0 (en) 1999-04-06 1999-06-02 Medical Biosystems Ltd Sequencing
US20030108867A1 (en) * 1999-04-20 2003-06-12 Chee Mark S Nucleic acid sequencing using microsphere arrays
AU751168B2 (en) * 1999-04-23 2002-08-08 Molecular Probes, Inc. Xanthene dyes and their application as luminescence quenching compounds
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
JP4150166B2 (en) 1999-05-07 2008-09-17 ロシュ ダイアグノスティックス ゲーエムベーハー High density labeling of DNA using modified polymerases or nucleotides with chromophores and DNA polymerase
US6635163B1 (en) 1999-06-01 2003-10-21 Cornell Research Foundation, Inc. Entropic trapping and sieving of molecules
US6054316A (en) * 1999-06-25 2000-04-25 Isis Pharmaceuticals Inc. Antisense inhibition of ETs-2 expression
JP2003507026A (en) 1999-08-13 2003-02-25 ユー.エス.ジェノミクス,インコーポレーテッド Method and apparatus for stretching a polymer
US6696022B1 (en) 1999-08-13 2004-02-24 U.S. Genomics, Inc. Methods and apparatuses for stretching polymers
US6927065B2 (en) 1999-08-13 2005-08-09 U.S. Genomics, Inc. Methods and apparatus for characterization of single polymers
US6762059B2 (en) 1999-08-13 2004-07-13 U.S. Genomics, Inc. Methods and apparatuses for characterization of single polymers
AU7086800A (en) 1999-08-30 2001-03-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The High speed parallel molecular nucleic acid sequencing
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
WO2001023610A2 (en) 1999-09-29 2001-04-05 Solexa Ltd. Polynucleotide sequencing
EP1218546A4 (en) 1999-09-30 2005-01-05 New England Biolabs Inc Incorporation of modified nucleotides by archaeon dna polymerases and related methods
US6309836B1 (en) 1999-10-05 2001-10-30 Marek Kwiatkowski Compounds for protecting hydroxyls and methods for their use
US6908736B1 (en) 1999-10-06 2005-06-21 Medical Biosystems, Ltd. DNA sequencing method
GB9923644D0 (en) 1999-10-06 1999-12-08 Medical Biosystems Ltd DNA sequencing
WO2001032930A1 (en) 1999-11-04 2001-05-10 California Institute Of Technology Methods and apparatuses for analyzing polynucleotide sequences
US6399335B1 (en) * 1999-11-16 2002-06-04 Advanced Research And Technology Institute, Inc. γ-phosphoester nucleoside triphosphates
US6329178B1 (en) 2000-01-14 2001-12-11 University Of Washington DNA polymerase mutant having one or more mutations in the active site
GB0002389D0 (en) 2000-02-02 2000-03-22 Solexa Ltd Molecular arrays
WO2001071354A2 (en) 2000-03-20 2001-09-27 Massachusetts Institute Of Technology Inorganic particle conjugates
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
CA2412567A1 (en) 2000-06-07 2001-12-13 Li-Cor, Inc. Charge-switch nucleotides
US20020168678A1 (en) 2000-06-07 2002-11-14 Li-Cor, Inc. Flowcell system for nucleic acid sequencing
GB0016473D0 (en) 2000-07-05 2000-08-23 Amersham Pharm Biotech Uk Ltd Sequencing method
GB0016472D0 (en) 2000-07-05 2000-08-23 Amersham Pharm Biotech Uk Ltd Sequencing method and apparatus
AU2007216737A1 (en) 2000-07-07 2007-10-04 Visigen Biotechnologies, Inc. Real-time sequence determination
US20070172866A1 (en) 2000-07-07 2007-07-26 Susan Hardin Methods for sequence determination using depolymerizing agent
GB0021977D0 (en) 2000-09-07 2000-10-25 Pyrosequencing Ab Method of sequencing DNA
US7597878B2 (en) 2000-09-19 2009-10-06 Li-Cor, Inc. Optical fluorescent imaging
JP3638516B2 (en) 2000-09-28 2005-04-13 株式会社日立製作所 Nucleic acid detection method and nucleic acid detection kit
EP1322936A2 (en) 2000-10-03 2003-07-02 California Institute Of Technology Microfluidic devices and methods of use
WO2002044425A2 (en) * 2000-12-01 2002-06-06 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
JP2004524525A (en) 2001-01-30 2004-08-12 ソレックサ リミテッド Preparation of polynucleotide array
US7297518B2 (en) 2001-03-12 2007-11-20 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US6514829B1 (en) * 2001-03-12 2003-02-04 Advanced Micro Devices, Inc. Method of fabricating abrupt source/drain junctions
AU2002307152A1 (en) 2001-04-06 2002-10-21 California Institute Of Technology Nucleic acid amplification utilizing microfluidic devices
US6320041B1 (en) 2001-04-13 2001-11-20 Trilink Biotechnologies, Inc. Pre-activated carbonyl linkers for the modification of oligonucleotides
WO2002086088A2 (en) 2001-04-24 2002-10-31 Li-Cor, Inc. Polymerases with charge-switch activity and methods of generating such polymerases
GB0112238D0 (en) 2001-05-18 2001-07-11 Medical Biosystems Ltd Sequencing method
US7118907B2 (en) 2001-06-06 2006-10-10 Li-Cor, Inc. Single molecule detection systems and methods
EP1402071A4 (en) 2001-06-08 2005-12-14 Us Genomics Inc Methods and products for analyzing nucleic acids based on methylation status
EP1402069A4 (en) 2001-06-08 2006-01-25 Us Genomics Inc Methods and products for analyzing nucleic acids using nick translation
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US7668697B2 (en) 2006-02-06 2010-02-23 Andrei Volkov Method for analyzing dynamic detectable events at the single molecule level
US6815064B2 (en) 2001-07-20 2004-11-09 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
GB0119719D0 (en) 2001-08-13 2001-10-03 Solexa Ltd DNA sequence analysis
US7041812B2 (en) * 2001-08-29 2006-05-09 Amersham Biosciences Corp Labeled nucleoside polyphosphates
US7033762B2 (en) 2001-08-29 2006-04-25 Amersham Biosciences Corp Single nucleotide amplification and detection by polymerase
US7223541B2 (en) 2001-08-29 2007-05-29 Ge Healthcare Bio-Sciences Corp. Terminal-phosphate-labeled nucleotides and methods of use
US7244566B2 (en) 2001-08-29 2007-07-17 Ge Healthcare Bio-Sciences Corp. Analyte detection
US7214428B2 (en) * 2001-09-17 2007-05-08 Invitrogen Corporation Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
DE60234382D1 (en) 2001-09-17 2009-12-24 Life Technologies Corp NANO CRYSTALS
WO2003025540A2 (en) * 2001-09-18 2003-03-27 U.S. Genomics, Inc. Differential tagging of polymers for high resolution linear analysis
US8423294B2 (en) 2001-09-18 2013-04-16 Pathogenetix, Inc. High resolution linear analysis of polymers
US7217562B2 (en) * 2002-04-16 2007-05-15 Princeton University Gradient structures interfacing microfluidics and nanofluidics, methods for fabrication and uses thereof
WO2003089670A2 (en) 2002-04-22 2003-10-30 Lawler Joseph F Jr Reagents for monitoring nuclei acid amplification and methods of using same
AU2003228649A1 (en) 2002-04-23 2003-11-10 U.S.Genomics, Inc. Compositions and methods related to two-arm nucleic acid probes
WO2004048514A2 (en) 2002-05-09 2004-06-10 U.S. Genomics, Inc. Methods for analyzing a nucleic acid
US7282330B2 (en) * 2002-05-28 2007-10-16 U.S. Genomics, Inc. Methods and apparati using single polymer analysis
US7371520B2 (en) * 2002-05-28 2008-05-13 U.S. Genomics, Inc. Methods and apparati using single polymer analysis
EP1543155A4 (en) * 2002-07-17 2006-08-16 Us Genomics Inc Methods and compositions for analyzing polymers using chimeric tags
EP1546353A4 (en) 2002-08-29 2006-02-01 Amersham Biosciences Corp Allele specific primer extension
DE602004015408D1 (en) 2003-01-23 2008-09-11 Us Genomics Inc METHOD FOR THE ANALYSIS OF POLYMER POPULATIONS
EP1590479B1 (en) 2003-02-05 2010-11-24 GE Healthcare Bio-Sciences Corp. Nucleic acid amplification
JP4896708B2 (en) 2003-02-05 2012-03-14 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション Terminal phosphate-labeled nucleotides with novel linkers
WO2004091795A2 (en) * 2003-04-10 2004-10-28 U.S. Genomics, Inc. Manipulation of polymers in a microchannel
US20050123944A1 (en) 2003-08-01 2005-06-09 U.S. Genomics, Inc. Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions
WO2005017205A2 (en) * 2003-08-04 2005-02-24 U. S. Genomics, Inc. Nucleic acid mapping using linear analysis
US20050042665A1 (en) * 2003-08-21 2005-02-24 U.S. Genomics, Inc. Quantum dots and methods of use thereof
US7491670B2 (en) 2003-09-23 2009-02-17 Dow Global Technologies Inc. Self limiting catalyst composition and propylene polymerization process
US20050142595A1 (en) * 2003-11-07 2005-06-30 U.S. Genomics, Inc. Intercalator FRET donors or acceptors
US20050112671A1 (en) * 2003-11-07 2005-05-26 U.S. Genomics, Inc. FRET efficiency methods
US7169560B2 (en) * 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
WO2005050171A2 (en) * 2003-11-17 2005-06-02 U.S. Genomics, Inc. Methods and compositions relating to single reactive center reagents
US7977048B2 (en) 2004-01-13 2011-07-12 Pathogenetix, Inc. Detection and quantification of analytes in solution using polymers
US20050196790A1 (en) 2004-02-05 2005-09-08 U.S. Genomics, Inc. Methods for detection and quantitation of minimum length polymers
ATE463584T1 (en) 2004-02-19 2010-04-15 Helicos Biosciences Corp METHOD FOR ANALYZING POLYNUCLEOTIDE SEQUENCES
US20060046258A1 (en) * 2004-02-27 2006-03-02 Lapidus Stanley N Applications of single molecule sequencing
US20050221408A1 (en) 2004-03-19 2005-10-06 U.S. Genomics, Inc. Compositions and methods for detection of single molecules
US20050239085A1 (en) 2004-04-23 2005-10-27 Buzby Philip R Methods for nucleic acid sequence determination
US7462452B2 (en) 2004-04-30 2008-12-09 Pacific Biosciences Of California, Inc. Field-switch sequencing
AU2005245981B2 (en) 2004-05-21 2011-05-19 Halliburton Energy Services, Inc. Methods and apparatus for measuring formation properties
US20050260609A1 (en) 2004-05-24 2005-11-24 Lapidus Stanley N Methods and devices for sequencing nucleic acids
US20070117104A1 (en) 2005-11-22 2007-05-24 Buzby Philip R Nucleotide analogs
WO2006007207A2 (en) 2004-05-25 2006-01-19 Helicos Biosciences Corporation Methods and devices for nucleic acid sequence determination
US20060024711A1 (en) * 2004-07-02 2006-02-02 Helicos Biosciences Corporation Methods for nucleic acid amplification and sequence determination
US7276720B2 (en) 2004-07-19 2007-10-02 Helicos Biosciences Corporation Apparatus and methods for analyzing samples
US20060012793A1 (en) 2004-07-19 2006-01-19 Helicos Biosciences Corporation Apparatus and methods for analyzing samples
EP1786932A4 (en) * 2004-08-23 2010-10-27 Us Genomics Inc Systems and methods for detecting and analyzing polymers
ATE556126T1 (en) * 2004-10-29 2012-05-15 Life Technologies Corp FUNCTIONALIZED FLUORESCENT NANOCRYSTALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2006055521A2 (en) 2004-11-16 2006-05-26 Helicos Biosciences Corporation Tirf single molecule analysis and method of sequencing nucleic acids
US7482120B2 (en) * 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
CA2596495A1 (en) 2005-02-09 2006-08-17 Pacific Biosciences Of California, Inc. Nucleotide compositions and uses thereof
US7130041B2 (en) 2005-03-02 2006-10-31 Li-Cor, Inc. On-chip spectral filtering using CCD array for imaging and spectroscopy
US20060263790A1 (en) 2005-05-20 2006-11-23 Timothy Harris Methods for improving fidelity in a nucleic acid synthesis reaction
US20070099212A1 (en) * 2005-07-28 2007-05-03 Timothy Harris Consecutive base single molecule sequencing
US7666593B2 (en) * 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US20070117102A1 (en) 2005-11-22 2007-05-24 Buzby Philip R Nucleotide analogs
US7935310B2 (en) 2005-11-28 2011-05-03 Pacific Biosciences Of California, Inc. Uniform surfaces for hybrid material substrate and methods for making and using same
US7998717B2 (en) * 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
JP2009519717A (en) 2005-12-16 2009-05-21 アプレラ コーポレイション Method and system for fixed phase sequencing
CA2640441C (en) 2006-02-15 2015-11-24 Ahmed Bouzid Fluorescence filtering system and method for molecular imaging
US20090075252A1 (en) * 2006-04-14 2009-03-19 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing
US7282337B1 (en) * 2006-04-14 2007-10-16 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing
US20080241938A1 (en) 2006-07-20 2008-10-02 Visigen Biotechnologies, Inc. Automated synthesis or sequencing apparatus and method for making and using same
US20080241951A1 (en) 2006-07-20 2008-10-02 Visigen Biotechnologies, Inc. Method and apparatus for moving stage detection of single molecular events
US8202972B2 (en) 2007-01-10 2012-06-19 General Electric Company Isothermal DNA amplification
WO2008137661A1 (en) 2007-05-03 2008-11-13 Helicos Biosciences Corporation Methods and compositions for sequencing a nucleic acid
US7678894B2 (en) 2007-05-18 2010-03-16 Helicos Biosciences Corporation Nucleotide analogs
EP2247741A4 (en) 2008-02-03 2011-02-23 Helicos Biosciences Corp Paired-end reads in sequencing by synthesis
US7767400B2 (en) 2008-02-03 2010-08-03 Helicos Biosciences Corporation Paired-end reads in sequencing by synthesis
US7790391B2 (en) 2008-03-28 2010-09-07 Helicos Biosciences Corporation Methods of equalizing representation levels of nucleic acid targets
WO2010051434A1 (en) 2008-10-31 2010-05-06 Helicos Biosciences Corporation Polymerases and methods of use thereof

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654267A (en) * 1982-04-23 1987-03-31 Sintef Magnetic polymer particles and process for the preparation thereof
US4994373A (en) * 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
US5200313A (en) * 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US6200748B1 (en) * 1984-01-16 2001-03-13 California Institute Of Technology Tagged extendable primers and extension products
US5755943A (en) * 1984-03-29 1998-05-26 Li-Cor, Inc. DNA sequencing
US6207421B1 (en) * 1984-03-29 2001-03-27 Li-Cor, Inc. DNA sequencing and DNA terminators
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5079352A (en) * 1986-08-22 1992-01-07 Cetus Corporation Purified thermostable enzyme
US5405776A (en) * 1988-01-13 1995-04-11 Life Technologies, Inc. Cloned genes encoding reverse transcriptase lacking RNase H activity
US5405776B1 (en) * 1988-01-13 1996-10-01 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking RNase H activity
US5498523A (en) * 1988-07-12 1996-03-12 President And Fellows Of Harvard College DNA sequencing with pyrophosphatase
US4997928A (en) * 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
US5720928A (en) * 1988-09-15 1998-02-24 New York University Image processing and analysis of individual nucleic acid molecules
US5091310A (en) * 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5198543A (en) * 1989-03-24 1993-03-30 Consejo Superior Investigaciones Cientificas PHI29 DNA polymerase
US5001050A (en) * 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5510270A (en) * 1989-06-07 1996-04-23 Affymax Technologies N.V. Synthesis and screening of immobilized oligonucleotide arrays
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5188934A (en) * 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
US5079169A (en) * 1990-05-22 1992-01-07 The Regents Of The Stanford Leland Junior University Method for optically manipulating polymer filaments
US7329496B2 (en) * 1990-12-06 2008-02-12 Affymetrix, Inc. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5405747A (en) * 1991-09-25 1995-04-11 The Regents Of The University Of California Office Of Technology Transfer Method for rapid base sequencing in DNA and RNA with two base labeling
US6048690A (en) * 1991-11-07 2000-04-11 Nanogen, Inc. Methods for electronic fluorescent perturbation for analysis and electronic perturbation catalysis for synthesis
US5403708A (en) * 1992-07-06 1995-04-04 Brennan; Thomas M. Methods and compositions for determining the sequence of nucleic acids
US5631134A (en) * 1992-11-06 1997-05-20 The Trustees Of Boston University Methods of preparing probe array by hybridation
US5707797A (en) * 1993-01-08 1998-01-13 Ctrc Research Foundation Color imaging method for mapping stretched DNA hybridized with fluorescently labeled oligonucleotide probes
US5706805A (en) * 1993-08-12 1998-01-13 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen tension in biological systems
US5494030A (en) * 1993-08-12 1996-02-27 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen in biological systems
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5620854A (en) * 1993-08-25 1997-04-15 Regents Of The University Of California Method for identifying biochemical and chemical reactions and micromechanical processes using nanomechanical and electronic signal identification
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5707804A (en) * 1994-02-01 1998-01-13 The Regents Of The University Of California Primers labeled with energy transfer coupled dyes for DNA sequencing
US5512462A (en) * 1994-02-25 1996-04-30 Hoffmann-La Roche Inc. Methods and reagents for the polymerase chain reaction amplification of long DNA sequences
US5599675A (en) * 1994-04-04 1997-02-04 Spectragen, Inc. DNA sequencing by stepwise ligation and cleavage
US5601982A (en) * 1995-02-07 1997-02-11 Sargent; Jeannine P. Method and apparatus for determining the sequence of polynucleotides
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US6362002B1 (en) * 1995-03-17 2002-03-26 President And Fellows Of Harvard College Characterization of individual polymer molecules based on monomer-interface interactions
US6015714A (en) * 1995-03-17 2000-01-18 The United States Of America As Represented By The Secretary Of Commerce Characterization of individual polymer molecules based on monomer-interface interactions
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
US7179906B2 (en) * 1996-04-01 2007-02-20 Applera Corporation Asymmetric benzoxanthene dyes
US6020481A (en) * 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
US5863727A (en) * 1996-05-03 1999-01-26 The Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5723298A (en) * 1996-09-16 1998-03-03 Li-Cor, Inc. Cycle labeling and sequencing with thermostable polymerases
US6210891B1 (en) * 1996-09-27 2001-04-03 Pyrosequencing Ab Method of sequencing DNA
US5858671A (en) * 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US6027709A (en) * 1997-01-10 2000-02-22 Li-Cor Inc. Fluorescent cyanine dyes
US6355420B1 (en) * 1997-02-12 2002-03-12 Us Genomics Methods and products for analyzing polymers
US7008766B1 (en) * 1997-07-28 2006-03-07 Medical Biosystems, Ltd. Nucleic acid sequence analysis
US6207229B1 (en) * 1997-11-13 2001-03-27 Massachusetts Institute Of Technology Highly luminescent color-selective materials and method of making thereof
US20070111350A1 (en) * 1997-11-25 2007-05-17 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US7037687B2 (en) * 1998-05-01 2006-05-02 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7645596B2 (en) * 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US20050042649A1 (en) * 1998-07-30 2005-02-24 Shankar Balasubramanian Arrayed biomolecules and their use in sequencing
US6210896B1 (en) * 1998-08-13 2001-04-03 Us Genomics Molecular motors
US6524829B1 (en) * 1998-09-30 2003-02-25 Molecular Machines & Industries Gmbh Method for DNA- or RNA-sequencing
US6221592B1 (en) * 1998-10-20 2001-04-24 Wisconsin Alumi Research Foundation Computer-based methods and systems for sequencing of individual nucleic acid molecules
US6232075B1 (en) * 1998-12-14 2001-05-15 Li-Cor, Inc. Heterogeneous assay for pyrophosphate detection
US6558945B1 (en) * 1999-03-08 2003-05-06 Aclara Biosciences, Inc. Method and device for rapid color detection
US6727059B1 (en) * 1999-05-10 2004-04-27 Centre National De La Recherche Scientifique (Cnrs) Method for controlling the fidelity and processivity of reverse transcriptase by incorporation and polymerization of nucleotide analogs accepted as substrates for the reverse transcription reaction without blocking its elongation
US7033764B2 (en) * 1999-05-19 2006-04-25 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US20030044781A1 (en) * 1999-05-19 2003-03-06 Jonas Korlach Method for sequencing nucleic acid molecules
US7052847B2 (en) * 1999-05-19 2006-05-30 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US20060078937A1 (en) * 1999-05-19 2006-04-13 Jonas Korlach Sequencing nucleic acid using tagged polymerase and/or tagged nucleotide
US7361466B2 (en) * 1999-05-19 2008-04-22 Cornell Research Foundation, Inc. Nucleic acid analysis using terminal-phosphate-labeled nucleotides
US7485424B2 (en) * 1999-05-19 2009-02-03 Cornell Research Foundation, Inc. Labeled nucleotide phosphate (NP) probes
US20060057606A1 (en) * 1999-05-19 2006-03-16 Jonas Korlach Reagents containing terminal-phosphate-labeled nucleotides for nucleic acid sequencing
US20020025529A1 (en) * 1999-06-28 2002-02-28 Stephen Quake Methods and apparatus for analyzing polynucleotide sequences
US7501245B2 (en) * 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US6982146B1 (en) * 1999-08-30 2006-01-03 The United States Of America As Represented By The Department Of Health And Human Services High speed parallel molecular nucleic acid sequencing
US20030055257A1 (en) * 1999-11-03 2003-03-20 Applera Corporation Water-soluble rhodamine dye conjugates
US6534269B2 (en) * 2000-02-23 2003-03-18 City Of Hope Pyrophosphorolysis activated polymerization (PAP): application to allele-specific amplification and nucleic acid sequence determination
US6869764B2 (en) * 2000-06-07 2005-03-22 L--Cor, Inc. Nucleic acid sequencing using charge-switch nucleotides
US20060063173A1 (en) * 2000-06-07 2006-03-23 Li-Cor, Inc. Charge switch nucleotides
US7329492B2 (en) * 2000-07-07 2008-02-12 Visigen Biotechnologies, Inc. Methods for real-time single molecule sequence determination
US20030064366A1 (en) * 2000-07-07 2003-04-03 Susan Hardin Real-time sequence determination
US20060057565A1 (en) * 2000-09-11 2006-03-16 Jingyue Ju Combinatorial fluorescence energy transfer tags and uses thereof
US20060063247A1 (en) * 2000-09-19 2006-03-23 Li-Cor, Inc. Cyanine dyes
US6995274B2 (en) * 2000-09-19 2006-02-07 Li-Cor, Inc. Cyanine dyes
US20040015964A1 (en) * 2001-04-25 2004-01-22 Mccann Thomas Matthew Methods and systems for load sharing signaling messages among signaling links in networks utilizing international signaling protocols
US20030064400A1 (en) * 2001-08-24 2003-04-03 Li-Cor, Inc. Microfluidics system for single molecule DNA sequencing
US7052839B2 (en) * 2001-08-29 2006-05-30 Amersham Biosciences Corp Terminal-phosphate-labeled nucleotides and methods of use
US7205048B2 (en) * 2001-09-17 2007-04-17 Invitrogen Corporation Functionalized fluorescent nanocrystal compositions and methods of making
US20070036502A1 (en) * 2001-09-27 2007-02-15 Levene Michael J Zero-mode waveguides
US7005518B2 (en) * 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
US20050042633A1 (en) * 2003-04-08 2005-02-24 Li-Cor, Inc. Composition and method for nucleic acid sequencing
US6982186B2 (en) * 2003-09-25 2006-01-03 Dongbuanam Semiconductor Inc. CMOS image sensor and method for manufacturing the same
US20080032307A1 (en) * 2004-07-28 2008-02-07 Helicos Biosciences, Inc. Use of Single-Stranded Nucleic Acid Binding Proteins In Sequencing
US20060062531A1 (en) * 2004-09-17 2006-03-23 Stephen Turner Fabrication of optical confinements
US20060061754A1 (en) * 2004-09-17 2006-03-23 Stephen Turner Arrays of optical confinements and uses thereof
US20060063264A1 (en) * 2004-09-17 2006-03-23 Stephen Turner Apparatus and method for performing nucleic acid analysis
US20060060766A1 (en) * 2004-09-17 2006-03-23 Stephen Turner Apparatus and methods for optical analysis of molecules
US20060061755A1 (en) * 2004-09-17 2006-03-23 Stephen Turner Apparatus and method for analysis of molecules
US20070048748A1 (en) * 2004-09-24 2007-03-01 Li-Cor, Inc. Mutant polymerases for sequencing and genotyping
US20070042398A1 (en) * 2005-06-30 2007-02-22 Li-Cor, Inc. Cyanine dyes and methods of use
US20070044538A1 (en) * 2005-09-01 2007-03-01 Li-Cor, Inc. Gas flux system chamber design and positioning method
US20080076189A1 (en) * 2006-03-30 2008-03-27 Visigen Biotechnologies, Inc. Modified surfaces for the detection of biomolecules at the single molecule level
US20080091005A1 (en) * 2006-07-20 2008-04-17 Visigen Biotechnologies, Inc. Modified nucleotides, methods for making and using same
US20080076123A1 (en) * 2006-09-27 2008-03-27 Helicos Biosciences Corporation Polymerase variants for DNA sequencing

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275395A1 (en) * 2000-07-07 2007-11-29 Susan Hardin Tagged monomers for use in sequence determination
US20100255463A1 (en) * 2000-07-07 2010-10-07 Susan Harsin Compositions and methods for sequence determination
US20070292867A1 (en) * 2000-07-07 2007-12-20 Susan Hardin Sequence determination using multiply tagged polymerizing agents
US20070172858A1 (en) * 2000-07-07 2007-07-26 Susan Hardin Methods for sequence determination
US20070172861A1 (en) * 2000-07-07 2007-07-26 Susan Hardin Mutant polymerases
US20070172863A1 (en) * 2000-07-07 2007-07-26 Susan Hardin Compositions and methods for sequence determination
US20070184475A1 (en) * 2000-07-07 2007-08-09 Susan Hardin Sequence determination by direct detection
US20030064366A1 (en) * 2000-07-07 2003-04-03 Susan Hardin Real-time sequence determination
US20070172866A1 (en) * 2000-07-07 2007-07-26 Susan Hardin Methods for sequence determination using depolymerizing agent
US20070172868A1 (en) * 2000-07-07 2007-07-26 Susan Hardin Compositions for sequence determination using tagged polymerizing agents and tagged monomers
US9243284B2 (en) 2000-12-01 2016-01-26 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US8314216B2 (en) 2000-12-01 2012-11-20 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US8648179B2 (en) 2000-12-01 2014-02-11 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US20090186343A1 (en) * 2003-01-28 2009-07-23 Visigen Biotechnologies, Inc. Methods for preparing modified biomolecules, modified biomolecules and methods for using same
US7668697B2 (en) 2006-02-06 2010-02-23 Andrei Volkov Method for analyzing dynamic detectable events at the single molecule level
US20070250274A1 (en) * 2006-02-06 2007-10-25 Visigen Biotechnologies, Inc. Method for analyzing dynamic detectable events at the single molecule level
US20080091005A1 (en) * 2006-07-20 2008-04-17 Visigen Biotechnologies, Inc. Modified nucleotides, methods for making and using same
US20080241951A1 (en) * 2006-07-20 2008-10-02 Visigen Biotechnologies, Inc. Method and apparatus for moving stage detection of single molecular events
US20080241938A1 (en) * 2006-07-20 2008-10-02 Visigen Biotechnologies, Inc. Automated synthesis or sequencing apparatus and method for making and using same
US20110003343A1 (en) * 2009-03-27 2011-01-06 Life Technologies Corporation Conjugates of biomolecules to nanoparticles
US9932573B2 (en) 2009-03-27 2018-04-03 Life Technologies Corporation Labeled enzyme compositions, methods and systems
US11542549B2 (en) 2009-03-27 2023-01-03 Life Technologies Corporation Labeled enzyme compositions, methods and systems
US9365838B2 (en) 2009-03-27 2016-06-14 Life Technologies Corporation Conjugates of biomolecules to nanoparticles
US9365839B2 (en) 2009-03-27 2016-06-14 Life Technologies Corporation Polymerase compositions and methods
US9567629B2 (en) 2009-03-27 2017-02-14 Life Technologies Corporation Labeled enzyme compositions, methods and systems
US9695471B2 (en) 2009-03-27 2017-07-04 Life Technologies Corporation Methods and apparatus for single molecule sequencing using energy transfer detection
US8603792B2 (en) 2009-03-27 2013-12-10 Life Technologies Corporation Conjugates of biomolecules to nanoparticles
US10093973B2 (en) 2009-03-27 2018-10-09 Life Technologies Corporation Polymerase compositions and methods
US10093974B2 (en) 2009-03-27 2018-10-09 Life Technologies Corporation Methods and apparatus for single molecule sequencing using energy transfer detection
US10093972B2 (en) 2009-03-27 2018-10-09 Life Technologies Corporation Conjugates of biomolecules to nanoparticles
US11008612B2 (en) 2009-03-27 2021-05-18 Life Technologies Corporation Methods and apparatus for single molecule sequencing using energy transfer detection
US11015220B2 (en) 2009-03-27 2021-05-25 Life Technologies Corporation Conjugates of biomolecules to nanoparticles
US11453909B2 (en) 2009-03-27 2022-09-27 Life Technologies Corporation Polymerase compositions and methods
WO2013028563A2 (en) 2011-08-19 2013-02-28 Synthetic Genomics, Inc. Integrated method for high-throughput identification of novel pesticidal compositions and uses therefor

Also Published As

Publication number Publication date
US20070172869A1 (en) 2007-07-26
US20070172859A1 (en) 2007-07-26
US8648179B2 (en) 2014-02-11
US20030134807A1 (en) 2003-07-17
US9243284B2 (en) 2016-01-26
US20100255464A1 (en) 2010-10-07
EP1354064A2 (en) 2003-10-22
US20130102050A1 (en) 2013-04-25
US20160244822A1 (en) 2016-08-25
US20180100191A1 (en) 2018-04-12
US9845500B2 (en) 2017-12-19
US20140127781A1 (en) 2014-05-08
US8314216B2 (en) 2012-11-20
WO2002044425A3 (en) 2003-08-21
WO2002044425A2 (en) 2002-06-06
US7211414B2 (en) 2007-05-01
US20100216122A1 (en) 2010-08-26
US20070172860A1 (en) 2007-07-26
US20110184163A1 (en) 2011-07-28
AU2002227156A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
US9845500B2 (en) Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US11447756B2 (en) Nucleotide transient binding for sequencing methods
EP0946752B1 (en) Method of sequencing dna based on the detection of the release of pyrophosphate
JP5160433B2 (en) Rapid parallel nucleic acid analysis
EP1497304B1 (en) Dual-labeled nucleotides
US7858311B2 (en) Composition and method for nucleic acid sequencing
WO2000036151A9 (en) A heterogeneous assay for pyrophosphate detection
JP2007524359A (en) Solid phase sequencing
CN104245956A (en) Composition for hot-start reverse transcription reaction or hot-start reverse transcription polymerase chain reaction
CN102083846A (en) Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides
JP2006513705A (en) Nucleic acid growth
US20060263790A1 (en) Methods for improving fidelity in a nucleic acid synthesis reaction

Legal Events

Date Code Title Description
AS Assignment

Owner name: LIFE TECHNOLOGIES CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VISIGEN BIOTECHNOLOGIES, INC.;REEL/FRAME:025361/0164

Effective date: 20090107

Owner name: VISIGEN BIOTECHNOLOGIES, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARDIN, SUSAN H.;BRIGGS, JAMES M.;TU, SHIAO-CHUN;AND OTHERS;SIGNING DATES FROM 20040106 TO 20040107;REEL/FRAME:025362/0991

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION